{
  "filename": "ehaa605.pdf",
  "title": "OP-EHEA200603 17..96",
  "type": "peripheral_arterial",
  "year": 2020,
  "total_pages": 81,
  "extracted_at": "2026-01-15T00:20:36.140794",
  "chapters": [
    {
      "number": "1",
      "title": "2020 ESC Guidelines on sports cardiology and",
      "start_page": 1,
      "end_page": 10,
      "content": "2020 ESC Guidelines on sports cardiology and\nexercise in patients with cardiovascular disease\nThe Task Force on sports cardiology and exercise in patients with\ncardiovascular disease of the European Society of Cardiology (ESC)\nAuthors/Task Force Members: Antonio Pelliccia* (Chairperson) (Italy),\nSanjay Sharma* (Chairperson) (United Kingdom), Sabiha Gati (United Kingdom),\nMaria B€ack (Sweden), Mats Bo¨rjesson (Sweden), Stefano Caselli (Switzerland),\nJean-Philippe Collet (France), Domenico Corrado (Italy), Jonathan A. Drezner\n(United States of America), Martin Halle (Germany), Dominique Hansen (Belgium),\nHein Heidbuchel (Belgium), Jonathan Myers (United States of America),\nJosef Niebauer (Austria), Michael Papadakis (United Kingdom),\nMassimo Francesco Piepoli (Italy), Eva Prescott (Denmark),\nJolien W. Roos-Hesselink (Netherlands), A. Graham Stuart (United Kingdom),\nRod S. Taylor (United Kingdom), Paul D. Thompson (United States of America),\nMonica Tiberi (Italy), Luc Vanhees (Belgium), Matthias Wilhelm (Switzerland)\nDocument Reviewers: Marco Guazzi (CPG Review Coordinator) (Italy), Andre´ La Gerche (CPG Review\nCoordinator) (Australia), Victor Aboyans (France), Paolo Emilio Adami (Italy), Johannes Backs\n(Germany), Aaron Baggish (United States of America), Cristina Basso (Italy), Alessandro Bifﬁ(Italy),\nChiara Bucciarelli-Ducci (United Kingdom), A. John Camm (United Kingdom), Guido Claessen (Belgium),\nVictoria Delgado (Netherlands), Perry M. Elliott (United Kingdom), Maurizio Galderisi† (Italy),\nChris P. Gale (United Kingdom), Belinda Gray (Australia), Kristina Hermann Haugaa (Norway),\nBernard Iung (France), Hugo A. Katus (Germany), Andre Keren (Israel), Christophe Leclercq (France),\n* Corresponding authors: Antonio Pelliccia, Department of Medicine, Institute of Sport Medicine and Science, Rome, Italy. Tel: þ39 06 3275 9230, Email: antonio.pelliccia@coni.\nit; ant.pelliccia@gmail.com.\nSanjay Sharma, Cardiology Clinical Academic Group, St George’s, University of London, London, United Kingdom. Tel: þ44 (0)20 8725 6878, Email: sasharma@sgul.ac.uk.\n† We would like to pay tribute to Professor Galderisi who passed away in March 2020.\nESC Committee for Practice Guidelines (CPG), National Cardiac Societies document reviewers and Author/Task Force Member afﬁliations: listed in the Appendix.\nESC entities having participated in the development of this document:\nAssociations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Cardiovascular Imaging (EACVI), European Association of\nPreventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).\nWorking Groups: Adult Congenital Heart Disease.\nThe content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of\nthe ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to\nOxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).\nDisclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientiﬁc and medical knowledge and the evidence available at\nthe time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other ofﬁcial recom-\nmendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encour-\naged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or\ntherapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and\naccurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do\nthe ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the competent\npublic health authorities, in order to manage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is also the\nhealth professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.\nV\nC The European Society of Cardiology 2020. All rights reserved. For permissions, please email: journals.permissions@oup.com.\nEuropean Heart Journal (2021) 42, 17\u000296\nESC GUIDELINES\ndoi:10.1093/eurheartj/ehaa605\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n........................................................................................................\nBasil S. Lewis (Israel), Lluis Mont (Spain), Christian Mueller (Switzerland), Steffen E. Petersen (United\nKingdom), Anna Sonia Petronio (Italy), Marco Rofﬁ(Switzerland), Kai Savonen (Finland), Luis Serratosa\n(Spain), Evgeny Shlyakhto (Russian Federation), Iain A. Simpson (United Kingdom), Marta Sitges (Spain),\nErik Ekker Solberg (Norway), Miguel Sousa-Uva (Portugal), Emeline Van Craenenbroeck (Belgium),\nCaroline Van De Heyning (Belgium), William Wijns (Ireland)\nThe disclosure forms of all experts involved in the development of these Guidelines are available on the\nESC website www.escardio.org/guidelines\nFor the Supplementary Data which include background information and detailed discussion of the data\nthat have provided the basis for the Guidelines see European Heart Journal online.\nClick here to access the corresponding chapter in ESC CardioMed - section 55 - Sports and heart disease\n...................................................................................................................................................................................................\nKeywords\nGuidelines • adult congenital heart disease • aortopathies • arrhythmias • cancer • cardiomyopathy • car-\ndiovascular risk factors • chronic coronary syndromes • exercise • heart failure • pregnancy • peripheral\nvascular disease • recommendations • risk stratiﬁcation • sport \u0002 special environments • valvular heart disease\nTable of Contents\nAbbreviations and acronyms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21\n1 Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22\n2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24\n3 Identification of cardiovascular disease and risk stratification in\nindividuals participating in recreational and competitive sports . . . . . . . 25\n3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25\n3.2 Definitions of recreational and competitive athletes . . . . . . . . . . . 25\n3.3 Exercise-related major adverse cardiovascular events . . . . . . . . . 25\n3.4 Incidence of sudden cardiac death in athletes . . . . . . . . . . . . . . . . . 26\n3.5 Aetiology of sudden cardiac death during exercise . . . . . . . . . . . . 26\n3.6 Screening modalities for cardiovascular disease in young\nathletes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26\n3.7 Screening for cardiovascular disease in older athletes . . . . . . . . . . 26\n4 Physical activity, leisure exercise, and competitive sports\nparticipation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27\n4.1 General introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27\n4.1.1 Definition and characteristics of exercise interventions . . . . 27\n4.1.1.1 Type of exercise . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27\n4.1.1.2 Exercise frequency . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28\n4.1.1.3 Exercise intensity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28\n4.1.1.4 Training volume . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28\n4.1.1.5 Type of training . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28\n4.1.2 Classification of exercise and sports . . . . . . . . . . . . . . . . . . . . . . 29\n4.2 Exercise recommendations in individuals with cardiovascular\nrisk factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30\n4.2.1 General introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30\n4.2.2 Obesity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34\n4.2.3 Hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35\n4.2.4 Dyslipidaemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35\n4.2.5 Diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36\n4.2.5.1 Effect of exercise on diabetic control, risk factors\nand outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36\n4.2.5.2 Recommendations for participation in exercise in\nindividuals with diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36\n4.2.5.3 Cardiac evaluation before exercise in\nindividuals with diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36\n4.3 Exercise and sports in ageing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37\n4.3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37\n4.3.2 Risk stratification, inclusion/exclusion criteria . . . . . . . . . . . . . 37\n4.3.3 Exercise modalities and recommendations for exercise and sport\nin the elderly . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37\n5 Exercise in clinical settings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38\n5.1 Exercise programmes for leisure-time and competitive\nsport participation in chronic coronary syndrome . . . . . . . . . . . . . . . . 38\n5.1.1 Individuals at risk of atherosclerotic coronary artery\ndisease and asymptomatic individuals in whom coronary\nartery disease is detected at screening . . . . . . . . . . . . . . . . . . . . . . . . . 39\n5.1.1.1 Recommendations for sports participation . . . . . . . . . . . 39\n5.1.2 Established (long-standing) chronic coronary syndrome . . . 40\n5.1.2.1 Antithrombotic treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . 42\n5.1.3 Myocardial ischaemia without obstructive disease in\nthe epicardial coronary artery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42\n5.1.4 Return to sport after acute coronary syndrome . . . . . . . . . . 42\n5.1.4.1 Competitive athletes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42\n5.1.4.2 Recreational athletes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42\n5.1.5 Anomalous origin of coronary arteries . . . . . . . . . . . . . . . . . . . 42\n5.1.5.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42\n5.1.5.2 Eligibility for sports . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42\n5.1.6 Myocardial bridging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44\n5.1.6.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44\n5.1.6.2 Eligibility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44\n5.2 Exercise recommendations in individuals with chronic\nheart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44\n5.2.1 Background: rationale for exercise in chronic heart\nfailure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44\n5.2.2 Risk stratification and preliminary evaluation . . . . . . . . . . . . . . 44\n18\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\n5.2.3 Exercise modalities and sports participation in heart\nfailure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45\n5.2.3.1 Aerobic/endurance exercise . . . . . . . . . . . . . . . . . . . . . . . . . 45\n5.2.3.2 Resistance exercise . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45\n5.2.3.3 Respiratory exercise . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45\n5.2.3.4 Aquatic exercise . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45\n5.2.4 Sports participation and return to sports . . . . . . . . . . . . . . . . . 46\n5.2.4.1 Competitive sports . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46\n5.2.4.2 Recreational sports . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46\n5.2.5 Heart failure with preserved ejection fraction . . . . . . . . . . . . . 47\n5.2.5.1 Exercise modalities and sports participation . . . . . . . . . . 47\n5.2.6 Exercise in individuals after heart transplantation . . . . . . . . . . 47\n5.2.6.1 Exercise modalities and sports participation . . . . . . . . . . 47\n5.3 Exercise recommendations in individuals with valvular\nheart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48\n5.3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48\n5.3.1.1 General principles in assessment and risk\nstratification of individuals with valvular heart disease\nprior to leisure exercise or competitive sports . . . . . . . . . . . . . . 48\n5.3.1.2 Surveillance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48\n5.3.2 Aortic valve stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48\n5.3.3 Aortic valve regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49\n5.3.4 Bicuspid aortic valve . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50\n5.3.5 Primary mitral regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51\n5.3.5.1 Mitral valve prolapse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52\n5.3.6 Mitral stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52\n5.3.7 Tricuspid regurgitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53\n5.4 Exercise recommendations in individuals with aortopathy . . . . . 53\n5.4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53\n5.4.2 Risk of dissection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54\n5.4.3 Sporting disciplines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54\n5.4.4 Effect on aortic diameter and wall stress . . . . . . . . . . . . . . . . . . 54\n5.4.5 Recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55\n5.5 Exercise recommendations in individuals with\ncardiomyopathies, myocarditis, and pericarditis . . . . . . . . . . . . . . . . . . . 55\n5.5.1 Hypertrophic cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . 55\n5.5.1.1 Risk stratification in hypertrophic cardiomyopathy . . . . 55\n5.5.1.2 Baseline assessment of patients with HCM . . . . . . . . . . . 55\n5.5.1.3 History . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55\n5.5.1.4 Resting and ambulatory ECG . . . . . . . . . . . . . . . . . . . . . . . . 56\n5.5.1.5 Echocardiography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56\n5.5.1.6 Cardiac magnetic resonance imaging . . . . . . . . . . . . . . . . . 56\n5.5.1.7 Exercise testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56\n5.5.1.8 Genetic testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56\n5.5.1.9 ESC risk score in HCM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56\n5.5.1.10 Exercise recommendation . . . . . . . . . . . . . . . . . . . . . . . . . 56\n5.5.1.11 Special considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56\n5.5.1.12 Follow-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56\n5.5.2 Arrhythmogenic cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . 57\n5.5.2.1 Risk stratification in arrhythmogenic\ncardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57\n5.5.2.2 Baseline assessment of patients with arrhythmogenic\ncardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57\n5.5.2.3 History . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58\n5.5.2.4 Resting and ambulatory ECG . . . . . . . . . . . . . . . . . . . . . . . . 58\n5.5.2.5 Echocardiography and cardiac magnetic resonance\nimaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58\n5.5.2.6 Exercise testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58\n5.5.2.7 Genetic testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58\n5.5.2.8 Exercise recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . 58\n5.5.2.9 Special considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58\n5.5.2.10 Follow-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58\n5.5.3 Exercise recommendations in individuals with left\nventricular non-compaction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59\n5.5.3.1 Risk stratification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59\n5.5.3.2 Follow-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59\n5.5.4 Exercise recommendations in individuals with\ndilated cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59\n5.5.4.1 Baseline assessment of patients with dilated\ncardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60\n5.5.4.2 Special considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60\n5.5.5 Exercise recommendations in individuals with\nmyocarditis and pericarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60\n5.5.5.1 Myocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60\n5.5.5.2 Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61\n5.5.5.3 Risk stratification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61\n5.5.5.4 Exercise recommendations for individuals with\nmyocarditis\n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61\n5.5.6 Pericarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61\n5.5.6.1 Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61\n5.5.6.2 Risk stratification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61\n5.5.6.3 Exercise recommendations for individuals with\npericarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62\n5.6 Exercise recommendations in individuals with arrhythmias\nand channelopathies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62\n5.6.1 A general management framework . . . . . . . . . . . . . . . . . . . . . . . 62\n5.6.2 Atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62\n5.6.2.1 Patients without atrial fibrillation . . . . . . . . . . . . . . . . . . . . . 62\n5.6.2.2 Prognostic and symptomatic relevance of AF\nduring sports . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63\n5.6.2.3 Impact of continuing sport on the natural\nprogression of atrial fibrillation after ablation . . . . . . . . . . . . . . . . 63\n5.6.3 Supraventricular tachycardia and Wolff-Parkinson-\nWhite syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64\n5.6.3.1 Prognostic and symptomatic relevance of\nparoxysmal supraventricular tachycardia without\npre-excitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64\n5.6.3.2 Prognostic and symptomatic relevance of\npre-excitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64\n5.6.4 Premature ventricular contractions and non-sustained\nventricular tachycardia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65\n5.6.4.1 Relation between number of premature\nventricular contractions and risk . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65\n5.6.4.2 Morphology of premature ventricular contractions . . . 65\n5.6.4.3 Premature ventricular contractions: response to\nexercise . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65\n5.6.4.4 Practical management of cardiac patients with\npremature ventricular contractions or non-sustained\nventricular tachycardia who want to engage in sports . . . . . . . . 66\n5.6.5 Long QT syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66\n5.6.6 Brugada syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67\n5.6.7 Following device implantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68\n5.6.7.1 Pacemakers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68\n5.6.7.2 Implantable cardioverter defibrillators . . . . . . . . . . . . . . . 68\nESC Guidelines\n19\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\n5.7 Exercise recommendations in individuals with adult\ncongenital heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69\n5.7.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69\n5.7.2 The increasing numbers of athletes with congenital\nheart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69\n5.7.3 Non-cardiac abnormalities in congenital heart disease\nand Paralympic sport . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69\n5.7.4 General considerations in the congenital heart\ndisease athlete . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69\n5.7.5 Sudden death during sport . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70\n5.7.6 Exercise in athletes with congenital heart disease:\ncurrent guidelines and recommendations . . . . . . . . . . . . . . . . . . . . . . 70\n5.7.7 Assessment of the athlete with congenital heart disease . . . 70\n6 Key messages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72\n7 Gaps in evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73\n8 Sex differences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74\n9 ‘What to do’ and ‘what not to do’ messages from the Guidelines . . . 75\n10 Supplementary data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78\n11 Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78\n12 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80\nList of tables\nTable 1 Classes of recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23\nTable 2 Levels of evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23\nTable 3 Characteristics of exercise . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28\nTable 4 Indices of exercise intensity for endurance sports from\nmaximal exercise testing and training zones . . . . . . . . . . . . . . . . . . . . . . . . . 30\nTable 5 Cardiovascular risk categories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33\nTable 6 Potential risks for older people during exercise . . . . . . . . . . . . . 38\nTable 7 Exercise prescription in the elderly . . . . . . . . . . . . . . . . . . . . . . . . . 38\nTable 8 Exercise activities for older people according to exercise\ntype and intensity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38\nTable 9 Borderline or uninterpretable ECG findings . . . . . . . . . . . . . . . . . 39\nTable 10 Factors determining risk of adverse events during\nintensive exercise and competitive sports in asymptomatic\nindividuals with long-standing coronary artery disease . . . . . . . . . . . . . . . 40\nTable 11 High-risk features for exercise-induced adverse cardiac\nevents in patients with atherosclerotic coronary artery disease . . . . . . 40\nTable 12 Optimal exercise training dose for patients with chronic\nheart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45\nTable 13 Factors influencing decreased exercise capacity\n(peak VO2) and reduced cardiac output in individuals with heart\ntransplants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47\nTable 14 Classification of risk to perform sports in patients with\naortic pathology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54\nTable 15 Findings during an invasive electrophysiological study\n(with the use of isoprenaline) indicating an accessory\npathway with increased risk of sudden death . . . . . . . . . . . . . . . . . . . . . . . . 48\nTable 16 Baseline parameters for assessment in congenital\nheart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55\nList of figures\nFigure Central illustration Moderate physical activity should be promoted\nin all individuals with cardiovascular disease . . . . . . . . . . . . . . . . . . . . . . . . . 24\nFigure 1 Components for expression of physical fitness . . . . . . . . . . . . . 27\nFigure 2 Sporting discipline in relation to the predominant component\n(skill, power, mixed and endurance) and intensity of exercise. Intensity of\nexercise must be individualized after maximal exercise testing, field test-\ning and/or after muscular strength testing . . . . . . . . . . . . . . . . . . . . . . . . . . . 29\nFigure 3a and 3b SCORE charts for European populations of\ncountries at HIGH and LOW cardiovascular disease risk . . . . . . . . . . . . 31\nFigure 4 Proposed algorithm for cardiovascular assessment in\nasymptomatic individuals with risk factors for and possible\nsubclinical chronic coronary syndrome before engaging in sports\nfor individuals aged >35 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34\nFigure 5 Clinical evaluation and recommendations for sports\nparticipation in individuals with established coronary artery disease . . . . 41\nFigure 6 Schematic representation of the most frequent\nanomalous origin of coronary arteries and associated risk of\nsudden cardiac death . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43\nFigure 7 Schematic representation of a myocardial bridge . . . . . . . . . . . 44\nFigure 8 Specific markers of increased risk of sudden cardiac\ndeath with mitral valve prolapse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52\nFigure 9 Pre-participation assessment of individuals with congenital\nheart disease. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55\nTables of recommendations\nGeneral recommendations for exercise and sports in healthy\nindividuals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33\nRecommendations for cardiovascular evaluation and regular\nexercise in healthy individuals aged >35 years . . . . . . . . . . . . . . . . . . . . . . . 34\nSpecial considerations for individuals with obesity, hypertension,\ndyslipidaemia, or diabetes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37\nRecommendations for exercise in ageing individuals . . . . . . . . . . . . . . . . . 38\nRecommendations for exercise in individuals at risk of\natherosclerotic coronary artery disease and asymptomatic\nindividuals in whom coronary artery disease is detected at\nscreening . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40\nRecommendations for exercise in individuals with long-standing\nchronic coronary syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41\nRecommendations for return to exercise after acute coronary\nsyndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42\nRecommendations for exercise in young individuals/athletes\nwith anomalous origins of coronary arteries . . . . . . . . . . . . . . . . . . . . . . . . 43\nRecommendations for exercise/sports in individuals with\nmyocardial bridging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44\nRecommendations for exercise prescription in heart failure\nwith reduced or mid-range ejection fraction . . . . . . . . . . . . . . . . . . . . . . . . 46\nRecommendations for participation in sports in heart failure . . . . . . . . . 46\nRecommendations for exercise and participation in sport in\nindividuals with heart failure with preserved ejection fraction . . . . . . . . 47\nRecommendations for exercise and participation in sport in\nheart transplant recipients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48\nRecommendations for exercise and participation in recreational/\nleisure-time sports in asymptomatic individuals with aortic stenosis . . . . 49\nRecommendations for participation in competitive sports in\nasymptomatic individuals with aortic stenosis . . . . . . . . . . . . . . . . . . . . . . . 49\nRecommendations for participation in recreational/leisure-time\nsports in asymptomatic individuals with aortic regurgitation . . . . . . . . . 50\nRecommendations for participation in competitive sports in\nasymptomatic individuals with aortic regurgitation . . . . . . . . . . . . . . . . . . 50\n20\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n............................................................................................................................................................................\nRecommendations for participation in recreational/leisure-time\nsports in asymptomatic individuals with mitral regurgitation . . . . . . . . . 51\nRecommendations for participation in competitive sports in\nasymptomatic individuals with mitral regurgitation . . . . . . . . . . . . . . . . . . 51\nRecommendations for participation in recreational/leisure-time\nsports in individuals with mitral stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53\nRecommendations for participation in competitive sports in\nasymptomatic individuals with mitral stenosis . . . . . . . . . . . . . . . . . . . . . . . 53\nRecommendations for exercise and participation in sports in\nindividuals with aortic pathology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55\nRecommendations for exercise and sports participation in\nindividuals with hypertrophic cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . 57\nRecommendations for exercise and sports participation in\nindividuals with arrhythmogenic cardiomyopathy . . . . . . . . . . . . . . . . . . . 58\nRecommendations for exercise in individuals with left ventricular\nnon-compaction cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59\nRecommendations for exercise in individuals with dilated\ncardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60\nRecommendations for exercise in individuals with myocarditis . . . . . . . 62\nRecommendations for exercise and sports participation in\nindividuals with pericarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62\nRecommendations for exercise in individuals with atrial fibrillation . . . 63\nRecommendations for exercise and sports participation in\nindividuals with paroxysmal supraventricular tachycardia and\npre-excitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65\nRecommendations for exercise in individuals with premature\nventricular contractions or non-sustained ventricular tachycardia . . . . 66\nRecommendations for exercise in long QT syndrome . . . . . . . . . . . . . . . 67\nRecommendations for exercise in Brugada syndrome . . . . . . . . . . . . . . . 67\nRecommendations for exercise in individuals with pacemakers\nand implantable cardioverter defibrillators . . . . . . . . . . . . . . . . . . . . . . . . . . 69\nRecommendations for exercise in individuals with congenital\nheart disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72\nAbbreviations and acronyms\nACE\nAngiotensin-converting enzyme\nACHD\nAdults with congenital heart disease\nACM\nArrhythmogenic cardiomyopathy\nACS\nAcute coronary syndromes\nAED\nAutomatic external deﬁbrillator\nAHA\nAmerican Heart Association\nAF\nAtrial ﬁbrillation\nAFL\nAtrial ﬂutter\nAMI\nAcute myocardial infarction\nAN-SUD\nAutopsy-negative sudden unexplained death\nAP\nAccessory pathway\nAOCA\nAnomalous origin of coronary arteries\nAR\nAortic valve regurgitation\nARVC\nArrhythmogenic right ventricular cardiomyopathy\nAS\nAortic valve stenosis\nASI\nAortic size index\nAVNRT\nAtrioventricular nodal re-entrant tachycardia\nAVRT\nAtrioventricular re-entrant tachycardia\nBAV\nBicuspid aortic valve\nBMI\nBody mass index\nBP\nBlood pressure\nBrS\nBrugada syndrome\nCAC\nCoronary artery calcium\nCAD\nCoronary artery disease\nCCS\nChronic coronary syndrome\nCCTA\nCoronary computed tomography angiography\nCHD\nCongenital heart disease\nCKD\nChronic kidney disease\nCMD\nCoronary microvascular dysfunction\nCMR\nCardiac magnetic resonance\nCPET\nCardiopulmonary exercise test\nCPR\nCardiopulmonary resuscitation\nCT\nComputed tomography\nCV\nCardiovascular\nCVA\nCerebrovascular accident\nCVD\nCardiovascular disease\nDBP\nDiastolic blood pressure\nDCM\nDilated cardiomyopathy\nEACPR\nEuropean Association for Cardiovascular Prevention\nand Rehabilitation\nEAPC\nEuropean Association of Preventive Cardiology\nECV\nExtracellular volume\nECG\nElectrocardiogram\nEDS\nEhlers Danlos syndrome\nEF\nEjection fraction\nEP\nElectrophysiological\nESC\nEuropean Society of Cardiology\nEx-R\nExercise-related\nexCR\nExercise-based cardiac rehabilitation\nFFR\nFractional ﬂow reserve\nFITT\nFrequency, intensity, time, and type\nHCM\nHypertrophic cardiomyopathy\nHDL\nHigh-density lipoprotein\nHF\nHeart failure\nHIIT\nHigh-intensity interval training\nHR\nHeart rate\nHFmrEF\nHeart failure with mid-range ejection fraction\nHFpEF\nHeart failure with preserved ejection fraction\nHFrEF\nHeart failure with reduced ejection fraction\nHRmax\nMaximal heart rate\nHRR\nHeart rate reserve\nHTAD\nHereditary thoracic aortic disease\nHTx\nHeart transplant\nICD\nImplantable cardioverter deﬁbrillator\nIMT\nIntima\u0002media thickness\nINOCA\nIschaemic and non-obstructive coronary artery disease\nLBBB\nLeft bundle branch block\nLDL\nLow-density lipoprotein\nLEAD\nLower extremity artery disease\nLGE\nLate gadolinium enhancement\nLV\nLeft ventricular\nLVEDD\nLeft ventricular end-diastolic diameter\nLVEF\nLeft ventricular ejection fraction\nLVNC\nLeft ventricular non-compaction\nLVOT\nLeft ventricular outﬂow tract\nLQTS\nLong QT syndrome\nESC Guidelines\n21\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n...........................................................................................................................................................................\nMACE\nMajor adverse cardiovascular events\nMB\nMyocardial bridge/bridging\nMCE\nModerate continuous exercise\nMET\nMetabolic equivalent\nMFS\nMarfan syndrome\nMI\nMyocardial infarction\nMR\nMitral regurgitation\nMS\nMitral stenosis\nMVA\nMitral valve area\nMVP\nMitral valve prolapse\nNSVT\nNon-sustained ventricular tachycardia\nNYHA\nNew York Heart Association\nOAC\nOral anticoagulants\nPA\nPhysical activity\nPAD\nPeripheral arterial disease\nPAP\nPulmonary artery pressure\nPCI\nPercutaneous coronary intervention\nPCSK-9\nProprotein convertase subtilisin/kexin type 9\nPET\nPositron emission tomography\nPH\nPulmonary hypertension\nPM\nPacemaker\nPSVT\nParoxysmal supraventricular tachycardia\nPVC\nPremature ventricular contraction\nPVI\nPulmonary vein isolation\nRBBB\nRight bundle branch block\nRM\nRepetition maximum\nRPE\nRating of perceived exertion\nRT-PCR\nReverse transcriptase polymerase chain reaction\nRV\nRight ventricular\nRVOT\nRight ventricular outﬂow tract\nSBP\nSystolic blood pressure\nSCA\nSudden cardiac arrest\nSCAD\nSpontaneous coronary artery dissection\nSCD\nSudden cardiac death\nSCORE\nSystematic Coronary Risk Evaluation\nsPAP\nSystolic pulmonary artery pressure\nSPECT\nSingle-photon emission computed tomography\nTIA\nTransient ischaemic attack\nTR\nTricuspid regurgitation\nT2DM\nType II diabetes mellitus\nUS\nUnited States\nVA\nVentricular arrhythmia\nVAD\nVentricular assist device\nVF\nVentricular ﬁbrillation\nVT\nVentricular tachycardia\nVO2\nOxygen consumption\nVO2max\nMaximum oxygen consumption\nVO2peak\nPeak oxygen consumption\nWADA\nWorld Anti-Doping Agency\nWPW\nWolff-Parkinson-White\n1. Preamble\nGuidelines summarize and evaluate available evidence with the aim of\nassisting health professionals in proposing the best management\nstrategies for an individual patient with a given condition. Guidelines\nand their recommendations should facilitate decision making of\nhealth professionals in their daily practice. However, the final deci-\nsions concerning an individual patient must be made by the responsi-\nble health professional(s) in consultation with the patient and\ncaregiver as appropriate.\nA great number of Guidelines have been issued in recent years by\nthe European Society of Cardiology (ESC), as well as by other soci-\neties and organizations. Because of their impact on clinical practice,\nquality criteria for the development of guidelines have been estab-\nlished in order to make all decisions transparent to the user. The rec-\nommendations for formulating and issuing ESC Guidelines can be\nfound on the ESC website (http://www.escardio.org/Guidelines-&-\nEducation/Clinical-Practice-Guidelines/Guidelines-development/Wri\nting-ESC-Guidelines). The ESC Guidelines represent the official posi-\ntion of the ESC on a given topic and are regularly updated.\nIn addition to the publication of Clinical Practice Guidelines, the\nESC carries out the EurObservational Research Programme of inter-\nnational registries of cardiovascular diseases and interventions which\nare essential to assess, diagnostic/therapeutic processes, use of\nresources and adherence to Guidelines. These registries aim at pro-\nviding a better understanding of medical practice in Europe and\naround the world, based on high-quality data collected during routine\nclinical practice.\nFurthermore, the ESC has developed and embedded, in some of\nits guidelines, a set of quality indicators (QIs) which are tools to evalu-\nate the level of implementation of the Guidelines and may be used by\nthe ESC, hospitals, healthcare providers and professionals to measure\nclinical practice as well as used in educational programmes, alongside\nthe key messages from the Guidelines, to improve quality of care and\nclinical outcomes.\nThe Members of this Task Force were selected by the ESC, includ-\ning representation from its relevant ESC sub-specialty groups, in\norder to represent professionals involved with the medical care of\npatients with this pathology. Selected experts in the field undertook a\ncomprehensive review of the published evidence for management of\na given condition according to ESC Committee for Practice\nGuidelines (CPG) policy. A critical evaluation of diagnostic and thera-\npeutic procedures was performed, including assessment of the\nrisk\u0002benefit ratio. The level of evidence and the strength of the rec-\nommendation of particular management options were weighed and\ngraded according to predefined scales, as outlined below.\nThe experts of the writing and reviewing panels provided declaration\nof interest forms for all relationships that might be perceived as real or\npotential sources of conflicts of interest. Their declarations of interest\nwere reviewed according to the ESC declaration of interest rules and\ncan be found on the ESC website (http://www.escardio.org/guidelines).\nThis process ensures transparency and prevents potential biases in the\ndevelopment and review processes. Any changes in declarations of\ninterest that arise during the writing period were notified to the ESC\nand updated. The Task Force received its entire financial support from\nthe ESC without any involvement from the healthcare industry.\nThe ESC CPG supervises and coordinates the preparation of\nnew Guidelines. The Committee is also responsible for the\nendorsement process of these Guidelines. The ESC Guidelines\nundergo extensive review by the CPG and external experts. After\nappropriate revisions the Guidelines are approved by all the\n22\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n..................................\nexperts involved in the Task Force. The finalized document is\napproved by the CPG for publication in the European Heart\nJournal. The Guidelines were developed after careful considera-\ntion of the scientific and medical knowledge and the evidence\navailable at the time of their dating.\nThe task of developing ESC Guidelines also includes the creation\nof educational tools and implementation programmes for the rec-\nommendations including condensed pocket guideline versions,\nsummary slides, booklets with essential messages, summary cards\nfor non-specialists and an electronic version for digital applications\n(smartphones, etc.). These versions are abridged and thus, for\nmore detailed information, the user should always access to the full\ntext version of the Guidelines, which is freely available via the ESC\nwebsite and hosted on the EHJ website. The National Cardiac\nSocieties of the ESC are encouraged to endorse, adopt, translate\nand implement all ESC Guidelines. Implementation programmes\nare needed because it has been shown that the outcome of disease\nmay be favourably influenced by the thorough application of clinical\nrecommendations.\nHealth professionals are encouraged to take the ESC Guidelines\nfully into account when exercising their clinical judgment, as well as in\nthe determination and the implementation of preventive, diagnostic\nTable 1\nClasses of recommendations\nClasses of recommendations\nClass I \nEvidence and/or general agreement \nthat a given treatment or procedure is \nIs recommended or is indicated\nWording to use\nClass III \nEvidence or general agreement that the \ngiven treatment or procedure is not \nuseful/effective, and in some cases \nmay be harmful.\nIs not recommended\n     Class IIb\nestablished by evidence/opinion.\nMay be considered\n \n   Class IIa\nWeight of evidence/opinion is in \nShould be considered\nClass II \n©ESC 2020\nTable 2\nLevels of evidence\nLevel of \nevidence A\nData derived from multiple randomized clinical trials \nor meta-analyses. \nLevel of \nevidence B\nData derived from a single randomized clinical trial\nor large non-randomized studies. \nLevel of \nevidence C\nConsensus of opinion of the experts and/or small studies, \nretrospective studies, registries.\n©ESC 2020\nESC Guidelines\n23\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................\nor therapeutic medical strategies. However, the ESC Guidelines do\nnot override in any way whatsoever the individual responsibility of\nhealth professionals to make appropriate and accurate decisions in\nconsideration of each patient’s health condition and in consultation\nwith that patient or the patient’s caregiver where appropriate and/or\nnecessary. It is also the health professional’s responsibility to verify\nthe rules and regulations applicable in each country to drugs and devi-\nces at the time of prescription.\n2. Introduction\nExercise recommendations and eligibility criteria for sports participa-\ntion in competitive athletes with cardiovascular disease (CVD) were\noriginally published by the Sports Cardiology Section of the\nEuropean Society of Cardiology (ESC) in 20051 and some aspects\nwere subsequently updated in 2018 and 2019.2,3 The overarching\naim of these recommendations was to minimize the risk of adverse\nevents in highly trained athletes. It is important to recognize, how-\never, that most of the exercising population engages in leisure sport\nand solo recreational exercise and, unlike elite athletes, these individ-\nuals have a higher prevalence of risk factors for atherosclerosis and\nestablished CVD.\nRegular physical activity (PA), including systematic exercise, is an\nimportant component of therapy for most CVDs and is associated\nwith reduced cardiovascular (CV) and all-cause mortality. In an era\nwhere there is an increasing trend towards a sedentary lifestyle and a\nrising prevalence of obesity and associated CVDs, the promotion of\nPA and regular exercise is more crucial than ever and at the forefront\nof priorities for all scientific CV societies. Even during routine\n©ESC 2020\nFigure Central illustration Moderate physical activity should be promoted in all individuals with cardiovascular disease. Appropriate risk stratifi-\ncation and optimal therapy are essential for providing exercise prescription for more vigorous activity. Individuals should be involved in the decision making\nprocess and a record of the discussion and exercise plan should be documented in the medical records.\n24\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\nconsultations for other considerations, physicians are encouraged to\npromote exercise in all patients.\nAlthough proportionately scarce, exercise may paradoxically trig-\nger sudden cardiac arrest (SCA) in individuals with CVD, particularly\nthose who were previously sedentary or have advanced CVD.4,5 In\nparallel with the drive to promote exercise in all individuals,6 it is\nanticipated that physicians will be confronted with an increasing num-\nber of enquiries from individuals with established risk factors for cor-\nonary artery disease (CAD) or established CVDs about participation\nin exercise programmes and recreational sports activities. Such con-\nsultations need to strike a balance between the multiple benefits of\nexercise, the small risk of sudden death, and the patient’s goals for\ncardiorespiratory fitness and ongoing participation in relatively stren-\nuous exercise following a CV diagnosis.\nThe current Guidelines for exercise and sports participation in\nindividuals with CVD are the first of a kind by the ESC. Sports cardiol-\nogy is a relatively novel and emerging sub-speciality, therefore the\nevidence base for the natural history of disease progression or risk of\ndeath during intensive exercise and competitive sport among individ-\nuals with CVD is relatively sparse. This is reflected by the fact that a\ndisproportionately large number of recommendations are reliant on\nthe wisdom and vast experience of the consensus group rather than\non large prospective studies. We acknowledge the inherent difficul-\nties in formulating recommendations for all scenarios in a heteroge-\nneous population with a diverse spectrum of CVDs in light of the\nlimited availability of evidence. Therefore, these recommendations\nshould not be considered as legally binding and should not discourage\nindividual physicians from practising outside the remit of this docu-\nment, based on their clinical experience in sports cardiology.\nWhere possible, the Guidelines have included the most up-to-date\nresearch in exercising individuals with CVD. The current Guidelines\nalso draw upon existing ESC Guidelines for the investigation, risk\nassessment, and management of individuals with CVDs to aid physi-\ncians when prescribing exercise programmes or providing advice for\nsports participation. We hope that the document will serve as a use-\nful clinical guide but also as an incentive for future research to chal-\nlenge established wisdom.\nIn line with good clinical practice, the present document encour-\nages shared decision making with the athlete patient and respects the\nautonomy of the individual after provision of detailed information\nabout the impact of sports and the potential risks of complications\nand/or adverse events (Central illustration). Similarly, all exercise pre-\nscription and related discussions between the individual and the\nphysician should be documented in the medical report.\n3. Identification of cardiovascular\ndisease and risk stratification in\nindividuals participating in\nrecreational and competitive\nsports\n3.1 Introduction\nHigher levels of PA and fitness are associated with lower all-cause\nmortality, lower rates of CVD, and lower prevalence of several\nknown malignancies.7\u000216 Despite the substantial health benefits pro-\nvided by regular PA, intense exercise may paradoxically act as a trig-\nger for life-threatening ventricular arrhythmias (VAs) in the presence\nof underlying CVD. Indeed, sudden cardiac death (SCD) is the leading\ncause of sports and exercise-related mortality in athletes.17\u000219 CV\nsafety during sports participation for individuals at all levels and ages\nis imperative to avoid catastrophic and often preventable SCD and\nhas become a common goal among medical and sports governing\norganizations.20\u000224\nPre-participation CV screening aimed at the detection of disorders\nassociated with SCD is universally supported by major medical soci-\neties.20\u000222,25,26 However, the best method for CV screening of\nyoung competitive athletes (<35 years old) remains controversial,\nand limited data are available to guide recommendations in master\nathletes (>_35 years old)\nScreening strategies must be tailored to the target population and\nthe specific disorders with highest risk. SCD in young athletes is\ncaused by a variety of structural and electrical disorders of the heart,\nincluding cardiomyopathies, ion channel disorders, coronary anoma-\nlies, and acquired cardiac conditions.17,27,28 In adult and senior ath-\nletes, atherosclerotic CAD is the primary condition leading to major\nadverse cardiovascular events (MACE).28,29\n3.2 Definitions of recreational and\ncompetitive athletes\nThe ESC defines an athlete as ‘an individual of young or adult age,\neither amateur or professional, who is engaged in regular exercise\ntraining and participates in official sports competition’.1,30 Similarly,\nthe American Heart Association (AHA) and others define a competi-\ntive athlete as an individual involved in regular (usually intense) train-\ning in organized individual or team sports, with an emphasis on\ncompetition and performance.31,32 Athletes involved in competitive\nsports span the age spectrum and can compete at the youth, high\nschool, academy, university, semi-professional, professional, national,\ninternational, and Olympic levels. As a distinction, a recreational ath-\nlete engages in sports for pleasure and leisure-time activity, whereas\na competitive athlete is highly trained with a greater emphasis on per-\nformance and winning. In a proposed classification of athletes based\non the minimum volume of exercise, ‘elite’ athletes (i.e. national\nteam, Olympians, and professional athletes) generally exercise >_10\nh/week; ‘competitive’ athletes [i.e. high school, college, and older\n(master) club level athletes] exercise >_6 h/week; and ‘recreational’\nathletes exercise >_4 h/week.33 This distinction is somewhat arbitrary\nsince some recreational athletes, such as long-distance cyclists and\nrunners, engage in exercise at higher volumes than some professional\nathletes participating in skill sports.\n3.3 Exercise-related major adverse cardi-\novascular events\nExercise-related MACE include SCA and SCD; acute coronary syn-\ndromes (ACS) such as myocardial ischaemia and myocardial infarc-\ntion (MI); transient ischaemic attacks (TIA) and cerebrovascular\naccidents (CVA); and supraventricular tachyarrhythmias.\nSCA is defined as an unexpected collapse due to a cardiac cause in\nwhich cardiopulmonary resuscitation (CPR) and/or defibrillation is\nprovided in an individual regardless of the survival outcome.17,27,32\nESC Guidelines\n25\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\nSCD is defined as a sudden unexpected death due to a cardiac cause,\nor a sudden death in a structurally normal heart at autopsy with no\nother explanation for death and a history consistent with cardiac-\nrelated death (i.e. requiring cardiac resuscitation).17,27,32 In order to\ncompare previously reported data on SCA and SCD using variable\ndefinitions, the timing of the event should be categorized as occurring\nduring the episode, within the first hour post-exercise, or between 1\nto 24 h post-exercise.30 The activity at the time of the event can be\nfurther characterized as occurring during training or competition, at\nrest, or during sleep.30\nExercise-induced ACS are most likely to affect adult and senior\nathletes and result from atherosclerotic plaque disruption and coro-\nnary thrombosis in most cases.34,35 More than 50% of patients who\nexperience acute MI (AMI) and SCA do not have pre-existing symp-\ntoms or a known history of CAD.36,37 In long-term endurance ath-\nletes, SCA and myocardial ischaemia can also occur from ‘demand’\nischaemia due to an imbalance between oxygen supply and demand\nresulting from stable calcified plaque and a fixed stenosis.38 In a study\nof United States (US) marathon and half-marathon races, none of the\nrunners with SCA with serious (>80% coronary artery stenosis in a\nproximal left coronary artery or three-vessel disease) coronary athe-\nrosclerosis had angiographic evidence of acute plaque rupture or\nthrombus.38\n3.4 Incidence of sudden cardiac death in\nathletes\nCurrent estimates of the incidence of SCD in competitive athletes\nrange from almost 1 in a million to 1 in 5000 athletes per year.17,39,40\nDifferences in current estimates are largely due to inconsistent study\nmethodology and heterogeneous population comparisons.\nBecause reporting of SCD in athletes is not mandatory in most\ncountries, studies risk underestimating the true incidence due to\nincomplete case ascertainment. For instance, studies using media\nreports as their main source to detect incidents of SCD identify only\n5 - 56% of cases, even in high-profile competitive athletes.41\u000244\nSimilarly, use of catastrophic insurance claims as the only method for\ncase identification missed 83% of SCD cases and 92% of all SCA cases\nin Minnesota high school athletes.40,45\nThe athlete population being studied also needs to be precisely\ndefined. Census population statistics, cross-sectional surveys, and\nself-reported athlete participation data all produce less reliable calcu-\nlations. Other study details should also be considered. Does the\nstudy include all cases of SCA (survivors plus deaths) or only SCD?\nDoes the study include cases occurring at any time (i.e. during exer-\ncise, rest, or sleep), or only those that occur during sports? Studies\nindicate that 56 - 80% of SCA in young athletes occurs during exer-\ncise with the remainder non-exertional.17,18,46\nEvidence supports that some athletes display a higher risk for SCA\nbased on sex, race, or sport.17,40,41,45\u000250 Incidence rates are consis-\ntently higher in male athletes than in female athletes, with a relative\nrisk ranging from 3: 1 to 9: 1 (male: female).17,45,47\u000249,51,52 Black ath-\nletes of African Caribbean descent also have a higher risk than white\nathletes. In US college athletes, males had a higher risk than females\n(1 in 38 000 vs. 1 in 122 000), and black athletes had a 3.2 times higher\nrisk than white athletes (1 in 21 000 vs. 1 in 68 000).17 Male basketball\nplayers had the highest annual risk of SCD (1 in 9000), and male black\nbasketball players had a risk of 1 in 5300.17 Based on available studies\nand a systematic review of the literature, a generally accepted annual\nincidence of all SCA is approximately 1 in 80 000 in high school-aged\nathletes and 1 in 50 000 in college-aged athletes.50 Male athletes,\nblack athletes, basketball (US) and soccer (Europe) athletes repre-\nsent higher risk groups. Limited estimates are available for youth, pro-\nfessional, and master athletes.\n3.5 Aetiology of sudden cardiac death\nduring exercise\nSCD in young athletes is usually caused by a genetic or congenital\nstructural cardiac disorder.17\u000219,42,53,54 However, autopsy-negative\nsudden unexplained death (AN-SUD), also referred to as sudden\narrhythmic death syndrome, is reported on post-mortem examina-\ntion in up to 44% of presumed SCD cases depending on the study\npopulation.17,28,42,53\u000256 In apparently healthy young athletes the\nprevalence of cardiac disorders associated with SCD is approxi-\nmately 0.3%, and this figure is supported by multiple studies using\nnon-invasive evaluation tools to detect cardiac disorders at elevated\nrisk of SCD.20,57\u000265\nIn athletes >35 years of age, more than 80% of all SCD is due to\natherosclerotic CAD, and vigorous physical exertion is associated\nwith an increased risk of AMI and SCD.34,66\u000270 The athletes at great-\nest risk are those with little or no background in systematic training.\n3.6 Screening modalities for\ncardiovascular disease in young athletes\nMost experts believe that early detection of potentially lethal disor-\nders in athletes can decrease CV morbidity and mortality through\nrisk stratification, disease-specific interventions, and/or exercise mod-\nifications.22,57,58,71 CV screening by history and physical examination\nor by electrocardiogram (ECG) presents unique challenges and limi-\ntations. Several studies have documented the low sensitivity and high\npositive\nresponse\nrate\nof\npre-participation\nhistory\nques-\ntionnaires.64,65,72\u000275 In CV screening studies in which experienced\nclinicians use contemporary ECG interpretation standards, ECG\nscreening outperforms history and physical examination in all statisti-\ncal measures of performance.58,59,62,64,65,74,76\nWhile echocardiography may identify additional structural disor-\nders, there is insufficient evidence to recommend an echocardiogram\nfor routine screening.77\n3.7 Screening for cardiovascular disease\nin older athletes\nThe recommendations and evidence base for CV screening in ath-\nletes >35 years of age are limited. CV screening in adult and senior\nathletes must target the higher prevalence of atherosclerotic CAD.\nHowever, routine screening for ischaemia with exercise testing in\nasymptomatic adults has a low positive predictive value and a high\nnumber of false-positive tests and is not recommended.78\u000280\nA screening ECG may still discover undiagnosed cardiomyopathies\nand primary electrical disorders in older athletes, and risk factor\nassessment for CVD may identify higher risk individuals who warrant\nadditional testing. Thus, consistent with a 2017 ESC position paper\non pre-participation CV screening, exercise ECG testing should be\nreserved for symptomatic athletes or those deemed at high risk of\n26\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 7",
          "page": 7,
          "content": "Class II |  |  | \n |  |  | \nClass IIa | Weight of | evidence/opinion is in | Should be considered\n |  |  | \nClass IIb | establishe | d by evidence/opinion. | May be considered",
          "rows": 5,
          "cols": 4
        }
      ],
      "keywords": [
        "cardiology",
        "ct",
        "heart failure",
        "guidelines",
        "sports",
        "imaging"
      ]
    },
    {
      "number": "2",
      "title": ".................................................................................................",
      "start_page": 11,
      "end_page": 20,
      "content": ".................................................................................................\nCAD based on the ESC Systematic Coronary Risk Evaluation\n(SCORE) system (see chapters 4 and 5).6,81\nExercise testing may also be useful to evaluate the blood pressure\n(BP) response to exercise, the occurrence of exercise-induced\narrhythmias, and to assess symptoms or physical performance and its\nrelation to exercise training.81 In adult and elderly individuals, espe-\ncially those naı¨ve to moderate to vigorous PA, exercise testing or car-\ndiopulmonary exercise testing (CPET) is a useful means to assess\noverall CV health and performance, allowing individualized recom-\nmendations regarding sports and exercise type and intensity, as will\nbe discussed in subsequent sections.82\n4. Physical activity, leisure\nexercise, and competitive sports\nparticipation\n4.1 General introduction\nRecommendations for prescription of exercise require a basic knowl-\nedge of physiological responses to exercise, along with an under-\nstanding\nof\nconcepts\nand\ncharacteristics\nof\nPA,\nexercise\ninterventions,\nand\ntheir\nimplications\nfor\nsports\nparticipation.\nAlthough exercise and PA are often used interchangeably, it is impor-\ntant to recognize that these terms differ. PA is defined as any bodily\nmovement produced by the skeletal muscle that results in energy\nexpenditure. Exercise or exercise training, on the other hand, by defi-\nnition, is PA that is structured, repetitive, and purposeful to improve\nor maintain one or more components of physical fitness.83\nPhysical fitness may be expressed by five major components\n(Figure 1):83 a morphological component (body mass relative to\nheight, body composition, subcutaneous fat distribution, abdominal\nvisceral fat, bone density, and flexibility);84 a muscular component\n(power or explosive strength, isometric strength, muscular endur-\nance);85 a motor component (agility, balance, coordination, speed of\nmovement);85 a cardiorespiratory component (endurance or sub-\nmaximal exercise capacity, maximal aerobic power, heart function,\nlung function, BP); and a metabolic component (glucose tolerance,\ninsulin sensitivity, lipid and lipoprotein metabolism, substrate oxida-\ntion characteristics).86\n4.1.1 Definition and characteristics of exercise\ninterventions\nThe basic tenets of exercise prescription have been described using\nthe ‘FITT’ concept (frequency, intensity, time, and type). The mode of\nexercise (Table 3) is also an important characteristic. The following\nsections will describe each of these components related to aerobic\nexercise followed by components of strength exercise.\n4.1.1.1 Type of exercise\nTraditionally, different forms of exercise are classified in binary terms\nas endurance or resistance (strength) exercise. However, this classifi-\ncation is somewhat oversimplified. Further classifications of exercise\nare metabolically related (aerobic vs. anaerobic exercise) or those\nrelated to the type of muscle contraction: isotonic [contraction\nagainst resistance in which the length of the muscle shortens (con-\ncentric) or lengthens (eccentric)] and isometric (static or without\nchange in length of the muscle).\nAerobic exercise refers to activity performed at an intensity that\nallows metabolism of stored energy to occur mainly through aerobic\nglycolysis. Besides the glycolytic pathway, fat metabolism (b-oxidation)\nis also involved during aerobic exercise. Aerobic exercise involves\nlarge muscle groups performing dynamic activities, resulting in\n©ESC 2020\nFigure 1 Components for expression of physical fitness.\nESC Guidelines\n27\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n........................................................................................................................................................................\nsubstantial increases in heart rate and energy expenditure. Examples\nof aerobic exercise include cycling, running, and swimming performed\nat low to moderate intensity.84 In contrast, anaerobic exercise refers\nto movement performed at high intensity unsustainable by oxygen\ndelivery alone and requiring metabolism of stored energy to be proc-\nessed largely by anaerobic glycolysis. A sustained isometric muscle\naction that is not working maximally but does not necessarily depend\nentirely upon oxygen during the muscle contraction is an example of\nanaerobic exercise. Another example of anaerobic exercise is inter-\nmittent high-intensity exercise.85\n4.1.1.2 Exercise frequency\nExercise frequency is usually expressed as the number of times an\nindividual engages in exercise per week. Guidelines suggest that mod-\nerate exercise should be performed most days of the week, amount-\ning to a minimum of 150 min/week.\n4.1.1.3 Exercise intensity\nOf all the basic elements of exercise prescription, exercise intensity is\ngenerally considered to be the most critical for achieving aerobic fit-\nness and to have the most favourable impact on risk factors.86,87\nAbsolute intensity refers to the rate of energy expenditure during\nexercise and is usually expressed in kcal/min or metabolic equivalents\n(METs).84,88 Relative exercise intensity refers to a fraction of an indi-\nvidual’s maximal power (load) that is maintained during exercise and\nis usually prescribed as a percentage of maximal aerobic capacity\n(VO2max) on the basis of a CPET.88 Training intensity can also be\nexpressed as a percentage of maximal heart rate (HRmax) recorded\nduring an exercise test89 or predicted on the basis of the equation\n[HRmax = 220 - age].90 The use of prediction equations for HRmax is\nnot recommended, because there is a large standard deviation\naround the regression line between age and HRmax.91 Alternatively,\nexercise intensity can be expressed relative to a percentage of a per-\nson’s HR reserve (HRR), which uses a percentage of the difference\nbetween HRmax and resting HR and adds it to the resting HR\n(Karvonen formula).92 There are caveats to the use of HR for pre-\nscribing and evaluating exercise intensity in persons using beta-block-\ners.93 Ideally, the HR derived for training should only be used if\nfunctional capacity was determined (an exercise test was performed)\nwhile taking the medication. Intensity is also commonly monitored\nusing the rate of perceived exertion scale (e.g. 12- 14 on the Borg\n6- 20 scale) or ‘talk test’, e.g. ‘to be able to talk while exercising’.91,94\nGeneral zones for various exercise intensities are shown in Table 4.\n4.1.1.4 Training volume\nExercise intensity is inversely related to exercise time. Their prod-\nuct (in kcal or kJ) defines the volume of each training unit, which in\nturn multiplied by frequency provides an estimate of the energy\nexpenditure of the training bout or session. The frequency of\ntraining sessions and the duration of the training period provide\ntotal energy expenditure of a training programme. Meeting the\nminimal activity guidelines equates to approximately 1000 kcal/\nweek or about 10 MET/h/week (the product of MET level and\nduration in hours per week). Training volume should increase\nweekly either by 2.5% in intensity95 or 2 mins’ duration,95 although\nthe rate of progression should be individualized according to the\nbiological adaptation of the individual. Training adaptation is also\ninfluenced by age, genetics,96 fitness, and environmental factors,\nsuch as hydration, heat, cold, and altitude.97\n4.1.1.5 Type of training\nAerobic training. Aerobic exercise training can either be continuous\nor interval based. There is a plethora of evidence and many guidelines\non continuous aerobic exercise, but there is also strong evidence\nemerging about the benefits of interval-type training. The interval\ndesign involves the completion of short bouts of exercise at high\nintensities, interspersed with recovery periods. When compared\nwith continuous training, this approach provides a greater challenge\nto the cardiopulmonary, peripheral, and metabolic systems and\nresults in a more efficient training effect.98 Interval training has been\nreported to be motivating, since the traditional continuous training\ncan often be tedious. Interval training should be employed only in sta-\nble cardiac patients because it places a higher stress on the CV sys-\ntem.99 Since intermittent training exposes subjects to near maximal\neffort, rest intervals of appropriate duration, preferably active ones,\nare recommended.100 The exercise to rest ratio varies.101 There are\na number of different approaches used, which should be individual-\nized according to fitness and comorbidities.\nTable 3\nCharacteristics of exercise\n©ESC 2020\nHR = heart rate; HRR = heart rate reserve; RM = repetition maximum; VO2 =\noxygen consumption; VO2peak = peak oxygen consumption.\n28\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n...........................................................................................\nResistance training. Exercise intensity: The intensity of resistance\nexercise is typically prescribed in terms of one repetition maximum\n(1 RM). One RM is defined as the maximum amount of weight a per-\nson can lift throughout a range of motion with one repetition. Even\nthough the performance of 1 RM appears to be a safe approach for\nevaluating strength102 and no significant CV events have been\nreported using this approach,103 for convenience and compliance\nreasons the use of multiple (usually five) repetitions (5 RM) is sug-\ngested. Five RM is the maximum amount of weight that can be per-\nformed five times. It has been reported that 1 RM can be accurately\nestimated from multiple repetitions and that 5 RM is an appropriate\nreflection of maximal strength.104\nExercise training zones: Resistance training using less than 20% 1 RM is\ngenerally considered aerobic endurance training. With more than\n20% 1 RM, the muscular capillaries become compressed during\nmuscle contraction resulting in a hypoxic stimulus responsible for\ntraining effects. The number of repetitions should be inversely related\nto the training intensity. A moderate training intensity of 30\u000250% 1\nRM with 15\u000230 repetitions is considered muscular endurance train-\ning. Higher training intensities of 50\u000270% 1 RM with 8\u000215 repeti-\ntions are optimal for strength gains.\nTraining volume: Optimal strength gains occur when resistance\ntraining is performed 2\u00023 times per week. Approaches to resist-\nance training often follow either a station or a circuit approach. In\nthe former approach, individuals typically complete all of the sets\nfor a given exercise per muscle group before moving to another\nexercise and muscle group. In the latter approach, individuals typi-\ncally perform one set of a given muscle group and then rotate to\nanother exercise and muscle group until the full set of exercises in\ncompleted per muscle group. One to three sets of 8\u000215\nrepetitions should be performed including flexion and extension\nof each muscle group. Multiple sets are superior to a single set.105\nA variety of 8\u000210 resistance exercises should be prescribed to\ncover most of the muscular groups.88 Muscular power is best\nmaintained when 3\u00025 min rest intervals are used instead of short\nrest intervals (<1 min).106\nMode of training: Resistance training can either be isometric (i.e.\nunchanged muscle length without joint movement) or dynamic (con-\ntraction with change in length of the muscle and movement of the\njoint throughout a range of motion). Isometric (static) muscle actions\nmay induce a Valsalva manoeuvre at moderate to high loads, if it is\nnot intentionally prevented by regular breathing, and may lead to an\nunnecessary fluctuation of BP. Dynamic training may include constant\nor variable resistance through the range of motion using either free\nweights or weight machines. In both of these modes, the type of con-\ntraction and the velocity of movement vary throughout the range of\nmotion. This type of muscle activity mirrors muscle loading faced in\ndaily activity. Muscles can contract in a concentric fashion, in which\nmuscle shortening is exhibited during the movement, or eccentric\nfashion, in which a lengthening of the muscle occurs. Resistance train-\ning is an advanced application in which participants carry out a series\nof rapid concentric and eccentric muscle actions often at a relatively\nhigh load.\n4.1.2 Classification of exercise and sports\nA precise classification of sports by using the different components of\nFITT is difficult because of the differences in the type of muscular\nwork, the mode, and the volume and intensity of exercise. Moreover,\nmost sports consist of an isotonic and isometric muscular\nFigure 2 Sporting discipline in relation to the predominant component (skill, power, mixed, and endurance) and intensity of exercise. Intensity of exer-\ncise must be individualized after maximal exercise testing, field testing and/or after muscular strength testing (Table 2).\nESC Guidelines\n29\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.................................................................................................................\ncomponent. For example, resistance activities can be performed in a\npredominantly dynamic manner or a predominantly static manner.\nSome sports require a high motor control component and level of\nskill, whereas other sports are performed at a low, moderate, high,\nor very high intensity. These intensities can vary depending upon the\ntype of sport or the professional, amateur, or recreational level of\nperforming the sports.\nWhen providing advice regarding an exercise programme or\nsports participation, the physician should indicate: (i) the type of\nsport; (ii) frequency and duration of the exercise programme; and (iii)\nthe intensity that appears most appropriate to the individual.\n(1)\nRegarding the choice of the most convenient sport, the physician\nmay indicate the type of sport as illustrated in Figure 2 (skill, power,\nmixed, or endurance), with specification of the frequency, duration,\nand intensity of muscular work to be preferentially maintained dur-\ning the exercise programme.\n(2)\nIn order to adequately prescribe the individual intensity of an endur-\nance or mixed type of exercise or sports, the individual should per-\nform a maximal exercise test with 12-lead ECG recording or\npreferentially, if possible, with simultaneous measurement of respi-\nratory gas exchange (CPET).\nKnowing a person’s maximal exercise capacity allows the health\nprofessional to determine a personally tailored exercise programme\nthat is safe and most likely to be effective. The exercise test permits\nthe formulation of the appropriate exercise prescription based on\nwell-recognized indices including heart rate reserve (HRR = HRmax -\nHRrest), VO2 reserve, the ventilatory threshold, or percentage of\nwork rate for a given individual.\nThe exercise test also permits an assessment of any abnormal CV\nresponses that might not otherwise be apparent during usual daily\nactivities (including symptoms, ECG abnormalities, arrhythmias, or\nabnormal BP response). Based on the exercise testing results, the\nphysician may indicate the intensity, mode, and duration of exercise\nthat appears most suitable to the individual patient (see Table 4).\nFor power sports or resistance training, additionally maximal mus-\ncular testing is warranted in order to determine 1 RM or 5 RM.\nPercentage of these values, number of repetitions, and number of\nseries will enable determination of the CV and muscular demand.\nAdditionally, field tests will facilitate appropriate prescriptions, mainly\nfor team sports.\nWhen prescribing power sports for individuals with CVD, one\nshould also consider the type of muscular work: isometric (static) or\nisotonic (dynamic) strength exercises. Additionally, the type and\namount of exercise training, when preparing for a sport, is very\nimportant. The amount of exercise work should be adapted gradually\naccording to the subject’s actual exercise tolerance and to the antici-\npated level of performance.\n4.2 Exercise recommendations in\nindividuals with cardiovascular risk\nfactors\n4.2.1 General introduction\nExercise has a positive effect on several risk factors for atherosclero-\nsis.6 Regular exercise reduces the risk of many adverse health out-\ncomes irrespective of age, sex, ethnicity, or the presence of\ncomorbidities. Indeed, there is a dose\u0002effect relationship between\nexercise and CV and all-cause mortality, with a 20\u000230% reduction in\nadverse\nevents\ncompared\nwith\nsedentary\nindividuals.107,108\nConsequently, European Guidelines recommend that healthy adults\nof all ages should perform a minimum of 150 min of moderate-\nintensity endurance exercise training over 5 days or 75 min of vigo-\nrous exercise per week over 3 days, with additional benefit derived\nby doubling the amount to 300 min of moderate-intensity or 150 min\nof vigorous-intensity aerobic PA per week.6\nWhile exercise is also beneficial in patients with established CVD,\nthe risk associated with vigorous exercise and sports in these individ-\nuals is increased. Importantly, CVD may be subclinical and unrecog-\nnized; therefore, consideration should be given to pre-participation\nassessment of risk in individuals with a higher likelihood of CVD.\nIndividuals with multiple risk factors are more likely to develop CVD.\nAssessment of the individual likelihood of subclinical CVD may be\nperformed by calculating the accumulated risk through established\nrisk scores such as the SCORE risk charts (Figure 3) and considering\nTable 4\nIndices of exercise intensity for endurance sports from maximal exercise testing and training zones\n©ESC 2020\nHRmax = maximum heart rate; HRR = heart rate reserve; RPE = rate of perceived exertion; VO2max = maximum oxygen consumption.\naAdapted from refs 84,85 using training zones related to aerobic and anaerobic thresholds. Low-intensity exercise is below the aerobic threshold; moderate is above the aerobic\nthreshold but not reaching the anaerobic zone; high intensity is close to the anaerobic zone; and very intense exercise is above the anaerobic threshold. The duration of exer-\ncise will also largely inﬂuence this division in intensity.\n30\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n180\n160\n140\n120\nWOMEN\nSCORE Cardiovascular Risk Chart\n10-year risk of fatal CVD\nHigh-risk regions of Europe\nMEN\nTotal cholesterol (mmol/L) \nAge\n70\n65\n60\n55\n50\nNon-smoker\nSmoker\n15\n8\n9\n7\n7\n8\n9\n40\n4\n<3%\n5\n6\n7\n4\n5\n6\n7\nSystolic blood pressure (mmHg) \n12\n13\n14\n10\n11\n12\n13\n10\n10\n21\n12\n13\n10\n10\n11\n12\n17\n19\n20\n14\n15\n16\n18\n14\n15\n180\n160\n140\n120\n9\n4\n4\n3\n3\n4\n4\n7\n8\n8\n5\n6\n6\n7\n5\n5\n15\n7\n7\n5\n5\n6\n7\n11\n12\n13\n9\n9\n10\n11\n8\n9\n180\n160\n140\n120\n5\n2\n2\n1\n1\n2\n2\n4\n4\n5\n3\n3\n3\n4\n2\n3\n10\n4\n4\n3\n3\n3\n3\n7\n8\n9\n5\n6\n6\n7\n4\n5\n180\n160\n140\n120\n3\n1\n1\n1\n1\n1\n1\n2\n2\n3\n1\n2\n2\n2\n1\n1\n7\n2\n2\n1\n1\n2\n2\n5\n5\n6\n3\n3\n4\n4\n2\n3\n180\n160\n140\n120\n2\n0\n0\n0\n0\n0\n0\n1\n1\n2\n1\n1\n1\n1\n1\n1\n4\n1\n1\n1\n1\n1\n1\n3\n3\n4\n2\n2\n2\n3\n1\n2\n180\n160\n140\n120\n1\n0\n0\n3–4%\n5–9%\n≥10%\n0\n0\n0\n0\n0\n0\n1\n0\n0\n0\n0\n0\n0\n2\n0\n0\n0\n0\n0\n1\n1\n2\n1\n1\n1\n1\n0\n1\nNon-smoker\nSmoker\n33\n16\n18\n13\n15\n17\n20\n4\n5\n6\n7\n4\n5\n6\n7\n24\n26\n30\n20\n22\n25\n28\n21\n24\n45\n23\n26\n19\n22\n25\n28\n33\n36\n40\n27\n31\n34\n39\n29\n33\n23\n9\n11\n7\n8\n10\n11\n15\n17\n20\n12\n14\n16\n18\n12\n14\n34\n14\n16\n11\n13\n15\n17\n23\n26\n30\n18\n21\n24\n27\n19\n22\n15\n5\n6\n4\n4\n5\n6\n10\n11\n13\n7\n8\n10\n11\n7\n8\n25\n9\n10\n6\n7\n9\n10\n16\n19\n22\n12\n14\n16\n19\n12\n14\n10\n3\n3\n2\n2\n3\n3\n6\n7\n9\n4\n5\n6\n7\n4\n5\n18\n5\n6\n4\n4\n5\n6\n11\n13\n16\n8\n9\n11\n13\n7\n9\n7\n2\n2\n1\n1\n1\n2\n4\n5\n6\n2\n3\n3\n4\n2\n3\n13\n3\n4\n2\n2\n3\n4\n8\n9\n11\n5\n6\n7\n9\n5\n6\n3\n0\n1\n0\n0\n0\n1\n2\n2\n2\n1\n1\n1\n2\n1\n1\n7\n1\n1\n1\n1\n1\n4\n4\n5\n2\n2\n3\n4\n2\n2\n0\n1\n©ESC 2020\nFigure 3a SCORE charts for European populations at high cardiovascular disease (CVD) risk109. The 10-year risk of fatal CVD in populations at high CVD risk is\nbased on the following risk factors: age, gender, smoking, systolic blood pressure, and total cholesterol. To convert the risk of fatal CVD to risk of total (fatal þ non-\nfatal) CVD, multiply by 3 in men and 4 in women, and slightly less in older people. Note: the SCORE chart is for use in people without overt CVD, diabetes (type 1 and\n2), chronic kidney disease, familial hypercholesterolaemia, or very high levels of individual risk factors because such people are already at high risk and need intensive risk\nfactor advice. Cholesterol: 1 mmol/L ¼ 38.67 mg/dL. The SCORE risk charts presented above differ slightly from those in the 2016 ESC/EAS Guidelines for the manage-\nment of dyslipidaemias and the 2016 European Guidelines on cardiovascular disease prevention in clinical practice, in that: (i) age has been extended from\n65 to 70 years; (ii) the interaction between age and each of the other risk factors has been incorporated, thus reducing the overestimation of risk in older persons in\nthe original SCORE charts; (iii) the cholesterol band of 8 mmol/L has been removed since such persons will qualify for further evaluation in any event.\nSCORE = Systematic Coronary Risk Evaluation.\nESC Guidelines\n31\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n180\n160\n140\n120\nWOMEN\nSCORE Cardiovascular Risk Chart\n10-year risk of fatal CVD\nLow-risk regions of Europe\nMEN\nTotal cholesterol (mmol/L) \nAge\n70\n65\n60\n55\n50\nNon-smoker\nSmoker\n9\n5\n5\n4\n4\n5\n5\n40\n4\n<3%\n5\n6\n7\n4\n5\n6\n7\nSystolic blood pressure (mmHg) \n7\n8\n8\n6\n6\n7\n7\n6\n6\n13\n7\n8\n6\n6\n7\n7\n11\n11\n12\n9\n9\n10\n11\n8\n9\n180\n160\n140\n120\n5\n2\n3\n2\n2\n2\n2\n4\n4\n5\n3\n3\n4\n4\n3\n3\n9\n4\n4\n3\n3\n3\n4\n7\n7\n8\n5\n6\n6\n7\n5\n5\n180\n160\n140\n120\n3\n1\n1\n1\n1\n1\n1\n2\n3\n3\n2\n2\n2\n2\n1\n2\n6\n2\n2\n2\n2\n2\n2\n4\n5\n5\n3\n3\n4\n4\n3\n3\n180\n160\n140\n120\n2\n1\n1\n0\n0\n0\n1\n1\n1\n2\n1\n1\n1\n1\n1\n1\n4\n1\n1\n1\n1\n1\n1\n3\n3\n3\n2\n2\n2\n3\n1\n2\n180\n160\n140\n120\n1\n0\n0\n0\n0\n0\n0\n1\n1\n1\n0\n0\n1\n1\n0\n0\n3\n1\n1\n0\n0\n0\n1\n2\n2\n2\n1\n1\n1\n2\n1\n1\n180\n160\n140\n120\n0\n0\n0\n3–4%\n5–9%\n≥10%\n0\n0\n0\n0\n0\n0\n0\n0\n0\n0\n0\n0\n0\n1\n0\n0\n0\n0\n0\n1\n1\n1\n0\n0\n0\n1\n0\n0\nNon-smoker\nSmoker\n17\n8\n9\n7\n8\n9\n10\n4\n5\n6\n7\n4\n5\n6\n7\n12\n14\n15\n10\n11\n13\n14\n10\n12\n24\n12\n13\n10\n11\n12\n14\n18\n20\n22\n15\n16\n18\n20\n15\n17\n12\n5\n5\n3\n4\n5\n5\n8\n9\n10\n6\n7\n8\n9\n6\n7\n18\n7\n8\n5\n6\n7\n8\n12\n14\n16\n9\n11\n12\n14\n9\n11\n8\n3\n3\n2\n2\n2\n3\n5\n6\n7\n4\n4\n5\n5\n3\n4\n13\n4\n5\n3\n4\n4\n5\n8\n10\n11\n6\n7\n8\n9\n6\n7\n5\n1\n2\n1\n1\n1\n2\n3\n4\n4\n2\n2\n3\n3\n2\n2\n9\n3\n3\n2\n2\n2\n3\n6\n7\n8\n4\n4\n5\n6\n3\n4\n3\n1\n1\n0\n1\n1\n1\n2\n2\n3\n1\n1\n2\n2\n1\n1\n6\n1\n2\n1\n1\n1\n2\n4\n5\n5\n2\n3\n3\n4\n2\n3\n1\n0\n0\n0\n0\n0\n0\n1\n1\n1\n0\n0\n1\n1\n0\n0\n3\n1\n1\n0\n0\n0\n2\n2\n3\n1\n1\n1\n2\n1\n1\n0\n1\n©ESC 2020\nFigure 3b SCORE chart for European populations at low cardiovascular disease (CVD) risk. The 10-year risk of fatal CVD in populations at low CVD\nrisk is based on the following risk factors: age, gender, smoking, systolic blood pressure, and total cholesterol. To convert the risk of fatal CVD to risk of\ntotal (fatal þ non-fatal) CVD, multiply by 3 in men and 4 in women, and slightly less in older people. Note: the SCORE chart is for use in people without\novert CVD, diabetes (type 1 and 2), chronic kidney disease, familial hypercholesterolaemia, or very high levels of individual risk factors because such people\nare already at high risk and need intensive risk factor advice. Cholesterol: 1 mmol/L = 38.67 mg/dL. The SCORE risk charts presented above differ slightly\nfrom those in the 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias and 2016 European Guidelines on cardiovascular disease prevention in\nclinical practice, in that: (i) age has been extended from 65 to 70 years; (ii) the interaction between age and each of the other risk factors has been incorpo-\nrated, thus reducing the overestimation of risk in older persons in the original SCORE charts; (iii) the cholesterol band of 8 mmol/L has been removed\nsince such persons will qualify for further evaluation in any event. SCORE = Systematic Coronary Risk Evaluation.\n32\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.......................................................................................\nindividual risk factors such as very high total cholesterol and low-\ndensity lipoprotein (LDL), diabetes mellitus, or a strong family history\nof CVD.6 Based on this assessment the individual CV risk can be cate-\ngorized from low to very high risk (Table 5).\nPreliminary evaluation should consist of a self-assessment relating\nto symptoms and calculation of SCORE. Individuals who are habitu-\nally active and at low or moderate risk should not have any restric-\ntions for exercise including competitive sports. Sedentary individuals\nand individuals at high or very high risk may engage in low-intensity\nexercise without further evaluation. Sedentary individuals and/or\nthose at high or very high risk planning to undertake high-intensity\nexercise as well as selected individuals planning to undertake\nmoderate-intensity exercise should undergo a physical examination,\n12-lead ECG, and exercise stress test. The aim of the exercise test is\nto identify prognostically important CAD and to assess the presence\nof exercise-induced arrhythmias. Individuals with symptoms, abnor-\nmal findings on physical examination, abnormal ECG, or abnormal\nexercise test should be investigated further according to current ESC\nGuidelines for chronic coronary syndromes.110 Following normal\ninvestigations, there should be no restrictions to sports participation.\nAll individuals should, however, be thoroughly informed that devel-\nopment of symptoms during exercise should prompt reassessment.\nWhile a normal exercise test and a high exercise capacity is associ-\nated with a good prognosis, the test has limited sensitivity in diagnos-\ning mild to moderate obstructive CAD.111,112 Currently there is no\nevidence\nfor\nincorporating\nroutine\ncardiac\nimaging\nin\npre-\nparticipation screening among asymptomatic individuals aged >35\nyears old with a normal exercise stress test. However, in asympto-\nmatic adults considered to be at high risk or very high risk (diabetes,\nstrong family history of CAD, previous risk assessment suggesting\nhigh risk for CAD) a functional imaging test or coronary computed\ntomography angiography (CCTA) should be considered in the risk\nassessment (Figure 4).110 Identification of atherosclerotic CAD should\nprompt aggressive management of risk factors and preventive medi-\ncal treatment. Among individuals with proven obstructive CAD, fur-\nther assessment and treatment is indicated.\nTable 5\nCardiovascular risk categories\n©ESC 2020\nGeneral recommendations for exercise and sports in\nhealthy individuals\nRecommendations\nClassa\nLevelb\nAt least 150 min/week of moderate-intensity, or\n75 min/week of vigorous-intensity aerobic exer-\ncise, or an equivalent combination thereof is\nrecommended in all healthy adults.113\u0002118\nI\nA\nA gradual increase in aerobic exercise to 300\nmin/week of moderate-intensity, or 150 min/\nweek of vigorous-intensity aerobic exercise, or\nan equivalent combination is recommended for\nadditional beneﬁts in healthy adults.114,116\nI\nA\nRegular assessment and counselling to promote\nadherence and, if necessary, to support an\nincrease in exercise volume over time are\nrecommended.119\nI\nB\nMultiple sessions of exercise spread throughout\nthe week, i.e. on 4\u00025 days a week and prefera-\nbly every day of the week, are\nrecommended.113,114\nI\nB\naClass of recommendation.\nbLevel of evidence.\nESC Guidelines\n33\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n..........................................................................................\n4.2.2 Obesity\nA person with a body mass index (BMI) >30 kg/m2 or (preferentially)\na waist circumference >94 cm for males and >80 cm for females\n(both for European Caucasians) is considered obese.120,121\nEuropean guidelines for obese individuals recommend that a mini-\nmum of 150 min/week of moderate-intensity endurance exercise\ntraining should be combined with three weekly sessions of resistance\nexercise.121 Such intervention leads to a reduction in intra-abdominal\nfat mass, increments in muscle and bone mass, attenuation in the\nweight loss-induced decline of resting energy expenditure, reduction\nin BP and chronic inflammation, and improvement in glucose toler-\nance, insulin sensitivity, lipid profile, and physical fitness.121,122 There\nis also a positive influence on the long-term maintenance of weight\nreduction, general well-being and self-esteem, and reduction in anxi-\nety and depression.121 The impact of exercise intervention alone on\nfat mass is modest.123 According to a series of large randomized con-\ntrolled trials a high endurance-type exercise volume, >225 min/week,\nis required to maximize fat mass loss in obese individuals.124\nA pre-participation CV assessment is warranted in obese indi-\nviduals who intend to engage in high-intensity exercise (Figure 4),\ndue to associated comorbidities such as type 2 diabetes, hyperten-\nsion, dyslipidaemia, and CV and respiratory diseases.121 Obese\nindividuals with a normal CV assessment should not have any\nrestrictions on exercise. There is evidence from healthy, non-\nobese and non-athletic individuals that running, and abrupt\nincreases in training volume, contribute to musculoskeletal\ninjuries.125\u0002127 Therefore, it may be reasonable to consider that\nobese individuals should limit high-volume weight-bearing exer-\ncises on a hard surface (i.e. <2 h/day) until a considerable\nRecommendations for cardiovascular evaluation and\nregular exercise in healthy individuals aged >35 years\nRecommendations\nClassa\nLevelb\nAmong individuals with low to moderate CVD\nrisk, the participation in all recreational sports\nshould be considered without further CV\nevaluation.\nIIa\nC\nCardiac screening with family history, symptoms,\nphysical examination, and 12-lead resting ECG\nshould be considered for competitive athletes.\nIIa\nC\nClinical evaluation, including maximal exercise\ntesting, should be considered for prognostic pur-\nposes in sedentary people and individuals with\nhigh or very high CV risk who intend to engage in\nintensive exercise programmes or competitive\nsports.\nIIa\nC\nIn selected individuals without known CAD who\nhave very high CVD risk (e.g. SCORE>10%, strong\nfamily history, or familial hypercholesterolaemia)\nand want to engage in high- or very high-intensity\nexercise, risk assessment with a functional imaging\ntest, coronary CCTA, or carotid or femoral artery\nultrasound imaging may be considered.\nIIb\nB\nCCTA = coronary computed tomography angiography; CV = cardiovascular;\nCVD = cardiovascular disease; SCORE = Systematic Coronary Risk Evaluation.\naClass of recommendation.\nbLevel of evidence.\n©ESC 2020\nFigure 4 Proposed algorithm for cardiovascular assessment in asymptomatic individuals aged >35-years-old with risk factors for cardiovascular disease and\npossible subclinical chronic coronary syndrome before engaging in sports. *Consider functional test or CCTA if exercise stress test is equivocal or the ECG is\nuninterpretable. aSee text for examples of functional imaging. bSingle-photon emission computed tomography: area of ischaemia >_10% of the left ventricular\nmyocardium; stress echocardiography: >_3 of 16 segments with stress-induced hypokinesia or akinesia; stress cardiovascular magnetic resonance: >_2 of 16 seg-\nments with stress perfusion defects or >_3 dobutamine-induced dysfunctional segments; coronary computed tomography angiography (CCTA): three-vessel\ndisease with proximal stenoses; left main disease; proximal left anterior descending disease.110 CVD = cardiovascular disease; ECG = electrocardiogram;\nSCORE = Systematic Coronary Risk Evaluation.\n34\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n..............................................................................................................................................................\nreduction in body weight is achieved. Moreover, if high-volume\nexercise (>2 h/day) is desired, a sufficient recovery time should be\nallowed for between periods of exercise (optimally 48 h). It is\nimportant to emphasize that good physical and muscular fitness\nand neuromuscular coordination may protect obese individuals\nfrom musculoskeletal injuries, hence non-weight-bearing exer-\ncises such as cycling or swimming128 may be beneficial. Finally,\nthere is no compelling evidence that resistance training, when\nexecuted properly, will increase the risk for musculoskeletal inju-\nries\nor\nprovoke\nmusculoskeletal\nsymptoms\nin\nobese\nindividuals.129\n4.2.3 Hypertension\nA person with a persistent systolic BP (SBP) >_140 mmHg and/or dia-\nstolic BP (DBP) >_90 mmHg is considered hypertensive.130,131\nHypertensive individuals should participate in at least 30 min of\nmoderate-intense dynamic aerobic exercise (walking, jogging, cycling,\nor swimming) for 5\u00027 days per week.132 Such exercise intervention\nis associated with a mean reduction in SBP of 7 mmHg and DBP of 5\nmmHg.133 Additional resistance training is highly effective in reducing\nBP further and resistance training 2\u00023 days per week is also\nadvised.132 Indeed, the BP-lowering effect of resistance and isometric\nexercise may be comparable to, or even greater than, that of aerobic\nexercise.134\nIf high-intensity sports participation is desired, a pre-participation\nCV assessment is warranted to identify athletes with exercise-\ninduced symptoms, excessive BP response to exercise130, and the\npresence of end organ damage. Individuals with symptoms suggestive\nof CAD require further assessment and optimization of medical ther-\napy before participation in sports. If arterial hypertension is poorly\ncontrolled (resting SBP > 160 mmHg), a maximal exercise test should\nbe postponed until the BP is controlled.\nNon-pharmacological measures should be considered as the\nfirst step in the management of hypertension in athletes, includ-\ning: restriction of salt intake and alcohol consumption, weight\nreduction if applicable, balanced diet (e.g. Mediterranean diet),\nand cessation of smoking. Aerobic exercise programmes should\nherein complement the individual’s training schedule.131 If such\nlifestyle changes do not lower BP after 3 months, antihyperten-\nsive drugs should be commenced if SBP remains >140 mmHg.\nAntihypertensive therapy alongside lifestyle intervention should\nbe considered in all individuals aged >65 years but <80 years,\nprovided it is well tolerated.131,132 It is important to consider\nthat beta-blockers are prohibited in certain competitive skill\nsports such as shooting [see World Anti-Doping Association\n(WADA) for complete list135], and can induce bradycardia and/\nor lower aerobic exercise capacity.131 Diuretics are prohibited in\nall competitive sports.135Angiotensin-converting enzyme (ACE)\ninhibitors, angiotensin II receptor blockers, and calcium antago-\nnists are the preferred drugs of choice in exercising individuals. It\nis noteworthy that the use of non-selective non-steroidal\ninflammatory drugs for musculoskeletal pain may contribute to\nraised BP.136\nWhen BP is uncontrolled, temporary restriction from competitive\nsports is recommended, with the possible exception of skill sports.131\nIn individuals with a high-risk profile, including those with end organ\ndamage [left ventricular (LV) hypertrophy, diastolic dysfunction,\nultrasound evidence of arterial wall thickening or atherosclerotic pla-\nque, hypertensive retinopathy, increased serum creatinine (men\n1.3\u00021.5 mg/dL, women 1.2\u00021.4 mg/dL), and/or microalbuminuria]\nin whom BP is controlled, participation in all competitive sports is\npossible, with the exception of the most intensive power disciplines\nsuch as discus/javelin throwing, shot-putting, and weightlifting (see\nsection 4.1).131\nDuring sports participation, regular follow-up is recommended\ndepending on the severity of hypertension and the category of risk. In\nindividuals with borderline BP readings, regular ambulatory assess-\nment of BP should be considered. In individuals with low or moderate\nCV risk and well-controlled BP, there should be no restrictions to\nsports participation, however, intensive heavy weightlifting, especially\nwhen this includes substantial isometric (static) muscle work, can\nhave a marked pressor effect and should be avoided. In this\ncontext, avoiding the Valsalva manoeuvre in particular is warranted\nbecause breath holding during muscular contraction is associated\nwith a greater elevation in SBP and DBP.135 When executed cor-\nrectly, high-intense dynamic resistance training (up to 80% of 1 RM),\nwith a low number of repetitions (n < 10) does not induce greater\nincrements in BP compared with low-intense dynamic resistance\ntraining (<50% of 1 RM) with a high number of repetitions (n >_\n20).137\u0002142\nSome individuals who are normotensive at rest will have an exag-\ngerated BP response to exercise. An exaggerated BP response to\nexercise increases the risk for incident hypertension in highly trained\nand normotensive athletes over a middle-term period.143 If SBP rises\nto >200 mmHg at a workload of 100 W during exercise testing,144\nantihypertensive medical therapy should be optimized and clinical\nevaluation, including ECG and echocardiography, should be consid-\nered, even if the athlete is normotensive at rest.131 Moreover, in\nyoung Olympic athletes a peak SBP of >220 mmHg in males and\n>200 mmHg in females measured during cycle ergometry are beyond\nthe 95th percentile.131\n4.2.4 Dyslipidaemia\nPhysical activity has favourable effects on lipid metabolism by reduc-\ning serum triglycerides by up to 50% and increasing high-density lipo-\nprotein (HDL) cholesterol by 5\u000210%.85,145 Exercise may also\nreduce LDL cholesterol by up to 5% and shift the more atherogenic\nsmall, dense LDL fraction towards larger LDL particles in a dose-\ndependent fashion.146 These metabolic improvements can be\nachieved through 3.5 - 7 h of moderately vigorous PA per week or\n30 - 60 min of exercise on most days.\nIn individuals with hypertriglyceridaemia or hypercholesterolae-\nmia, a higher intensity of exercise is recommended, as this may\nESC Guidelines\n35\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n................................................................................................................................................................\nimprove the lipid profile and reduce CV risk. Before embarking on\nhigh-intensity exercise, a clinical assessment should be performed\nincluding symptomatic status, and a maximal exercise stress test,\nfunctional imaging test, or CCTA may be considered in the risk\nassessment110 (Figure 4), particularly in individuals with familial hyper-\ncholesterolaemia. Among athletes with hypercholesterolaemia, regu-\nlar exercise will rarely reduce LDL cholesterol to normal or near-\nnormal values; therefore, guidelines on pharmacological treatment in\nprimary and secondary prevention should be followed strictly.\nIndividuals with dyslipidaemia should be assessed at least every 2\u00025\nyears for primary prevention and annually for secondary prevention.\nPharmacological intervention, particularly with statins, is superior\nto exercise and lifestyle intervention alone for reducing LDL choles-\nterol and improving prognosis.147 Despite the minor effects of endur-\nance exercise on serum LDL cholesterol, the clinically beneficial\nrelationship between increased physical fitness and reduced CV\nevents remains beyond the effects of statins.147,148\nPhysically active individuals with dyslipidaemia may experience\nmuscle pain and soreness or tendinopathy accompanied by elevated\nmuscle enzymes.149 In these cases, measures such as stopping medi-\ncation temporarily followed by repeat challenge with another statin\ndrug, with or without an alternate day regimen, or introducing other\nlipid-lowering agents such as ezetimibe or proprotein convertase\nsubtilisin/kexin type 9 (PCSK-9) inhibitors should be considered.109\nIndividuals who develop rhabdomyolysis due to a statin should be\nprescribed an alternative lipid-lowering agent.\n4.2.5 Diabetes mellitus\nPhysical inactivity is a major cause of type 2 diabetes mellitus\n(T2DM).150 The risk of developing T2DM is 50\u000280% higher in indi-\nviduals who are physically inactive compared to their active counter-\nparts. However, exercise does not entirely compensate for the effect\nof obesity.151\u0002154 Diabetes is also independently associated with an\naccelerated decline in muscular strength and, partly because of\nhyperglycaemia, may lead to reduced joint mobility.\n4.2.5.1 Effect of exercise on diabetic control, risk factors and outcomes\nAerobic exercise in patients with T2DM improves glycaemic control\nand reduces visceral fat and insulin resistance. Exercise also has bene-\nficial effects on BP and lipid profile, and leads to modest weight\nloss.155,156 Both aerobic and resistance training promote prolonged\nadaptations in skeletal muscle, adipose tissue, and the liver associated\nwith enhanced insulin action.157 Observational studies have shown\nlower mortality with exercise in both type 1 diabetes mellitus and\nT2DM.158\nIn patients with pre-diabetes or metabolic syndrome, both aerobic\nand resistance exercise may prevent the development of overt dia-\nbetes.159\u0002162 Intensity of exercise seems to be of greater importance\nthan the volume of exercise; individuals who exercise at moderate or\nhigh intensity have a lower risk of developing metabolic impairment\ncompared with those who have a similar energy expenditure at a\nlower intensity.160,163\nThe effects on muscle insulin sensitivity are observed with a rela-\ntively low volume of exercise (400 kcal/week) in previously sedentary\nadults, but increase with higher volumes of exercise.164 The optimal\ncombination of duration and intensity is not well established. High-\nintensity interval training may be superior to moderate aerobic train-\ning in achieving metabolic effects and improvement in exercise\ncapacity; however, whether long-term results are superior is\nunknown.165,166\nDiabetes is a cause of coronary microvascular dysfunction (CMD),\nwhich is associated with lower exercise capacity and adverse out-\ncomes167,168 and can be improved by exercise training.162,169\u0002171\nLarge randomized trials have confirmed the beneficial effect of exer-\ncise intervention on glycaemic control and risk factors, but this has\nnot translated into a significant improvement in survival, partly\nbecause of suboptimal long-term maintenance of lifestyle changes.172\nDuring an acute bout of exercise, glucose uptake in the muscles is\nincreased for up to 2 h afterwards through mechanisms that are inde-\npendent of insulin. The exercise-induced hypoglycaemic effect can be\ndiminished by performing resistance training or interval training in\npatients with type 1 diabetes.173 There is a dose\u0002response relation-\nship between intensity and volume of exercise and duration of glu-\ncose uptake by skeletal muscle that may last up to 48 h after exercise.\nThese factors must be considered in individuals with diabetes who\nare undertaking intensive exercise or competitive sports in order to\navoid hypoglycaemia.\n4.2.5.2 Recommendations for participation in exercise in individuals with\ndiabetes mellitus\nBoth aerobic and resistance training are effective for glycaemic con-\ntrol, BP reduction, weight loss, peak exercise capacity, and dyslipide-\nmia.174 A programme combining aerobic and resistance training has\nbeen shown to be superior in terms of glycaemic control, whereas\nthe effect on other outcomes is unproven.174\u0002176\nThe ideal exercise programme to achieve the full potential of ben-\nefits in patients with diabetes is daily exercise of at least moderate\nintensity, e.g. brisk walking, for at least 30 min, resistance training for\n15 min on most days, and lighter-intensity activities (standing, walk-\ning) every 30 min. This can be supplemented by flexibility and balance\nexercise, particularly in older individuals or patients with microvascu-\nlar complications due to their diabetes.\n4.2.5.3 Cardiac evaluation before exercise participation in individuals\nwith diabetes mellitus\nIndividuals with diabetes have a priori a higher likelihood of subclinical\nCAD; therefore, all individuals with diabetes should undergo CV\nassessment as outlined in Figure 4 before taking up an exercise pro-\ngramme of high intensity. This should be supplemented by an evalua-\ntion of glycaemic status, including risk factors for hypoglycaemia,\nhistory of hypoglycaemic episodes, presence of autonomic neuropa-\nthy, and antidiabetic treatment.177\nAsymptomatic individuals with diabetes mellitus and a normal CV\nassessment and maximal exercise test may engage in all sports but\nshould\nbe\nwarned\nabout\nthe\npotential\nrisk\nof\niatrogenic\n36\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "12 13 14 15 |  |  | \n10 11 12 13 |  |  | \n8 | 9 | 10 10 | \n7 | 7 | 8 | 9",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "17 19 20 21 |  |  | \n14 15 16 18 |  |  | \n12 | 13 | 14 15 | \n10 | 10 | 11 | 12",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "24 26 30 33 |  |  | \n20 22 25 28 |  |  | \n16 | 18 | 21 24 | \n13 | 15 | 17 | 20",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "33 36 40 45 |  |  | \n27 31 34 39 |  |  | \n23 | 26 | 29 33 | \n19 | 22 | 25 | 28",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "7 8 8 9 |  |  | \n5 6 6 7 |  |  | \n4 | 4 | 5 5 | \n3 | 3 | 4 | 4",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "11 12 13 15 |  |  | \n9 9 |  | 10 11 | \n7 | 7 | 8 9 | \n5 | 5 | 6 | 7",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "15 17 20 23 |  |  | \n12 14 16 18 |  |  | \n9 | 11 | 12 14 | \n7 | 8 | 10 | 11",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "23 26 30 34 |  |  | \n18 21 24 27 |  |  | \n14 | 16 | 19 22 | \n11 | 13 | 15 | 17",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "4 4 |  | 5 5 | \n3 3 3 4 |  |  | \n2 | 2 | 2 | 3\n1 | 1 | 2 | 2",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "7 8 9 |  |  | 10\n5 6 6 7 |  |  | \n4 | 4 | 4 | 5\n3 | 3 | 3 | 3",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "10 11 13 15 |  |  | \n7 8 |  | 10 11 | \n5 | 6 | 7 8 | \n4 | 4 | 5 | 6",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "16 19 22 25 |  |  | \n12 14 16 19 |  |  | \n9 | 10 | 12 14 | \n6 | 7 | 9 | 10",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "2 2 |  | 3 3 | \n1 2 2 2 |  |  | \n1 | 1 | 1 1 | \n1 | 1 | 1 | 1",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "5 5 6 7 |  |  | \n3 3 4 4 |  |  | \n2 | 2 | 2 | 3\n1 | 1 | 2 | 2",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "6 7 9 |  |  | 10\n4 | 5 6 7 |  | \n3 | 3 | 4 | 5\n2 | 2 | 3 | 3",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "11 13 16 18 |  |  | \n8 9 |  | 11 13 | \n5 | 6 | 7 9 | \n4 | 4 | 5 | 6",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "1 1 2 2 |  |  | \n1 1 1 1 |  |  | \n0 | 0 | 1 1 | \n0 | 0 | 0 | 0",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "3 3 4 4 |  |  | \n2 2 2 |  |  | 3\n1 | 1 | 1 2 | \n1 | 1 | 1 | 1",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "4 | 5 6 7 |  | \n2 | 3 3 4 |  | \n2 | 2 | 2 | 3\n1 | 1 | 1 | 2",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "8 9 |  | 11 13 | \n5 6 7 9 |  |  | \n3 | 4 | 5 6 | \n2 | 2 | 3 | 4",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "0 0 1 1 |  |  | \n0 0 0 0 |  |  | \n0 | 0 | 0 0 | \n0 | 0 | 0 | 0",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "1 1 2 2 |  |  | \n1 1 1 1 |  |  | \n0 | 0 | 0 1 | \n0 | 0 | 0 | 0",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "2 2 2 |  |  | 3\n1 1 1 2 |  |  | \n0 | 1 | 1 1 | \n0 | 0 | 0 | 1",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "4 4 |  | 5 7 | \n2 2 |  | 3 4 | \n1 | 1 | 2 2 | \n1 | 1 | 1 | 1",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "7 8 8 9 |  |  | \n6 6 7 7 |  |  | \n5 | 5 | 6 6 | \n4 | 4 | 5 | 5",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "11 11 12 13 |  |  | \n9 9 |  | 10 11 | \n7 | 8 | 8 9 | \n6 | 6 | 7 | 7",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "12 14 15 17 |  |  | \n10 11 13 14 |  |  | \n8 | 9 | 10 12 | \n7 | 8 | 9 | 10",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "18 20 22 24 |  |  | \n15 16 18 20 |  |  | \n12 | 13 | 15 17 | \n10 | 11 | 12 | 14",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "4 4 |  | 5 5 | \n3 3 4 4 |  |  | \n2 | 3 | 3 3 | \n2 | 2 | 2 | 2",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "7 7 8 9 |  |  | \n5 6 6 7 |  |  | \n4 | 4 | 5 5 | \n3 | 3 | 3 | 4",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "8 9 |  | 10 12 | \n6 7 8 9 |  |  | \n5 | 5 | 6 7 | \n3 | 4 | 5 | 5",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "12 14 16 18 |  |  | \n9 | 11 12 14 |  | \n7 | 8 | 9 | 11\n5 | 6 | 7 | 8",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "2 | 3 3 3 |  | \n2 2 2 2 |  |  | \n1 | 1 | 1 2 | \n1 | 1 | 1 | 1",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "4 | 5 5 6 |  | \n3 3 4 4 |  |  | \n2 | 2 | 3 3 | \n2 | 2 | 2 | 2",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "5 6 7 8 |  |  | \n4 4 |  | 5 5 | \n3 | 3 | 3 4 | \n2 | 2 | 2 | 3",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "8 | 10 11 13 |  | \n6 7 8 9 |  |  | \n4 | 5 | 6 7 | \n3 | 4 | 4 | 5",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "1 1 2 2 |  |  | \n1 1 1 1 |  |  | \n1 | 1 | 1 1 | \n0 | 0 | 0 | 1",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "3 3 3 4 |  |  | \n2 2 2 |  |  | 3\n1 | 1 | 1 2 | \n1 | 1 | 1 | 1",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "3 4 4 |  |  | 5\n2 2 |  | 3 3 | \n1 | 2 | 2 2 | \n1 | 1 | 1 | 2",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "6 7 8 9 |  |  | \n4 4 |  | 5 6 | \n3 | 3 | 3 4 | \n2 | 2 | 2 | 3",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "1 1 1 1 |  |  | \n0 0 1 1 |  |  | \n0 | 0 | 0 0 | \n0 | 0 | 0 | 0",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "2 2 2 |  |  | 3\n1 1 1 2 |  |  | \n1 | 1 | 1 1 | \n0 | 0 | 0 | 1",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "2 2 |  | 3 3 | \n1 1 2 2 |  |  | \n1 | 1 | 1 1 | \n0 | 1 | 1 | 1",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "4 | 5 5 6 |  | \n2 | 3 3 4 |  | \n1 | 2 | 2 | 3\n1 | 1 | 1 | 2",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "0 0 0 0 |  |  | \n0 0 0 0 |  |  | \n0 | 0 | 0 0 | \n0 | 0 | 0 | 0",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "1 1 1 1 |  |  | \n0 0 0 1 |  |  | \n0 | 0 | 0 0 | \n0 | 0 | 0 | 0",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "1 1 1 1 |  |  | \n0 0 1 1 |  |  | \n0 | 0 | 0 0 | \n0 | 0 | 0 | 0",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "2 2 |  | 3 3 | \n1 1 1 2 |  |  | \n1 | 1 | 1 1 | \n0 | 0 | 0 | 1",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 17",
          "page": 17,
          "content": "Recommendations | Classa | Levelb\n |  | \nAt least 150 min/week of moderate-intensity, or\n75 min/week of vigorous-intensity aerobic exer-\ncise, or an equivalent combination thereof is\nrecommended in all healthy adults.113\u0002118 | I | A\nA gradual increase in aerobic exercise to 300\nmin/week of moderate-intensity, or 150 min/\nweek of vigorous-intensity aerobic exercise, or\nan equivalent combination is recommended for\nadditional benefits in healthy adults.114,116 | I | A\nRegular assessment and counselling to promote\nadherence and, if necessary, to support an\nincrease in exercise volume over time are\nrecommended.119 | I | B",
          "rows": 5,
          "cols": 3
        },
        {
          "title": "Table on page 18",
          "page": 18,
          "content": " | Classa Levelb\nRecommendations | \n | \nAmong individuals with low to moderate CVD\nrisk, the participation in all recreational sports\nshould be considered without further CV\nevaluation. | IIa C\nCardiac screening with family history, symptoms,\nphysical examination, and 12-lead resting ECG\nshould be considered for competitive athletes. | IIa C\nClinical evaluation, including maximal exercise\ntesting, should be considered for prognostic pur-\nposes in sedentary people and individuals with\nhigh or very high CV risk who intend to engage in\nintensive exercise programmes or competitive\nsports. | IIa C\nIn selected individuals without known CAD who\nhave very high CVD risk (e.g. SCORE>10%, strong\nfamily history, or familial hypercholesterolaemia)\nand want to engage in high- or very high-intensity\nexercise, risk assessment with a functional imaging\ntest, coronary CCTA, or carotid or femoral artery\nultrasound imaging may be considered. | IIb B",
          "rows": 7,
          "cols": 2
        }
      ],
      "keywords": [
        "moderate",
        "intervention",
        "ct",
        "risk",
        "recommendation"
      ]
    },
    {
      "number": "3",
      "title": "hypoglycaemia in the event of inadequate caloric intake. Importantly,",
      "start_page": 21,
      "end_page": 30,
      "content": "........................................................................................................................................................................\nhypoglycaemia in the event of inadequate caloric intake. Importantly,\nall patients with diabetes should be aware of warning symptoms and\nattention should be given to chest discomfort or unusual breathless-\nness during exercise as this may be indicative of CAD.\n4.3 Exercise and sports in ageing\n4.3.1 Introduction\nThe elderly are defined as adults aged above 65 years. Similar to the\ngeneral population, higher exercise capacity in this age group is also\nassociated with reduced mortality.179 A physically active lifestyle\nmaintained through middle and older age translates into better\nhealth180 and longevity.181\u0002185 Commencing a new exercise regimen\namong sedentary elderly individuals has shown significant health\nimprovements180,186 including cognitive capacity.187\u0002190 Moreover,\nregular exercise exerts beneficial effects in reducing the risk of devel-\noping CV and metabolic disease through improved control of CV risk\nfactors,191,192 also preserving cognitive function.187\u0002190 Importantly,\nexercise helps to preserve neuromuscular competence,193,194 thus\nmaintaining balance and coordination, which reduces the risk of\nfalling.195,196\n4.3.2 Risk stratification, inclusion/exclusion criteria\nModerate-intensity exercise is generally safe for older healthy people\nand medical consultation before starting or progressing the level of\nexercise programme is not usually required.81,197 The general recom-\nmendation for exercise implementation for the general population\nalso applies to healthy elderly people.\nNevertheless, due to potential risks of exercising among the eld-\nerly (Table 6), the European Association of Preventive Cardiology\n(EAPC) recommends self-assessment by a brief questionnaire81 to\ndetermine the need for advice from health professionals, but this\napproach has not been tested prospectively.\nCommunity-dwelling frail or sedentary older adults may have a\nslightly increased risk of falls during exercise; however, there is no\nevidence\nof\nserious\nadverse\noutcomes,\ninjury,\nor\nCV\nevents.195,196,198,199 Exercise interventions to improve balance in\nthose diagnosed with dementia bring numerous benefits without an\nincreased risk of adverse outcomes.200 Resistance exercise in older\nadults is rarely associated with adverse events.201,202 No major risks\nhave been reported in older individuals performing low- and\nmoderate-intensity aerobic exercise, and even more intense aerobic\nactivities are associated with a relatively small risk.203\u0002205 CV events\nduring intense exercise occur at a rate of around 1 event per 100\nyears of vigorous activity.206 Risks are highest during the first few\nweeks of beginning vigorous exercise; therefore both exercise inten-\nsity and duration should be increased gently (for example, every 4\nweeks).81,197,207\u0002210 Among older individuals who are well prepared\nand accustomed to intense exercise, participation in competitive vig-\norous sports does not confer higher risk compared with younger\nadults.38,211\n4.3.3 Exercise modalities and recommendations for\nexercise and sport in the elderly\nThe physical exercises for elderly persons should be designed\naccording to their biological age, exercise experience, functional\ncapacity, safety, ageing trajectories, comorbidity, lifestyle habits, and\nprevious experience of exercise.\nElderly people should perform endurance and strength exercise,\nand specific exercises for flexibility and balance (Table 7).201,212,213\nEndurance exercise exerts beneficial effects on the cardiorespiratory\nsystem and resistance exercise prevents the decrease in muscle mass\nand sarcopenia.192 Achieving >150 min/week moderate-intensity\naerobic exercise (i.e. walking or other moderate intensity aerobics-\ntype activities) is associated with at least 30% lower risk of morbidity,\nmortality, disability, frailty, and dementia compared with being inac-\ntive.212,214,215 The strength exercises for the major muscle groups\nshould be performed at least twice a week (8\u000210 different exercises,\n10\u000215 repetitions).\nAccustomed senior athletes should continue performing exercise\nand sports activities, without any predetermined age limit.38,211,216\nSports activities for older people according to exercise type and\nintensity are reported in Table 8. Annual clinical assessment including\na maximal exercise test (preferably with simultaneous CPET) is rec-\nommended in master athletes performing a high level of sports and\nexercise programmes.217\nSpecial considerations for individuals with obesity,\nhypertension, dyslipidaemia, or diabetes\nRecommendations\nClassa\nLevelb\nIn obese individuals (BMI>_30 kg/m2 or a waist cir-\ncumference >80 cm for females or >94 cm for\nmales) resistance training >_3 times per week, in\naddition to moderate or vigorous aerobic exercise\n(at least 30 min, 5\u00027 days per week) is recom-\nmended to reduce CVD risk.121\nI\nA\nIn individuals with well-controlled hypertension,\nresistance training >_3 times per week in addition to\nmoderate or vigorous aerobic exercise (at least 30\nmin, 5\u00027 days per week) is recommended to\nreduce blood pressure and CVD risk. 132\nI\nA\nAmong individuals with diabetes mellitus, resistance\ntraining >_3 times per week in addition to moderate\nor vigorous aerobic exercise (at least 30 min, 5\u00027\ndays per week) is recommended to improve insulin\nsensitivity and achieve a better CVD risk\nproﬁle.176,178\nI\nA\nAmong adults with well-controlled hypertension\nbut high risk and/or target organ damage, high-inten-\nsity resistance exercise is not recommended.\nIII\nC\nIn individuals with uncontrolled hypertension\n(SBP>160 mmHg) high-intensity exercise is not rec-\nommended until blood pressure has been\ncontrolled.\nIII\nC\nCVD = cardiovascular disease; SBP = systolic blood pressure.\naClass of recommendation.\nbLevel of evidence.\nESC Guidelines\n37\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n............................................................ 5. Exercise in clinical settings\n5.1 Exercise programmes for\nleisure-time and competitive sport\nparticipation in chronic coronary\nsyndrome\nAtherosclerotic CAD is the predominant cause of exercise-related\n(Ex-R) cardiac events including ACS, AMI, and SCA in individuals with\nestablished chronic coronary syndrome (CCS), or SCD as a primary\npresentation in individuals >35 years of age.218 In addition to athero-\nsclerotic CAD, other entities, including an anomalous origin of a cor-\nonary\nartery\n(AOCA),219\nmyocardial\nbridge\n(MB),220\nand\nspontaneous coronary artery dissection (SCAD),221 are also associ-\nated with myocardial ischaemia, and potentially with Ex-R SCD.\nPhysical inactivity is a risk factor for CAD, but somewhat paradoxi-\ncally, vigorous physical exertion transiently increases the risk for\nAMI66 and SCD.216 Overall, the benefits of regular exercise greatly\noutweigh the Ex-R risk, even in individuals with CCS. Moderate- to\nvigorous-intensity exercise is strongly associated with a reduced\nTable 6\nPotential risks for older people during exercise\n©ESC 2020\nTable 7\nExercise prescription in the elderly\n©ESC 2020\nRecommendations for exercise in ageing individuals\nRecommendations\nClassa\nLevelb\nAmong adults aged 65 years or older who are\nﬁt and have no health conditions that limit\ntheir mobility, moderate-intensity aerobic\nexercise for at least 150 min/week is\nrecommended.212,214,215\nI\nA\nIn older adults at risk of falls, strength training\nexercises to improve balance and coordina-\ntion on at least 2 days a week are\nrecommended.201,212,214,215\nI\nB\nA full clinical assessment including a maximal\nexercise test should be considered in seden-\ntary adults aged 65 years or older who wish to\nparticipate in high-intensity activity.\nIIa\nC\nContinuation of high- and very high-intensity\nactivity, including competitive sports, may be\nconsidered in asymptomatic elderly athletes\n(master athletes) at low or moderate CV risk.\nIIb\nC\nCV = cardiovascular.\naClass of recommendation.\nbLevel of evidence.\nTable 8\nExercise activities for older people according to\nexercise type and intensity\n©ESC 2020\n38\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.................................................................................................................................\nincidence of adverse outcomes from CAD, but prolonged, high-\nintensity endurance exercise has been associated with increased cor-\nonary artery calcium (CAC), a marker of atherosclerosis,58,222 and\ncoronary plaques58 but without an increase in mortality112 in the\nmedium term. Importantly, the diagnosis of myocardial injury is also\nmore complex in athletes because intense exercise may increase\nserologic markers of myocardial injury, including cardiac troponin I\nand T.223,224\n5.1.1 Individuals at risk of atherosclerotic coronary artery\ndisease and asymptomatic individuals in whom coronary\nartery disease is detected at screening\nAthletes or individuals participating in sports or regular exercise\ntraining may have risk factors for CAD and/or subclinical CCS.225\nSuch individuals may be identified by routine pre-participation\nscreening as recommended by the ESC21 or by pre-evaluation of\nmaster athletes, as suggested by the European Association for\nCardiovascular Prevention and Rehabilitation (EACPR) 2011207 and\nthe AHA.226\nIn addition to the SCORE risk stratification described earlier\n(Table 5), the increasing use of cardiac imaging techniques allows the\nidentification of a greater number of individuals with asymptomatic\nCCS,227 including competitive master athletes.227\nNewer predictive measures, such as high-sensitive C-reactive pro-\ntein and carotid intima\u0002media thickness (IMT) add little to the tradi-\ntional risk factors.110 The exception is CAC, which provides\nadditional predictive information in individuals with a moderate-risk\nprofile,228 dividing them into low- or high-risk individuals. The most\nprudent and cost-effective method of utilizing CAC may thus be addi-\ntive to the traditional risk factors,229 as suggested by the EAPC.230\nClinical evaluation of asymptomatic individuals with possible sub-\nclinical CCS should include (Figure 4):112\n(1)\nAssessment of risk of CVD110 (Table 5)\n(2)\nConsideration of intensity of intended exercise programme\n(3)\nClinical evaluation, including maximal exercise stress test\n(4)\nFurther diagnostic testing in selected individuals.\nMany middle-aged individuals in the general population can be\nexpected to have some level of subclinical CCS as assessed with\nimaging techniques. Anatomical coronary imaging alone does not\nprovide information relating to the coronary flow and reserve, which\nis important in assessing the risk of Ex-R ischaemia or SCD/SCA;\ntherefore functional evaluation is necessary. Several methods of\nstress testing (e.g. cycle ergometry or treadmill testing), stress echo-\ncardiography, adenosine or dobutamine stress cardiac magnetic reso-\nnance (CMR), or positron emission tomography (PET)/single-photon\nemission computed tomography (SPECT), can be used to detect\ninducible myocardial ischaemia231. Exercise stress-echo is preferred\nin athletes because it is free from radiation and does not involve\nadministration of drugs.\nExercise testing is the most widely available functional test, and\nprovides information on exercise capacity, heart rate, and BP\nresponse, and detection of exercise-induced arrhythmias,2 but has a\nlower specificity for myocardial ischaemia than other functional tests,\nespecially in asymptomatic and low-risk individuals. It is recom-\nmended that a truly maximal exercise test232 (with or without CPET)\nshould be performed when evaluating individuals with possible sub-\nclinical (or clinical) CCS who intend to or are participating in system-\natic exercise including recreational or competitive sports. Whether\nthe initial exercise test includes imaging or not depends on factors\nsuch as the baseline ECG (Table 9) and feasibility of performing func-\ntional imaging tests in a given institute.\n• If the clinical assessment, including a maximal exercise test is nor-\nmal, the presence of ‘relevant CAD’ is assumed to be unlikely\n(Figure 4).\n• In the event of a borderline or uninterpretable exercise test result,\nit is recommended that a more specific imaging stress test is per-\nformed such as stress-echocardiography, CMR perfusion imaging,\nor SPECT. Maximal exercise SPECT and exercise echocardiogra-\nphy or nuclear perfusion techniques utilizing exercise rather than\npharmacological stress may preferentially be used, depending on\navailability and local expertise.\n• If the exercise test is positive, an invasive coronary angiogram\nshould be performed to confirm the presence, extent, and\nseverity of CAD (Figure 4).\n5.1.1.1 Recommendations for sports participation\nIndividuals at risk of CAD and asymptomatic individuals in whom CAD\nis detected at screening should have aggressive management of risk fac-\ntors for atherosclerosis.6,131,132,202 Considering the benefits of exercise\non primary and secondary prevention of CCS,6,234 individuals with risk\nfactors should be restricted from competitive sport only when there is\nsubstantial risk of an adverse event, as indicated by functional tests, or\nwhen there is evidence of disease progression during serial evalua-\ntions.233 Exercise recommendations should be individually tailored\nbased on the intensity of the exercise and the sporting discipline.\nParticipation in competitive endurance, power, and mixed disciplines\n(see sections 4.2 and 5.1.3) generally requires vigorous effort and is\nmore likely to induce myocardial ischaemia, whereas leisure sports or\nintentional recreational exercise allows for greater control of physical\neffort. Individuals with a high risk of atherosclerotic CAD and asympto-\nmatic individuals in whom CAD is detected at screening who partici-\npate in intensive exercise should be assessed with a maximal exercise\ntest or functional imaging test on an annual basis.\nTable 9\nBorderline or uninterpretable ECG ﬁndings\n©ESC 2020\nESC Guidelines\n39\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n...................................................................\n5.1.2 Established (long-standing) chronic coronary\nsyndrome\nAll individuals with established (long-standing) CCS should be\nencouraged to perform the minimal PA recommendations for gen-\neral and CV health.235 This applies to individuals with stable angina,\nasymptomatic and symptomatic individuals stabilized <1 year after\nACS, or individuals with recent revascularization, and asymptomatic\nand symptomatic individuals >1 year after initial diagnosis or revascu-\nlarization.110 Advice on intensive exercise and participation in most\ncompetitive sports in asymptomatic individuals with long-standing\nCCS should be based on several factors, which are determined\nthrough clinical history, exercise stress testing, or functional imaging\nand echocardiography (Table 10).\nIndividuals with long-standing CCS who do not show any abnormal-\nities on a maximal exercise test or functional imaging test, or have\nunimpaired LV function, may be considered as low risk for an exercise-\ninduced adverse event236\u0002238 (Table 11). Such individuals may engage\nin all competitive sports on an individual basis (Figure 5). Some restric-\ntions may apply for high-intensity power, mixed, and endurance sports\n(see Figure 2, section 4.1.2) for older patients (>60 years old) with CCS.\nThis is due to the fact that age is an additional, strong predictor of\nadverse events during exercise. There are no restrictions in low-risk\npatients for skills sports regardless of age (Figure 2).\nIndividuals with inducible ischaemia during functional testing,\ndespite adequate treatment, should undergo coronary angiography;\nthose with high-risk lesions on coronary angiography (Table 11)\nshould have revascularization prior to considering high-intensity\nexercise programmes or competitive sport (Figure 5). Individuals with\nhigh-risk coronary features may gradually return to sport 3\u00026\nmonths after successful revascularization pending a normal maximal\nexercise or functional imaging test.\nWhen ischaemia cannot be treated despite adequate therapy,\nincluding revascularization, the individual should be restricted from\ncompetitive sports, with the possible exception of individually rec-\nommended low-intensity skill sports. Such individuals may engage in\nregular recreational exercise of low and moderate intensity provided\nrisk factors and symptoms are treated adequately and there is regular\nclinical surveillance. These individuals may also participate in leisure\nsports, 2\u00023 times/week, in selected cases, if the intended activity is\nbelow (around 10 beats) the ischaemic threshold and below the level\nof arrhythmias.231\n5.1.2.1 Antithrombotic treatment\nIndividuals with CAD should receive conventional antithrombotic\ntreatment for secondary prevention, according to published guide-\nlines for the general population.233,239,240 Individuals taking dual anti-\nplatelet agents should avoid sports with bodily collision, especially\nwhen they are combined with oral anticoagulants, due to the risk of\nhaemorrhage.241\nRecommendations for exercise in individuals at risk of\natherosclerotic coronary artery disease and asympto-\nmatic individuals in whom coronary artery disease is\ndetected at screening\nRecommendations\nClassa\nLevelb\nAmong individuals with asymptomatic CCS, deﬁned\nas CAD without inducible myocardial ischaemia on\na functional imaging or conventional exercise stress\ntest, 233 participation in all types of exercise, includ-\ning competitive sports, should be considered based\non individual assessment.\nIIa\nC\nCAD = coronary artery disease; CCS = chronic coronary syndrome.\naClass of recommendation.\nbLevel of evidence.\nTable 10\nFactors determining risk of adverse events dur-\ning intensive exercise and competitive sports in asympto-\nmatic individuals with long-standing coronary artery\ndisease\n©ESC 2020\nTable 11\nHigh-risk features for exercise-induced adverse\ncardiac events in patients with atherosclerotic coronary\nartery disease233\n©ESC 2020\nACS = acute coronary syndrome; FFR = fractional ﬂow reserve; iFR = instant\nﬂow reserve; NSVT = non-sustained ventricular tachycardia; PCI = percutaneous\ncoronary intervention.\n40\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n©ESC 2020\nFigure 5 Clinical evaluation and recommendations for sports participation in individuals with established coronary artery disease. CCS = chronic coro-\nnary syndrome; LAD = left anterior descending coronary artery; LM = left main coronary artery; LVEF = left ventricular ejection fraction. *With docu-\nmented ischaemia or a haemodynamically relevant lesion defined by FFR <0.8 or iFR <0.9.\nRecommendations for exercise in individuals with long-standing chronic coronary syndrome\nRecommendations\nClassa\nLevelb\nRisk stratiﬁcation for exercise-induced adverse events is recommended in individuals with established (long-standing) chronic cor-\nonary syndrome (CCS) prior to engaging in exercise.233\nI\nC\nRegular follow-up and risk stratiﬁcation of patients with CCS is recommended.233\nI\nB\nIt is recommended that individuals at high risk of an adverse event from CAD are managed according to the current Guidelines\non CCS.233\nI\nC\nCompetitive or leisure sports activities (with some exceptions such as older athletes and sports with extreme CV demands)\nshould be considered in individuals at low risk of exercise-induced adverse events (Table 11).233\nIIa\nC\nLeisure-time exercise, below the angina and ischaemic thresholds, may be considered in individuals at high risk of exercise-\ninduced adverse events (Table 11), including those with persisting ischaemia.233\nIIb\nC\nCompetitive sports are not recommended in individuals at high risk of exercise-induced adverse events or those with residual\nischaemia, with the exception of individually recommended skill sports.233\nIII\nC\nCAD = coronary artery disease; CCS = chronic coronary syndrome; CV = cardiovascular.\naClass of recommendation.\nbLevel of evidence.\nESC Guidelines\n41\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n....................................................................................................\n5.1.3 Myocardial ischaemia without obstructive disease in\nthe epicardial coronary artery\nIschaemia and non-obstructive CAD (INOCA) is an under-\nrecognized entity associated with increased risk of adverse events242\nthat is usually detected during evaluation of anginal symptoms. Stress\nCMR and PET can detect abnormal coronary flow reserve and sug-\ngest coronary microvascular dysfunction with non-critical lesions.\nThere are no established treatments for microvascular angina.\nHowever, the panel suggests adhering to the same exercise recom-\nmendations as for long-standing CCS.\n5.1.4 Return to sport after acute coronary syndrome\nExercise-based cardiac rehabilitation (exCR) reduces cardiac\nmortality, hospital readmission,234234 and anxiety.243 Individuals\nwho have experienced an ACS, cardiac surgery, or percutaneous\nintervention\nshould\nbe\nreferred\nto\nan\nearly\nexCR\npro-\ngramme,235,242 soon after the discharge,6,235,244 for 8\u000212 weeks\nafter the cardiac event.235,244 Every week that exercise is delayed\nrequires an additional month of exercise to accomplish the same\nlevel of benefit.245\nExercising individuals with CAD may start performing low- to\nmoderate-intensity recreational sporting activities in parallel with\nparticipation in the structured progressive exercise programmes. All\ntypes of sports activities may be considered, at an appropriate inten-\nsity level; however, careful attention should be paid to the develop-\nment of new symptoms.218\nIn general, structured outpatient exercise programmes, for 3\u00026\nmonths, are required to achieve the appropriate level of activity for\nsports participation in patients with CAD. In individuals with non-ST\nsegment elevation MI or CCS who have had complete revascularization\nand do not have residual ischaemia, exercise training can be progressed\nat a faster pace until the recommended exercise level is reached.\n5.1.4.1 Competitive athletes\nCareful individual evaluation is required before starting high-intensity\ncompetitive sports. In competitive athletes, an echocardiogram, max-\nimal exercise test with 12-lead ECG recording or CPET is recom-\nmended for risk stratification before return to sports (see section\n5.1.2). CPET specifically adds information on aerobic and anaerobic\nthresholds, guiding exercise intensity prescription and progression\n(see section 4.2).\n5.1.4.2 Recreational athletes\nFor individuals intending to participate in non-competitive, recrea-\ntional sports and leisure-time activity, similar principles apply\nregarding risk stratification. A symptom-limited/maximal exercise\ntest should precede the return to sports. Higher-risk patients with\nCCS (Table 11) are not eligible for competitive sports (see section\n5.1.2); however, low-intensity skill sports, such as golf, may be\nconsidered, at intensities below the angina threshold. If aerobic\nexercise is not tolerated, predominantly strength-related sports\nwith a small amount of muscular work are recommended\n(Figure 2, section 4.1.2).\n5.1.5 Anomalous origin of coronary arteries\n5.1.5.1 Background\nThe prevalence of AOCA (left and right coronary artery) is 0.44% in\nthe general population of adolescents.246 AOCA is considered to be\na common cause of SCD in young athletes17,18,247,248 but is rarely\nimplicated in individuals >40 years of age.249,250\nChest pain, exertional syncope and SCD may be the first mani-\nfestation of AOCA,251 however, over two thirds of patients are\nasymptomatic.252 Mechanisms leading to SCD likely include\nrepeated bursts of ischaemia with consequent increase in myocar-\ndial fibrosis and a proclivity to develop VAs during exercise.\nIschaemia may result from the compression of the anomalous ves-\nsel coursing between the aorta and the pulmonary artery and/or\nfrom the acute angled take-off from the aorta and/or the proximal\nintramural course of the anomalous vessel (Figure 6).253 Both left\nand right anomalous coronary origins have been implicated in Ex-\nR SCD, although the risk has traditionally been thought to be con-\nsiderably higher with an anomalous left coronary artery origin.252\nExercise testing rarely reveals myocardial ischaemia and multi-\nslice contrast-enhanced CT, CCTA, or CMR are the mainstay of\ndiagnosis.\n5.1.5.2 Eligibility for sports\nEligibility for competitive sports is based on the anatomical\ntype of AOCA and on the presence of ischaemia. A highly posi-\ntive inotropic and positive chronotropic exercise stress test is\nthe best approach to demonstrate or rule out ischaemia. AOCA\nwith acute angled take-off from the aorta resulting in a slit-like\norifice with reduced lumen and anomalous coursing between the\naorta and the pulmonary artery is associated with the greatest\nrisk for SCA/SCD whether or not the anomalous artery origi-\nnates from the left or right sinus of Valsalva, and strong consider-\nation should be given to surgical correction of such an anomaly\nRecommendations for return to exercise after acute\ncoronary syndrome\nRecommendations\nClassa\nLevelb\nExercise-based cardiac rehabilitation is recom-\nmended in all individuals with CAD to reduce\ncardiac mortality and rehospitalization.234\nI\nA\nDuring the initial period, motivational and psy-\nchological support, and individualized recom-\nmendations on how to progress the amount and\nintensity of sports activities, should be consid-\nered in patients with CAD.\nIIa\nB\nAll sports activities should be considered, at an\nindividually adapted intensity level in low-risk\nindividuals with CCS.\nIIa\nC\nCAD = coronary artery disease; CCS = chronic coronary syndrome.\naClass of recommendation.\nbLevel of evidence.\n42\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............\nin symptomatic individuals. Prior to successful correction,\nparticipation in sports, other than low-intensity skill sports, is\ndiscouraged\nregardless\nof\nsymptoms.\nWe\nare\nunable\nto\nprovide exercise or sport recommendations for older patients\n(>40 years) with AOCA, due to the paucity of studies.\nHowever, recreational exercise of moderate intensity seems rea-\nsonable, but a cautious approach is advised to more vigorous\nexercise.\n©ESC 2020\nFigure 6 Schematic representation of the most frequent anomalous origin of coronary arteries and associated risk of sudden cardiac death. RCA = right\ncoronary artery; LMCA = left main coronary artery; LAD = left anterior descending artery; LCCA = left circumflex coronary artery.\nRecommendations for exercise in young individuals/athletes with anomalous origins of coronary arteries\nRecommendations\nClassa\nLevelb\nWhen considering sports activities, evaluation with imaging tests to identify high-risk patterns and an exercise stress test to check for\nischaemia should be considered in individuals with AOCA.\nIIa\nC\nIn asymptomatic individuals with an anomalous coronary artery that does not course between the large vessels, does not have a slit-\nlike oriﬁce with reduced lumen and/or intramural course, competition may be considered, after adequate counselling on the risks,\nprovided there is absence of inducible ischaemia.\nIIb\nC\nAfter surgical repair of an AOCA, participation in all sports may be considered, at the earliest 3 months after surgery, if they are asympto-\nmatic and there is no evidence of inducible myocardial ischaemia or complex cardiac arrhythmias during maximal exercise stress test.\nIIb\nC\nParticipation in most competitive sports with a moderate and high cardiovascular demand among individuals with AOCA with an\nacutely angled take-off or an anomalous course between the large vessels is not recommended.c\nIII\nC\nAOCA = anomalous origin of coronary arteries.\naClass of recommendation.\nbLevel of evidence.\ncThis recommendation applies whether the anomaly is identiﬁed as a consequence of symptoms or discovered incidentally, and in individuals <40 years of age.\nESC Guidelines\n43\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................\n5.1.6 Myocardial bridging\n5.1.6.1 Background\nMyocardial bridging (MB) refers to a condition when some of the\nmyocardium overlies a segment of an epicardial coronary artery\n(referred to as a tunnelled artery) and most commonly affects the\nleft anterior descending artery (Figure 7). The prevalence of MB varies\nfrom 0.5\u000212% and up to 5\u000275% according to diagnostic angiogra-\nphy or CT scan series.254 MBs are traditionally considered as benign;\nhowever, the association between myocardial ischaemia and MBs\nhas increased their clinical relevance. MB may be discovered at\nimaging after an abnormal exercise ECG and should also be sus-\npected in individuals who present with exertional angina or syncope.\nCoronary artery compression together with a Venturi (suction)\neffect are the potential underlying mechanisms for exercise-induced\nischaemia.248\nEvaluation of individuals with MB aims primarily at assessing the\nmorphologic characteristics of the anatomical anomaly (i.e. number\nof MB, depth and overall length of the tunnelled vessel) and the pres-\nence of inducible ischaemia. A positive inotropic and positive chrono-\ntropic stress test is the best approach to demonstrate myocardial\nischaemia. MB without other underlying associated diseases [e.g.\nhypertrophic cardiomyopathy (HCM)] and with no evidence of indu-\ncible myocardial ischaemia has a good prognosis.255 However, in\nadult/senior individuals, it has been shown that the arterial compres-\nsion in MB may be directly related to the atherosclerotic burden,\nproximal to the MB.256 These individuals should be considered in the\nsame category as individuals with CAD and treated appropriately if\nnecessary, although the vast majority of MB is clinically silent. Beta-\nblockers should be used when patients are symptomatic or myocar-\ndial ischaemia is established. Surgical repair may be considered, while\ncoronary stenting is discouraged.255\n5.1.6.2 Eligibility\nPatients with MB and evidence of ischaemia should be restricted\nfrom participation in competitive sports and should receive appropri-\nate advice regarding leisure-time activities.\n5.2 Exercise recommendations in\nindividuals with chronic heart failure\n5.2.1 Background: rationale for exercise in chronic heart\nfailure\nMost of the evidence regarding exercise in chronic heart failure (HF)\nis derived from studies implementing exercise training programmes\nthat are considered safe and highly recommended in stable patients\non optimal medical therapy.257\u0002260Meta-analyses of these studies\nhave demonstrated a significant improvement in exercise tolerance\nand quality of life and a modest effect on all-cause and HF-specific\nmortality and hospitalization.261\u0002267\n5.2.2 Risk stratification and preliminary evaluation\nExercise intervention should only be initiated in a clinically stable indi-\nvidual after medical therapy for HF has been optimized. Key compo-\nnents before commencing an exercise programme and sports\nparticipation include:\n(1)\nExclusion of contraindications to exercise: Contraindications to initiating\nan exercise programme in chronic HF include hypotension or\nhypertension at rest or during exercise, unstable cardiac disease,\ndeteriorating symptoms of HF, myocardial ischaemia despite ther-\napy (exercise may be permitted up to ischaemic threshold), or\nsevere and suboptimally treated pulmonary disease.258\n(2)\nPerforming a baseline assessment: A thorough cardiological evaluation\nis required, including assessment of comorbidities and HF severity\n(e.g. by assessment of blood natriuretic peptides and echocardiogra-\nphy). A maximal exercise test (preferably CPET) is important to\nassess functional capacity, exercise-induced arrhythmias or haemo-\ndynamic abnormalities and for prescription of exercise intensity,\nbased on VO2peak, or on resting and maximal heart rate during exer-\ncise [e.g. HRR or Borg’s rating of perceived exertion (RPE)].265,266\n(3)\nOptimizing medical therapy: All individuals with HF should be treated\naccording to current Guidelines,257 including device implantation\nwhen required.267\n©ESC 2020\nFigure 7 Schematic representation of a myocardial bridge. LAD = left\nanterior descending coronary artery.\nRecommendations for exercise/sports in individuals\nwith myocardial bridging\nRecommendations\nClassa\nLevelb\nParticipation in competitive and leisure-time\nsports should be considered in asymptomatic\nindividuals with myocardial bridging and without\ninducible ischaemia or ventricular arrhythmia\nduring maximal exercise testing.\nIIa\nC\nCompetitive sports are not recommended in\nindividuals with myocardial bridging and persis-\ntent ischaemia or complex cardiac arrhythmias\nduring maximal exercise stress testing.\nIII\nC\naClass of recommendation.\nbLevel of evidence.\n44\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n..................................................................................\nThe exercise session should be individually tailored for several\nweeks, according to symptoms and objective findings during exercise\ntesting such as maximal exercise capacity, heart rate response, or\narrhythmias. In atrial fibrillation (AF), exercise can only be monitored\nby power or Borg’s RPE.\nHigh-risk patients should be counselled more frequently during the\ninitial phases. Ideally exercise should be supervised through an exercise-\nbased cardiac rehabilitation programme while non-supervised home-\nbased sessions should be gradually added.260 When all these measures\nare followed, the overall risk of exercise is low, even during higher-\nintensity exercises and in patients with more severe HF.268,269\nFollow-up examinations for exercise recommendations should be\nscheduled at least every 3\u00026 months. Intervals between examinations\nshould depend on disease severity and comorbidities, setting of the\nsessions (supervised vs. home-based), patient’s age and adherence.\n5.2.3 Exercise modalities and sports participation in heart\nfailure\nFollowing risk factor control and therapy optimization, the individual\nwith HF should be encouraged to start exercise programmes without\ndelay.242,244,270 Initially home-based exercise programmes may also\nbe prescribed and monitored.270,271\nIn uncomplicated cases low to moderate-intensity recreational\nsporting activities may be considered in parallel to the structured\nexercise programme. When prescribed, maximal exercise intensities\nshould be monitored, for example, by heart rate monitors. If moni-\ntoring does not reveal any exercise-induced arrhythmias or other\nabnormalities, then all types of recreational sports activities are per-\nmitted (see Figure 2, section 4.1.2).\n5.2.3.1 Aerobic/endurance exercise\nAerobic exercise is recommended for stable patients [New York\nHeart Association (NYHA) class I\u0002III], because of its well-\ndemonstrated efficacy and safety.260 Recommendations on optimal\nexercise dose have been previously described in ESC and AHA\nGuidelines.242,270\u0002272 The most commonly evaluated exercise mode\nis moderate continuous exercise (MCE).242,270\u0002272 In patients in\nNYHA functional class III, exercise intensity should be maintained at a\nlower intensity (<40% of VO2peak), according to perceived symptoms\nand clinical status during the first 1\u00022 weeks. This should be followed\nby a gradual increase in intensity to 50\u000270% VO2peak, and if toler-\nated, up to 85% VO2peak as the primary aim.270,271\nRecently, high-intensity interval training (HIIT) programmes have\nbeen considered as an alternative exercise modality for low-risk\npatients.269 The most recent meta-analysis showed that HIIT was supe-\nrior to MCE in improving VO2peak in individuals with HF with reduced\n(<40%) ejection fraction (HFrEF) in the short term.273 However, this\nsuperiority\ndisappeared\nin\nsubgroup\nanalysis\nof\nisocaloric\nprotocols. HITT programmes may be recommended initially to prepare\nlow risk patients with stable HF who want to return to high intensity\naerobic and mixed endurance sports (Figure 2, section 4.1.2).\n5.2.3.2 Resistance exercise\nResistance exercise training may complement, but not substitute,\naerobic exercise training because it reverses skeletal muscle mass\nloss and deconditioning without excessive stress on the heart.270,274\nThe training intensity can preferably be set at the level of resistance\nat which the patient can perform 10\u000215 repetitions at 15 on Borg’s\nRPE scale (Table 12).242,270 In patients with altered skeletal muscle\nfunction and muscle wasting, exercise training should focus initially\non increasing muscle mass by using resistance programmes.275,276\nResistance programmes may specifically be considered for low-\nrisk stable patients, who want to return to strength-related power\nsports, e.g. weightlifting (Figure 2, section 4.1.2). A meta-analysis\nshowed that resistance exercise as a single intervention has the\ncapacity to increase muscle strength, aerobic capacity, and quality of\nlife in HFrEF patients who are unable to participate in aerobic exer-\ncise programmes.277 Also, in advanced HF or in patients with very\nlow exercise tolerance, resistance exercise can be safely applied if\nsmall muscle groups are trained.270,277,278\n5.2.3.3 Respiratory exercise\nInspiratory muscle training improves VO2peak, dyspnoea, and muscle\nstrength,279\u0002282 and it typically involves several sessions per week\nwith intensity ranging from 30% to 60% of maximal inspiratory pres-\nsure, and duration from 15\u000230 min for an average of 10\u000212\nweeks.279 This training modality should be recommended to the\nmost severely deconditioned individuals as an initial alternative who\nmay then transition to conventional exercise training and sports par-\nticipation, to optimize cardiopulmonary benefits.280\n5.2.3.4 Aquatic exercise\nAquatic exercise has not been recommended for individuals\nwith HF, due to concerns that the increase in central blood\nTable 12\nOptimal exercise training dose for patients\nwith chronic heart failure\n©ESC 2020\n1 RM = one repetition maximum; RPE = rating of perceived exertion; VO2peak =\npeak oxygen consumption.\nESC Guidelines\n45\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.................................................................................................\nvolume and cardiac preload as a consequence of hydrostatic\npressure may not be tolerated.283 However, a recent meta-analysis\nhas shown that aquatic exercise training may be safe and clinically\neffective.284\n5.2.4 Sports participation and return to sports\nIn addition to risk stratification (section 5.2.3), the evaluation for par-\nticipation in sports includes intensity and type of sports (competitive\nvs. recreational), and determining the individual fitness level.\n5.2.4.1 Competitive sports\nParticipation in competitive sports may be considered in a group\nof selected low-risk individuals. A thorough individual evaluation\nusing a maximal exercise test (or preferably CPET) is recom-\nmended before returning to sports, particularly before starting\nmoderate- to high-intensity sports, mixed and power sports\n(Figure 2, section 4.1.2).\nAsymptomatic individuals with preserved (>_50%) EF (HFpEF) or\nwith mid-range (>_40\u000259%) EF (HFmrEF) who are optimally treated\nmay be eligible to participate in some competitive sports in the\nabsence of exercise-induced arrhythmias or exercise-induced hypo-\ntension. In such cases, a progressive increase in exercise dose is rec-\nommended. The duration of this process is dependent upon the\nfunctional capacity and perceived symptoms. Some restrictions may\napply to high-intensity endurance, mixed and power sports with high\ndemands, especially in older patients. No restrictions should apply\nfor skill-related sports.\nAsymptomatic patients with HFrEF who are optimally treated\nmay only be considered safe to perform specific low-intensity skill\nsports at a competitive level (Figure 2). Higher-risk patients includ-\ning those who are suboptimally treated, those that remain in\nNYHA II or III despite optimal therapy, and those with exercise-\ninduced arrhythmias or exercise-induced hypotension should not\nparticipate in competitive sports, particularly those sports with\nmoderate to high cardiopulmonary strain during training or\ncompetition.\n5.2.4.2 Recreational sports\nFor patients intending to participate in recreational sports and\nleisure-time activity, similar principles apply regarding risk stratifica-\ntion. A progressive increase in exercise dose is recommended. Low-\nto moderate-intensity skill, power, mixed, and endurance sports may\nbe considered in all asymptomatic individuals.\nAs with competitive sports, high-intensity recreational sports\nshould only be considered in asymptomatic individuals with HFmrEF\n(EF 40\u000249%) who do not have exercise-induced arrhythmias or\nexercise-induced hypotension. Asymptomatic individuals with HFrEF\nwho are optimally treated may engage in low- to moderate-intensity\nskill-related recreational sports, and selectively in low-intensity\nendurance sports (Figure 2).\nIn patients with HFrEF with very low exercise tolerance, frequent\ndecompensation,\nor\npatients\nwith\nLV\nassist\ndevices\n(see\nSupplementary Data), participation in low-intensity skill-related sports\nis possible, if tolerated. Regular low-intensity endurance activities, e.g.\nwalking or cycling, should generally be recommended to improve\nbasic exercise capacity.\nRecommendations for exercise prescription in heart\nfailure with reduced or mid-range ejection fraction\nRecommendations\nClassa\nLevelb\nRegular discussion about exercise participation\nand provision of an individualized exercise pre-\nscription is recommended in all individuals with\nheart failure.260,261,285\nI\nA\nExercise-based cardiac rehabilitation is recom-\nmended in all stable individuals to improve exer-\ncise capacity, quality of life, and to reduce the\nfrequency of hospital readmission.260,261,285\nI\nA\nBeyond annual cardiac assessment, clinical reas-\nsessment should be considered when the inten-\nsity of exercise is increased.\nIIa\nC\nMotivational and psychological support and indi-\nvidualized recommendations on how to progress\nthe amount and intensity of sports activities\nshould be considered.\nIIa\nC\nLow- to moderate-intensity recreational sport-\ning activities and participation in structured exer-\ncise programmes may be considered in stable\nindividuals.\nIIb\nC\nHigh-intensity interval training programmes may\nbe considered in low-risk patients who want to\nreturn to high-intensity aerobic and mixed\nendurance sports.\nIIb\nC\naClass of recommendation.\nbLevel of evidence.\nRecommendations for participation in sports in heart\nfailure\nRecommendations\nClassa\nLevelb\nBefore considering a sport activity, a preliminary\noptimization of heart failure risk factor control\nand therapy, including device implantation (if\nappropriate), is recommended.\nI\nC\nParticipation in sports activities should be con-\nsidered in individuals with heart failure who are\nat low risk, based on a complete assessment and\nexclusion of all contraindications, in stable condi-\ntion for at least 4 weeks, optimal treatment, and\nNYHA functional class I status.\nIIa\nC\nNon-competitive (low- to moderate-intensity rec-\nreational) skill, power, mixed, or endurance sports\nmay be considered in stable, asymptomatic, and\noptimally treated individuals with HFmrEF.\nIIb\nC\nHigh-intensity recreational sports, adapted to\nthe capabilities of the individual patient, may be\nconsidered in selected stable, asymptomatic, and\noptimally treated individuals with HFmrEF with\nan age-matched exercise capacity beyond\naverage.\nIIb\nC\nContinued\n46\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 21",
          "page": 21,
          "content": " |  | Levelb\nRecommendations | Classa | \n |  | \nIn obese individuals (BMI>30 kg/m2 or a waist cir-\n_\ncumference >80 cm for females or >94 cm for\nmales) resistance training >3 times per week, in\n_\naddition to moderate or vigorous aerobic exercise\n(at least 30 min, 5\u00027 days per week) is recom-\nmended to reduce CVD risk.121 | I | A\nIn individuals with well-controlled hypertension,\nresistance training >3 times per week in addition to\n_\nmoderate or vigorous aerobic exercise (at least 30\nmin, 5\u00027 days per week) is recommended to\nreduce blood pressure and CVD risk. 132 | I | A\nAmong individuals with diabetes mellitus, resistance\ntraining >3 times per week in addition to moderate\n_\nor vigorous aerobic exercise (at least 30 min, 5\u00027\ndays per week) is recommended to improve insulin\nsensitivity and achieve a better CVD risk\nprofile.176,178 | I | A\nAmong adults with well-controlled hypertension\nbut high risk and/or target organ damage, high-inten-\nsity resistance exercise is not recommended. | III | C\nIn individuals with uncontrolled hypertension\n(SBP>160 mmHg) high-intensity exercise is not rec-\nommended until blood pressure has been\ncontrolled. | III | C",
          "rows": 8,
          "cols": 3
        },
        {
          "title": "Table on page 22",
          "page": 22,
          "content": " | \nRecommendations | Classa Levelb\n | \nAmong adults aged 65 yea\nfit and have no health con\ntheir mobility, moderate-i\nexercise for at least 150 m\nrecommended.212,214,215 | rs or older who are\nditions that limit\nntensity aerobic I A\nin/week is\nIn older adults at risk of fa\nexercises to improve bala\ntion on at least 2 days a w\nrecommended.201,212,214,2 | lls, strength training\nnce and coordina-\nI B\neek are\n15\nA full clinical assessment i\nexercise test should be co\ntary adults aged 65 years\nparticipate in high-intensit | ncluding a maximal\nnsidered in seden-\nIIa C\nor older who wish to\ny activity.\nContinuation of high- and\nactivity, including competi\nconsidered in asymptoma\n(master athletes) at low o | very high-intensity\ntive sports, may be\nIIb C\ntic elderly athletes\nr moderate CV risk.",
          "rows": 7,
          "cols": 2
        },
        {
          "title": "Table on page 24",
          "page": 24,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nAmong individuals with asymptomatic CCS, defined\nas CAD without inducible myocardial ischaemia on\na functional imaging or conventional exercise stress\ntest, 233 participation in all types of exercise, includ-\ning competitive sports, should be considered based\non individual assessment. | IIa | C",
          "rows": 4,
          "cols": 3
        },
        {
          "title": "Table on page 25",
          "page": 25,
          "content": " | \nRecommendations | Classa Levelb\n | \nRisk stratification for exercise-induced adverse events is recommended in individuals with established (long-\nonary syndrome (CCS) prior to engaging in exercise.233 | standing) chronic cor-\nI C\nRegular follow-up and risk stratification of patients with CCS is recommended.233 | I B\nIt is recommended that individuals at high risk of an adverse event from CAD are managed according to the\non CCS.233 | current Guidelines\nI C\nCompetitive or leisure sports activities (with some exceptions such as older athletes and sports with extrem\nshould be considered in individuals at low risk of exercise-induced adverse events (Table 11).233 | e CV demands)\nIIa C\nLeisure-time exercise, below the angina and ischaemic thresholds, may be considered in individuals at high ri\ninduced adverse events (Table 11), including those with persisting ischaemia.233 | sk of exercise-\nIIb C\nCompetitive sports are not recommended in individuals at high risk of exercise-induced adverse events or t\nischaemia, with the exception of individually recommended skill sports.233 | hose with residual\nIII C",
          "rows": 9,
          "cols": 2
        },
        {
          "title": "Table on page 26",
          "page": 26,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nExercise-based cardiac rehabilitation is recom-\nmended in all individuals with CAD to reduce\ncardiac mortality and rehospitalization.234 | I | A\nDuring the initial period, motivational and psy-\nchological support, and individualized recom-\nmendations on how to progress the amount and\nintensity of sports activities, should be consid-\nered in patients with CAD. | IIa | B\nAll sports activities should be considered, at an\nindividually adapted intensity level in low-risk\nindividuals with CCS. | IIa | C",
          "rows": 6,
          "cols": 3
        },
        {
          "title": "Table on page 27",
          "page": 27,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nWhen considering sports activities, evaluation with imaging tests to identify high-risk patterns and an exercise stress test to check for\nischaemia should be considered in individuals with AOCA. | IIa | C\nIn asymptomatic individuals with an anomalous coronary artery that does not course between the large vessels, does not have a slit-\nlike orifice with reduced lumen and/or intramural course, competition may be considered, after adequate counselling on the risks,\nprovided there is absence of inducible ischaemia. | IIb | C\nAfter surgical repair of an AOCA, participation in all sports may be considered, at the earliest 3 months after surgery, if they are asympto-\nmatic and there is no evidence of inducible myocardial ischaemia or complex cardiac arrhythmias during maximal exercise stress test. | IIb | C\nParticipation in most competitive sports with a moderate and high cardiovascular demand among individuals with AOCA with an\nacutely angled take-off or an anomalous course between the large vessels is not recommended.c | III | C",
          "rows": 7,
          "cols": 3
        },
        {
          "title": "Table on page 28",
          "page": 28,
          "content": " |  | Levelb\nRecommendations | Classa | \n |  | \nParticipation in competitive and leisure-time\nsports should be considered in asymptomatic\nindividuals with myocardial bridging and without\ninducible ischaemia or ventricular arrhythmia\nduring maximal exercise testing. | IIa | C\nCompetitive sports are not recommended in\nindividuals with myocardial bridging and persis-\ntent ischaemia or complex cardiac arrhythmias\nduring maximal exercise stress testing. | III | C",
          "rows": 5,
          "cols": 3
        },
        {
          "title": "Table on page 30",
          "page": 30,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nRegular discussion about exercise participation\nand provision of an individualized exercise pre-\nscription is recommended in all individuals with\nheart failure.260,261,285 | I | A\nExercise-based cardiac rehabilitation is recom-\nmended in all stable individuals to improve exer-\ncise capacity, quality of life, and to reduce the\nfrequency of hospital readmission.260,261,285 | I | A\nBeyond annual cardiac assessment, clinical reas-\nsessment should be considered when the inten-\nsity of exercise is increased. | IIa | C\nMotivational and psychological support and indi-\nvidualized recommendations on how to progress\nthe amount and intensity of sports activities\nshould be considered. | IIa | C\nLow- to moderate-intensity recreational sport-\ning activities and participation in structured exer-\ncise programmes may be considered in stable\nindividuals. | IIb | C\nHigh-intensity interval training programmes may\nbe considered in low-risk patients who want to\nreturn to high-intensity aerobic and mixed\nendurance sports. | IIb | C",
          "rows": 9,
          "cols": 3
        },
        {
          "title": "Table on page 30",
          "page": 30,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nBefore considering a sport activity, a preliminary\noptimization of heart failure risk factor control\nand therapy, including device implantation (if\nappropriate), is recommended. | I | C | \nParticipation in sports activities should be con-\nsidered in individuals with heart failure who are\nat low risk, based on a complete assessment and\nexclusion of all contraindications, in stable condi-\ntion for at least 4 weeks, optimal treatment, and\nNYHA functional class I status. | IIa | C | \nNon-competitive (low- to moderate-intensity rec-\nreational) skill, power, mixed, or endurance sports\nmay be considered in stable, asymptomatic, and\noptimally treated individuals with HFmrEF. | IIb | C | \nHigh-intensity recreational sports, adapted to\nthe capabilities of the individual patient, may be\nconsidered in selected stable, asymptomatic, and\noptimally treated individuals with HFmrEF with\nan age-matched exercise capacity beyond\naverage. | IIb | C | ",
          "rows": 7,
          "cols": 4
        }
      ],
      "keywords": [
        "moderate",
        "intervention",
        "ct",
        "caloric",
        "inadequate",
        "hypoglycaemia",
        "importantly",
        "risk",
        "intake",
        "event"
      ]
    },
    {
      "number": "4",
      "title": "5.2.5 Heart failure with preserved ejection fraction",
      "start_page": 31,
      "end_page": 40,
      "content": ".......................................................................................................................\n5.2.5 Heart failure with preserved ejection fraction\nExercise-based cardiac rehabilitation programmes are a cornerstone\nin the holistic prevention and management of HFpEF.260,285 Exercise\nintervention for 12\u000224 weeks increases functional capacity and qual-\nity of life.286\u0002292 The beneficial effects seem to be mediated by\nimprovement in oxidative muscle metabolism and vascular func-\ntion.293 In obese patients, weight reduction has been shown to have\nsimilar effects to exercise alone,288 therefore a stable weight reduc-\ntion of 10% over 2\u00024 years is recommended.294\n5.2.5.1 Exercise modalities and sports participation\nHigher endurance intensities such as HIIT (4 \u0003 4 min at 85\u000290%\npeak heart rate, with 3 min active recovery) have revealed positive\neffects on myocardial function, but data are limited to a small group\nof patients with diabetes.295 HIIT performed over 4 weeks signifi-\ncantly improved VO2peak and LV diastolic function.296 Higher-\nintensity exercise should be limited to stable patients and could be\ngradually introduced after 4 weeks of MCE.\nExercise sessions should start with short phases of 10 min of\nendurance and 10 min of resistance exercises, which should gradually\nbe extended in time over a period of 4 weeks. The final aim should\nbe at least 30\u000245 min for >_3 days per week. Depending on the\npatient’s symptomatic status and functional capacity, intervals of\nhigher intensity may be introduced.\nDuration of intervention seems to be important for inducing func-\ntional and structural CV changes in HFpEF. Interventions over 2 years\nin healthy individuals reversed early signs of diastolic dysfunc-\ntion.297,298 Regarding sports participation refer to section 5.2.3.\n5.2.6 Exercise in individuals after heart transplantation\nThe exercise capacity in heart transplantation (HTx) recipients is\nreduced by 50\u000260% compared with healthy age and sex-matched\nindividuals in the general population,300\u0002302 due to several factors\n(Table\n13).303\nExercise\nreduces\nCV\nrisk\ninduced\nby\npost-\ntransplantation\nimmunosuppressive\nmedical\ntherapy,304\nand\nincreases physical performance,305 enabling HTx patients to achieve\nlevels comparable to age-matched controls.306 HTx recipients partic-\nipating in exercise-based cardiac rehabilitation programmes reveal a\nfavourable outcome with respect to hospital readmission and long-\nterm survival.305,307,308\nImprovements in exercise capacity are primarily dependent on the\nvolume of exercise. Increased functional capacity is primarily due to\nperipheral adaptations in the skeletal muscle including increased oxi-\ndative capacity and capillary conductance. Cardiac allograft neural\nreinnervation also contributes to improved functional capacity in the\nfirst year.304,309,310 If these occur, training can be performed at high\nlevels, enabling selected HTx patients to perform marathon runs or\ntriathlons.304,309,310\n5.2.6.1 Exercise modalities and sports participation\nA combination of endurance and resistance exercise is considered\nto be the preferred exercise programme. Mean endurance\nexercise intensity should start at a moderate intensity (60% VO2peak),\nwhich can later be increased to 80% of VO2peak, a regimen level\napplied in the majority of exercise intervention studies in HTx.305 In\nuncomplicated cases these intensities can be increased to maximum\nlevels.\nIt is recommended that individuals should perform up to five\nbouts of 30 min of exercise per week; however, exercise duration\nand frequency have ranged from 30 min to 90 min for 2 to 5 times\nper week, in previous HTx studies.305,311 Both endurance and resist-\nance training is included in these training sessions; however, an addi-\ntional 2\u00023 sessions of resistance training may be performed\neach week.\nResistance exercise should focus on large muscle groups using\nown body weight exercises or exercises on weight machines. Upper\nbody resistance exercise should start at least 3 months after surgery,\nand intensity should gradually increase from low to moderate but can\nNon-competitive (low-intensity recreational\nskill-related sports) may be considered (when\ntolerated) in stable, optimally treated individuals\nwith HFrEF.\nIIb\nC\nHigh-intensity power and endurance sports are\nnot recommended in patients with HFrEF irre-\nspective of symptoms.\nIII\nC\nHFmrEF = heart failure with mid-range ejection fraction; HFrEF = heart failure\nwith reduced ejection fraction; NYHA = New York Heart Association.\naClass of recommendation.\nbLevel of evidence.\nRecommendations for exercise and participation in\nsport in individuals with heart failure with preserved\nejection fraction\nRecommendations\nClassa\nLevelb\nModerate endurance and dynamic resistance\nexercise, together with lifestyle intervention and\noptimal treatment of cardiovascular risk factors\n(i.e. arterial hypertension and type 2 diabetes)\nare recommended.287,289\u0002292,299\nI\nC\nCompetitive sports may be considered in\nselected stable patients without abnormalities\non maximal exercise testing.\nIIb\nC\naClass of recommendation.\nbLevel of evidence.\nRefer also to the recommendation in section 5.2.5.\nTable 13\nFactors inﬂuencing decreased exercise capacity\n(peak VO2) and reduced cardiac output in individuals with\nheart transplants\n©ESC 2020\nESC Guidelines\n47\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\nalso be performed up to submaximal intensities, in case of uncompli-\ncated disease (see section 4.1.1).\nA major limitation of endurance exercise is the reduced chrono-\ntropic response to exercise because of allograft denervation. Apart\nfrom chronotropic incompetence, other pathophysiological changes\npresent after HTx should also be considered when prescribing and\nconducting an exercise programme (Table 13). Exercise-induced\nischaemia from cardiac allograft vasculopathy should be considered,\nparticularly when performing higher-intensity exercise, which has\nbeen advocated to have some superior effects on improving exercise\ncapacity in these patients.311,312\nFeasibility and safety of sports participation in stable asymptomatic\nHTx patients, after therapy optimization, has been reported.\nTherefore, participation in competitive sports, avoiding high-intensity\npower and endurance disciplines, may be considered in selected\nindividuals.\n5.3 Exercise recommendations\nin individuals with valvular heart\ndisease\n5.3.1 Introduction\nValvular heart disease affects approximately 1\u00022% of young exer-\ncising individuals in the general population. Reports on the natural\nhistory of valvular heart disease in athletes are sparse; however,\nthere is a theoretical possibility that a large stroke volume, coupled\nwith vigorous mechanical contractions of the heart, and an\nincreased chronotropic state induced by exercise may accelerate\nvalve dysfunction. The ensuing effects on chronic stenotic or\nregurgitant lesions may cause compensatory cardiac hypertrophy,\nimpaired ventricular function,\nmyocardial\nischaemia, cardiac\narrhythmias, and possibly SCD.\n5.3.1.1 General principles in assessment and risk stratification of individ-\nuals with valvular heart disease prior to leisure exercise or competitive\nsports\nThere are no prospective studies examining the impact of exercise\non the progression of valvular disease; therefore, general guidance\npresented in this section is based on consensus opinions and long-\nterm follow-up studies from non-athletic populations. Most individu-\nals with valvular heart disease are asymptomatic or mildly sympto-\nmatic and some may aspire to engage in regular exercise\nprogrammes including leisure and competitive sports. The manage-\nment of these individuals requires assessment of the symptomatic\nstatus, functional capacity, the nature of the valvular lesion, and\nimpact of the resulting loading conditions on cardiac structure and\nfunction. All individuals should be assessed with a clinical history,\nphysical examination, ECG, echocardiography, and exercise stress\ntest. The clinical history should enquire about cardiac symptoms and\nfunctional capacity. Echocardiography should focus on the valve mor-\nphology and function with particular attention to the severity and the\nimpact of cardiac chamber size and function. Exercise testing should\nresemble the intensity of the sport being engaged in and should focus\non inducibility of symptoms, arrhythmias, myocardial ischaemia, and\nthe haemodynamic (BP) response to exercise. Some individuals may\nrequire exercise echocardiography to assess the severity of the valve\ndefect.\nAsymptomatic individuals with mild to moderate valvular dysfunc-\ntion who have preserved ventricular function and show good func-\ntional capacity without exercise-inducible myocardial ischaemia,\nabnormal haemodynamic response, or arrhythmias are considered\nto be at low risk and may participate in all sports. Indeed, mild valvular\nregurgitation (mostly tricuspid and pulmonary) are common among\ntrained athletes and likely represent a feature of the athlete’s heart.\nConversely, individuals with exertional symptoms, moderate or\nsevere valvular dysfunction, left or right ventricular dysfunction, pul-\nmonary hypertension, and exercise-induced cardiac arrhythmias or\nabnormal haemodynamic response are considered to be at high risk\nand should be considered for invasive intervention.\n5.3.1.2 Surveillance\nAll individuals with valvular heart disease should be assessed on a reg-\nular basis. The frequency of the assessment may vary from 6 monthly\nto 2 yearly depending on symptomatic status and the severity of valve\ndysfunction.\n5.3.2 Aortic valve stenosis\nAortic valve stenosis (AS) is most frequently the result of an age-\ndependent degenerative process causing progressive thickening, cal-\ncification, and reduced mobility of the cusps.313 AS causes an increase\nin transvalvular pressure gradient and LV workload, with consequent\nLV hypertrophy, fibrosis, and increased myocardial oxygen demand.\nLeft ventricular ejection fraction (LVEF) is usually preserved. Affected\nindividuals may have a normal cardiac output at rest and even during\nexercise, therefore, some individuals with AS are capable of good\nexercise performance. Nonetheless, severe AS is associated with\nincreased risk of heart failure and SCD from mechanical outflow\nobstruction, malignant VAs, or coronary hypoperfusion.18,314\nThe diagnosis and grading of AS during echocardiography is based\non well-established criteria.315 Specifically, severe AS is defined by: (i)\nRecommendations for exercise and participation in\nsport in heart transplant recipients\nRecommendations\nClassa\nLevelb\nRegular exercise through cardiac rehabilitation,\ncombining moderate-intensity aerobic and resist-\nance exercise, is recommended to revert patho-\nphysiology to pre-transplantation time, reduce\ncardiovascular risk induced by post-transplanta-\ntion medical treatment, and improve clinical\noutcome.305\u0002312\nI\nB\nRecreational (low-intensity recreational) sports\nparticipation should be considered and encour-\naged in stable, asymptomatic individuals after\ntherapy optimization.\nIIa\nC\nEligibility for competitive sports involving low-\nand moderate-intensity exercise may be consid-\nered in selected, asymptomatic individuals with\nan uncomplicated follow-up.304,309,310\nIIb\nC\naClass of recommendation.\nbLevel of evidence.\n48\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................\na transvalvular Doppler velocity >_4.0 m/s; (ii) a mean gradient >_40\nmmHg; and (iii) a calculated aortic valve area <1.0 cm2 or an indexed\narea (recommended in athletes) <0.6 cm2/m2.315 In cases with a low\ngradient (<40 mmHg) and calculated valve area <1.0 cm2, with EF <\n50% and stroke volume index <35 mL/m2, low-dose dobutamine\nstress echocardiography is recommended to identify pseudo-severe\nAS or true severe AS.315,316 Assessment of the aortic valve calcium\nscore with CT can be useful in borderline cases where the severity of\nAS remains unclear.313,316\nExercise testing is particularly important to assess the haemody-\nnamic response in AS and to serve as a guide to exercise prescription\nin cases of asymptomatic moderate and severe AS. A progressive\ndrop in SBP with exercise, or failure to increase SBP by at least 20\nmmHg, identifies subjects at higher risk.317Exercise-induced ventricu-\nlar tachycardia should also be considered a criterion for exercise\nrestrictions.\nAsymptomatic individuals with mild AS may participate in all\nsports. Asymptomatic athletes with severe AS should not participate\nin any competitive or leisure sports with the exception of low-\nintensity skill sports. However, low-intensity aerobic exercise could\nbe encouraged in asymptomatic individuals to improve functional\ncapacity and general well-being.\nIndividuals with symptomatic AS should not participate in any\ncompetitive sport or recreational sport/exercise and valve replace-\nment is recommended. Mild exercise, that does not provoke symp-\ntoms, may be considered in these individuals for general health\nbenefits.\n5.3.3 Aortic valve regurgitation\nAortic valve regurgitation (AR) is usually caused by a congenitally\nabnormal valve (i.e. bicuspid valve), degeneration of a tricuspid valve,\nor loss of coaptation due to aortic root enlargement.313,318 Less\ncommon causes of AR include infective endocarditis or aortic\ndissection.\nThe haemodynamic consequence of chronic AR is characterized\nby a pressure and volume overload that typically leads to a dilated\nand hypertrophied LV. To accommodate the concomitant forward\nflow from the mitral valve and the backward flow from the aortic\nvalve during diastole, the LV progressively increases in size and mass.\nThis remodelling may occasionally be difficult to distinguish from car-\ndiac adaptation in athletes, especially in males with a large body size\nwho engage in endurance activities, and therefore LV size should be\ninterpreted in the context of the sport participated in, and the gender\nand body surface area of the individual.319 Males with a LV end-\ndiastolic diameter >35 mm/m2 or a LV end-systolic diameter >50\nmm, and females with a LV end-diastolic diameter >40 mm/m2 or a\nLV end-systolic diameter >40 mm, should be considered to have\npathological LV enlargement, irrespective of the level of physical\ntraining. These individuals should be closely monitored for a progres-\nsive increase in LV end-systolic diameter.\nIn individuals with suboptimal echocardiographic images, CMR has\nthe advantages of providing an accurate assessment of LV volume\nand EF, flow calculations and detecting the presence of myocardial\nscar,319 in individuals with severe AR. Furthermore, the whole thora-\ncic aorta can be visualized during the same examination.\nAsymptomatic individuals with mild and moderate AR may partici-\npate in all sports. Asymptomatic individuals with severe AR, moder-\nately dilated LV, and good LV systolic function may participate in\nRecommendations for exercise and participation in rec-\nreational/leisure-time sports in asymptomatic individu-\nals with aortic stenosis\nAortic stenosisc\nRecommendation\nClassa\nLevelb\nMild\nParticipation in all recreational\nsports, if desired, is recommended.\nI\nC\nModerate\nParticipation in all recreational\nsports involving low to moderate\nintensity, if desired, should be con-\nsidered in individuals with\nLVEF>_50%, good functional\ncapacity, and normal exercise test.\nIIa\nC\nSevere\nParticipation in all recreational\nsports/exercise involving low inten-\nsity, if desired, may be considered in\nindividuals with LVEF>_50% and nor-\nmal BP response during exercise.\nIIb\nC\nParticipation in competitive or rec-\nreational sports/exercise of moder-\nate and high intensity is not\nrecommended.\nIII\nC\nBP = blood pressure; LVEF = left ventricular ejection fraction.\naClass of recommendation.\nbLevel of evidence.\ncFor mixed valvular disease, the recommendation for the predominant lesion\n(stenotic or regurgitant) should be followed.\nRecommendations for participation in competitive\nsports in asymptomatic individuals with aortic stenosis\nAortic stenosisc\nRecommendation\nClassa\nLevelb\nMild\nParticipation in all competitive\nsports, if desired, is recommended.\nI\nC\nModerate\nParticipation in all competitive\nsports involving low to moderate\neffort, if desired, may be considered\nin individuals with LVEF>_50%, good\nfunctional capacity, and normal BP\nresponse during exercise.\nIIb\nC\nSevere\nParticipation in low-intensity skill\nsports may be considered in a select\ngroup of individuals with LVEF>_50%.\nIIb\nC\nParticipation in sports or exercise of\nmoderate or high intensity is not\nrecommended.\nIII\nC\nBP = blood pressure; LVEF = left ventricular ejection fraction.\naClass of recommendation.\nbLevel of evidence.\ncFor mixed valvular disease, the recommendation for the predominant lesion\nshould be followed.\nESC Guidelines\n49\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n......................................................\nsports involving low and moderate intensity and may be considered\nfor more intensive exercise on an individual basis. Such individuals\nrequire more frequent surveillance on a 6-monthly basis to assess LV\nfunction. In asymptomatic individuals with severe AR and reduced\nLVEF, surgical valve replacement/repair is indicated, and they should\nnot participate in competitive sports but may participate in leisure\nsports involving only low-intensity exercise. Surgery is recommended\nin symptomatic individuals with severe AR. These individuals should\nnot participate in competitive or leisure sports; however, low-\nintensity aerobic exercise activity is encouraged to improve func-\ntional capacity and general well-being.\n5.3.4 Bicuspid aortic valve\nBicuspid aortic valve (BAV) is a common congenital abnormality with\na prevalence of 1\u00022% in the general population.320 BAV may be\nassociated with AS or AR and increased risk for ascending aortic\naneurysm or dissection, and SCD.28,321 Compared with Marfan\nsyndrome, the risk of aortopathy is lower; nonetheless BAV is much\nmore frequent, and the relative risk of aortic dissection has been\nreported to be eight times greater than with a tricuspid aortic\nvalve.321 BAV may not be identified during physical examination in\nthe absence of valve dysfunction;58,322 however, the outcome of\nyoung individuals without valvular dysfunction is good.323,324\nIt is unclear whether intensive exercise accelerates aortic dilatation\nin the long term. A previous study comparing athletes with BAV,\nnon-athletes with BAV, and athletes with a normal aortic valve\nreported that athletes with BAV showed a 0.11 ± 0.59 mm/year\nincrease in aortic size at the sinuses of Valsalva and 0.21 ± 0.44 mm/\nyear for the proximal ascending aorta, which was not dissimilar to\nnon-athletes with a BAV.325 Currently, expert consensus panels\nadvise a cautious approach to sports activities when the ascending\naorta is above the normal limits (see section 5.4). In the absence of\naortopathy, exercise recommendations for individuals with BAV are\nidentical\nto\nthose\nin individuals with\ntricuspid\naortic\nvalve\ndysfunction.\nRecommendations for participation in recreational/leisure-time sports in asymptomatic individuals with aortic\nregurgitation\nAortic regurgitationc\nRecommendation\nClassa\nLevelb\nMild\nParticipation in all recreational sports, if desired, is recommended.\nI\nC\nModerate\nParticipation in all recreational sports, if desired, should be considered in asymptomatic indi-\nviduals with a non-dilated LV with LVEF>50% and normal exercise stress test.\nIIa\nC\nSevere\nParticipation in all recreational sports involving low and moderate intensity, if desired, may\nbe considered with a mild or moderately dilated LV with LVEF>50% and normal exercise\nstress test.\nIIb\nC\nParticipation in any moderate- or high-intensity recreational exercise is not recommended\nwith LVEF<_50% and/or exercise-induced arrhythmias.\nIII\nC\nLV = left ventricle; LVEF = left ventricular ejection fraction.\naClass of recommendation.\nbLevel of evidence.\ncFor mixed valvular disease, the recommendation for the predominant lesion should be followed.\nRecommendations for participation in competitive sports in asymptomatic individuals with aortic regurgitation\nAortic regurgitationc\nRecommendation\nClassa\nLevelb\nMild\nParticipation in all competitive sports, if desired, is recommended.\nI\nC\nModerate\nParticipation in all competitive sports, if desired, should be considered in individuals with\nLVEF>50% and normal exercise test.\nIIa\nC\nSevere\nParticipation in most competitive sports involving low to moderate intensity may be consid-\nered in individuals with a mild or moderately dilated LV with LVEF>50% and normal exercise\nstress test.\nIIb\nC\nParticipation in any moderate- or high-intensity competitive sports is not recommended in\nindividuals with severe AR and/or LVEF<_50% and/or exercise-induced arrhythmias\nIII\nC\nAR = aortic regurgitation; LV = left ventricle; LVEF = left ventricular ejection fraction.\naClass of recommendation.\nbLevel of evidence.\ncFor mixed valvular disease, the recommendation for the predominant lesion should be followed.\n50\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.................................\n5.3.5 Primary mitral regurgitation\nMost individuals with mitral valve disease have primary mitral regurgi-\ntation (MR) from myxomatous disease.326 MR is confirmed and quan-\ntified by echocardiography. General recommendations regarding\nexercise and sports are based on symptomatic status, severity of MR,\nLV function, systolic pulmonary artery pressure (sPAP), and the pres-\nence or absence of arrhythmias during exercise. Both athletic training\nand MR may be associated with an enlarged LV cavity; however, an\nenlarged LV that is disproportionate to the level of exercise may be\nsuggestive of severe MR and an indication to refrain from competitive\nor leisure sports involving moderate- or high-intensity exercise.\nAsymptomatic individuals with mild or moderate MR may com-\npete in all sports if they have good functional capacity, preserved LV\nfunction, sPAP < 50 mmHg and absence of complex arrhythmias dur-\ning exercise. Individuals with symptomatic MR and reduced exercise\ncapacity or individuals with MR with exercise-induced complex\narrhythmias should not participate in competitive or leisure sport;\nhowever, low-intensity aerobic exercise should be encouraged to\nimprove functional capacity and general well-being. Individuals on\nlong-term anticoagulation therapy for AF should not engage in con-\ntact/collision sport.\nRecommendations for participation in recreational/leisure-time sports in asymptomatic individuals with mitral\nregurgitation\nMitral regurgitationc,d\nRecommendation\nClassa\nLevelb\nMild\nParticipation in all sports, if desired, is recommended.\nI\nC\nModerate\nParticipation in all recreational sports, if desired, should be considered in individuals fulﬁlling the following:\n• LVEDD<60 mm327 or <35.3 mm/m2 in men and <40 mm/m2 in women\n• LVEF>_60%\n• Resting sPAP<50 mmHg\n• Normal exercise test\nIIa\nC\nSevere\nParticipation in all recreational sports involving low and moderate intensity, if desired, may be considered in\nindividuals fulﬁlling the following:\n• LVEDD<60 mm327 or <35.3 mm/m2 in men and <40 mm/m2 in women\n• LVEF>_60%\n• Resting sPAP<50 mmHg\n• Normal exercise test\nIIb\nC\nLVEDD = left ventricular end-diastolic diameter; LVEF = left ventricular ejection fraction; MR = mitral regurgitation; sPAP = systolic pulmonary artery pressure.\naClass of recommendation.\nbLevel of evidence.\ncFor mixed valvular disease, the recommendation for the predominant valve lesion should be followed.\ndNo collision or body contact sports if anticoagulated for atrial ﬁbrillation.\nRecommendations for participation in competitive sports in asymptomatic individuals with mitral regurgitation\nMitral regurgitationc,d\nRecommendation\nClassa\nLevelb\nMild\nParticipation in all competitive sports, if desired, is recommended.\nI\nC\nModerate\nParticipation in all competitive sports, if desired, should be considered in individuals fulﬁlling\nthe following:\n• LVEDD<60 mm327 or <35.3 mm/m2 in men and <40 mm/m2 in women\n• LVEF>_60%\n• Resting sPAP<50 mmHg\n• Normal exercise test\nIIa\nC\nSevere\nParticipation in competitive sports involving low exercise intensity, if desired, may be considered in individuals\nfulﬁlling the following:\n• LVEDD<60 mm327 or <35.3 mm/m2 in men and <40 mm/m2 in women\n• LVEF>_60%\n• Resting sPAP<50 mmHg\n• Normal exercise test\nIIb\nC\nParticipation in competitive sports is not recommended in individuals with a LVEF<60%\nIII\nC\nLVEDD = left ventricular end-diastolic diameter; LVEF = left ventricular ejection fraction; MR = mitral regurgitation; sPAP = systolic pulmonary artery pressure.\naClass of recommendation.\nbLevel of evidence.\ncFor mixed valvular disease, the recommendation for the predominant valve lesion should be followed.\ndNo collision or body contact sports if anticoagulated for atrial ﬁbrillation.\nESC Guidelines\n51\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.................................................................................................\n5.3.5.1 Mitral valve prolapse\nMitral valve prolapse (MVP) is characterized by fibro-myxomatous\nchanges of the mitral valve leaflets and has a prevalence of\n1\u00022.4%.328,329 The diagnosis of MVP is defined as >2 mm displace-\nment of one or both leaflets of the mitral valve beyond the annulus\nwithin the left atrium in end-systole.330 MVP is generally benign with\na 10-year mortality risk of 5%.331 The majority of individuals are iden-\ntified incidentally during cardiac auscultation, or echocardiography.\nThe most common complication of MVP is the progression to\nchronic severe MR, in 5\u000210% of individuals with MVP. Other compli-\ncations include HF from chronic MR, pulmonary hypertension, infec-\ntive endocarditis, supraventricular and VAs, and, occasionally,\nSCD.313 In the Italian cardiac pathology registry of 650 SCDs in young\nadults, 7% were attributed to MVP.332 Most decedents showed scar-\nring in the infero-basal wall and papillary muscles and bi-leaflet pro-\nlapse. Myocardial scarring, mitral valve annular disjunction (i.e. an\nabnormal atrial displacement of the mitral valve leaflet hinge point\nduring systole),333 T-wave inversion in the inferior leads and VAs aris-\ning from the LV [right bundle branch block (RBBB) morphology]\nwere high-risk features for SCD.334 The mechanical strain of MVP on\npapillary muscles and adjacent myocardium is thought to be responsi-\nble for the myocardial scarring, which may be a possible mechanism\nfor life-threatening arrhythmias in some individuals.335,336\nIn general, exercising individuals with MVP have an excellent prog-\nnosis. In a recent Italian study of 7449 young competitive athletes,\nMVP was identified in 2.9%. During a follow-up period of 8 ± 2 years\nthere were no fatalities.337 Adverse events, including progressive MR\nwith LV dilatation, ischaemic stroke, and AF occurred at a rate of\n0.5% per annum and were more common in older athletes with base-\nline mitral valve disjunction or VAs.\nIndividuals with MVP should be evaluated with an exercise test and\n24-hour ECG. Individuals with inferior T-wave inversion or\nventricular premature beats arising from the LV should undergo a\nCMR imaging scan to check specifically for myocardial fibrosis affect-\ning the infero-basal wall. Other potentially high-risk markers include\nevidence of mechanical dispersion detected by speckled tracking\nechocardiography,338 coexisting prolongation of the QT interval and\nmitral annular disjunction.333\nGiven the relatively benign nature of MVP, asymptomatic patients\nwith mild or moderate MR can participate in all competitive sports\nand leisure sports in the absence of the aforementioned risk factors\n(Figure 8). Asymptomatic patients with severe MR but none of the\nabove high-risk markers may compete in low- to moderate-intensity\nsports after detailed discussion with their specialist in the presence of\nLV end-diastolic diameter (LVEDD) <60 mm (or <35.5 mm/m2 in\nmen and <40 mm/m2 in women) with LVEF >_ 60%, resting sPAP <\n50 mmHg, and normal exercise test.\nSymptomatic patients with MVP and any of the aforementioned\nhigh-risk features (Figure 8) should not participate in recreational\nor competitive sports; however, low-intensity aerobic exercise\nshould be encouraged to improve functional capacity and general\nwell-being.\n5.3.6 Mitral stenosis\nAlthough rheumatic valve disease is uncommon in the western\nworld, the increase in emigration patterns means that cardiologists\nmay encounter individuals with rheumatic mitral stenosis (MS) who\naspire to exercise. Individuals with advanced MS are usually sympto-\nmatic and incapable of engaging in exercise regimens with a high CV\ndemand. The risk stratification of exercising individuals with MS is\nbased largely on a detailed echocardiogram with specific interest in\nthe severity of the lesion and accompanying systolic PAP. In addition,\nassessment should include a maximal exercise stress test to identify\nconcealed symptoms and functional capacity.\nFigure 8 Specific markers of increased risk of sudden cardiac death (SCD) with mitral valve prolapse. LV = left ventricular; MR = mitral regurgitation;\nMV = mitral valve. Adapted from Gati et al.336\n52\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n........................................\nAsymptomatic individuals with mild MS [mitral valve area (MVA)\n1.5\u00022.0 cm2] and moderate MS (MVA 1.0\u00021.5 cm2) who are in sinus\nrhythm and demonstrate good functional capacity on exercise testing\nand a normal sPAP may participate in all competitive and leisure\nsports. Mildly symptomatic individuals with severe MS (MVA < 1.0\ncm2) may only participate in leisure exercise involving physical effort\nof low intensity. Individuals with symptomatic MS should be referred\nfor intervention and advised to abstain from participation in sports\nand recreational exercise of moderate or high intensity. Individuals\nwith AF should be anticoagulated and avoid contact/collision sport. In\ncases of balloon mitral valvuloplasty with good results (i.e. MVA > 2.0\ncm2) regular exercise and competitive sport may be considered in\nasymptomatic individuals with good functional capacity.\n5.3.7 Tricuspid regurgitation\nTricuspid regurgitation (TR) is usually secondary to left heart disease,\npulmonary hypertension, or right ventricular (RV) dysfunction. In\nmost patients with secondary TR, exercise limitations relate to the\nunderlying pathology.\nMild TR is common in athletes and accompanied by physiological\ndilatation of the inferior vena cava, which is easily collapsible with\ninspiration. Severe TR is characterized by increasing tricuspid annular\ndilatation and RV remodelling that eventually leads to RV dysfunction\nand a non-reactive inferior vena cava. Individuals with severe TR may\nalso have a reduced exercise capacity due to an impaired cardiac out-\nput response with exercise.339 Furthermore, they may experience\nincreased right- and left-sided filling pressures during exercise, the lat-\nter being due to diastolic ventricular interaction.340\nIn general, asymptomatic patients with TR who have good func-\ntional capacity, non-dilated right ventricle, preserved ventricular func-\ntion, sPAP<40 mmHg, and absence of complex arrhythmias may\ncompete in all competitive and recreational sports.\n5.4 Exercise recommendations in\nindividuals with aortopathy\n5.4.1 Introduction\nThoracic aortic aneurysms are largely asymptomatic until a sudden\nand catastrophic event, including aortic rupture or dissection, occurs,\nRecommendations for participation in recreational/leisure-time sports in individuals with mitral stenosis\nMitral stenosisc,d\nRecommendation\nClassa\nLevelb\nMild (MVA 1.5\u00022.0 cm2)\nParticipation in all recreational sports, if desired, is recommended in individuals with a resting\nsPAP<40 mmHg and normal exercise test.\nI\nC\nModerate (MVA 1.0\u00021.5 cm2)\nParticipation in all recreational sports involving low and moderate intensity, if desired, may be\nconsidered in individuals with resting sPAP<40 mmHg and a normal exercise test.\nIIb\nC\nSevere (MVA<1 cm2)\nParticipation in leisure sports of moderate or high intensity is not recommended.\nIII\nC\nMVA = mitral valve area; sPAP = systolic pulmonary artery pressure.\naClass of recommendation.\nbLevel of evidence.\ncFor mixed valvular disease, the recommendation for the predominant valve lesion should be followed.\ndNo collision or body contact sports if anticoagulated for atrial ﬁbrillation.\nRecommendations for participation in competitive sports in asymptomatic individuals with mitral stenosis\nMitral stenosisc,d\nRecommendation\nClassa\nLevelb\nMild (MVA 1.5\u00022.0 cm2)\nParticipation in all competitive sports, if desired, is recommended in individuals with a resting\nsPAP<40 mmHg and a normal exercise test.\nI\nC\nModerate (MVA 1.0\u00021.5 cm2)\nParticipation in all competitive sports involving low intensity may be considered in individuals\nwith a resting sPAP<40 mmHg and normal exercise test.\nIIb\nC\nSevere (MVA<1.0 cm2)\nParticipation in competitive sports is not recommended.\nIII\nC\nMVA = mitral valve area; sPAP = systolic pulmonary artery pressure.\naClass of recommendation.\nbLevel of evidence.\ncFor mixed valvular disease, the recommendation for the predominant valve lesion should be followed.\ndNo collision or body contact sports if anticoagulated for atrial ﬁbrillation.\nESC Guidelines\n53\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................\nwhich can be rapidly fatal. Advanced age, male sex, long-term history\nof arterial hypertension, and the presence of aortic aneurysm confer\nthe greatest population attributable risk for aortic dissection.\nHowever, patients with genetic connective tissue disorders such as\nMarfan (MFS), Loeys Dietz, Turner, or Ehlers Danlos (EDS) syn-\ndromes, and patients with BAV are at increased risk at a much\nyounger age. BAV has a prevalence of about 1\u00022% in the general\npopulation. These patients have a relatively low risk for aortic dissec-\ntion in comparison with patients with hereditary thoracic aortic dis-\nease (HTAD). Having a family history of aortic dissection or sudden\ndeath is a risk factor and a larger diameter of the aorta carries a higher\nrisk, although dissection can occur at any diameter and especially in\nEDS\npatients\nthere\nis\nno\nclear\nassociation\nwith\naortic\ndiameter.341\u0002343\nA dilated aortic root (>40 mm) is not a feature of athlete’s heart,\nwith only a small minority of young athletes (0.3%) having an enlarged\naortic root diameter.344\u0002347 During follow-up no progressive\nenlargement of the aortic diameter was observed in these athletes,\nand no aortic events occurred during a 5-year period.347\n5.4.2 Risk of dissection\nBecause of the increase in BP and wall stress associated with intensive\nexercise and sports, such activities are potentially associated with an\nenhanced risk of expansion of the aorta and acute aortic dissection.\nHowever, daily exercise is important in maintaining an ideal BP, heart\nrate, and body weight and a sedentary lifestyle is an important modifi-\nable risk factor for CV disease and mortality. Physical activity is\nadvised in all patients with aortic pathology, even when the aorta is\ndilated.\nThere are no randomized controlled trials on competitive sports\nin patients with thoracic aortic disease, or any prospective data\nregarding the risks of competitive athletics in patients after surgical\ncorrection; however, even after aortic root replacement, patients\nwith MFS and other HTAD remain at risk of aortic complications.\nOne small prospective cohort study evaluated the feasibility and\neffects of a 3-week rehabilitation training programme in 19 MFS\npatients with a mean age of 47 years. During the 1-year follow-up,\nthere were no adverse events but there was improvement in physical\nfitness and reduction in psychological distress. These effects were\ndetectable after 3 weeks of rehabilitation, and mostly persisted\nthrough the 1-year follow-up. Unfortunately, no information on\naortic diameters was provided.348\n5.4.3 Sporting disciplines\nExercise-related acute thoracic aortic dissections are described in\nthe literature in a total of 49 case reports. Of these, 42 patients suf-\nfered Stanford type A thoracic aortic dissections. In the majority (26/\n49)\nweightlifting\nwas\nassociated\nwith\naortic\ndissection.349\nFurthermore, a recently published retrospective cohort study of 615\npatients with acute type A aortic dissection found that 4.1% cases\nwere related to sports activities. The type of sports most often\nreported was golf (32%), but this was not corrected for the percent-\nage of participants in the sport and probably reflects that golfers are\nfrequently older with an increased risk of hypertension and hence\nthe potential for dissection.350\n5.4.4 Effect on aortic diameter and wall stress\nOne cross-sectional study, which included 58 competitive athletes\nwith BAV, showed no correlation between aortic dimensions and\nduration of training.351 Two studies compared athletes and sedentary\nindividuals with BAV and reported no difference in aortic growth\nrate between the two groups.\nTwo MFS mouse models investigating the effects of mild-\nmoderate dynamic exercise on the aortic wall showed a reduction in\nthe growth rate of the aortic diameter in mice with MFS that per-\nformed mild to moderate dynamic exercise compared to sedentary\nmice with MFS.352,353 Among exercising mice, the aortic wall became\nstronger and a larger mechanical stress was required to induce aortic\nrupture. An optimum protective effect was found at a training inten-\nsity level of 55\u000265% of maximum oxygen uptake (VO2max).\nTable 14\nClassiﬁcation of risk to perform sports in patients with aortic pathology\n©ESC 2020\nASI = aortic size index; BAV = bicuspid aortic valve; HTAD = hereditary thoracic aortic disease; MFS = Marfan syndrome.\n54\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\n5.4.5 Recommendations\nRegular exercise has a well-documented benefit for fitness, psycho-\nlogical well-being, and social interaction, as well as a positive effect on\nhypertension and concomitant future risk of dissection. Most individ-\nuals with aortic pathology benefit from a certain minimal exercise\nprogramme and can at least participate in recreational sports\n(Table 14). Some lesions are not compatible with endurance training\nand athletic sports, due to their high risk of dissection or rupture.\nRecommendations for exercise and sports should be individualized\nand based on the underlying diagnosis, the aortic diameter, family his-\ntory for dissection or sudden death (risk factor), and the pre-existing\nfitness and experience. An exercise test with an assessment of blood\npressure response is recommended before engaging in sports.\n5.5 Exercise recommendations in\nindividuals with cardiomyopathies,\nmyocarditis, and pericarditis\nCardiomyopathies are an important cause of SCD/SCA in young indi-\nviduals and exercise has been implicated as a trigger for fatal\narrhythmias.17\u000219,28 The detection of a cardiomyopathy in an individ-\nual has important implications with respect to ongoing participation\nin exercise. The advent of preventive strategies for SCD has led to a\nsignificant expansion in the number of predominantly asymptomatic\nyoung patients with cardiomyopathies who aspire to exercise. When\nadvising such individuals, it is essential to strike a balance between\nprotecting patients from the potentially adverse effects of exercise\nand depriving them of the multiple benefits of exercise.\n5.5.1 Hypertrophic cardiomyopathy\nThe diagnosis of HCM is based on the presence of unexplained LV\nhypertrophy, defined as a maximum end-diastolic wall thickness >_15\nmm, in any myocardial segment on echocardiography, CMR, or CT\nimaging.355 HCM may also be considered in individuals with a lesser\ndegree of LV hypertrophy (wall thickness >_13 mm) in the context of\na family history of definite HCM or a positive genetic test.355\n5.5.1.1 Risk stratification in hypertrophic cardiomyopathy\nCircumstantial evidence and a large systematic collection of young\nSCDs in sports in the US suggest that exercise increases the risk of\nSCD/SCA in individuals with HCM.18 Consistently, previous consen-\nsus recommendations have restricted all athletes with HCM from\ncompetitive sports.1,356,357\nMore recently, relatively small longitudinal clinical studies indicate\nthat the risk of SCD during exercise may be considerably lower than\ninitially considered. Lampert et al. reported that individuals with\nHCM who continued participating in sports after implantable cardi-\noverter defibrillator (ICD) implantation did not reveal an increased\nnumber of shocks during exercise.358,359 In a cross-sectional study of\n187 patients with HCM, vigorous exercise was not associated with\nthe occurrence of VAs.358 Pelliccia et al. reported outcomes in a\ncohort of 35 athletes with HCM, engaged in training and competi-\ntions for 5 to 31 years (mean 15 ± 8). During a 9-year follow-up\nperiod, there were no differences in the incidence of symptoms or\nmajor events between athletes who ceased exercise (n = 20) com-\npared with athletes who continued competitive sports (n = 15).360 In\na post-mortem series, only 23% of 194 deaths from HCM occurred\nduring sport, and affected males with a mean age of 30 years.361\nFinally, individuals with HCM who participated in rehabilitation pro-\ngrammes demonstrated a significant improvement in functional\ncapacity without adverse events.362,363\nIn conclusion, there is limited evidence to indicate that all individu-\nals with HCM are vulnerable to fatal arrhythmias during exercise and\nsport participation. In this regard, systematic restriction from com-\npetitive sports in all affected individuals is probably unjustified and a\nmore liberal approach to sports participation is reasonable in some\nindividuals after careful evaluation.3 This is particularly important for\nthe majority of individuals with HCM who wish to participate in ama-\nteur sports or leisure-time exercise to maintain their physical and\npsychological well-being.\n5.5.1.2 Baseline assessment of patients with HCM\nA systematic approach is required when assessing an individual with\nHCM who requests exercise advice. The baseline evaluation should\ninclude a comprehensive personal and family history with considera-\ntion of the age of the individual and years of exercise prior to diagno-\nsis, assessment of the severity of the HCM phenotype, and the\npresence of any conventional risk factors for SCD/SCA. In older\npatients with HCM, the physician should review the presence of car-\ndiac comorbidities such as hypertension and ischaemic heart disease,\nwhich may confer a worse prognosis in HCM.364,365\n5.5.1.3 History\nThe presence of symptoms attributed to HCM should prompt more\nconservative exercise recommendations. Individuals with a history of\ncardiac arrest or unheralded syncope and individuals with exercise-\nRecommendations for exercise and participation in\nsports in individuals with aortic pathology\nRecommendations\nClassa\nLevelb\nPrior to engaging in exercise, risk stratiﬁcation,\nwith careful assessment including advanced imag-\ning of the aorta (CT/CMR) and exercise testing\nwith blood pressure assessment is\nrecommended.\nI\nC\nRegular follow-up including risk assessment is\nrecommended.\nI\nC\nDynamic exercise should be considered more\nsuitable than static exercise.\nIIa\nC\nParticipation in competitive or leisure-time\nsports activities (except power sports) should\nbe considered in low-risk individuals (Table 14).\nIIa\nC\nParticipation in individualized leisure exercise\nprogrammes may be considered in high-risk indi-\nviduals (Table 14).\nIIb\nC\nCompetitive sports are not recommended in\nindividuals who are at high risk (Table 14).\nIII\nC\nCMR = cardiac magnetic resonance; CT = computed tomography.\naClass of recommendation.\nbLevel of evidence.\nESC Guidelines\n55\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n....................................................................................................................................................................\ninduced symptoms should be advised to engage in low-intensity rec-\nreational sports only.\n5.5.1.4 Resting and ambulatory ECG\nThe resting 12-lead ECG has limited value in risk stratification.\nAmbulatory ECG monitoring, preferably for 48 h, is important for\ndetecting ventricular and supraventricular arrhythmias. The monitor-\ning period should include an exercise session. Asymptomatic non-\nsustained ventricular tachycardia (NSVT) confers considerable risk of\nSCD in younger individuals (<_35 years).355 Paroxysmal supraventric-\nular arrhythmias may pose significant implications for functional\ncapacity and, in the case of AF, for stroke prevention.366\n5.5.1.5 Echocardiography\nIn relation to risk stratification for SCD the clinician should assess the\nfollowing echocardiographic indices: (i) LV wall thickness; (ii) LV out-\nflow tract (LVOT) gradient; and (iii) left atrial diameter.355 All individ-\nuals should have the LVOT gradient assessed at rest, during the\nValsalva manoeuvre, on standing suddenly, and after light exercise on\nthe spot, such as repeated squats. By convention, LVOT obstruction\nis defined as a peak pressure gradient >_30 mmHg at rest or during\nphysiological provocation. A gradient >_50 mmHg is considered to be\nhaemodynamically important. Exercise stress echocardiography\nshould be considered in individuals with exertional symptoms who\nhave resting systolic anterior motion of the mitral valve leaflets but\nwho do not reveal LVOT obstruction or show only mild to moderate\nLVOT obstruction with the aforementioned manoeuvres.\n5.5.1.6 Cardiac magnetic resonance imaging\nCMR imaging is increasingly recognized as a necessary tool for con-\nfirming diagnosis and to assess risk stratification in individuals with\nHCM. Late gadolinium enhancement (LGE), indicative of myocardial\nfibrosis, may be present in up to 75% of patients with HCM and, by\nitself, is a poor discriminator of outcomes. However, the presence of\nextensive (>_15% of LV myocardium) LGE may identify individuals at\nincreased risk of ventricular tachyarrhythmias and SCD.367\u0002370\n5.5.1.7 Exercise testing\nExercise testing (or CPET) should be part of the routine evaluation\nto assess functional capacity in an individual with HCM who intends\nto exercise. In addition, an abnormal BP response to exercise\n(defined as <20 mmHg increase in SBP from baseline, or exercise-\ninduced hypotension)371,372 and the presence of exercise-induced\nsymptoms or arrhythmias are markers of high risk and should result\nin more conservative exercise recommendations.\n5.5.1.8 Genetic testing\nCurrently genetic testing is reserved for familial cascade screening. It\ndoes not inform decisions relating to the risk of SCD/SCA and should\nnot be performed for exercise risk stratification.\n5.5.1.9 ESC risk score in HCM\nThe ESC risk score uses seven variables (age, syncope, family\nhistory of SCD from HCM, maximal LV wall thickness, left atrial\ndiameter, LV outflow obstruction, NSVT) to assess the risk\nof SCD of patients with HCM.355,373 This information can be\ninserted into an online calculator (https://doc2do.com/hcm/\nwebHCM.html) to estimate individualized 5-year risk to provide\nguidance on whether a prophylactic ICD is indicated. For\nthe purposes of these Guidelines the risk of SCD is defined as low\nif <4%, moderate if between >_4% and <6%, and high if >_6% in\n5 years.\n5.5.1.10 Exercise recommendation\nOn completion of the baseline evaluation, the physician should con-\nsider: (i) the presence of symptoms; (ii) ESC risk score; (iii) presence\nof resting or inducible LVOT obstruction during exercise; (iv) the\nhaemodynamic (BP) response to exercise; and (v) the presence of\nresting or exercise-induced arrhythmias before recommending the\nappropriate form and intensity of exercise.\nAlthough these Guidelines advocate for a more liberal approach\nto sports participation, it is indisputable that even the absence of\nall major risk factors does not convey immunity to SCD.374 In addi-\ntion, the ESC risk score relies on evidence derived from predomi-\nnantly non-athletic cohorts.373 Whereas there are no data to\nsuggest that this approach to risk estimation is less valid in athletic\nindividuals, one has to consider that it may not accurately reflect\nthe risk of SCD in individuals exposed to the haemodynamic and\nmetabolic stresses of high-intensity sports. Therefore, when advis-\ning an individual with HCM regarding participation in high-intensity\nexercise programmes and competitive sports, this consideration\nshould be an integral part of the discussion during the shared\ndecision-making process.\n5.5.1.11 Special considerations\nThe age of an individual may have an impact on risk. The mean age\nof death in the largest series of SCD from the US was 18 years,\nwith 65% of deaths occurring in athletes <_17 years.354 Although\nyoung age should not exclude an individual from high-intensity\nexercise in the absence of additional risk factors, it should be con-\nsidered in the discussion with the individual and the parents or\nguardians. In addition, specific sports may pose a higher risk for\nSCD, such as highly dynamic, start\u0002stop sports like basketball and\nfootball.17,58\nIndividuals who have a positive genotype but who do not reveal\nany phenotypic structural or arrhythmia features of HCM may engage\nin all sports. Such individuals should be assessed annually for pheno-\ntypic features and risk stratification purposes.\n5.5.1.12 Follow-up\nAnnual follow-up is recommended for most individuals with HCM\nwho exercise on a regular basis. More frequent (6-monthly) follow-\nup should be considered in adolescent individuals and young adults\nwhose phenotype, and therefore risk of SCD, may still be evolving\nand who are more vulnerable to exercise-related SCD.58,239Follow-\nup evaluation should focus on assessment of disease progression and\nrisk stratification. New symptoms should prompt interruption of\nexercise and re-evaluation.\n56\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 31",
          "page": 31,
          "content": "Non-competitive (low-intensity recreational\nskill-related sports) may be considered (when\ntolerated) in stable, optimally treated individuals\nwith HFrEF. | IIb | C\nHigh-intensity power and endurance sports are\nnot recommended in patients with HFrEF irre-\nspective of symptoms. | III | C",
          "rows": 2,
          "cols": 3
        },
        {
          "title": "Table on page 31",
          "page": 31,
          "content": " |  | \nRecommendations | Classa | Levelb\nModerate endurance and dynamic resistance\nexercise, together with lifestyle intervention and\noptimal treatment of cardiovascular risk factors\n(i.e. arterial hypertension and type 2 diabetes)\nare recommended.287,289\u0002292,299 | I | C\nCompetitive sports may be considered in\nselected stable patients without abnormalities\non maximal exercise testing. | IIb | C",
          "rows": 4,
          "cols": 3
        },
        {
          "title": "Table on page 32",
          "page": 32,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nRegular exercise through cardiac rehabilitation,\ncombining moderate-intensity aerobic and resist-\nance exercise, is recommended to revert patho-\nphysiology to pre-transplantation time, reduce\ncardiovascular risk induced by post-transplanta-\ntion medical treatment, and improve clinical\noutcome.305\u0002312 | I | B\nRecreational (low-intensity recreational) sports\nparticipation should be considered and encour-\naged in stable, asymptomatic individuals after\ntherapy optimization. | IIa | C\nEligibility for competitive sports involving low-\nand moderate-intensity exercise may be consid-\nered in selected, asymptomatic individuals with\nan uncomplicated follow-up.304,309,310 | IIb | C",
          "rows": 6,
          "cols": 3
        },
        {
          "title": "Table on page 33",
          "page": 33,
          "content": " |  |  | \n | Aortic stenosisc |  | \n |  |  | \n | Recommendation | Classa | Levelb\n |  |  | \nMild | Participation in all competitive\nsports, if desired, is recommended. | I | C\nModerate | Participation in all competitive\nsports involving low to moderate\neffort, if desired, may be considered\nin individuals with LVEF>50%, good\n_\nfunctional capacity, and normal BP\nresponse during exercise. | IIb | C\nSevere | Participation in low-intensity skill\nsports may be considered in a select\ngroup of individuals with LVEF>50%.\n_ | IIb | C\n | Participation in sports or exercise of\nmoderate or high intensity is not\nrecommended. | III | C",
          "rows": 9,
          "cols": 4
        },
        {
          "title": "Table on page 33",
          "page": 33,
          "content": " |  |  | \n | Aortic stenosisc |  | \n |  |  | \n | Recommendation | Classa | Levelb\nMild | Participation in all recreational\nsports, if desired, is recommended. | I | C\nModerate | Participation in all recreational\nsports involving low to moderate\nintensity, if desired, should be con-\nsidered in individuals with\nLVEF>50%, good functional\n_\ncapacity, and normal exercise test. | IIa | C\nSevere | Participation in all recreational\nsports/exercise involving low inten-\nsity, if desired, may be considered in\nindividuals with LVEF>50% and nor-\n_\nmal BP response during exercise. | IIb | C\n | Participation in competitive or rec-\nreational sports/exercise of moder-\nate and high intensity is not\nrecommended. | III | C",
          "rows": 8,
          "cols": 4
        },
        {
          "title": "Table on page 34",
          "page": 34,
          "content": " |  |  | \n | Aortic regurgitationc |  | \n |  |  | \n | Recommendation | Classa | Levelb\n |  |  | \nMild | Participation in all recreational sports, if desired, is recommended. | I | C\nModerate | Participation in all recreational sports, if desired, should be considered in asymptomatic indi-\nviduals with a non-dilated LV with LVEF>50% and normal exercise stress test. | IIa | C\nSevere | Participation in all recreational sports involving low and moderate intensity, if desired, may\nbe considered with a mild or moderately dilated LV with LVEF>50% and normal exercise\nstress test. | IIb | C\n | Participation in any moderate- or high-intensity recreational exercise is not recommended\nwith LVEF<50% and/or exercise-induced arrhythmias.\n_ | III | C",
          "rows": 9,
          "cols": 4
        },
        {
          "title": "Table on page 34",
          "page": 34,
          "content": " | Aortic regurgitationc |  | \n |  |  | \n | Recommendation | Classa | Levelb\n |  |  | \nMild | Participation in all competitive sports, if desired, is recommended. | I | C\nModerate | Participation in all competitive sports, if desired, should be considered in individuals with\nLVEF>50% and normal exercise test. | IIa | C\nSevere | Participation in most competitive sports involving low to moderate intensity may be consid-\nered in individuals with a mild or moderately dilated LV with LVEF>50% and normal exercise\nstress test. | IIb | C\n | Participation in any moderate- or high-intensity competitive sports is not recommended in\nindividuals with severe AR and/or LVEF<50% and/or exercise-induced arrhythmias\n_ | III | C",
          "rows": 8,
          "cols": 4
        },
        {
          "title": "Table on page 35",
          "page": 35,
          "content": " |  |  | \n | Mitral regurgitationc,d |  | \n |  |  | \n | Recommendation | Classa | Levelb\n |  |  | \nMild | Participation in all sports, if desired, is recommended. | I | C\nModerate | Participation in all recreational sports, if desired, should be considered in individuals fulfilling the following:\n• LVEDD<60 mm327 or <35.3 mm/m2 in men and <40 mm/m2 in women\n• LVEF> _60%\n• Resting sPAP<50 mmHg\n• Normal exercise test | IIa | C\nSevere | Participation in all recreational sports involving low and moderate intensity, if desired, may be considered in\nindividuals fulfilling the following:\n• LVEDD<60 mm327 or <35.3 mm/m2 in men and <40 mm/m2 in women\n• LVEF> _60%\n• Resting sPAP<50 mmHg\n• Normal exercise test | IIb | C",
          "rows": 8,
          "cols": 4
        },
        {
          "title": "Table on page 35",
          "page": 35,
          "content": " |  |  | \n | Mitral regurgitationc,d |  | \n |  |  | \n | Recommendation | Classa | Levelb\n |  |  | \nMild | Participation in all competitive sports, if desired, is recommended. | I | C\nModerate | Participation in all competitive sports, if desired, should be considered in individuals fulfilling\nthe following:\n• LVEDD<60 mm327 or <35.3 mm/m2 in men and <40 mm/m2 in women\n• LVEF> _60%\n• Resting sPAP<50 mmHg\n• Normal exercise test | IIa | C\nSevere | Participation in competitive sports involving low exercise intensity, if desired, may be considered in individuals\nfulfilling the following:\n• LVEDD<60 mm327 or <35.3 mm/m2 in men and <40 mm/m2 in women\n• LVEF>60%\n_\n• Resting sPAP<50 mmHg\n• Normal exercise test | IIb | C\n | Participation in competitive sports is not recommended in individuals with a LVEF<60% | III | C",
          "rows": 9,
          "cols": 4
        },
        {
          "title": "Table on page 37",
          "page": 37,
          "content": " |  |  | \n | Mitral stenosisc,d |  | \n |  |  | \n | Recommendation | Classa | Levelb\n |  |  | \nMild (MVA 1.5\u00022.0 cm2) | Participation in all recreational sports, if desired, is recommended in individuals with a resting\nsPAP<40 mmHg and normal exercise test. | I | C\nModerate (MVA 1.0\u00021.5 cm2) | Participation in all recreational sports involving low and moderate intensity, if desired, may be\nconsidered in individuals with resting sPAP<40 mmHg and a normal exercise test. | IIb | C\nSevere (MVA<1 cm2) | Participation in leisure sports of moderate or high intensity is not recommended. | III | C",
          "rows": 8,
          "cols": 4
        },
        {
          "title": "Table on page 37",
          "page": 37,
          "content": " |  |  | \n | Mitral stenosisc,d |  | \n |  |  | \n | Recommendation | Classa | Levelb\n |  |  | \nMild (MVA 1.5\u00022.0 cm2) | Participation in all competitive sports, if desired, is recommended in individuals with a resting\nsPAP<40 mmHg and a normal exercise test. | I | C\nModerate (MVA 1.0\u00021.5 cm2) | Participation in all competitive sports involving low intensity may be considered in individuals\nwith a resting sPAP<40 mmHg and normal exercise test. | IIb | C\nSevere (MVA<1.0 cm2) | Participation in competitive sports is not recommended. | III | C",
          "rows": 8,
          "cols": 4
        },
        {
          "title": "Table on page 39",
          "page": 39,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nPrior to engaging in exercise, risk stratification,\nwith careful assessment including advanced imag-\ning of the aorta (CT/CMR) and exercise testing\nwith blood pressure assessment is\nrecommended. | I | C\nRegular follow-up including risk assessment is\nrecommended. | I | C\nDynamic exercise should be considered more\nsuitable than static exercise. | IIa | C\nParticipation in competitive or leisure-time\nsports activities (except power sports) should\nbe considered in low-risk individuals (Table 14). | IIa | C\nParticipation in individualized leisure exercise\nprogrammes may be considered in high-risk indi-\nviduals (Table 14). | IIb | C\nCompetitive sports are not recommended in\nindividuals who are at high risk (Table 14). | III | C",
          "rows": 9,
          "cols": 3
        }
      ],
      "keywords": [
        "ejection",
        "ct",
        "intervention",
        "fraction",
        "preserved",
        "failure",
        "heart failure",
        "risk",
        "symptomatic",
        "heart"
      ]
    },
    {
      "number": "5",
      "title": "5.5.2 Arrhythmogenic cardiomyopathy",
      "start_page": 41,
      "end_page": 50,
      "content": ".............................................................................................................................................................................\n5.5.2 Arrhythmogenic cardiomyopathy\nArrhythmogenic right ventricular cardiomyopathy (ARVC) is defined\npathologically by the presence of fibro-fatty replacement of the right\nventricle and clinically by life-threatening VAs. The condition was ini-\ntially recognized as a predominantly RV disease, and diagnosis is cur-\nrently based on probabilistic Task Force Criteria that encompass\nelectrophysiological, anatomical, functional, and clinical features of\nthe disease.375 Since its first description, the concept of ARVC has\nevolved to include concealed or subclinical phenotypes and biventric-\nular disease. It is now well established that both ventricles are\naffected in most cases.376\u0002378 This has led to the development of a\nnew term, arrhythmogenic cardiomyopathy, that embraces an array\nof diagnostic terms for different (genetic and acquired) pathologies.\nAlthough the definition of ‘arrhythmogenic cardiomyopathy’ is yet to\nbe agreed, it can be considered as an umbrella term for a family of dis-\neases that are characterized by biventricular myocardial abnormal-\nities, including fibro-fatty infiltration and scarring, identified by\npathological examination and/or cardiac imaging and VA.\nThe term arrhythmogenic cardiomyopathy (ACM) is used\nthroughout these recommendations; however, it is important to rec-\nognize that most of the literature on the influence of exercise on dis-\nease progression and risk of SCD is derived from cohorts with\nclassical ARVC. This is reflected in the recommendations provided in\nthese Guidelines. It is possible therefore that the recommendations\nmay not accurately reflect predominantly LV disease, which consti-\ntutes a small proportion of the disease spectrum where the impact of\nexercise on disease phenotype and risk is less clarified than the RV\nvariant. Where appropriate, guidance is provided for other condi-\ntions that can be reasonably considered under the umbrella of ACM\n[including subtypes of dilated cardiomyopathy (DCM)].\n5.5.2.1 Risk stratification in arrhythmogenic cardiomyopathy\nACM accounts for a significant proportion of SCDs in young and ath-\nletic individuals.28 Established risk factors for SCD that should\nprompt consideration for an ICD include aborted SCD, unheralded\nsyncope, ventricular tachycardia, and impaired RV and/or LV systolic\nfunction.379 A novel risk prediction model for VAs has recently been\nproposed but is yet to be validated.380 Regular and high-intensity\nexercise programmes are associated with acceleration of the disease\nprocess and worse outcomes.381\u0002389\nIn an experimental model of heterozygous plakoglobin-deficient\nmice, exercise training accelerated RV dysfunction and arrhyth-\nmias.382 Similar results have been confirmed in human desmosomal\nmutation carriers participating in vigorous (>70% VO2max) endurance\nsports.384 Similar findings were reported in patients with ACM and\nasymptomatic gene-positive family members, despite a more conser-\nvative definition of athletic status (exercise with intensity >_6 METs\nfor >_4 h/week for >_6 years).386 Recently, the results from the North\nAmerican multidisciplinary study reported that patients engaging in\ncompetitive sports were at two-fold increased risk of ventricular\ntachyarrhythmias or death and earlier presentation of symptoms,\ncompared with patients who participated in recreational sports and\nsedentary individuals.385 Among patients engaging in competitive\nsports, early age of sports initiation was associated with premature\npresentation of symptoms and adverse clinical profile. Reducing exer-\ncise intensity was associated with a substantial decrease in the risk of\nventricular tachyarrhythmias or death, to the same level as inactive\npatients.385 Finally, in a multinational registry of 393 competitive ath-\nletes implanted with an ICD who continued to participate in regular\ncompetitions, 20% of athletes with ACM received a shock during\nexertion compared to 10% at rest, during a median follow-up of 44\nmonths. The diagnosis of ACM was the only variable associated with\nreceiving appropriate shocks during competition.359,389\n5.5.2.2 Baseline assessment of patients with arrhythmogenic\ncardiomyopathy\nA systematic approach is required when assessing individuals with\nACM who request exercise advice. The baseline evaluation should\ninclude a comprehensive history of symptoms and family history of\nACM or SCD, assessment of the severity of the ACM phenotype,\nand the presence of any conventional risk factors for SCD/SCA.\nRecommendations for exercise and sports participation\nin individuals with hypertrophic cardiomyopathy\nRecommendations\nClassa\nLevelb\nExercise recommendations\nParticipation in high-intensity exercise/competitive\nsports, if desired (with the exception of those\nwhere occurrence of syncope may be associated\nwith harm or death), may be considered for indi-\nviduals who do not have any markers of increased\nriskc following expert assessment.\nIIb\nC\nParticipation in low- or moderate-intensity recrea-\ntional exercise, if desired, may be considered for\nindividuals who have any markers of increased\nriskc following expert assessment .\nIIb\nC\nParticipation in all competitive sports, if desired,\nmay be considered for individuals who are gene\npositive for HCM but phenotype negative.\nIIb\nC\nParticipation in high-intensity exercise (including\nrecreational and competitive sports) is not recom-\nmended for individuals who have ANY markers of\nincreased riskc.\nIII\nC\nFollow-up and further considerations relating to risk\nAnnual follow-up is recommended for individuals\nwho exercise on a regular basis.\nI\nC\nSix-monthly follow-up should be considered in\nadolescent individuals and young adults who are\nmore vulnerable to exercise-related SCD.\nIIa\nC\nAnnual assessment should be considered for gen-\notype-positive/phenotype-negative individuals for\nphenotypic features and risk stratiﬁcation\npurposes.\nIIa\nC\nBP = blood pressure; ESC = European Society of Cardiology; HCM = hypertro-\nphic cardiomyopathy; LVOT = left ventricular outﬂow tract obstruction cardio-\nmyopathy; SCD = sudden cardiac death.\naClass of recommendation.\nbLevel of evidence.\ncMarkers of increased risk include: (i) cardiac symptoms or history of cardiac\narrest or unexplained syncope; (ii) moderate ESC risk score (>_4%) at 5 years; (iii)\nLVOT gradient at rest >30 mmHg; (iv) abnormal BP response to exercise; (v)\nexercise-induced arrhythmias.\nRefer to Table 4 for different indices of exercise intensity and training zones.\nESC Guidelines\n57\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n................................................................\n5.5.2.3 History\nSyncope due to presumed arrhythmia is an important risk marker\nfor SCD/SCA and a predictor of future appropriate ICD\ntherapies.390\u0002394 The presence of symptoms attributed to ACM\nshould reinforce the conservative exercise recommendations.\nIndividuals with a history of cardiac arrest or unheralded syncope\nand individuals with exercise-induced symptoms should be\nadvised to engage only in low-intensity recreational exercise\nprogrammes.\n5.5.2.4 Resting and ambulatory ECG\nApart from its diagnostic utility, the 12-lead ECG may provide useful\ninformation relating to risk stratification in ACM. The presence of exten-\nsive T-wave inversion affecting >_3 precordial leads or T-wave inversion\nin two of the three inferior leads confers some additional risk for SCD/\nSCA.395,396\nAmbulatory ECG monitoring is important for detecting VAs.\nEvery effort should be made for the monitoring period to\ninclude the proposed exercise session. The presence of NSVT or\nsignificant burden of ventricular ectopy (>_1000/24 h), even in\nasymptomatic individuals, confers an increased risk of fatal\narrhythmias.392,393,397\n5.5.2.5 Echocardiography and cardiac magnetic resonance imaging\nIn relation to risk stratification for SCD, the clinician should\nassess the severity of RV and LV involvement in terms of ventric-\nular dilatation and systolic dysfunction. CMR imaging is more use-\nful\nthan\nechocardiography\nfor\nassessing\nRV\nwall\nmotion\nabnormalities and can also quantify the degree of myocardial fat\ninfiltration and/or scar. The more extensive the disease the\nhigher the arrhythmic risk.398,399\n5.5.2.6 Exercise testing\nExercise testing should be part of the routine assessment of every\nindividual with ACM who wishes to exercise, as it can provide infor-\nmation regarding functional capacity and risk stratification. Exercise\ntesting in patients with ACM should not be performed during ‘hot\nphases’. The presence of exercise-induced symptoms or arrhythmias\nshould result in more conservative recommendations.\n5.5.2.7 Genetic testing\nGenotype may also be of prognostic value. In the ARVC variant, a\nnumber of studies have reported that carriers of multiple pathogenic\nvariants in the same desmosomal gene or mutations in >_2 genes may\nhave an almost four-fold higher arrhythmic risk than those with a sin-\ngle mutation.400 Particular genotypes such as DSP and TMEM43, but\nalso LMNA and FLNC, associated with other ACM phenotypes (see\nsection 5.5.4) have a propensity for high arrhythmic burden that can\npre-date the structural phenotype.401,402\n5.5.2.8 Exercise recommendations\nThe overall scientific evidence supports the concept that in patients\nwith ACM participation in high-intensity sports should be discour-\naged, because it is associated with accelerated disease progression,\ngreater risk of VAs and major events. This recommendation is also\napplicable to genetic carriers of pathogenic variants for ACM even in\nthe absence of overt disease phenotype.\n5.5.2.9 Special considerations\nYoung age of presentation and male sex are associated with\nincreased risk of malignant arrhythmias in ACM.379 Although young\nage should not exclude an individual from moderate-intensity exer-\ncise in the absence of high-risk features, age should be considered in\nthe discussion with the patient and the parents. In addition, one\nshould consider that specific highly dynamic, start\u0002stop sports, such\nas basketball and football, may pose a higher risk of SCD particularly\nin athletes who compete at the highest level.17,365\n5.5.2.10 Follow-up\nAn annual follow-up is recommended for most individuals\nwith ACM who exercise on a regular basis. More frequent (6-\nmonthly) follow-up should be considered for adolescent and\nyoung adults whose ACM phenotype, and therefore risk of SCD,\nmay still be evolving, particularly if they engage in moderate- to\nhigh-intensity exercise. More frequent follow-up should also be\nconsidered in individuals with high arrhythmic risk genotypes such\nas DSP, TMEM43, and carriers of multiple pathogenic variants.\nNew symptoms should prompt interruption of exercise and re-\nevaluation.\nRecommendations for exercise and sports participation\nin individuals with arrhythmogenic cardiomyopathy\nRecommendations\nClassa\nLevelb\nExercise recommendations\nParticipation in 150 min of low-intensity exercise\nper week should be considered for all individuals.\nIIa\nC\nParticipation in low- to moderate-intensity recrea-\ntional exercise/sports, if desired, may be consid-\nered for individuals with no history of cardiac\narrest/VA, unexplained syncope, minimal struc-\ntural cardiac abnormalities, <500 PVCs/24 h and\nno evidence of exercise-induced complex VAs.\nIIb\nC\nParticipation in high-intensity recreational exercise/\nsports or any competitive sports is not recom-\nmended in individuals with ACM, including those\nwho are gene positive but phenotype negative.384,386\nIII\nB\nFollow-up and further considerations relating to risk\nAnnual follow-up is recommended for individuals\nwho exercise on a regular basis.\nI\nC\nSix-monthly follow-up should be considered in\nadolescent individuals and young adults who are\nmore vulnerable to exercise-related SCD.\nIIa\nC\nAnnual assessment should be considered for geno-\ntype-positive/phenotype-negative individuals for\nphenotypic features and risk stratiﬁcation purposes.\nIIa\nC\nSix-monthly follow-up should also be considered\nin individuals with high arrhythmic risk genotypes\nsuch as DSP, TMEM43, and carriers of multiple\npathogenic variants.\nIIa\nC\nACM = arrhythmogenic cardiomyopathy; PVC = premature ventricular contrac-\ntion; SCD = sudden cardiac death; VA = ventricular arrhythmia.\naClass of recommendation.\nbLevel of evidence.\nRefer to Table 4 for different indices of exercise intensity and training zones.\n58\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.....................................................................................................\n5.5.3 Exercise recommendations in individuals with left\nventricular non-compaction\nLV non-compaction (LVNC) is an unclassified cardiomyopathy char-\nacterized by prominent trabeculation and deep recesses that com-\nmunicate with the LV cavity.403,404 Clinical presentation of LVNC\nincludes progressive LV systolic dysfunction, ventricular tachyar-\nrhythmias, and thromboembolic events.404\nAthletes often demonstrate LV hypertrabeculation and up to 8% fulfil\nthe echocardiographic criteria for a diagnosis of LVNC.405 It is hypothe-\nsized that an increased cardiac preload may unmask LV trabecular mor-\nphology.406 Therefore, among athletic individuals, the suspicion of\nLVNC should only be considered in those who fulfil echocardiographic\ncriteria for LVNC but also have either LV systolic dysfunction (EF <\n50%), symptoms suggestive of cardiac disease, or a positive family his-\ntory of LVNC.407\u0002409 Additional echocardiographic criteria include a\nvery thin compacted epicardial layer (5 mm in end-diastole on CMR, or\n<8 mm in systole) and abnormal myocardial relaxation (average E’ < 9\ncm/s on tissue Doppler imaging).404,405,410,411 Such athletes will require\nfurther assessment with CMR, exercise echocardiography, and Holter\nmonitor to assess the presence of LV fibrosis, cardiac thrombi, contrac-\ntile reserve, and exercise-induced complex arrhythmias.405,406\n5.5.3.1 Risk stratification\nThe clinical outcomes of LVNC are determined by the presence of\nsymptoms, severity of LV dysfunction, and the nature of the VAs.\nThere are no reported adverse cardiac events in the absence of LV\ndysfunction regardless of the severity of LV trabeculation.405\u0002409\n5.5.3.2 Follow-up\nRegular follow-up is recommended for individuals with LVNC. New\nsymptoms should prompt interruption of exercise and re-evaluation.\n5.5.4 Exercise recommendations in individuals with\ndilated cardiomyopathy\nDCM is characterized by LV or biventricular systolic dysfunction with\nor without dilatation that are not explained by abnormal loading con-\nditions or CAD. Possible causes include genetic predisposition, myo-\ncarditis, drugs, toxins, peripartum cardiomyopathy, and, in some\ncases, the cumulative effect of more than one factor.412\nThe clinical spectrum of disease may range from a mild phenotypic\nexpression characterized by absence of symptoms, isolated LV dilata-\ntion and normal or low-normal systolic function, to an overt disease\nphenotype with limiting symptoms and significant systolic dysfunc-\ntion. Ventricular arrhythmias are common in DCM, particularly in\nindividuals with previous myocarditis, or with lamin A/C mutations\nand filamin C mutations.413,414 The risk of SCD in DCM is 2\u00023% per\nyear and increases with lower EF and higher NYHA class.415 Exercise\ntraining improves functional capacity, ventricular function, and quality\nof life in patients with DCM and should therefore be considered as\nan integral part of the management of affected individuals.416,417\nHowever, intensive exercise and competitive sports are reported as\na cause of SCD in DCM. 28,46,58,413,418\nLV cavity enlargement in trained individuals that is not associated\nwith systolic dysfunction and outside the context of a familial disease,\nrepresents a benign physiological adaptation if it is consistent with the\ntype of sports participated (usually, endurance sports) and the body size\nof the athlete. Conversely, a mildly reduced EF (45\u000250%) in an athlete\nwith an enlarged LV cavity should not merely be considered as a normal\nadaptation. In such cases assessment of LV function during exercise may\nprovide important diagnostic clues.319 Failure to increase EF at peak\nexercise by >10% compared with the baseline value may suggest a\npathological condition.319,419,420 The presence of diastolic dysfunction\nor reduced peak oxygen consumption on CPET may also provide sup-\nporting information for the differential diagnosis. CMR has emerged as\nan important tool for the diagnosis and risk stratification of DCM.\nRecommendations for exercise in individuals with left\nventricular non-compaction cardiomyopathy\nRecommendation for diagnosis\nClassa\nLevelb\nA diagnosis of LVNC in athletic individuals should\nbe considered if they fulﬁl imaging criteria, in asso-\nciation with cardiac symptoms, family history of\nLVNC or cardiomyopathy, LV systolic (EF<50%)\nor diastolic (E’<9 cm/s) dysfunction, a thin com-\npacted epicardial layer (<5 mm in end-diastole on\nCMR, or <8 mm in systole on echocardiography),\nor abnormal 12-lead ECG.404,405,410,411\nIIa\nB\nExercise recommendations\nParticipation in high-intensity exercise and all\ncompetitive sports, if desired, with the exception\nwhere syncope may cause serious harm or death,\nmay be considered in asymptomatic individuals\nwith LVNC and LVEF>_50% and absence of fre-\nquent and/or complex VAs.\nIIb\nC\nParticipation in recreational exercise programmes of\nlow to moderate intensity, if desired, may be consid-\nered in individuals with LVEF 40\u000249% in the absence\nof syncope and frequent or complex VAs on ambula-\ntory Holter monitoring or exercise testing.\nIIb\nC\nContinued\nParticipation in high- or very high-intensity exer-\ncise including competitive sports, if desired, may\nbe considered for individuals who are gene posi-\ntive for LVNC but phenotype negative (with the\nexception of lamin A/C or ﬁlamin C carriers).\nIIb\nC\nParticipation in high-intensity exercise or competi-\ntive sports is not recommended in individuals with\nany of the following: symptoms, LVEF<40% and/or\nfrequent and/or complex VAs on ambulatory\nHolter monitoring or exercise testing.\nIII\nC\nFollow-up and further considerations\nAnnual assessment for risk stratiﬁcation is recom-\nmended for individuals with LVNC and genotype-\npositive/phenotype-negative individuals who exer-\ncise on a regular basis.\nI\nC\nCMR = cardiac magnetic resonance; ECG = electrocardiogram; EF = ejection\nfraction; LV = left ventricular; LVEF = left ventricular ejection fraction; LVNC =\nleft ventricular non-compaction; VA = ventricular arrhythmia.\naClass of recommendation.\nbLevel of evidence.\nESC Guidelines\n59\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.........................................................................\nSpecifically, the presence of LGE, with the typical mid-wall distribution,\nhas been associated with increased risk of VAs and SCD.319,419,421\u0002424\n5.5.4.1 Baseline assessment of patients with dilated\ncardiomyopathy\nClinical evaluation of affected individuals who request exercise advice\nshould aim to: (i) ascertain the potential aetiology; (ii) assess the clini-\ncal status including exercise history and functional capacity; (iii)\nreview the degree of LV dilatation and dysfunction; (iv) assess the\nhaemodynamic response to exercise; and (v) assess the presence of\nexercise-induced symptoms or arrhythmias.\nIn general, symptomatic individuals with DCM should abstain from\nmost competitive and leisure sports or recreational exercise associated\nwith moderate or high exercise intensity. A select group of asympto-\nmatic individuals with DCM who have mildly impaired LV function\n(LVEF 45\u000250%) without exercise-induced arrhythmias or significant\nmyocardial fibrosis may participate in most competitive sports.\n5.5.4.2 Special considerations\nAlthough the natural history of most pathogenic variants is unknown, it\nwould be reasonable to permit intensive exercise and competitive\nsports in most individuals with pathogenic variants implicated in DCM in\nthe absence of overt features of DCM. Special consideration, however,\nshould be given to individuals with pathogenic variants that are associ-\nated with an increased risk of life-threatening arrhythmias such as lamin\nA/C or filamin C mutations. There is emerging evidence that exercise\nmay have an adverse effect on cardiac function and risk for potentially\nfatal arrhythmias in individuals harbouring pathogenic variants in lamin\nA/C.425\u0002427 Affected individuals should not engage in any competitive\nsports or recreational exercise of high or very high intensity irrespective\nof the severity of LV dysfunction and dilatation.428,429\n5.5.4.3 Follow-up.\nRegular follow-up is recommended for most individuals with DCM. New\nsymptoms should prompt interruption of exercise and re-evaluation\n5.5.5 Exercise recommendations in individuals with\nmyocarditis and pericarditis\n5.5.5.1 Myocarditis\nMyocarditis is a non-ischaemic inflammatory disease of the myocar-\ndium, which may cause cardiac dysfunction and arrhythmias.\nMyopericarditis is defined as a primary pericarditis with associated\nmyocardial inflammation and biomarker evidence of myocyte\nnecrosis.430,431 The aetiology of myocarditis is heterogenous, but\nviral infection is the most common cause in the developed world.\nEnterovirus, Coxsackie B virus, parvovirus B-19, and human herpesvi-\nrus 6 are the most frequently responsible infectious pathogens.432,433\nIn the context of young individuals, toxins such as cocaine and\namphetamine-based supplements should also be evaluated in the\nclinical history.430\nThe clinical presentation is highly variable and the diagnosis can be\nchallenging. The illness may be proceeded by coryzal symptoms and\nathletic individuals may present with non-specific features of general\nmalaise, fatigue, or diarrhoea.430,431 At the other extreme, myocarditis\nmay simulate MI or present with symptomatic supraventricular and\nVAs unexplained by other causes, HF, cardiogenic shock, or SCD.\nApproximately 50% of individuals reveal full resolution of LV func-\ntion within 30 days, 25% show persistent cardiac dysfunction, and\n12\u000225% progress to fulminant HF. LV dysfunction is an important\nprognostic factor in the long term.28,434\nRecommendations for exercise in individuals with\ndilated cardiomyopathy\nRecommendations\nClassa\nLevelb\nParticipation in low- to moderate-intensity recrea-\ntional exercise should be considered in all individu-\nals with DCM, regardless of the EF, in the absence\nof limiting symptoms, and exercise-induced VAs.\nIIa\nC\nParticipation in high- or very high-intensity exer-\ncise including competitive sports (with the excep-\ntion of those where occurrence of syncope may\nbe associated with harm or death) may be consid-\nered in asymptomatic individuals who fulﬁl all of\nthe following: (i) mildly reduced LV systolic func-\ntion (EF 45\u000250%); (ii) absence of frequent and/or\ncomplex VAs on ambulatory Holter monitoring\nor exercise testing; (iii) absence of LGE on CMR;\n(iv) ability to increase EF by 10\u000215% during exer-\ncise; and (v) no evidence of high-risk genotype\n(lamin A/C or ﬁlamin C).\nIIb\nC\nContinued\nParticipation in all competitive sports may be con-\nsidered in individuals with DCM who are geno-\ntype positive and phenotype negative, with the\nexception of carriers of high-risk mutations (lamin\nA/C or ﬁlamin C).\nIIb\nC\nParticipation in high- or very high-intensity exer-\ncise including competitive sports is not recom-\nmended for individuals with a DCM and any of the\nfollowing: (i) symptoms or history of cardiac\narrest or unexplained syncope; (ii) LVEF<45%; (iii)\nfrequent and/or complex VAs on ambulatory\nHolter monitoring or exercise testing; (iv) exten-\nsive LGE (>20%) on CMR; or (v) high-risk geno-\ntype (lamin A/C or ﬁlamin C).\nIII\nC\nFollow-up recommendations\nAnnual follow-up is recommended for individuals\nwith DCM who exercise on a regular basis.\nI\nC\nSix-monthly follow-up should be considered in\nindividuals with high-risk mutations and adolescent\nindividuals and young adults whose DCM pheno-\ntype may still be evolving and who are more vul-\nnerable to exercise-related SCD.\nIIa\nC\nAnnual assessment should be considered for gen-\notype-positive/phenotype-negative individuals for\nphenotypic features and risk stratiﬁcation\npurposes.\nIIa\nC\nCMR = cardiac magnetic resonance; DCM = dilated cardiomyopathy; EF = ejec-\ntion fraction; LGE = late gadolinium enhancement; SCD = sudden cardiac death;\nVA = ventricular arrhythmia.\naClass of recommendation.\nbLevel of evidence.\n60\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n..........................................................................................................................................................................\n5.5.5.2 Diagnosis\nSerum cardiac troponin is usually elevated in myopericarditis and is a\nsensitive\nmarker\nof\ncardiac\ninflammation-induced\nmyocyte\nnecrosis.435\nThe ECG has low sensitivity and electrical anomalies are non-\nspecific. ECG patterns vary from non-specific T-wave and ST-\nchanges to ST-segment elevation mimicking MI, left bundle branch\nblock (LBBB), or frequent and/or complex ventricular and supraven-\ntricular arrhythmias, or atrioventricular block, or low QRS voltages in\nthe presence of a pericardial effusion.436\nRecognized echocardiographic features of overt myocarditis\ninclude a non-dilated LV cavity with increased myocardial wall thick-\nness (when oedema is present), or mildly dilated LV cavity with a\nthinned myocardial wall, usually with regional wall motion abnormal-\nities.437 The global LV systolic function may range from being almost\nnormal to severely depressed. Regional wall motion abnormalities\nmay be present.438\nCMR is the most useful diagnostic tool and has excellent sensitivity\nfor detecting myocardial hyperaemia, inflammation, oedema and/or\nfocal scar.439,440 The Lake Louise Criteria and LGE are now comple-\nmented by CMR techniques of T1/T2 mapping and extracellular vol-\nume fraction (ECV).440\u0002442 The extent and distribution of LGE with\nnon-ischaemic pattern are independent predictors of CV events dur-\ning follow-up.439,440,443\u0002447 Namely, a 10% increase of LGE volume\nconveys a 79% increase in the risk of major CV events.448,449\nEndomyocardial biopsy is the gold standard for the diagnosis of\nmyocarditis.450,451 A histological diagnosis allows distinction\nbetween the different types of inflammatory processes, (i.e. giant\ncell myocarditis), and guides treatment in life-threatening presen-\ntations.430,445,452 The diagnostic yield of endomyocardial biopsy\ncan be improved by analysing the viral genome through DNA-\nRNA extraction and reverse transcriptase polymerase chain reac-\ntion (RT-PCR) amplification, which has the advantage of identify-\ning the disease-causing pathogen.445\n5.5.5.3 Risk stratification\nCase series have established myocarditis as a risk factor for SCD,\nwhich accounts for up to 2\u000220% of sudden death in ath-\nletes.17,18,28,430,453,454 Murine models have shown that daily exercise\nin mice infected with Coxsackie virus is associated with increased\nviral titres, fulminant myocarditis, and sudden death.455 These animal\nmodels provide some insight into the mechanisms of SCD with exer-\ncise, which appears to cause an accelerated and progressive inflam-\nmatory response.455\u0002458\n5.5.5.4 Exercise recommendations for individuals with myocarditis\nAthletic individuals with a probable or definitive diagnosis of recent\nmyocarditis should be advised to abstain from competitive sports or\nleisure sports while active inflammation is present, regardless of age,\nsex, or extent of LV systolic dysfunction.459,460\nThe duration of myocardial inflammation can be highly variable\nand may take several months for full resolution. Both the ESC and\nAHA recommend abstinence from moderate- to high-intensity\nexercise for a period of 3\u00026 months,459,460 although the precise\ntiming for return to competitive or recreational sports involving\nmoderate- or high-intensity exercise may be guided by the\npresence of inflammation on T2-weighted images and LGE uptake\non CMR.3,461\nIndividuals with myocarditis should have a comprehensive evaluation\nafter complete recovery to assess the risk of exercise-related SCD.\nImaging studies, exercise stress test, and Holter monitor provide essen-\ntial information for risk stratification. Depressed LV function, presence\nof LGE and complex VAs during exercise or Holter monitoring are\nrecognized risk markers for adverse outcomes.455,462,463\nRepeat evaluation should consist of measurement of troponin and\nbiomarkers of inflammation, echocardiography, and prolonged ECG\nmonitoring. Individuals without evidence of ongoing inflammation\nshould undergo an exercise stress test. A CMR should be repeated if\nmyocardial oedema or LGE was present during the acute illness.\nReturn to sporting activities should be considered, in asymptomatic\nindividuals, with normal troponin and biomarkers of inflammation,\nnormal LV systolic function on echocardiography and CMR, no evi-\ndence of ongoing inflammation or myocardial fibrosis on CMR, good\nfunctional capacity, and absence of complex arrhythmias during exer-\ncise on prolonged ECG monitoring .430,434,453,459,460,464\nIndividuals with previous myocarditis are at risk of recurrence and\nsilent clinical progression, and the presence of LGE during the acute\npresentation is associated with increased incidence of major adverse\ncardiac events; therefore, periodic re-evaluation is advised on an\nannual basis.443,445,454,463\nAmong individuals with healed myocarditis with persistence of\nLGE on CMR but no myocardial oedema at 3\u00026 months, those who\nare asymptomatic, with normal troponin and biomarkers of inflam-\nmation, normal LV systolic function, no evidence of ongoing inflam-\nmation on CMR, and absence of complex arrhythmias during\nexercise on prolonged ECG monitoring (48 h Holter ECG and exer-\ncise stress testing), should be evaluated on a case by case basis and\nmay return to competitive sports on an individual basis. In contrast,\nindividuals with extensive myocardial scar (>20% LGE) and persistent\nLV dysfunction should abstain from exercise programmes and sports\nactivities involving moderate or high physical intensity.\n5.5.6 Pericarditis\nPericarditis is defined as an inflammatory disorder of the pericar-\ndium,430,465 which may be preceded by upper respiratory or gastroin-\ntestinal symptoms. As with myocarditis, viral pathogens are the most\ncommonly implicated pathogens in the western world.\n5.5.6.1 Diagnosis\nThe ECG is non-specific but may reveal characteristic concave ST-\nsegment elevation in most leads and/or PQ depression in the acute\nphase. Echocardiography may reveal a pericardial effusion. CMR\nshould be considered in individuals with raised cardiac troponin levels\nto assess for concomitant myocardial inflammation. Furthermore,\nCMR will identify active inflammation of the pericardium, thickened\npericardial layers, and any signs of pericardial constriction.\n5.5.6.2 Risk stratification\nPericarditis is generally associated with an excellent prognosis.430,465,466\nHowever, there are a subset of patients who may be at greater risk of\nrecurrence and these include individuals with a temperature >38\u0004C at\nESC Guidelines\n61\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n...................................................................................................\npresentation, large pericardial effusion, and those who are resistant to\ntherapy with non-steroidal anti-inflammatory drugs.465,466\n5.5.6.3 Exercise recommendations for individuals with pericarditis\nExercise should be avoided in individuals during active pericarditis.\nIndividuals can return to exercise after complete resolution of the\nactive disease.467 Individuals with a milder clinical course and rapid\nresolution can return to sporting activities within 30 days. However,\nin more severe cases, it may be necessary to wait for a period of 3\nmonths for complete resolution followed by re-evaluation before\nreturning to sports.\nAsymptomatic individuals with a small pericardial effusion occa-\nsionally detected on echocardiography in the absence of clinical cor-\nrelates should be monitored with periodic surveillance, but should\nnot be restricted from sports participation. Competitive sports and/\nor moderate- to high-intensity leisure-time activities should be\navoided in individuals with constrictive pericarditis. Individuals with\nmyopericarditis should be managed according to the recommenda-\ntions for myocarditis.\n5.6 Exercise recommendations in\nindividuals with arrhythmias and\nchannelopathies\n5.6.1 A general management framework\nWhen individuals with known arrhythmias or with a potentially\narrhythmogenic condition want to engage in sports activity, three\nprinciple questions should guide management: (1) is there an\nincreased risk for life-threatening arrhythmias?; (2) how does one\ncontrol symptoms due to arrhythmias, during sports, but also at\nrest?; and (3) what is the impact of sports on the natural progression\nof the arrhythmogenic condition? The general view on the associa-\ntion between sports and arrhythmias is that exercise sets the stage\nfor an arrhythmia in the context of an underlying and pre-existing\ncondition, be it structural, electrical, inherited, or acquired. Moreover,\nregular exercise programmes may induce or accelerate the progres-\nsion of ARVC,382,384 even among those without underlying muta-\ntions.383,387,468 Conceptually, all the structural and functional cardiac\nadaptations to regular intensive exercise may contribute to the devel-\nopment of arrhythmias, at the atrial, nodal, and ventricular level.469\nThis concept explains why recommendations for sports participation\nin individuals with arrhythmogenic conditions are so complex.\n5.6.2 Atrial fibrillation\n5.6.2.1 Patients without atrial fibrillation\nModerate, regular PA is a cornerstone in the prevention of AF\nthrough modifying many of its predisposing factors.297,470\u0002473\nPatients at risk of AF should therefore be motivated to exercise (see\nsection 4.2). Conversely, AF is more prevalent in active and former\nmale master athletes and those performing high-intensity endurance\nsports, suggesting a U-shaped relationship between habitual exercise\nand AF.471,474\u0002477 478\u0002481 This association has not been confirmed in\nwomen.474\nRecommendations for exercise in individuals with\nmyocarditis\nRecommendations\nClassa\nLevelb\nComprehensive evaluation, using imaging studies,\nexercise stress test and Holter monitoring, is rec-\nommended following recovery from acute myo-\ncarditis to assess the risk of exercise-related\nSCD.455,462,463\nI\nB\nReturn to all forms of exercise including competi-\ntive sports should be considered after 3\u00026\nmonths in asymptomatic individuals, with normal\ntroponin and biomarkers of inﬂammation, normal\nLV systolic function on echocardiography and\nCMR, no evidence of ongoing inﬂammation or\nmyocardial ﬁbrosis on CMR, good functional\ncapacity, and absence of frequent and/or complex\nVAs on ambulatory Holter monitoring or exercise\ntesting.430,434,453,459,460,464\nIIa\nC\nAmong individuals with a probable or deﬁnitive\ndiagnosis of recent myocarditis, participation in\nleisure-time or competitive sports while active\ninﬂammation is present is not\nrecommended.459,460\nIII\nC\nParticipation in moderate- to high-intensity exer-\ncise for a period of 3\u00026 months after acute myo-\ncarditis is not recommended.459\u0002461,467\nIII\nB\nParticipation in leisure exercise or competitive\nsports involving high intensity in individuals with\nresidual myocardial scar and persistent LV dys-\nfunction is not recommended.\nIII\nC\nCMR = cardiovascular magnetic resonance; LV = left ventricular; SCD = sudden\ncardiac death; VA = ventricular arrhythmia.\naClass of recommendation.\nbLevel of evidence.\nRecommendations for exercise in individuals with\npericarditis\nRecommendations\nClassa\nLevelb\nReturn to all forms of exercise including competi-\ntive sports is recommended after 30 days to 3\nmonths for individuals who have recovered com-\npletely from acute pericarditis, depending on clini-\ncal severity.459,460\nI\nC\nParticipation in leisure-time or competitive sports\nis not recommended for individuals with a prob-\nable or deﬁnitive diagnosis of recent pericarditis\nwhile active inﬂammation is present, regardless of\nage, sex, or extent of LV systolic\ndysfunction.459,460\nIII\nC\nParticipation in moderate- to high-intensity exer-\ncise, including competitive sports, is not recom-\nmended for individuals with constrictive\npericarditis.\nIII\nC\nLV = left ventricle.\naClass of recommendation.\nbLevel of evidence.\n62\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n5.6.2.2 Prognostic and symptomatic relevance of AF during sports\nUnderlying structural heart disease or pre-excitation should always\nbe excluded before advising sports activity in individuals with recog-\nnized AF. It is also important to exclude hyperthyroidism, alcohol\nabuse, and (illicit) drug use. Intensive sports participation should be\ntemporarily stopped until an identified underlying cause is corrected.\nRapid atrioventricular nodal conduction of AF during exercise may\nlead to symptoms, including dizziness, syncope, fatigue, or impaired\nphysical performance. Therefore, the individual should be instructed to\nstop PA on the emergence of symptoms and rate control should be\noptimized. Rapid 1: 1 conduction can occur, especially during atrial\ntachycardia or atrial flutter (AFL); therefore, if AFL has been docu-\nmented, prophylactic cavo-tricuspid isthmus ablation should be consid-\nered. If there is evidence for adequate rate control while in AF through\nan exercise stress test or ECG monitoring during training or competi-\ntion, all sports participation is possible in asymptomatic individuals.\nAchieving adequate rate control can be difficult, however. Beta-\nblockers are the logical choice but may not be tolerated due to their\nimpact on physical performance. Calcium-channel blockers and digi-\ntalis are usually not potent enough when used alone. Often a combi-\nnation of individually titrated negatively chronotropic agents is\nneeded, while avoiding sinus bradycardia at rest or chronotropic\nincompetence during exercise.\nRhythm control is equally complicated. Class III antiarrhythmic drugs\nare usually insufficient for control (sotalol) or relatively contraindicated\nin a young population (amiodarone). Although class I drugs may be able\nto prevent recurrences of AF, they should not be used in monotherapy,\nsince these may increase the propensity to develop AFL (‘class I AFL’),\nwhich in the absence of adequate rate control may lead to 1: 1 atrioven-\ntricular conduction, high ventricular rates, and very profound intraven-\ntricular conduction slowing, with haemodynamic compromise.482,483\nTherefore, prophylactic cavo-tricuspid-isthmus ablation should be con-\nsidered if class I drugs are prescribed in monotherapy in athletes.\nIn patients with sporadic AF, class I drugs may be considered only\nfor acute cardioversion, i.e. as a ‘pill-in-the-pocket’ approach. These\npatients should refrain from sports as long as AF persists, and until\ntwo half-lives of the antiarrhythmic drug have passed.484\nPrescription of oral anticoagulants (OAC) depends on the clinical\nrisk profile (mainly CHA2DS2-VASc score).485 Sports with direct bodily\ncontact or prone to trauma should be avoided in patients on OAC.486\nCatheter ablation by pulmonary vein isolation (PVI) should be consid-\nered if drug therapy fails or as first-line therapy if drug therapy is not\ndesired.487 Several small series have shown that the outcome of PVI in\nathletes with paroxysmal AF is similar to that in non-athletic\npatients.488,489\n5.6.2.3 Impact of sports continuation on the natural progression of atrial\nfibrillation after ablation\nIf there are no recurrences of AF within 1 month of a successful abla-\ntion procedure, sports activity may be resumed. It is unknown\nwhether continuation of sports after successful PVI might progress\nthe disease process and lead to recurrence of non-pulmonary vein-\ndependent AF in the future. Therefore, no firm recommendation can\nbe made about the ‘safe’ dose of sports after ablation.\nRecommendations for exercise in individuals with atrial\nﬁbrillation\nRecommendations\nClassa\nLevelb\nRegular physical activity is recommended to pre-\nvent AF.297,470\u0002473\nI\nA\nEvaluation and management of structural heart\ndisease, thyroid dysfunction, alcohol or drug\nabuse, or other primary causes of AF is recom-\nmended before engaging in sports.485\nI\nA\nCounselling about the effect of long-lasting intense\nsports participation on (recurrence of) AF is rec-\nommended in individuals with AF who exercise\nvigorously for prolonged periods, especially in\nmiddle-aged men.471,475,481,490\nI\nB\nAF ablation is recommended in exercising\nindividuals with recurrent symptomatic AF, and/\nor in those who do not want drug therapy,\ngiven its impact on athletic performance.488,489\nI\nB\nThe ventricular rate while exercising with AF\nshould be considered in every exercising indi-\nvidual (by symptoms and/or by ECG monitor-\ning), and titrated rate control should be\ninstituted.\nIIa\nC\nParticipation in sports without antiarrhythmic\ntherapy should be considered in individuals with-\nout structural heart disease, and in whom AF is\nwell tolerated.\nIIa\nC\nCavo-tricuspid isthmus ablation should be consid-\nered in those with documented ﬂutter who want\nto engage in intensive exercise, to prevent atrial\nﬂutter 1 : 1 atrioventricular conduction.\nIIa\nC\nProphylactic cavo-tricuspid isthmus ablation to\nprevent ﬂutter should be considered in individu-\nals with AF who want to engage in intensive\nexercise and in whom class I drug therapy is\ninitiated.\nIIa\nC\nThe use of class I antiarrhythmic drugs as mono-\ntherapy, without proof of adequate rate control\nof AF/AFL during vigorous exercise, is not\nrecommended.482,483\nIII\nC\nAfter ingestion of pill-in-the-pocket ﬂecainide or\npropafenone, participation in intensive sports is\nnot recommended until two half-lives of the anti-\narrhythmic drug have elapsed (i.e. up to 2\ndays).484\nIII\nC\nSports with direct bodily contact or prone to\ntrauma are not recommended in exercising indi-\nviduals with AF who are anticoagulated.485\nIII\nA\nAF = atrial ﬁbrillation; AFL = atrial ﬂutter; ECG = electrocardiogram.\naClass of recommendation.\nbLevel of evidence.\nESC Guidelines\n63\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n...................................................................................................................\n5.6.3 Supraventricular tachycardia and Wolff-Parkinson-\nWhite syndrome\nThe term paroxysmal supraventricular tachycardia (PSVT) includes\n(i) atrioventricular nodal re-entrant tachycardia (AVNRT; most com-\nmon); (ii) atrioventricular re-entrant tachycardia (AVRT) involving an\naccessory pathway; or (iii) atrial tachycardia.\nVentricular pre-excitation on the resting ECG is due to an acces-\nsory pathway (AP) with antegrade conduction. The prevalence of\npre-excitation in the general population varies from 0.1\u00020.3%.491,492\nWolff-Parkinson-White (WPW) syndrome is defined as the presence\nof paroxysmal arrhythmias in a patient with pre-excitation.\n5.6.3.1 Prognostic and symptomatic relevance of paroxysmal supraven-\ntricular tachycardia without pre-excitation\nPSVT without pre-excitation and without associated structural heart\ndisease is not life-threatening, although the arrhythmia may result in\ndizziness and exhaustion that requires cessation of exercise. Syncope\nis uncommon. Pre-excitation, however, may be associated with sud-\nden death (see later); therefore, it is important to exclude the pres-\nence of latent pre-excitation, by performing carotid sinus massage or\nan adenosine-test in sinus rhythm.493\nAthletes with PSVT should stop exercise in the event of palpita-\ntions since rapid heart rates may cause (pre)syncope. Individuals with\nproven PSVT without pre-excitation should be educated on how to\nsafely perform vagal manoeuvres (such as carotid sinus massage or,\npreferably, Valsalva manoeuvre) to facilitate termination of the\narrhythmia.494 Exercise may be resumed after termination of the\narrhythmia. Prophylactic drug treatment with beta-blockers or cal-\ncium antagonists with atrioventricular nodal blocking properties can\nbe considered, although it has limited efficacy. Class I drugs have no\nrole in the management of PSVT, since they can cause life-\nthreatening arrhythmias (see earlier).\nIf competitive athletic activity is desired, curative treatment by\nablation should be considered. Ablation outcome is equally safe and\nhas similar acute success rates in athletes and non-athletes.495 If the\nPSVT is only sporadic and transient and not associated with haemo-\ndynamic consequences, even when it develops during exercise, or in\ncases where ablation is not desired or unsuccessful, sports activity is\npermissible when there is no increased risk of a fatality from a poten-\ntial loss of consciousness (such as motorsports drivers, parachute\njumpers, divers, and so on).\n5.6.3.2 Prognostic and symptomatic relevance of pre-excitation\nIt has been estimated that one third of patients with WPW syndrome\nmay develop AF and, in such cases, rapid conduction over the AP can\nlead to ventricular fibrillation (VF) and sudden death. Given the fact\nthat AF is more common in athletes, pre-excitation constitutes a\nprognostic concern in athletes. The risk for sudden death in patients\nwith\npre-excitation\nvaries\nin\npopulation-based\nstudies\nfrom\n0.15\u00020.20%, and usually presents during exercise or emotional\nstress.496\nEvaluation of the athlete with ventricular pre-excitation should\nexclude associated structural cardiac disease, such as HCM or Ebstein\nanomaly. Minimal or ‘latent’ pre-excitation can be unmasked on a 12-\nlead ECG during sinus rhythm by vagal manoeuvres or intravenous\nadministration of adenosine. Prolongation of the PR interval without a\nchange in the QRS morphology, or transient atrioventricular block,\nexcludes non-intermittent latent pre-excitation. Pre-excitation may be\nintermittent, which usually indicates low risk properties of the pathway.\nHowever, some accessory pathways may be potentiated by adrenergic\nstimuli. Therefore, exercise testing excluding pre-excitation at peak\nexercise is recommended before clearance for sports.\nAblation of the AP is recommended in competitive and recrea-\ntional athletes with pre-excitation and documented arrhythmias. In\nthe event of transient, infrequent well-tolerated arrhythmia (even\nduring exercise), good anticipation of an ablation procedure with\nincreased risk (e.g. anteroseptal AP), or reluctance of the athlete to\nundergo ablation, management should be guided by assessment of\nthe antegrade conduction characteristics of the AP using either non-\ninvasive tests or an invasive electrophysiological (EP) study.\nNon-invasive\ninvestigation\nexamines\nfor\nintermittent\npre-\nexcitation on ECG or Holter, for abrupt disappearance of pre-\nexcitation after administration of a low dose of class I drugs, or for its\nabrupt disappearance during an exercise test.497 In cases of a long\nrefractory period and hence low risk for sudden death, continuation\nof sports activity is permitted without ablation on the understanding\nthat sporting activity should be stopped in the event of recurrence of\npalpitations.\nIn competitive athletes with asymptomatic pre-excitation an EP\nstudy is warranted to evaluate the risk for sudden death. In the event\nof a high-risk finding (Table 15), ablation of the AP is recommended.\nFor athletes who refuse ablation, or if the procedure is associated\nwith high risk, such as an anteroseptal accessory pathway, participa-\ntion in competitive sports activities can be discussed on an individual\ncase by case basis including the use of pharmacological therapy,\nalthough there are currently no data about its efficacy. Sports in\nwhich the potential loss of consciousness could be fatal should be\ndiscouraged.\nIn recreational athletes with asymptomatic pre-excitation, risk\nassessment may first be pursued via non-invasive testing.497 The sen-\nsitivity of non-invasive screening for AP properties that facilitate a fast\nventricular response to AF/AFL is good, but its specificity is low.498\nOf note, in children younger than 12 years, the risk of AF-induced\nVF and sudden death is very low. Generally, a conservative approach\nTable 15\nFindings during an invasive electrophysiological\nstudy (with the use of isoprenaline) indicating an accessory\npathway with increased risk of sudden death\n©ESC 2020\nAF = atrial ﬁbrillation; AVRT = atrioventricular re-entrant tachycardia.\n64\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\nis recommended in this age group, although one study499 suggested\nthat prophylactic assessment and ablation reduces the risk of sudden\ndeath. There is a knowledge gap in the benefit/risk ratio of this\napproach and large-scale studies are required to address the issue.\nLeisure-time and low- to medium-intensity exercise programmes\ncan generally be resumed 1 week after ablation if there is no particu-\nlar risk of recurrence of arrhythmia.\nResuming competitive sports is possible after 1\u00023 months, with\nfurther ECG follow-up at 6 months and 1 year (given the very small\nrisk for late recurrence of pre-excitation).\nAlthough there may be an association between (type of) AVNRT\nand history of sports, there are no data about higher recurrence rate\npost ablation when sports are resumed or not, and hence no reason\nto limit exercise programmes for such reason.\n5.6.4 Premature ventricular contractions and\nnon-sustained ventricular tachycardia\n5.6.4.1 Relation between number of premature ventricular contractions\nand risk\nOnly a minority of athletes exhibit frequent or complex VA with a\nprevalence similar to that of their sedentary counterparts.502\u0002505\nPremature ventricular contractions (PVCs) may be a marker of\nunderlying heart disease, the presence of which would confer an\nunfavourable prognosis even in asymptomatic individuals. Specific\ncharacteristics of the PVCs, including morphology (origin from the\napex or free wall of the LV or RV), high burden, complexity (e.g. cou-\nplets, triplets, or non-sustained runs), multifocal origin, and/or\nincreasing frequency with exercise should alert to the possibility of\nelectrical, ischaemic, or structural heart disease.505,506\nThere is no absolute threshold of the number of PVCs that can be\nused as a cut-off for underlying disease. One study has shown that in\nasymptomatic athletes with >2000 PVCs per day, there was a 30%\nchance of finding an underlying structural or cardio-genetic\ndisease.503\n5.6.4.2 Morphology of premature ventricular contractions\nThe morphology of the PVCs may provide important prognostic\ninformation since some foci of origin are recognized as benign. The\nmost prevalent entity in this respect are PVCs originating from the\nright or left ventricular outflow regions (RVOT/LVOT), showing a\nclear inferior axis with high voltages in the inferior limb leads. Early\nprecordial transition (in V2, and certainly when V1 shows a right bun-\ndle branch morphology) suggests a left-sided origin.507 RVOT/LVOT\nPVCs are thought to be the result of triggered activity, i.e. a local cel-\nlular cause, which has no negative prognostic implications. Although\nthese RVOT/LVOT arrhythmias usually occur in structurally normal\nhearts, they may be the expression of subclinical arrhythmogenic car-\ndiomyopathy. Cardiac imaging tests can help exclude structural heart\ndisease in such athletes.\nLess common locations of focal PVCs are around the mitral or tri-\ncuspid annulus, most often in a postero-septal location. These have a\nsuperior axis with LBBB or RBBB morphology. The PVCs originating\nfrom the His-Purkinje system typically have relatively narrow QRS\ncomplex with RBBB morphology and either left anterior or left pos-\nterior hemi-block. Lastly, intramyocardial foci may occur, often\nrelated to the papillary muscles or moderator band.508\nPVCs of differing morphologies from the RV (i.e., wide LBBB and\nsuperior axis) in individuals with normal LV function should prompt\ninvestigations to exclude arrhythmogenic cardiomyopathy or sarcoi-\ndosis. Similarly, wide RBBB pattern, with superior axis and multifocal\nPVCs of LV origin should trigger investigations for non-ischaemic\ncardiomyopathy.\nVery rarely, otherwise ‘benign’ PVCs arising from the Purkinje net-\nwork may give rise to polymorphic ventricular tachycardia (VT) or\nVF due to their short coupling interval.509,510 In such patients, the\nmalignant electrical presentation mandates aggressive treatment.\nFinally, frequent but otherwise benign PVCs (usually defined as\n>10\u000215% of the total number of beats per 24 h) can impair LV func-\ntion over time (PVC-induced cardiomyopathy), which may be rever-\nsible with medical treatment or catheter ablation.511,512\n5.6.4.3 Premature ventricular contractions: response to exercise\nReduction or resolution of PVCs with increasing exercise load is typi-\ncal of idiopathic and benign VAs, particularly those with an outflow\ntract morphology.513,514 PVCs induced by exercise should be consid-\nered as a ‘red flag’, because VAs associated with heart diseases are\noften made worse by adrenergic stimulation.19,502,511,512,515\u0002520 A\nhigher prevalence of myocardial substrates (mainly mid-wall or sube-\npicardial non-ischaemic LV scars) was found in a CMR study among\nathletes with exercise-induced PVCs compared to those with\nexercise-suppressed VAs (56% vs. 21%).516\nRecommendations for exercise and sports participation\nin individuals with paroxysmal supraventricular tachy-\ncardia and pre-excitation\nRecommendations\nClassa\nLevelb\nIn individuals with palpitations, a comprehensive\nassessment to exclude (latent) pre-excitation,\nstructural heart disease, and VAs is\nrecommended.500\nI\nB\nParticipation in all sports activities is recom-\nmended in individuals PSVT without pre-\nexcitation.500\nI\nC\nAblation of the accessory pathway is recom-\nmended in competitive and recreational athletes\nwith pre-excitation and documented\narrhythmias.500\nI\nC\nIn competitive/professional athletes with asymp-\ntomatic pre-excitation, an EP study is recom-\nmended to evaluate the risk for sudden\ndeath.497,500\nI\nB\nIn competitive athletes with PSVT but without\npre-excitation, curative treatment by ablation\nshould be considered.\nIIa\nC\nEP = electrophysiological; PSVT = paroxysmal supraventricular tachycardia; VA =\nventricular arrhythmia.\naClass of recommendation.\nbLevel of evidence.\nESC Guidelines\n65\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n........................................................................................................................................................\nOf note, exercise-induced isolated or repetitive PVCs with multi-\nple morphologies, especially with beat-to-beat alternating morpholo-\ngies (so-called ‘bi-directional’ pattern), may be the expression of\ncatecholaminergic polymorphic VT, which can degenerate into\nVF.518,521\n5.6.4.4 Practical management of cardiac patients with premature ven-\ntricular contractions or non-sustained ventricular tachycardia who want\nto engage in sports\nThe most important task in individuals with PVCs or NSVT who\nwant to engage in sports is to exclude underlying structural or familial\narrhythmogenic conditions, since sports activity may trigger sustained\nVT. It has been suggested that the presence of >_2 PVCs on a baseline\nECG (or even >_1 PVC in the case of high-endurance athletes) should\nprompt a more thorough evaluation.522Work-up includes a family\nhistory, assessment of the number, morphology, and complexity of\nPVCs by Holter and 12-lead ECG, inducibility by exertion (via exer-\ncise test or long-term ECG recording during sports activities), and\ntailored additional imaging.1 Further diagnostic evaluation with\nmolecular genetic testing may be indicated in selected cases if the sus-\npicion for familial disease is high. Finally, repeat evaluation may be\nneeded after 6 months to 2 years. Recommendations for sports par-\nticipation of athletes with PVC should be individualized based on\nevaluation for underlying cardiac conditions as described earlier, and\noften requires shared decision making.\n5.6.5 Long QT syndrome\nThe\nQT\nand\ncorrected\nQTc\nintervals\nvary\nby\nsex\nand\nphysical training. Congenital long QT syndrome (LQTS) should be\ndistinguished from acquired forms, i.e. due to circumstances, which\ncan be reversed and prevented. Once acquired LQTS is established,\nsports activity should be prohibited until the underlying cause is\ncorrected.\nA definitive diagnosis of congenital LQTS is often difficult.523\nCongenital LQTS should be suspected on a routine ECG or 4 min\ninto recovery after an exercise stress test,524 if the corrected QTc\ninterval according to Bazett’s formula is >_470 ms or >_480 ms in\nasymptomatic male or female athletes, respectively.525 A QTc of\n>_500 ms is diagnostic.526 In the case of a borderline long QTc\ninterval and a negative personal and familial history, subclinical\narrhythmias should be excluded by exercise testing and long-term\nECG recording.\nSince the risk of cardiac events during sports activities is largely\ngene-specific, genetic testing and cascade screening of family members\nshould be performed following a clinical diagnosis of LQTS. Individuals\nwith LQT1 are at highest risk during stressful exercise.527,528\nSymptomatic athletes should not engage in competitive sports.\nIndividuals with LQT1 should not engage in sports that involve div-\ning into cold water since this is associated with increased risk of\narrhythmias. General precautions include avoidance of QT-\nprolonging drugs, dehydration, and electrolyte imbalance. Beta-\nblocker therapy is extremely effective in LQT1 and additional\ntherapies are only needed to control more severe cases or specific\ngenotypes.529\nSurvivors of SCA (certainly while taking beta-blocker therapy)\nshould be referred for an ICD. Similarly, individuals who have experi-\nenced sudden syncope despite beta-blocker therapy should also be\nreferred for an ICD or sympathetic cardiac denervation.530 ICD\nimplantation does not constitute clearance for intensive or competi-\ntive sports. Continued sports participation with an ICD is possible,\nbut specific recommendations apply (see section 5.5.6). American\nguidelines are more lenient with respect to participation in competi-\ntive sport (except for LQT1), provided that precautions include the\npresence of an automatic external defibrillator (AED) ‘as part of the\nathlete’s personal sports safety gear’.531 We consider such obligation\nto be impractical (e.g. winter sports, water sports), and it places an\nadded responsibility on clubs or other bystanders, which cannot be\njustified by a medical recommendation for an individual athlete.\nMoreover, although LQTS-related cardiac arrest is uncommon, even\nduring competitive sports,527 AED efficacy is not 100% in such\ncases.532\nIn asymptomatic LQTS mutation carriers without a prolonged QT\ninterval, i.e. <470 ms in men and <480 ms in women (‘genotype posi-\ntive/phenotype negative’), shared decision making is required, balanc-\ning the risk for arrhythmias with psychological well-being. A negative\nexercise stress test has no predictive value.\nRecommendations for exercise in individuals with pre-\nmature ventricular contractions or non-sustained ven-\ntricular tachycardia\nRecommendations\nClassa\nLevelb\nIn exercising individuals with >_2 PVCs on a base-\nline ECG (or >_1 PVC in the case of high-endur-\nance athletes) thorough evaluation (including a\ndetailed family history) to exclude underlying\nstructural or arrhythmogenic conditions is\nrecommended.503,522\nI\nC\nAmong individuals with frequent PVCs and non-\nsustained VT a thorough investigation with\nHolter monitoring, 12-lead ECG, exercise test,\nand suitable imaging is recommmended.503\nI\nC\nIt is recommended that all competitive and lei-\nsure-time sports activities are permitted, with\nperiodic re-evaluation in individuals without fam-\nilial or structural underlying disease.503\nI\nC\nECG = electrocardiogram; PVC = premature ventricular contractions; VT = ven-\ntricular tachycardia.\naClass of recommendation.\nbLevel of evidence.\n66\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 41",
          "page": 41,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nExercise recommendations |  | \nParticipation in high-intensity exercise/competitive\nsports, if desired (with the exception of those\nwhere occurrence of syncope may be associated\nwith harm or death), may be considered for indi-\nviduals who do not have any markers of increased\nriskc following expert assessment. | IIb | C\nParticipation in low- or moderate-intensity recrea-\ntional exercise, if desired, may be considered for\nindividuals who have any markers of increased\nriskc following expert assessment . | IIb | C\nParticipation in all competitive sports, if desired,\nmay be considered for individuals who are gene\npositive for HCM but phenotype negative. | IIb | C\nParticipation in high-intensity exercise (including\nrecreational and competitive sports) is not recom-\nmended for individuals who have ANY markers of\nincreased riskc. | III | C\nFollow-up and further considerations relating to risk |  | \nAnnual follow-up is recommended for individuals\nwho exercise on a regular basis. | I | C\nSix-monthly follow-up should be considered in\nadolescent individuals and young adults who are\nmore vulnerable to exercise-related SCD. | IIa | C\nAnnual assessment should be considered for gen-\notype-positive/phenotype-negative individuals for\nphenotypic features and risk stratification\npurposes. | IIa | C",
          "rows": 12,
          "cols": 3
        },
        {
          "title": "Table on page 42",
          "page": 42,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nExercise recommendations |  | \nParticipation in 150 min of low-intensity exercise\nper week should be considered for all individuals. | IIa | C\nParticipation in low- to moderate-intensity recrea-\ntional exercise/sports, if desired, may be consid-\nered for individuals with no history of cardiac\narrest/VA, unexplained syncope, minimal struc-\ntural cardiac abnormalities, <500 PVCs/24 h and\nno evidence of exercise-induced complex VAs. | IIb | C\nParticipation in high-intensity recreational exercise/\nsports or any competitive sports is not recom-\nmended in individuals with ACM, including those\nwho are gene positive but phenotype negative.384,386 | III | B\nFollow-up and further considerations relating to risk |  | \nAnnual follow-up is recommended for individuals\nwho exercise on a regular basis. | I | C\nSix-monthly follow-up should be considered in\nadolescent individuals and young adults who are\nmore vulnerable to exercise-related SCD. | IIa | C\nAnnual assessment should be considered for geno-\ntype-positive/phenotype-negative individuals for\nphenotypic features and risk stratification purposes. | IIa | C\nSix-monthly follow-up should also be considered\nin individuals with high arrhythmic risk genotypes\nsuch as DSP, TMEM43, and carriers of multiple\npathogenic variants. | IIa | C\n |  | ",
          "rows": 13,
          "cols": 3
        },
        {
          "title": "Table on page 43",
          "page": 43,
          "content": "Participation in high- or very high-intensity exer-\ncise including competitive sports, if desired, may\nbe considered for individuals who are gene posi-\ntive for LVNC but phenotype negative (with the\nexception of lamin A/C or filamin C carriers). | IIb | C | \nParticipation in high-intensity exercise or competi-\ntive sports is not recommended in individuals with\nany of the following: symptoms, LVEF<40% and/or\nfrequent and/or complex VAs on ambulatory\nHolter monitoring or exercise testing. | III | C | \nFollow-up and further considerations |  |  | \nAnnual assessment for risk stratification is recom-\nmended for individuals with LVNC and genotype-\npositive/phenotype-negative individuals who exer-\ncise on a regular basis. | I | C | ",
          "rows": 4,
          "cols": 4
        },
        {
          "title": "Table on page 43",
          "page": 43,
          "content": " |  |  | \nRecommendation for diagnosis | Classa | Levelb | \n |  |  | \nA diagnosis of LVNC in athletic individuals should\nbe considered if they fulfil imaging criteria, in asso-\nciation with cardiac symptoms, family history of\nLVNC or cardiomyopathy, LV systolic (EF<50%)\nor diastolic (E’<9 cm/s) dysfunction, a thin com-\npacted epicardial layer (<5 mm in end-diastole on\nCMR, or <8 mm in systole on echocardiography),\nor abnormal 12-lead ECG.404,405,410,411 | IIa | B | \nExercise recommendations |  |  | \nParticipation in high-intensity exercise and all\ncompetitive sports, if desired, with the exception\nwhere syncope may cause serious harm or death,\nmay be considered in asymptomatic individuals\nwith LVNC and LVEF>50% and absence of fre-\n_\nquent and/or complex VAs. | IIb | C | \nParticipation in recreational exercise programmes of\nlow to moderate intensity, if desired, may be consid-\nered in individuals with LVEF 40\u000249% in the absence\nof syncope and frequent or complex VAs on ambula-\ntory Holter monitoring or exercise testing. | IIb | C | ",
          "rows": 7,
          "cols": 4
        },
        {
          "title": "Table on page 44",
          "page": 44,
          "content": "Participation in all competitive sports may be con-\nsidered in individuals with DCM who are geno-\ntype positive and phenotype negative, with the\nexception of carriers of high-risk mutations (lamin\nA/C or filamin C). | IIb | C | \nParticipation in high- or very high-intensity exer-\ncise including competitive sports is not recom-\nmended for individuals with a DCM and any of the\nfollowing: (i) symptoms or history of cardiac\narrest or unexplained syncope; (ii) LVEF<45%; (iii)\nfrequent and/or complex VAs on ambulatory\nHolter monitoring or exercise testing; (iv) exten-\nsive LGE (>20%) on CMR; or (v) high-risk geno-\ntype (lamin A/C or filamin C). | III | C | \nFollow-up recommendations |  |  | \nAnnual follow-up is recommended for individuals\nwith DCM who exercise on a regular basis. | I | C | \nSix-monthly follow-up should be considered in\nindividuals with high-risk mutations and adolescent\nindividuals and young adults whose DCM pheno-\ntype may still be evolving and who are more vul-\nnerable to exercise-related SCD. | IIa | C | \nAnnual assessment should be considered for gen-\notype-positive/phenotype-negative individuals for\nphenotypic features and risk stratification\npurposes. | IIa | C | ",
          "rows": 6,
          "cols": 4
        },
        {
          "title": "Table on page 44",
          "page": 44,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nParticipation in low- to moderate-intensity recrea-\ntional exercise should be considered in all individu-\nals with DCM, regardless of the EF, in the absence\nof limiting symptoms, and exercise-induced VAs. | IIa | C | \nParticipation in high- or very high-intensity exer-\ncise including competitive sports (with the excep-\ntion of those where occurrence of syncope may\nbe associated with harm or death) may be consid-\nered in asymptomatic individuals who fulfil all of\nthe following: (i) mildly reduced LV systolic func-\ntion (EF 45\u000250%); (ii) absence of frequent and/or\ncomplex VAs on ambulatory Holter monitoring\nor exercise testing; (iii) absence of LGE on CMR;\n(iv) ability to increase EF by 10\u000215% during exer-\ncise; and (v) no evidence of high-risk genotype\n(lamin A/C or filamin C). | IIb | C | ",
          "rows": 5,
          "cols": 4
        },
        {
          "title": "Table on page 46",
          "page": 46,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nReturn to all forms of exercise including competi-\ntive sports is recommended after 30 days to 3\nmonths for individuals who have recovered com-\npletely from acute pericarditis, depending on clini-\ncal severity.459,460 | I | C | \nParticipation in leisure-time or competitive sports\nis not recommended for individuals with a prob-\nable or definitive diagnosis of recent pericarditis\nwhile active inflammation is present, regardless of\nage, sex, or extent of LV systolic\ndysfunction.459,460 | III | C | \nParticipation in moderate- to high-intensity exer-\ncise, including competitive sports, is not recom-\nmended for individuals with constrictive\npericarditis. | III | C | ",
          "rows": 6,
          "cols": 4
        },
        {
          "title": "Table on page 46",
          "page": 46,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nComprehensive evaluation, using imaging studies,\nexercise stress test and Holter monitoring, is rec-\nommended following recovery from acute myo-\ncarditis to assess the risk of exercise-related\nSCD.455,462,463 | I | B | \nReturn to all forms of exercise including competi-\ntive sports should be considered after 3\u00026\nmonths in asymptomatic individuals, with normal\ntroponin and biomarkers of inflammation, normal\nLV systolic function on echocardiography and\nCMR, no evidence of ongoing inflammation or\nmyocardial fibrosis on CMR, good functional\ncapacity, and absence of frequent and/or complex\nVAs on ambulatory Holter monitoring or exercise\ntesting.430,434,453,459,460,464 | IIa | C | \nAmong individuals with a probable or definitive\ndiagnosis of recent myocarditis, participation in\nleisure-time or competitive sports while active\ninflammation is present is not\nrecommended.459,460 | III | C | \nParticipation in moderate- to high-intensity exer-\ncise for a period of 3\u00026 months after acute myo-\ncarditis is not recommended.459\u0002461,467 | III | B | \nParticipation in leisure exercise or competitive\nsports involving high intensity in individuals with\nresidual myocardial scar and persistent LV dys-\nfunction is not recommended. | III | C | ",
          "rows": 8,
          "cols": 4
        },
        {
          "title": "Table on page 47",
          "page": 47,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nRegular physical activity is recommended to pre-\nvent AF.297,470\u0002473 | I | A\nEvaluation and management of structural heart\ndisease, thyroid dysfunction, alcohol or drug\nabuse, or other primary causes of AF is recom-\nmended before engaging in sports.485 | I | A\nCounselling about the effect of long-lasting intense\nsports participation on (recurrence of) AF is rec-\nommended in individuals with AF who exercise\nvigorously for prolonged periods, especially in\nmiddle-aged men.471,475,481,490 | I | B\nAF ablation is recommended in exercising\nindividuals with recurrent symptomatic AF, and/\nor in those who do not want drug therapy,\ngiven its impact on athletic performance.488,489 | I | B\nThe ventricular rate while exercising with AF\nshould be considered in every exercising indi-\nvidual (by symptoms and/or by ECG monitor-\ning), and titrated rate control should be\ninstituted. | IIa | C\nParticipation in sports without antiarrhythmic\ntherapy should be considered in individuals with-\nout structural heart disease, and in whom AF is\nwell tolerated. | IIa | C\nCavo-tricuspid isthmus ablation should be consid-\nered in those with documented flutter who want\nto engage in intensive exercise, to prevent atrial\nflutter 1 : 1 atrioventricular conduction. | IIa | C\nProphylactic cavo-tricuspid isthmus ablation to\nprevent flutter should be considered in individu-\nals with AF who want to engage in intensive\nexercise and in whom class I drug therapy is\ninitiated. | IIa | C\nThe use of class I antiarrhythmic drugs as mono-\ntherapy, without proof of adequate rate control\nof AF/AFL during vigorous exercise, is not\nrecommended.482,483 | III | C\nAfter ingestion of pill-in-the-pocket flecainide or\npropafenone, participation in intensive sports is\nnot recommended until two half-lives of the anti-\narrhythmic drug have elapsed (i.e. up to 2\ndays).484 | III | C\nSports with direct bodily contact or prone to\ntrauma are not recommended in exercising indi-\nviduals with AF who are anticoagulated.485 | III | A",
          "rows": 14,
          "cols": 3
        },
        {
          "title": "Table on page 49",
          "page": 49,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIn individuals with palpitations, a comprehensive\nassessment to exclude (latent) pre-excitation,\nstructural heart disease, and VAs is\nrecommended.500 | I | B | \nParticipation in all sports activities is recom-\nmended in individuals PSVT without pre-\nexcitation.500 | I | C | \nAblation of the accessory pathway is recom-\nmended in competitive and recreational athletes\nwith pre-excitation and documented\narrhythmias.500 | I | C | \nIn competitive/professional athletes with asymp-\ntomatic pre-excitation, an EP study is recom-\nmended to evaluate the risk for sudden\ndeath.497,500 | I | B | \nIn competitive athletes with PSVT but without\npre-excitation, curative treatment by ablation\nshould be considered. | IIa | C | ",
          "rows": 8,
          "cols": 4
        },
        {
          "title": "Table on page 50",
          "page": 50,
          "content": " |  | Levelb\nRecommendations | Classa | \n |  | \nIn exercising individuals with >2 PVCs on a base-\n_\nline ECG (or >1 PVC in the case of high-endur-\n_\nance athletes) thorough evaluation (including a\ndetailed family history) to exclude underlying\nstructural or arrhythmogenic conditions is\nrecommended.503,522 | I | C\nAmong individuals with frequent PVCs and non-\nsustained VT a thorough investigation with\nHolter monitoring, 12-lead ECG, exercise test,\nand suitable imaging is recommmended.503 | I | C\nIt is recommended that all competitive and lei-\nsure-time sports activities are permitted, with\nperiodic re-evaluation in individuals without fam-\nilial or structural underlying disease.503 | I | C",
          "rows": 6,
          "cols": 3
        }
      ],
      "keywords": [
        "cardiomyopathy",
        "arrhythmogenic",
        "ct",
        "risk",
        "imaging",
        "icd",
        "diagnosis",
        "recommendation"
      ]
    },
    {
      "number": "6",
      "title": "..................................................................................",
      "start_page": 51,
      "end_page": 60,
      "content": "..................................................................................\n5.6.6 Brugada syndrome\nThe Brugada syndrome (BrS) is an inherited cardiac ion channel dis-\norder with an elevated risk of VF and SCD in individuals with a struc-\nturally normal heart.533,534 Although BrS was initially described as a\npurely electrical disease, minor structural RV abnormalities have\nbeen described,535\u0002538 suggesting that the disease may be the result\nof early repolarization or delayed depolarization.509 The diagnosis is\nbased on the presence of the type 1 Brugada pattern on the 12-lead\nECG (coved-type ST-segment elevation >_2 mm followed by a nega-\ntive T-wave in >_1 mm of the right precordial leads positioned in the\nfourth, third, or second intercostal space), either spontaneously or\nfollowing provocation by a sodium ion channel blocker.523,539,540\nMost individuals with BrS remain asymptomatic throughout their\nlives. In the majority of cases, events occur during sleep or rest, dur-\ning febrile states or, occasionally, from heat stroke.541\u0002549 Patients\nwho have suffered a SCA or an arrhythmic syncope should undergo\nICD implantation.247,511 Risk stratification in the asymptomatic popu-\nlation with spontaneous type 1 ECG pattern is more challeng-\ning.247,511 There is controversial evidence that exercise testing\nshowing an aggravating phenotype during exercise or early recovery,\nor EP study, are efficient at detecting individuals at risk of SCD. In\nasymptomatic patients with only inducible type 1 Brugada ECG\npattern, preventive measures are recommended, such as avoidance\nof triggering drugs (www.brugadadrugs.org), electrolyte imbalance,\nand increases in core temperature >39\u0004C (e.g. by minimizing immer-\nsion in hot tubs, saunas, and steam rooms; by avoiding sports in\nwarm/humid conditions; or by abstaining from prolonged endurance\nevents such as triathlons and marathons). During febrile illness, fever\nshould be treated aggressively.247,511\nOne could speculate that an enhanced vagal reaction during recov-\nery550 and a predominant vagal tone at rest551 may increase the sus-\nceptibility of highly trained individuals to develop arrhythmias during\nrecovery or at rest. However, there are no reports directly linking\nexercise or sports training to cardiac events and there are no large\nprospective studies evaluating the effect of exercise and sports in\nBrS.\nAsymptomatic patients with the spontaneous type I BrS ECG pat-\ntern may compete in all sports except endurance sports associated\nwith an increase in core temperature >39\u0004C (e.g. marathon running\nand triathlons). Similar rules apply to asymptomatic genotype-\npositive/phenotype-negative individuals and those with the concealed\nform of BrS.\nIf treated with an ICD, provided precautionary measures are taken\nand the patient has been asymptomatic for >_3 months, resumption\nof all sport, including competitive sport, may be considered, after\nshared decision making, and also taking into consideration the findings\nfrom the ICD registry (see later).\nRecommendations for exercise in long QT syndrome\nRecommendations\nClassa\nLevelb\nIt is recommended that all exercising individuals\nwith LQTS with prior symptoms or prolonged\nQTc be on therapy with beta-blockers at target\ndose.529\nI\nB\nIt is recommended that exercising individuals\nwith LQTS should avoid QT prolonging drugs\n(www.crediblemeds.org) and electrolyte imbal-\nance such as hypokalaemia and\nhypomagnesaemia.529\nI\nB\nShared decision making should be considered\nregarding sports participation in patients with\ngenotype-positive/phenotype-negative LQTS\n(i.e. <470/480 ms in men/women). Type and set-\nting of sports (individual vs. team), type of muta-\ntion, and extent of precautionary measures\nshould be considered in this context.\nIIa\nC\nParticipation in high-intensity recreational and\ncompetitive sports, even when on beta-blockers,\nis not recommended in individuals with a\nQTc>500 ms or a genetically conﬁrmed LQTS\nwith a QTc>_470 ms in men or >_480 ms in\nwomen.\nIII\nB\nParticipation in competitive sports (with or with-\nout ICD) is not recommended in individuals with\nLQTS and prior cardiac arrest or arrhythmic\nsyncope.\nIII\nC\nICD = implantable cardioverter deﬁbrillator; LQTS = long QT syndrome.\naClass of recommendation.\nbLevel of evidence.\nRecommendations for exercise in Brugada syndrome\nRecommendations\nClassa\nLevelb\nICD implantation is recommended in patients\nwith BrS with episodes of arrhythmic syncope\nand/or aborted SCD.247\nI\nC\nFollowing implantation of an ICD, resumption of\nleisure or competitive sports should be consid-\nered after shared decision making in individuals\nwho have not experienced recurrent arrhyth-\nmias over 3 months after ICD implantation.\nIIa\nC\nIn asymptomatic individuals with BrS, asympto-\nmatic mutation carriers and asymptomatic ath-\nletes with only an inducible ECG pattern,\nparticipation in sports activities that are not\nassociated with an increase in core temperature\n>39\u0004C (e.g. endurance events under extremely\nhot and/or humid conditions) may be\nconsidered.\nIIb\nC\nPrescription of drugs that may aggravate BrSc,\nelectrolyte abnormalities, and sports practice\nthat increases core temperature >39\n\u0004C are not\nrecommended in individuals with overt BrS or\nphenotypically negative mutation carriers.\nIII\nC\nBrS = Brugada syndrome; ECG = electrocardiogram; ICD = implantable cardi-\noverter deﬁbrillator; SCD = sudden cardiac death.\naClass of recommendation.\nbLevel of evidence.\ncFor example, www.brugadadrugs.org.\nESC Guidelines\n67\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n................................................................................................................................................\n5.6.7 Following device implantation\n5.6.7.1 Pacemakers\nPacemaker (PM) implantation is common. Generally, individuals\nimplanted with a PM have less severe disease and comorbidities than\npatients with an ICD. Moreover, there is less risk of malfunction for a\nPM than for an ICD during sports.552 For all these reasons, recom-\nmendations for sports practice are more liberal in patients with a PM\nthan in patients with an ICD. Patients with a PM may participate in\ncompetitive or recreational sports in the absence of structural or\nother heart disease for which exercise may be prohibited.\nIn the first weeks after device implantation, sports activities that\nincrease the risk of lead dislocation (e.g. strong upper extremity\nmovements) should be avoided. Exercise testing and/or Holter moni-\ntoring during sports may improve individualized programming of the\nupper sensor and the tracking rate and exclude inappropriate rate\nacceleration in other circumstances (e.g. horse riding).553\nFor all patients with cardiac devices (PM, cardiac resynchronization\ntherapy, and ICD), sports activities associated with a risk of chest\ntrauma should be avoided.554\u0002557 Some sports such as soccer, bas-\nketball, and baseball may be possible while wearing appropriate pad-\nding. It is noteworthy that sports with pronounced arm movements\nsuch as volleyball, basketball, tennis, golf, and climbing may increase\nthe risk for late lead damage due to subclavian crush (with insulation\nor conductor failure).554,558,559 Implantation on the contralateral side\nof the dominant arm, fixation within the pocket, or submuscular\nplacement may improve durability of the system. It is not known\nwhether subcostal or epicardial implant techniques provide long-\nterm benefit. Electromagnetic interference is unlikely with modern\ndevices, and no cases have been reported, but it should always be\nsuspected and closely evaluated in specific athletic environments\nwith electronic equipment (e.g. fencing). Myopotential inhibition may\nresult in inhibition of pacing, a problem that is more common with\nunipolar electrodes, although it can usually be corrected with appro-\npriate reprogramming of the device.560,561 Bipolar leads are less sen-\nsitive to this problem, but may have a reduced longevity.\n5.6.7.2 Implantable cardioverter defibrillators\nA large multinational ICD Sports Safety Registry has shown that after\na median follow-up of 44 months, there were no deaths or arrhyth-\nmia or shock-related physical injury in 440 athletes who continued\norganized competitive or high-risk sports after ICD implanta-\ntion.359,389 An additional analysis in 82 non-professional recreational\nathletes confirmed these reassuring outcomes,562 which is relevant\nfor the many ICD recipients who want to continue recreational\nsports activities after implantation. Therefore, shared decision making\nis appropriate when deciding whether or not to continue sports and\nthe level of participation with an ICD.\nHowever, three important considerations come into play. First, if\nsport is contraindicated because it can contribute to the progression\nof the underlying disease (such as in arrhythmogenic cardiomyopathy\nor lamin A/C mutations),384,425 an ICD cannot be considered as a\nsubstitute for sports restriction, and participation in moderate- and\nhigh-intensity exercise should be discouraged. Recommendations in\nsuch circumstances should have a lifetime perspective and be based\non the optimal preservation of structural cardiac integrity. The ICD,\nhowever, may allow for light to moderate exercise without concerns\nabout risk of arrhythmia or shocks, and may help individuals to regain\nautonomy and overcome fears relating to exercising unattended.\nThe second consideration is that ICD shocks in general, even\nwhen appropriate and safe, will have a psychological impact on the\nathlete; 30\u000240% of the athletes who experienced shocks in the mul-\ntinational ICD Sports Safety Registry stopped participation, at least\ntemporarily, out of fear of repeat shocks.389 Moreover, the propor-\ntion of athletes with appropriate and inappropriate shocks during\nexercise was higher in competitive than in recreational sports,\nemphasizing the known triggering effect of high-intensity exercise.562\nConsidering that ICD therapy is lifelong, where quality of life is not\nonly dependent on the ability to perform sports activities, but also\nand mostly on continued trust in the device, physicians should be\naware that their own belief in the effectiveness and safety of ICD\ntherapy during sports should not implicitly put pressure on the ath-\nlete to continue sports. Again, informed decision making needs to re-\nevaluate all options of the athlete aftershocks, including continuing,\nreducing, or stopping sports.563,564\nThird, situations where loss of focus or loss of consciousness could\ncause harm to a third party or the athlete (such as in motor sports,\ndiving, mountain climbing, even cycling) should be avoided.\nThe athlete must be aware of the programmed detection rate cut-\noffs to be able to avoid reaching those during exercise. Conversely,\ndetection zones need to be programmed sufficiently high to allow for\nadequately high heart rates during the desired exercise levels. This\npractice proved safe and reduced the occurrence of shocks in the\nICD Sports Safety Database.565 The most common cause of inappro-\npriate shocks in individuals with an ICD is the occurrence of sinus\ntachycardia and supraventricular arrhythmias.566,567 Underlying heart\ndisease and endurance sport itself carries a higher risk for developing\nAF.474,480,568 Implantation of a dual system ICD for the sole reason of\natrial arrhythmia detection and discrimination is not warranted\nbecause it is usually not effective.565,569\u0002572 Given the fact that many\nof these athletes are young, there is a higher risk for long-term lead\ncomplications when more leads are implanted; therefore, implanta-\ntion of more complex ICD systems, and their indication, should be\nweighed in every patient. Routine inclusion of athletes in remote\nmonitoring programmes is highly recommended.\n68\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n........................................................................................................................................................................\n5.7 Exercise recommendations in\nindividuals with adult congenital heart\ndisease\n5.7.1 Introduction\nCongenital heart disease (CHD) has a prevalence of 8\u00029 per 1000\nlive births and is the most common birth defect.573 Most children\nwith CHD survive to adulthood, including over 85% with complex\ndisease. Regular exercise is important for adults with congenital heart\ndisease (ACHD) and exercise participation should be discussed at\nevery patient encounter.574 However, CHD represents a spectrum\nof conditions with widely varying physiological consequences.\nIndividualized assessment is essential before advising on sports partic-\nipation. This requires detailed understanding of the congenital heart\ndefect, its physiological consequences, and the effect of surgical or\ntranscatheter intervention.\n5.7.2 The increasing numbers of athletes with congenital\nheart disease\nAthletes with CHD include those with minor unoperated lesions and\npalliated and repaired CHD. Some athletes will be diagnosed with\nCHD\nfor\nthe\nfirst\ntime\nduring\npre-participation\nscreening.\nApproximately 1 in 150 adults have a congenital heart defect. This is an\nincrease of over 50% in the last 10 years and reflects improved diagno-\nsis and long-term survival.575 Overall 90% of adults with CHD are in\nNYHA functional class I or II.576 The number of professional and rec-\nreational athletes with CHD is unknown but the elite athlete popula-\ntion is likely to be small. In a study of 2352 Olympian athletes, only nine\n(0.4%) had a congenital heart defect.577 However, many more CHD\npatients compete at a recreational level. It is likely that the number of\nathletes with CHD is increasing due to improved survival, better\nunderstanding of the benefits of exercise, and the increased number of\nprofessional athletes from countries where poorly developed health-\ncare systems are associated with under-diagnosis of CHD.573,574\n5.7.3 Non-cardiac abnormalities in congenital heart dis-\nease and Paralympic sport\nCHD has a multifactorial aetiology, but there is a significant genetic\ncomponent and a recurrence risk of 2\u00025%.578 The genetic origin\nmay be due to a chromosome anomaly, a heritable syndrome with\nMendelian\npattern,\nor\nsporadic\nwith\nvariable\npenetrance.578\nApproximately 14% of patients with CHD have additional non-\ncardiac abnormalities.579 Thus, 44% of ACHD patients have lung\nfunction abnormalities.580 This can make advising sports participation\nfor the ACHD athlete more difficult. There is no specific classification\nfor CHD in Paralympic sport.\n5.7.4 General considerations in the congenital heart\ndisease athlete\nThere is considerable variation in the haemodynamic consequences\nand prognosis of different CHD lesions. Furthermore, the consequen-\nces of any individual lesion can vary hugely between individuals. Thus,\nEbstein’s anomaly may present in infancy with pulmonary hypoplasia\ndue to compression by a giant right atrium or may present in late mid-\ndle age with supraventricular tachycardia and minimal haemodynamic\nconsequences. Similarly, a ventricular septal defect may be small and\nasymptomatic, or large presenting with HF in infancy, or may present\nwith extreme cyanosis, reduced exercise capacity, and Eisenmenger\nsyndrome in the adult. Consequently, these recommendations are\nbased on a physiological assessment rather than underlying anatomic\ndiagnosis. An understanding of the range of severity and a lesion-based\nknowledge of potential complications is essential. The cardiologist\nshould work in conjunction with a CHD specialist. Athletes with CHD\nwho participate in regular training and competitive sports should\nundergo a comprehensive annual assessment that includes clinical\nexamination, ECG, echocardiogram, and exercise stress test, ideally\nCPET.\nMany athletes with CHD will have undergone corrective or pallia-\ntive surgery. In young adults with post-surgical CHD, valve\nRecommendations for exercise in individuals with pace-\nmakers and implantable cardioverter deﬁbrillators\nRecommendations\nClassa\nLevelb\nIt is recommended that individuals with\nimplanted devices with/without resynchroniza-\ntion and underlying disease follow the recom-\nmendations pertaining to the underlying\ndisease.384,425\nI\nB\nParticipation in sports and exercise (except colli-\nsion sports) should be considered in individuals\nwith pacemaker therapy who do not have patho-\nlogical substrates for fatal arrhythmias.\nIIa\nC\nPrevention of direct impact to the implanted\ndevice by adapting the site of lead and/or device\nimplantation, padding, or restricting direct impact\nsports should be considered.\nIIa\nC\nHolter recordings and device interrogation dur-\ning and after resuming sports should be consid-\nered to allow appropriate tailoring of rate-\nresponsive pacing parameters, exclusion of myo-\npotential or electromagnetic inhibition, and\ndetection of VAs.\nIIa\nC\nShared decision making should be considered dur-\ning decisions relating to continuation of intensive\nor competitive sports participation in individuals\nwith an ICD, taking into account the effect of\nsports on the underlying substrate, the fact that\nintensive sports will trigger more appropriate and\ninappropriate shocks, the psychological impact of\nshocks on the athlete/patient, and the potential\nrisk for third parties.\nIIa\nC\nAn ICD is not recommended as a substitute for\ndisease-related recommendations when these\nmandate sports restrictions.\nIII\nC\nICD = implantable cardioverter deﬁbrillator; VA = ventricular arrhythmia.\naClass of recommendation.\nbLevel of evidence.\nESC Guidelines\n69\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\nincompetence and arrhythmias are common problems, but with\nincreasing age arrhythmias and HF predominate. In master athletes,\nproblems related to previous corrective or palliative surgery become\nprevalent. These include cardiac arrhythmias, systemic ventricular\ndysfunction, valvar incompetence, and prosthetic conduit obstruc-\ntion. Redo valve or conduit surgery and arrhythmia ablation due to\nre-entry arrhythmias (secondary to surgical scar) are frequent in this\nage group. In addition, with increasing age, acquired CVD may\ndevelop.581,582 This is of particular relevance in the assessment of the\nmaster athlete with CHD.\n5.7.5 Sudden death during sport\nSCD in CHD is rare (<0.1% per year)583 and only 8% of deaths occur\nduring exercise.584 Many complex CHD patients at highest risk of\nSCD have reduced exercise tolerance and cannot participate in sig-\nnificant athletic activity. However, some diagnostic groups, e.g. post\ntetralogy of Fallot repair, carry a risk of SCD but can still compete in\nelite sport.585 Other high-risk congenital lesions such as anomalous\ncoronary origin, mitral valve prolapse, and aortopathy are described\nin sections 5.1, 5.3, and 5.4, respectively. In a large population-based\nstudy of SCD in CHD patients under 35 years, 87% of SCD was due\nto a presumed arrhythmia and 41% occurred in patients with undiag-\nnosed CHD.586Activity-related SCD was more common in the\nundiagnosed group (18% vs. 4%), which supports the case for pre-\nparticipation athletic screening.586 It is not known whether exercise\nintensity is a risk factor for SCD in CHD. There is reasonable evi-\ndence that moderate to vigorous exercise is safe in most ACHD\npatients even when symptomatic (NYHA II\u0002III).576,587,588 However,\ncardiac arrhythmias are a common cause of hospital admission in\nACHD and extreme exercise may expose a latent arrhythmic\nsubstrate.589,590\n5.7.6 Exercise in athletes with congenital heart disease:\ncurrent guidelines and recommendations\nRegular structured exercise is safe and effective therapy for most\npatients with CHD. This is true for most diagnostic groups, including\nsymptomatic patients, and includes aerobic and strength-based exer-\ncise.588,591\u0002596 Exercise intolerance in CHD is a strong predictor of\nboth outcome and SCD.576 Specific precautions are necessary in\nextreme environments including underwater sports and this is con-\nsidered below (see Supplementary Data, section 4). This is particularly\ntrue if there is a potential for a right to left shunt. Guidelines are avail-\nable for exercise assessment and prescription in both children and\nadults with CHD, although these are not specifically designed for the\nathlete.597,598 The paediatric guidelines are based primarily on the\nunderlying anatomical diagnosis, but the teenage and young adult\nCHD guidelines have taken a functional approach based on underly-\ning haemodynamics and arrhythmia risk. This latter approach is better\nsuited for assessment of the ACHD athlete (Figure 9).\n5.7.7 Assessment of the athlete with congenital heart\ndisease\nThe guidelines for exercise prescription in adolescents and adults\nwith CHD use a structured methodology described by Budts et al.597\nThis can be modified for use in the assessment of athletes with CHD.\nStage 1. A full history and physical examination are carried out.\nThis should include details of underlying CHD diagnosis, any trans-\ncatheter or surgical interventions, current medications and CV symp-\ntoms (at rest and on exercise). Attention should be paid to any\nassociated non-cardiac diagnoses including pulmonary dysfunction. A\nfull exercise and sports participation history should be taken including\nprecise details of current training schedule and any dietary supple-\nments. Details of the planned or current sports activity should be\nestablished to include an assessment of the static component and\nintensity as described in section 4.1 (see Figure 2). If necessary, advice\nshould be sought from a sports fitness coach or sports medicine\nspecialist.\nStage 2. The following five baseline parameters should then be\nevaluated597 (Table 16).\n(1)\nVentricular function\nAssessment of ventricular function can usually be achieved using\nechocardiography. The aim is to establish whether function is\nreduced (EF < 55%), and if so, is it mild (45\u000255%), moderate\n(30\u000245%), or severe (<30%). This is used for baseline assessment\nand subsequent monitoring of the effects of exercise training.\nEchocardiography can also evaluate inflow and outflow abnormalities,\nwhich may become more severe during acute exercise (e.g. LV out-\nflow obstruction or systemic atrioventricular valve regurgitation).\nCMR scanning may be a preferable modality in complex disease. This\nhas the additional benefit of evaluating intracardiac scar, which may\ninform the assessment of arrhythmia risk.599,600\n(2)\nPulmonary artery pressure\nPulmonary hypertension (PH) is diagnosed when the mean PAP is\n>20 mmHg.601 PH may occur in the context of a chronic left\u0002right\nshunt (e.g. atrial septal defect, ventricular septal defect, patent ductus\narteriosus) that allows unrestricted volume/pressure overload.\nEventually this can result in supra-normal PAP with reversal of shunt-\ning and elevated pulmonary vascular resistance (Eisenmenger syn-\ndrome). An increased RV afterload limits the ability to increase\ncardiac output by increasing stroke volume and can impair LV func-\ntion through disruption of normal RV\u0002LV interaction.\nFew CHD patients with significant PH will take part in competitive\nsports due to reduced exercise capacity. However, some athletes\nwith CHD will have mild elevation of pulmonary vascular resistance\nthat may be exacerbated by factors such as altitude training.602 PAP\nrises during exercise. This rise is accentuated with increasing age and\nmay be exaggerated in CHD athletes due to elevated pulmonary vas-\ncular resistance.603 In addition, valvar pulmonary stenosis or distal\nstenoses in branch pulmonary arteries may cause exercise-related\nRV hypertension. The non-invasive assessment of PH can be difficult\nand full assessment guidelines have been published.604,605 Further\ninformation can be gained by CPET and a VO2 of >25.2 mL/min/kg\nmakes significant PH unlikely.606 As PH can also be a late postopera-\ntive complication after surgical correction of CHD607 the assessment\nof PAP should be part of every echocardiographic examination in ath-\nletes with CHD. Although exercise training is generally regarded as\nsafe in PH, competitive sport is not recommended.1,608\n(3)\nAortic assessment\nMany CHD patients are at risk of aortic dilatation, in particular,\npatients with tetralogy of Fallot, coarctation of the aorta and certain\n70\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\nsyndromes such as 22q11 microdeletion and Turner syndrome.\nHowever, aortic dissection is very rare in CHD.609 Athletes have\nmildly increased aortic dimensions in comparison to sedentary con-\ntrols, but it is not known if this has a cumulative effect in CHD ath-\nletes with aortic dilatation.345 The presence of ascending aorta\ndilatation should lead to assessment for coarctation of the aorta as\nthis can be associated with severe coarctation, which may be missed\non clinical assessment but may cause severe exercise-related hyper-\ntension.610 Exercise risks in aortopathy are described in detail in sec-\ntion 5.4. Contact sports should be avoided in patients with dilated\naortas >5 cm.\n(4)\nArrhythmia assessment\nArrhythmias are responsible for 25% of CHD hospital admissions.\nOver 80% are atrial but life-threatening VAs can occur.611\nIndependent risk factors include increasing age, male gender, double\noutlet right ventricle, atrioventricular septal defect, HF, obstructive\nsleep apnoea, transposition of the great arteries, congenitally cor-\nrected transposition, and tetralogy of Fallot.599 Assessment of the\nCHD athlete should include a symptom history with evaluation of\npalpitations, presyncope and syncope, particularly during exercise.\n©ESC 2020\nFigure 9 Pre-participation assessment of individuals with congenital heart disease.598 CPET = cardiopulmonary exercise test; HR = heart rate; MHR =\nmaximum heart rate; RPE = rate of perceived exertion. A\u0002E represent pathways linking static and intensity components for each column. After assess-\nment of CPET and the five variables (Table 16), an individual recommendation can be given (solid arrow). If a higher static level sport is chosen, then a lower\nintensity level is advised (dotted arrow).\nTable 16\nBaseline parameters for assessment in congeni-\ntal heart disease\n©ESC 2020\nCMR = cardiac magnetic resonance; ECG = electrocardiogram.\nESC Guidelines\n71\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.......\nArrhythmias may be the first sign of underlying haemodynamic dete-\nrioration and new-onset arrhythmias should lead to a full haemody-\nnamic assessment. Detailed guidelines for the assessment and\ntreatment of arrhythmias in CHD are available.612 In the athlete,\narrhythmia therapy may be complicated by the need to minimize the\nnegative chronotropic effects of antiarrhythmic treatment, which\nmay affect performance. If symptomatic arrhythmias are present then\nan exercise ECG, prolonged ECG monitoring, loop recorder implan-\ntation, and even electrophysiology testing might be required. This\nshould be coordinated by an electrophysiologist with expertise in\nCHD.\n(5)\nAssessment of saturations/lung function\nCHD athletes should be assessed for the potential of an underlying\nintracardiac right to left shunt. This can be assessed using pulse oxi-\nmetry, but a resting saturation >95% does not exclude exercise-\nrelated central cyanosis, and exercise assessment is essential. The\npotential for a pulmonary cause of cyanosis must be considered and\nlung function should be assessed as part of a cardiopulmonary exer-\ncise test. Even after surgical correction of the cardiac defect there\nmay be residual intracardiac shunting.\nStage 3. Cardiopulmonary exercise testing\nCPET is invaluable in risk stratifying the adult with CHD and can\npredict outcome.613,614 It is also extremely useful in the evaluation of\nthe athlete with CHD as it allows an assessment of PAP, respiratory\nproblems, cardiac output, exercise-related haemodynamics, and\narrhythmias. This should be used in conjunction with an evaluation of\neffort such as the Borg scale.615 Normal CPET values are available for\nnon-athlete CHD patients.616 CPET should be carried out in con-\njunction with a 12-lead ECG to allow detection of arrhythmias and\nevaluate chronotropic incompetence. Reduced VO2max and peak\noxygen pulse may reflect reduced stroke volume and are found in\ncomplex CHD as well as in other forms of CHD, including repaired\ntetralogy of Fallot, aortic regurgitation, and coarctation of the aorta.\nIn CHD, ventilatory anaerobic threshold may be reduced and this\nimpairs gas exchange efficiency in dynamic and endurance sports.\nThis may relate to previous thoracotomy or lung disease. Similarly,\nthere may be an elevated minute ventilation/carbon dioxide produc-\ntion (VE/VCO2) slope,601 indicating an inadequate pulmonary vascu-\nlar bed.610,611,613\u0002616 Reduced skeletal muscle mass is common in\nadults with CHD and can contribute to decreased tissue oxygen\nuptake. The extent to which this is modified in athletes with CHD\nhas not been evaluated. However, even in complex disease, regular\nresistance exercise participation improves muscle mass and regular\nexercise participation is a dominant factor in determining long-term\noutcome.593,617\nStage 4. Exercise intensity and prescription\nAn assessment of the athlete’s sports and exercise participation\nshould take place as discussed in the introduction (Table 16). This\nshould include an assessment of the intensity, aerobic and resistance\ncomponents (isometric and dynamic), and the overall volume of\nexercise, which should include training and competition. The haemo-\ndynamic consequences should be considered in light of an under-\nstanding of known lesion-specific consequences and individual\nathlete-specific changes identified on assessment.\nStage 5. Follow-up and repeat assessment\nIn the CHD athlete, serial assessment should be carried out—usu-\nally on an annual basis—while participating in sport. This recognizes\nthe age-related changes that occur in the CHD athlete and the\npotential for onset of degenerative CVD.\n6. Key messages\nCV screening before participation in recreational and competitive\nsports is aimed at the detection of disorders associated with SCD\nand has the potential to lower CV risk through disease-specific and\nindividualized patient management.\nCV screening in adult and senior athletes should target the higher\nprevalence of atherosclerotic CAD including an assessment of CVD\nrisk factors and exercise stress test. CAC scoring may be performed\nin asymptomatic athletes with a moderate atherosclerotic risk\nprofile.\nHealthy adults of all ages and individuals with known cardiac dis-\nease should exercise on most days, totalling at least 150 min/week of\nmoderate-intensity exercise.\nIndividuals with CAD, at low risk for exercise-induced adverse\nevents, should be considered eligible for competitive or leisure sports\nactivities, with few exceptions.\nCompetitive sports are not recommended in individuals with\nCAD, at high risk of exercise-induced adverse events or those with\nresidual ischaemia, with the exception for individually low-intensity\nskill sports.\nExercise programmes in HF improve exercise tolerance and qual-\nity of life and have a modest effect on all-cause and HF-specific mor-\ntality, and all-cause hospitalization and HF-specific hospitalization.\nExercise recommendations for individuals with congeni-\ntal heart disease\nRecommendations\nClassa\nLevelb\nParticipation in regular moderate exercise is rec-\nommended in all individuals with\nCHD.588,591\u0002594,619\nI\nB\nA discussion on exercise participation and provi-\nsion of an individualized exercise prescription is\nrecommended at every CHD patient\nencounter.574,597,598,617\nI\nB\nAssessment for ventricular function, pulmonary\nartery pressure, aortic size, and arrhythmia risk\nis recommended in all athletes with\nCHD.342,348,573,597\nI\nC\nCompetitive sports participation should be con-\nsidered for CHD athletes in NYHA class I or II\nwho are free from potentially serious arrhyth-\nmias after individual tailored evaluation and\nshared decision making.573,595,597,598\nIIa\nC\nCompetitive sports are not recommended for\nindividuals with CHD who are in NYHA class\nIII\u0002IV or with potentially serious\narrhythmias.605,608\nIII\nC\nCHD = congenital heart disease; NYHA = New York Heart Association.\naClass of recommendation.\nbLevel of evidence.\n72\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\nAsymptomatic individuals with mild valvular heart disease may par-\nticipate in all sporting activities including competitive sports.\nA select group of asymptomatic individuals with moderate valve\ndisease who have good functional capacity and no evidence of myo-\ncardial ischaemia, complex arrhythmias, or haemodynamic compro-\nmise on a maximal exercise stress test may be considered for\ncompetitive\nsports\nafter\ncareful\ndiscussion\nwith\nan\nexpert\ncardiologist.\nImplementation of healthy lifestyle behaviours including sports par-\nticipation decreases the risk of CV events and mortality in individuals\nwith aortopathies.\nIndividuals with acute myocarditis or pericarditis should abstain\nfrom all sports while active inflammation is present.\nIndividuals with cardiomyopathy or resolved myocarditis or peri-\ncarditis, who wish to participate in regular sports, should undergo\ncomprehensive evaluation, including an exercise test, to assess the\nrisk of exercise-induced arrhythmias.\nIndividuals who are genotype positive/phenotype negative or have\na mild cardiomyopathy phenotype and absence of symptoms or any\nrisk factors, may be able to participate in competitive sports. A nota-\nble exception is arrhythmogenic cardiomyopathy where high-\nintensity exercise and competitive sports should be discouraged.\nManaging sports participation in individuals with arrhythmogenic\nconditions is guided by three principles: (i) preventing life-threatening\narrhythmias during exercise; (ii) symptom management to allow\nsports; and (iii) preventing sports-induced progression of the arrhyth-\nmogenic condition. In each case, these three basic questions need to\nbe addressed.\nPre-excitation should be excluded in all athletes with PSVT, and\nablation of the accessory pathway is recommended if present.\nIn individuals with PVCs who want to engage in sports, underlying\nstructural or familial arrhythmogenic conditions must be excluded,\nsince sports activity may trigger more malignant arrhythmias if those\nunderlying conditions are present.\nAthletes with electrical abnormalities of genetic origin, such as the\ninherited ion channelopathies, require assessment and shared deci-\nsion making in which cardiogeneticists are involved, given the com-\nplex interplay of genotype, phenotype, potential modifiers, and\nexercise.\nIndividuals with pacemakers should not be discouraged from par-\nticipation in sport because of the device but need to tailor their\nsports participation according to the underlying disease.\nParticipation in leisure-time and competitive sport in patients with\nan ICD may be considered, but requires shared and individualized\ndecision making, based on a higher likelihood of appropriate and inap-\npropriate shocks during sports, and the potential consequences of\nshort episodes of loss of consciousness.\nPatients with CHD should be encouraged to exercise and should\nbe given a personalized exercise prescription.\n7. Gaps in evidence\nOutcomes in exercising individuals with cardiovascular dis-\neases. The natural history and absolute risk of conditions associated\nwith SCD in athletes identified through CV screening is largely\nunknown, making it difficult to quantify short- and long-term risk.\nProspective outcomes data, including the occurrence of major CV\nevents and other CV morbidity, is needed to better guide risk stratifi-\ncation, management, and eligibility recommendations for athletes\ndiagnosed with CVD.\nCardiovascular evaluation in master athletes. Current\nmethods for screening individuals for atherosclerotic CAD are based\non symptoms and a maximal exercise test; however, they do not\nidentify individuals with mild to moderate atherosclerotic plaques.\nMore knowledge on the optimal pre-participation screening algo-\nrithm for identifying individuals at risk of adverse cardiac events dur-\ning exercise is required.\nSafety of high-intensity exercise in cardiovascular disease.\nThere are limited data on the safety of high-intensity exercise training\nand sports participation in healthy individuals with a high burden of\nrisk factors; more information can be gained through high-quality\nprospective studies in the future.\nRisk of anomalous origins of the coronary arteries in\nolder individuals. Although AOCA from the opposite sinus of\nValsalva are a recognized cause of mortality in young athletes, more\nknowledge is required on the risk of high-intensity exercise in older\nindividuals (>40 years old), with this congenital abnormality.\nRisk of myocardial bridge. The precise significance of MB in\ncausing MI or sudden death during exercise is unknown.\nBenefit of regular exercise on survival in chronic heart\nfailure. Although exercise improves functional capacity and quality\nof life in individuals with HF, strong evidence on the benefit of regular\nexercise on survival is still lacking.\nRole of high-intensity exercise in chronic heart failure.\nThe impact of high-intensity exercise in asymptomatic individuals\nwith HF with reduced and preserved systolic function is unknown\nand large multicentre studies are required to facilitate exercise pre-\nscription in the future.\nInitiation of an exercise programme after decompen-\nsated heart failure. The start time of an exercise programme of\nmoderate-high intensity and return to sports after an acute event in\nHF is unknown.\nAquatic exercise in heart failure. The safety of aquatic exer-\ncise in HF needs to be confirmed by larger trials.\nEffect of exercise on the natural history of valvular heart\ndisease. There is a paucity data on the effects of regular intensive\nexercise in individuals with valvular heart disease. Large-scale longitu-\ndinal studies are required to provide more evidence-based guidelines\non exercise prescription in individuals with valvular heart disease.\nEffect of exercise on the natural history of aortopathies.\nThere is a lack of knowledge on the impact of sport on progression\nof aortic disease and risk of dissection or aortic rupture among indi-\nviduals with aortopathy. The impact of beta-blockers on progression\nof aortic disease among individuals with aortopathy who participate\nin regular exercise is unknown and should be investigated in a\nrandomized controlled trial.\nOptimal safe exercise dose in cardiomyopathy. With an\nexception for arrhythmogenic cardiomyopathy, current practice\nrelating to exercise recommendations in individuals with cardiomy-\nopathy or following myopericarditis are largely based on circumstan-\ntial evidence. Large, adequately powered randomized prospective\nstudies are necessary to provide evidence-based recommendations\nfor optimal exercise prescription without compromising safety. Such\nESC Guidelines\n73\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\nstudies should also prove useful for validating current risk stratifica-\ntion protocols derived from a relatively sedentary population.\nExercise and atrial fibrillation. The threshold lifetime sports\nactivity for increasing the risk of developing AF is unknown. It is also\nunknown whether ongoing participation in vigorous exercise at the\nsame intensity after successful AF ablation is associated with a higher\nrisk of AF recurrence.\nBenefit of invasive electrophysiological studies in adoles-\ncents with accessory pathways. The benefit/risk ratio of early\ninvasive EP evaluation of AP conduction properties in young athletes\nwith asymptomatic pre-excitation (<12\u000214 years old), and prophy-\nlactic ablation, remains unclear and requires large-scale studies for\nclarification.\nExercising with an implantable cardioverter defibrillator.\nAlthough an international registry has shown absence of sports-\nrelated sudden death or injury in individuals with an ICD who per-\nform competitive, high-intensive recreational or high-risk sports,\nmany data are sparse and have not examined specific athletic popula-\ntions with reduced LV function, catecholaminergic polymorphic VT.\nMoreover, the long-term physical and psychological impact of appro-\npriate and inappropriate shocks, which become more frequent with\nincreasing sports intensity, is unknown.\nArrhythmic risk of exercise in adult congenital heart dis-\nease. The relationship between intensity of exercise and risk of\narrhythmias in individuals with CHD is unknown and further research\nis needed. Although exercise prescription is recommended in CHD\npatients, further studies are necessary to identify the optimal method\nof improving adherence to an exercise prescription.\n8. Sex differences\nFor many years sports participation, especially at the highest eche-\nlons, has been dominated by males, but the last four decades have\nwitnessed an increasing number of females participating in a large\nvariety of sporting disciplines at elite level. Females constituted 45%\nof all athletes at the 2016 Rio Olympics and participated in 26 of the\n28 different sporting disciplines including those that were traditionally\nconsidered to be ‘male sports’, such as footfall, rugby, and boxing.\nAlthough the guidelines in this document are applicable to both\nsexes, there are some pertinent sex-based differences relative to\nexercise and sport including: (i) the incidence of SCD during exercise;\n(ii) quantitative differences in CV adaptation to regular intensive\nexercise and the overlap with cardiomyopathy; (iii) the predilection\nof adverse events with specific CVDs in women; and (iv) the additive\nhaemodynamic effects of exercise in pregnant women with a struc-\nturally abnormal heart.\nCurrent evidence suggests a significantly lower prevalence of\nexercise-related SCD in females who represent a small minority of\nathletes dying suddenly with a male to female ratio ranging from 3 to\n10: 1.17,18,46,49,52,620 This disproportionately lower incidence of SCD\namong young competitive female athletes also holds true for older\nrecreational athletes where deaths in males are 20-fold greater than\nin females.\nApart from a lower incidence of exercise-related SCD, there\nappear to be sex differences related to the diseases predisposing to\nSCD. Unlike males, female athletes rarely succumb to SCD from\nHCM. In the US National Registry, females comprised only 3% of the\n302 individuals who died from HCM.621 Potential determinants of\nthis disproportionate prevalence of death in males may include a\nlower absolute volume and intensity of training load in females, which\ncould make them less susceptible to ventricular tachyarrhythmias.\nHowever, it is also plausible that certain protective metabolic or hor-\nmonal mechanisms could reduce the arrhythmic risk during intense\nphysical exertion in females with HCM. This observation is relevant\nto prescription of intensive exercise or competitive sports in HCM,\nwhich is relatively conservative, but could be of less concern and\nmore liberal in affected females in the future. The diagnosis of HCM\nin an athlete is also relevant in this regard, because male athletes, par-\nticularly those competing in endurance sports, show quantitatively\ngreat structural changes within the heart including LV hypertrophy.\nApproximately 2% of white male athletes and 13% of black male ath-\nletes show a LV wall thickness of 12\u000215 mm that overlaps with mor-\nphologically mild HCM and can pose a diagnostic dilemma. In\ncontrast female athletes rarely reveal a LV wall thickness >12 mm or\nconcentric LV remodelling, hence the diagnosis of HCM is clear-cut.3\nIn contrast, a different scenario is represented in females with\nMVP, where recommendation for participation in intensive exercise\nwarrants a more detailed risk stratification. In the Italian pathology\nregistry of 650 SCDs, 7% were attributed to MVP. Of these, the\nmajority (60%) were female who presented a marked elongation of\nboth leaflets due to an extensive myxomatous degeneration.332\nIt is also noteworthy that the majority of exercise-related SCDs in\nyoung females are associated with a structurally normal heart at\nautopsy. This observation from several registries suggests that genetic\nelectrical diseases (namely, LQTS, Brugada syndrome, or catechola-\nminergic polymorphic VT) are likely responsible for a significant pro-\nportion of these deaths. Differences in cardiac repolarization\nbetween men and women have been reported in healthy subjects\nand in individuals with LQTS.622 Healthy females also have a longer\nQTc interval compared with males. Therefore, they are more often\nclinically affected by the syndrome than men, despite the equal sex\ndistribution of the disease genotype. Females are also at a higher risk\nthan males of developing arrhythmias in response to QT-prolonging\ndrugs,\nand\nelectrolyte\ndisturbances\ncompared\nwith\nmales.\nFurthermore, female sex is an independent risk factor for cardiac\nevents in LQTS.623 Unfortunately, little is known about the influence\nof sex hormones on cardiac repolarization, except that androgens\nmay shorten the QTc interval. Based on these considerations, we\nrecommend particular caution when advising competitive sports in\nwomen with a probable or definite diagnosis of LQTS.\nPregnancy is associated with a 50% increase in plasma volume and\ncardiac output. The stresses of exercise in pregnant women with\nstructural heart disease have the potential to cause haemodynamic\ncompromise. Moderate aerobic exercise is generally safe in all\nwomen and is associated with a lower prevalence of excessive weight\ngain, post-partum obesity, gestational diabetes, and pre-eclampsia.\nFemale athletes may continue training intensively during pregnancy,\nalthough it is recommended that women do not exceed a heart\nrate of >90% of the maximum predicted for age to reduce the risk\nof foetal bradycardia. Pregnant women with known structural heart\ndisease require evaluation before embarking on intensive exercise\nprogrammes. Exercise or sports involving forceful physical contact,\nrisk of falling or abdominal trauma, heavy lifting, scuba diving, and\n74\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............\nexercising at high altitude in an unacclimatized state are not\nrecommended.\nFinally, females represent the largest population of obese individu-\nals worldwide and females with T2DM have a higher prevalence of\ncardiovascular complications and death compared with men. In this\nregard all women should be incentivized to engage in regular PA and\nexercise programmes irrespective of age, ethnicity, and CV\nmorbidities.\nRecommendations: What to do and what not to do for exercise and sports in healthy individuals\nClassa\nLevelb\nGeneral recommendations for exercise and sports in healthy individuals\nAt least 150 min/week of moderate-intensity, or 75 min/week of vigorous-intensity aerobic exercise or an equivalent combination\nthereof is recommended in all healthy adults.\nI\nA\nRegular assessment and counselling to promote adherence and, if necessary, to support an increase in exercise volume over time are\nrecommended.\nI\nB\nMultiple sessions of exercise spread throughout the week, i.e. on 4\u00025 days a week and preferably every day of the week, are\nrecommended.\nI\nB\nSpecial considerations for individuals with obesity, hypertension, dyslipidaemia, or diabetes\nIn obese individuals (BMI>_30 kg/m2 or a waist circumference >80 cm for females or >94 cm for males) resistance training >_3 times\nper week, in addition to moderate or vigorous aerobic exercise (at least 30 min, 5\u00027 days per week) is recommended to reduce\nCVD risk.\nI\nA\nIn individuals with well-controlled hypertension, resistance training >_3 times per week in addition to moderate or vigorous aerobic\nexercise (at least 30 min, 5\u00027 days per week) is recommended to reduce blood pressure and CVD risk.\nI\nA\nAmong individuals with diabetes mellitus, resistance training >_3 times per week) in addition to moderate or vigorous aerobic exercise\n(at least 30 min, 5\u00027 days per week) is recommended to improve insulin sensitivity and achieve a better CVD risk proﬁle.\nI\nA\nIn individuals with uncontrolled hypertension (SBP>160 mmHg) high-intensity exercise is not recommended until BP has been\ncontrolled.\nIII\nC\nRecommendations for exercise in ageing individuals\nAmong adults aged 65 years or older who are ﬁt and have no health conditions that limit their mobility, moderate-intensity aerobic\nexercise for at least 150 min/week is recommended.\nI\nA\nIn older adults at risk of falls, strength training exercises to improve balance and coordination on at least 2 days a week are\nrecommended.\nI\nB\nRecommendations for exercise in individuals with coronary artery disease\nRecommendations for exercise in individuals with long-standing chronic coronary syndrome\nRisk stratiﬁcation for exercise-induced adverse events is recommended in individuals with established (long-standing) CCS prior to\nengaging in exercise.\nI\nC\nCompetitive sports are not recommended in individuals at high risk of exercise-induced adverse events or those with residual ischae-\nmia, with the exception of individually recommended skill sports.\nIII\nC\nRecommendations for return to exercise after acute coronary syndrome\nExercise-based cardiac rehabilitation is recommended in all individuals with CAD to reduce cardiac mortality and rehospitalization.\nI\nA\nRecommendations for exercise in young individuals/athletes with anomalous origins of coronary arteries\nParticipation in most competitive sports with a moderate and high CV demand among individuals with AOCA with an acutely angled\ntake-off or an anomalous course between the large vessels is not recommended.\nIII\nC\nRecommendations for exercise/sports in individuals with myocardial bridging\nCompetitive sports are not recommended in individuals with myocardial bridging and persistent ischaemia or complex cardiac\narrhythmias during maximal exercise stress testing.\nIII\nC\nRecommendations for exercise in chronic heart failure\nRecommendations for exercise prescription in heart failure with reduced or mid-range ejection fraction\nRegular discussion about exercise participation and provision of an individualized exercise prescription is recommended in all individ-\nuals with HF.\nI\nA\nExercise-based cardiac rehabilitation is recommended in all stable individuals to improve exercise capacity and quality of life and to\nreduce the frequency of hospital readmission.\nI\nA\nContinued\n9. ‘What to do’ and ‘what not to do’ messages from the Guidelines\nESC Guidelines\n75\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\nRecommendations for participation in sports in heart failure\nBefore considering a sport activity, a preliminary optimization of HF risk factor control and therapy, including device implantation (if\nappropriate), is recommended.\nI\nC\nHigh-intensity power and endurance sports are not recommended in patients with HFrEF irrespective of symptoms.\nIII\nC\nRecommendations for exercise and participation in sports in individuals with heart failure and preserved ejection fraction\nModerate endurance and dynamic resistance exercise, together with lifestyle intervention and optimal treatment of CV risk factors\n(i.e. arterial hypertension and type 2 diabetes) are recommended.\nI\nC\nRecommendations for exercise and participation in sports in individuals with heart transplant recipients\nRegular exercise through cardiac rehabilitation combining moderate-intensity aerobic and resistance exercise is recommended to\nrevert pathophysiology to pre-transplantation time, reduce CV risk induced by post-transplantation medical treatment, and improve\nclinical outcome.\nI\nB\nRecommendations for exercise in asymptomatic individuals with valvular heart disease\nParticipation in competitive or recreational sports/exercise of moderate and high intensity is not recommended in individuals with\nsevere aortic stenosis.\nIII\nC\nParticipation in competitive or recreational sports/exercise of moderate and high intensity is not recommended in individuals with\nsevere aortic regurgitation with LVEF<_50% and/or exercise-induced arrhythmias.\nIII\nC\nParticipation in competitive sports is not recommended in individuals with severe mitral regurgitation with a LVEF<60%.\nIII\nC\nParticipation in any competitive sport, or leisure sports/exercise of mild to moderate intensity, is not recommended in individuals\nwith severe (MVA<1 cm2) mitral stenosis.\nIII\nC\nRecommendations for exercise in individuals with aortic pathology\nPrior to engaging in exercise, risk stratiﬁcation, with careful assessment including advanced imaging of the aorta (CT/CMR) and exer-\ncise testing with BP assessment, is recommended.\nI\nA\nCompetitive sports are not recommended in individuals who are at high risk (Table 14).\nIII\nC\nRecommendations for exercise in individuals with cardiomyopathy\nGeneral recommendation\nAnnual assessment for risk stratiﬁcation is recommended in all individuals with cardiomyopathy who exercise regularly.\nI\nC\nRecommendations for exercise and sports participation in individuals with hypertrophic cardiomyopathy\nParticipation in high-intensity exercise (including recreational and competitive sports) is not recommended in individuals who have\nANY markers of increased risk [(i) cardiac symptoms or history of cardiac arrest or unexplained syncope; (ii) moderate ESC risk\nscore (>_4%) at 5 years; (iii) LVOT gradient at rest >30 mmHg; (iv) abnormal BP response to exercise; (v) exercise-induced\narrhythmias].\nIII\nC\nRecommendations for exercise and sports participation in individuals with arrhythmogenic cardiomyopathy\nParticipation in high-intensity recreational exercise/sports or any competitive sports is not recommended in individuals with ACM\nincluding those who are genotype positive and phenotype negative.\nIII\nC\nRecommendations for exercise and sports participation in individuals with left ventricular non-compaction cardiomyopathy\nParticipation in high-intensity exercise or competitive sports is not recommended in individuals with symptoms, LVEF<40% and/or\nfrequent and/or complex VAs on ambulatory Holter monitoring or exercise testing.\nIII\nC\nRecommendations for exercise and sports participation in individuals with dilated cardiomyopathy\nParticipation in high- or very high-intensity exercise including competitive sports is not recommended for individuals with a DCM and\nany of the following: (i) symptoms or history of cardiac arrest or unexplained syncope; (ii) LVEF<45%; (iii) frequent and/or complex\nVAs on ambulatory Holter monitoring or exercise testing; (iv) extensive LGE (>20%) on CMR; or (v) high-risk genotype (lamin A/C\nor ﬁlamin C).\nIII\nC\nRecommendations for exercise in individuals with myocarditis and pericarditis\nComprehensive evaluation, using imaging studies, exercise stress test, and Holter monitoring, is recommended following recovery\nfrom acute myocarditis to assess the risk of exercise-related SCD.\nI\nB\nReturn to all forms of exercise including competitive sports is recommended after 30 days to 3 months of rest for individuals who\nhave recovered completely from acute pericarditis, depending on clinical severity.\nI\nC\nAmong individuals with a probable or deﬁnitive diagnosis of recent myocarditis or pericarditis, participation in leisure-time or com-\npetitive sports while active inﬂammation is present is not recommended.\nIII\nC\nParticipation in moderate- to high-intensity exercise for a period of 3\u00026 months after acute myocarditis is not recommended.\nIII\nB\nParticipation in moderate- to high-intensity exercise, including competitive sports, is not recommended for individuals with constric-\ntive pericarditis.\nIII\nC\nContinued\n76\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 51",
          "page": 51,
          "content": " |  | Levelb\nRecommendations | Classa | \n |  | \nIt is recommended that all exercising individuals\nwith LQTS with prior symptoms or prolonged\nQTc be on therapy with beta-blockers at target\ndose.529 | I | B\nIt is recommended that exercising individuals\nwith LQTS should avoid QT prolonging drugs\n(www.crediblemeds.org) and electrolyte imbal-\nance such as hypokalaemia and\nhypomagnesaemia.529 | I | B\nShared decision making should be considered\nregarding sports participation in patients with\ngenotype-positive/phenotype-negative LQTS\n(i.e. <470/480 ms in men/women). Type and set-\nting of sports (individual vs. team), type of muta-\ntion, and extent of precautionary measures\nshould be considered in this context. | IIa | C\nParticipation in high-intensity recreational and\ncompetitive sports, even when on beta-blockers,\nis not recommended in individuals with a\nQTc>500 ms or a genetically confirmed LQTS\nwith a QTc>470 ms in men or >480 ms in\n_ _\nwomen. | III | B\nParticipation in competitive sports (with or with-\nout ICD) is not recommended in individuals with\nLQTS and prior cardiac arrest or arrhythmic\nsyncope. | III | C",
          "rows": 8,
          "cols": 3
        },
        {
          "title": "Table on page 51",
          "page": 51,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nICD implantation is recommended in patients\nwith BrS with episodes of arrhythmic syncope\nand/or aborted SCD.247 | I | C\nFollowing implantation of an ICD, resumption of\nleisure or competitive sports should be consid-\nered after shared decision making in individuals\nwho have not experienced recurrent arrhyth-\nmias over 3 months after ICD implantation. | IIa | C\nIn asymptomatic individuals with BrS, asympto-\nmatic mutation carriers and asymptomatic ath-\nletes with only an inducible ECG pattern,\nparticipation in sports activities that are not\nassociated with an increase in core temperature\n>39\u0004C (e.g. endurance events under extremely\nhot and/or humid conditions) may be\nconsidered. | IIb | C\nPrescription of drugs that may aggravate BrSc,\nelectrolyte abnormalities, and sports practice\nthat increases core temperature >39\u0004C are not\nrecommended in individuals with overt BrS or\nphenotypically negative mutation carriers. | III | C",
          "rows": 7,
          "cols": 3
        },
        {
          "title": "Table on page 53",
          "page": 53,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIt is recommended that individuals with\nimplanted devices with/without resynchroniza-\ntion and underlying disease follow the recom-\nmendations pertaining to the underlying\ndisease.384,425 | I | B | \nParticipation in sports and exercise (except colli-\nsion sports) should be considered in individuals\nwith pacemaker therapy who do not have patho-\nlogical substrates for fatal arrhythmias. | IIa | C | \nPrevention of direct impact to the implanted\ndevice by adapting the site of lead and/or device\nimplantation, padding, or restricting direct impact\nsports should be considered. | IIa | C | \nHolter recordings and device interrogation dur-\ning and after resuming sports should be consid-\nered to allow appropriate tailoring of rate-\nresponsive pacing parameters, exclusion of myo-\npotential or electromagnetic inhibition, and\ndetection of VAs. | IIa | C | \nShared decision making should be considered dur-\ning decisions relating to continuation of intensive\nor competitive sports participation in individuals\nwith an ICD, taking into account the effect of\nsports on the underlying substrate, the fact that\nintensive sports will trigger more appropriate and\ninappropriate shocks, the psychological impact of\nshocks on the athlete/patient, and the potential\nrisk for third parties. | IIa | C | \nAn ICD is not recommended as a substitute for\ndisease-related recommendations when these\nmandate sports restrictions. | III | C | ",
          "rows": 9,
          "cols": 4
        },
        {
          "title": "Table on page 56",
          "page": 56,
          "content": " |  | \nRecommendations | Classa | Levelb\n |  | \nParticipation in regular moderate exercise is rec-\nommended in all individuals with\nCHD.588,591\u0002594,619 | I | B\nA discussion on exercise participation and provi-\nsion of an individualized exercise prescription is\nrecommended at every CHD patient\nencounter.574,597,598,617 | I | B\nAssessment for ventricular function, pulmonary\nartery pressure, aortic size, and arrhythmia risk\nis recommended in all athletes with\nCHD.342,348,573,597 | I | C\nCompetitive sports participation should be con-\nsidered for CHD athletes in NYHA class I or II\nwho are free from potentially serious arrhyth-\nmias after individual tailored evaluation and\nshared decision making.573,595,597,598 | IIa | C\nCompetitive sports are not recommended for\nindividuals with CHD who are in NYHA class\nIII\u0002IV or with potentially serious\narrhythmias.605,608 | III | C",
          "rows": 8,
          "cols": 3
        },
        {
          "title": "Table on page 59",
          "page": 59,
          "content": " |  |  | \nRecommendations: What to do and what not to do for exercise and sports in healthy individuals | Classa | Levelb | \n |  |  | \nGeneral recommendations for exercise and sports in healthy individuals |  |  | \nAt least 150 min/week of moderate-intensity, or 75 min/week of vigorous-intensity aerobic exercise or an equivalent combination\nthereof is recommended in all healthy adults. | I | A | \nRegular assessment and counselling to promote adherence and, if necessary, to support an increase in exercise volume over time are\nrecommended. | I | B | \nMultiple sessions of exercise spread throughout the week, i.e. on 4\u00025 days a week and preferably every day of the week, are\nrecommended. | I | B | \nSpecial considerations for individuals with obesity, hypertension, dyslipidaemia, or diabetes |  |  | \nIn obese individuals (BMI>30 kg/m2 or a waist circumference >80 cm for females or >94 cm for males) resistance training >3 times\n_ _\nper week, in addition to moderate or vigorous aerobic exercise (at least 30 min, 5\u00027 days per week) is recommended to reduce\nCVD risk. | I | A | \nIn individuals with well-controlled hypertension, resistance training >3 times per week in addition to moderate or vigorous aerobic\n_\nexercise (at least 30 min, 5\u00027 days per week) is recommended to reduce blood pressure and CVD risk. | I | A | \nAmong individuals with diabetes mellitus, resistance training >3 times per week) in addition to moderate or vigorous aerobic exercise\n_\n(at least 30 min, 5\u00027 days per week) is recommended to improve insulin sensitivity and achieve a better CVD risk profile. | I | A | \nIn individuals with uncontrolled hypertension (SBP>160 mmHg) high-intensity exercise is not recommended until BP has been\ncontrolled. | III | C | \nRecommendations for exercise in ageing individuals |  |  | \nAmong adults aged 65 years or older who are fit and have no health conditions that limit their mobility, moderate-intensity aerobic\nexercise for at least 150 min/week is recommended. | I | A | \nIn older adults at risk of falls, strength training exercises to improve balance and coordination on at least 2 days a week are\nrecommended. | I | B | \nRecommendations for exercise in individuals with coronary artery disease |  |  | \nRecommendations for exercise in individuals with long-standing chronic coronary syndrome |  |  | \nRisk stratification for exercise-induced adverse events is recommended in individuals with established (long-standing) CCS prior to\nengaging in exercise. | I | C | \nCompetitive sports are not recommended in individuals at high risk of exercise-induced adverse events or those with residual ischae-\nmia, with the exception of individually recommended skill sports. | III | C | \nRecommendations for return to exercise after acute coronary syndrome |  |  | \nExercise-based cardiac rehabilitation is recommended in all individuals with CAD to reduce cardiac mortality and rehospitalization. | I | A | \nRecommendations for exercise in young individuals/athletes with anomalous origins of coronary arteries |  |  | \nParticipation in most competitive sports with a moderate and high CV demand among individuals with AOCA with an acutely angled\ntake-off or an anomalous course between the large vessels is not recommended. | III | C | \nRecommendations for exercise/sports in individuals with myocardial bridging |  |  | \nCompetitive sports are not recommended in individuals with myocardial bridging and persistent ischaemia or complex cardiac\narrhythmias during maximal exercise stress testing. | III | C | \nRecommendations for exercise in chronic heart failure |  |  | \nRecommendations for exercise prescription in heart failure with reduced or mid-range ejection fraction |  |  | \nRegular discussion about exercise participation and provision of an individualized exercise prescription is recommended in all individ-\nuals with HF. | I | A | \nExercise-based cardiac rehabilitation is recommended in all stable individuals to improve exercise capacity and quality of life and to\nreduce the frequency of hospital readmission. | I | A | ",
          "rows": 29,
          "cols": 4
        },
        {
          "title": "Table on page 60",
          "page": 60,
          "content": "Recommendations for participation in sports in heart failure |  |  | \nBefore considering a sport activity, a preliminary optimization of HF risk factor control and therapy, including device implantation (if\nappropriate), is recommended. | I | C | \nHigh-intensity power and endurance sports are not recommended in patients with HFrEF irrespective of symptoms. | III | C | \nRecommendations for exercise and participation in sports in individuals with heart failure and preserved ejection fraction |  |  | \nModerate endurance and dynamic resistance exercise, together with lifestyle intervention and optimal treatment of CV risk factors\n(i.e. arterial hypertension and type 2 diabetes) are recommended. | I | C | \nRecommendations for exercise and participation in sports in individuals with heart transplant recipients |  |  | \nRegular exercise through cardiac rehabilitation combining moderate-intensity aerobic and resistance exercise is recommended to\nrevert pathophysiology to pre-transplantation time, reduce CV risk induced by post-transplantation medical treatment, and improve\nclinical outcome. | I | B | \nRecommendations for exercise in asymptomatic individuals with valvular heart disease |  |  | \nParticipation in competitive or recreational sports/exercise of moderate and high intensity is not recommended in individuals with\nsevere aortic stenosis. | III | C | \nParticipation in competitive or recreational sports/exercise of moderate and high intensity is not recommended in individuals with\nsevere aortic regurgitation with LVEF<50% and/or exercise-induced arrhythmias.\n_ | III | C | \nParticipation in competitive sports is not recommended in individuals with severe mitral regurgitation with a LVEF<60%. | III | C | \nParticipation in any competitive sport, or leisure sports/exercise of mild to moderate intensity, is not recommended in individuals\nwith severe (MVA<1 cm2) mitral stenosis. | III | C | \nRecommendations for exercise in individuals with aortic pathology |  |  | \nPrior to engaging in exercise, risk stratification, with careful assessment including advanced imaging of the aorta (CT/CMR) and exer-\ncise testing with BP assessment, is recommended. | I | A | \nCompetitive sports are not recommended in individuals who are at high risk (Table 14). | III | C | \nRecommendations for exercise in individuals with cardiomyopathy |  |  | \nGeneral recommendation |  |  | \nAnnual assessment for risk stratification is recommended in all individuals with cardiomyopathy who exercise regularly. | I | C | \nRecommendations for exercise and sports participation in individuals with hypertrophic cardiomyopathy |  |  | \nParticipation in high-intensity exercise (including recreational and competitive sports) is not recommended in individuals who have\nANY markers of increased risk [(i) cardiac symptoms or history of cardiac arrest or unexplained syncope; (ii) moderate ESC risk\nscore (>4%) at 5 years; (iii) LVOT gradient at rest >30 mmHg; (iv) abnormal BP response to exercise; (v) exercise-induced\n_\narrhythmias]. | III | C | \nRecommendations for exercise and sports participation in individuals with arrhythmogenic cardiomyopathy |  |  | \nParticipation in high-intensity recreational exercise/sports or any competitive sports is not recommended in individuals with ACM\nincluding those who are genotype positive and phenotype negative. | III | C | \nRecommendations for exercise and sports participation in individuals with left ventricular non-compaction cardiomyopathy |  |  | \nParticipation in high-intensity exercise or competitive sports is not recommended in individuals with symptoms, LVEF<40% and/or\nfrequent and/or complex VAs on ambulatory Holter monitoring or exercise testing. | III | C | \nRecommendations for exercise and sports participation in individuals with dilated cardiomyopathy |  |  | \nParticipation in high- or very high-intensity exercise including competitive sports is not recommended for individuals with a DCM and\nany of the following: (i) symptoms or history of cardiac arrest or unexplained syncope; (ii) LVEF<45%; (iii) frequent and/or complex\nVAs on ambulatory Holter monitoring or exercise testing; (iv) extensive LGE (>20%) on CMR; or (v) high-risk genotype (lamin A/C\nor filamin C). | III | C | \nRecommendations for exercise in individuals with myocarditis and pericarditis |  |  | \nComprehensive evaluation, using imaging studies, exercise stress test, and Holter monitoring, is recommended following recovery\nfrom acute myocarditis to assess the risk of exercise-related SCD. | I | B | \nReturn to all forms of exercise including competitive sports is recommended after 30 days to 3 months of rest for individuals who\nhave recovered completely from acute pericarditis, depending on clinical severity. | I | C | \nAmong individuals with a probable or definitive diagnosis of recent myocarditis or pericarditis, participation in leisure-time or com-\npetitive sports while active inflammation is present is not recommended. | III | C | \nParticipation in moderate- to high-intensity exercise for a period of 3\u00026 months after acute myocarditis is not recommended. | III | B | \nParticipation in moderate- to high-intensity exercise, including competitive sports, is not recommended for individuals with constric-\ntive pericarditis. | III | C | ",
          "rows": 32,
          "cols": 4
        }
      ],
      "keywords": [
        "ct",
        "asymptomatic",
        "risk",
        "symptomatic",
        "icd",
        "diagnosis"
      ]
    },
    {
      "number": "7",
      "title": "Recommendations for exercise in individuals with arrhythmias and implantable cardiac devices",
      "start_page": 61,
      "end_page": 70,
      "content": "Recommendations for exercise in individuals with arrhythmias and implantable cardiac devices\nExercise recommendations in individuals with atrial ﬁbrillation\nRegular physical activity is recommended to prevent AF.\nI\nA\nEvaluation and management of structural heart disease, thyroid dysfunction, alcohol or drug abuse, or other primary causes of AF is\nrecommended before engaging in sports.\nI\nA\nAF ablation is recommended in exercising individuals with recurrent, symptomatic AF and/or in those who do not want drug therapy,\ngiven its impact on athletic performance.\nI\nB\nSports with direct bodily contact or prone to trauma are not recommended in exercising individuals with AF who are anticoagulated.\nIII\nC\nRecommendations for exercise and sports participation in individuals with paroxysmal supraventricular tachycardia and pre-excitation\nIn individuals with palpitations, a comprehensive assessment to exclude (latent) pre-excitation, structural heart disease, and VAs is\nrecommended.\nI\nB\nAblation of the accessory pathway is recommended in competitive and recreational athletes with pre-excitation and documented\narrhythmias.\nI\nC\nIn competitive/professional athletes with asymptomatic pre-excitation, an EP study is recommended to evaluate the risk for sudden\ndeath.\nI\nB\nExercise recommendations in individuals with premature ventricular contractions or non-sustained ventricular tachycardia\nIn exercising individuals with >_2 PVCs on a baseline ECG (or >_1 PVC in case of high-endurance athletes) a thorough evaluation\n(including a detailed family history) to exclude underlying structural or arrhythmogenic conditions is recommended.\nI\nC\nAmong individuals with frequent PVCs and non-sustained VT a thorough investigation with Holter monitoring, 12-lead ECG, exercise\ntest, and suitable imaging is recommended.\nI\nC\nExercise recommendations in long QT syndrome\nIt is recommended that all exercising individuals with LQTS with prior symptoms or prolonged QTc be on therapy with beta-block-\ners at target dose.\nI\nB\nIt is recommended that exercising individuals with LQTS should avoid QT-prolonging drugs (www.crediblemeds.org) and electrolyte\nimbalance such as hypokalaemia and hypomagnesaemia.\nI\nB\nParticipation in high-intensity recreational and competitive sports, even when on beta-blockers, is not recommended in individuals\nwith a QTc>500 ms or a genetically conﬁrmed LQTS with a QTc>_470 ms in males or >_480 ms in females.\nIII\nB\nParticipation in competitive sports (with or without ICD) is not recommended in individuals with LQTS and prior cardiac arrest or\narrhythmic syncope.\nIII\nC\nExercise recommendations in Brugada syndrome\nICD implantation is recommended in patients with BrS with episodes of arrhythmic syncope and/or aborted SCD.\nI\nC\nPrescription of drugs that may aggravate BrS, electrolyte abnormalities, and sports practices that increase core temperature >39\n\u0004C\nare not recommended in individuals with overt BrS or phenotypically negative mutation carriers.\nIII\nC\nExercise recommendations in individuals with implantable cardiac electronic devices\nIt is recommended that individuals with implanted devices with/without resynchronization and underlying disease follow the recom-\nmendations pertaining to the underlying disease.\nI\nB\nAn ICD is not recommended as a substitute for disease-related recommendations when these mandate sports restrictions.\nIII\nC\nRecommendations for patients with congenital heart disease\nParticipation in regular moderate exercise is recommended in all individuals with CHD.\nI\nB\nA discussion on exercise participation and provision of an individualized exercise prescription is recommended at every CHD patient\nencounter.\nI\nB\nCompetitive sport is not recommended for individuals with CHD who are in NYHA class III\u0002IV or with potentially serious\narrhythmias.\nIII\nC\nRecommendations for exercise in pregnancy\nAmong pregnant women without medical or obstetric contraindications, participation in at least 150 min/week of moderate-intensity\naerobic exercise before, during, and after pregnancy is recommended.\nI\nB\nRe-evaluation before continuing exercise or training is recommended in pregnant woman if they experience excessive shortness of\nbreath, severe chest pain, dizziness or syncope, regular painful contractions, vaginal bleeding, or amniotic ﬂuid leakage.\nI\nA\nAmong women with CVD who were habitually engaged in strength training or power sport disciplines before pregnancy, discussing\nthe option with the medical team before continuing and avoiding the Valsalva manoeuvre is recommended.\nI\nA\nExercise or sport involving forceful physical contact, risk of falling or abdominal trauma, heavy lifting, scuba diving, or exercising at\nhigh altitude when unacclimatized are not recommended.\nIII\nC\nContinued\nESC Guidelines\n77\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n..................\n10. Supplementary data\nSupplementary Data with additional Supplementary Figures, Tables,\nand text complementing the full text are available on the European\nHeart Journal website and via the ESC website at www.escardio.org/\nguidelines.\n11. Appendix\nAuthor/Task Force Member Affiliations: Sabiha Gati, Faculty\nof Medicine, National Heart & Lung Institute, Imperial College,\nLondon, United Kingdom and Cardiology, Royal Brompton &\nHarefield Hospital NHS Foundation Trust, London, United Kingdom;\nVigorous exercise associated with a maximal predicted heart rate >90% of the predicted heart rate is not recommended during\npregnancy.\nIII\nB\nExercising while lying supine on a hard surface is not recommended after the ﬁrst trimester due to the risk of decreased venous\nreturn and uterine blood ﬂow.\nIII\nB\nRecommendations for exercise in chronic kidney disease\nLow- to moderate-intensity aerobic exercise training (up to 150 min/week), and low- to moderate-intensity resistance exercise train-\ning (2 day per week, 8\u000212 exercises, 12\u000215 repetitions), and ﬂexibility exercises are recommended in all individuals with CKD.\nI\nA\nAmong patients with established osteodystrophy/osteoporosis, or coagulopathies, participation in contact sports is not\nrecommended.\nIII\nC\nParticipation in sport is not recommended in the following circumstances: electrolyte abnormalities, recent changes to the ECG,\nexcess inter-dialysis weight gain, changing or titration of medication regimen, pulmonary congestion, and increasing peripheral\noedema.\nIII\nC\nRecommendations for exercise in individuals with cancer\nRegular exercise during and after cancer therapy is recommended to reduce cancer-related fatigue, and improve quality of life, physi-\ncal ﬁtness, and prognosis.\nI\nA\nAmong individuals treated with cardiotoxic medications, echocardiography before participation in high-intensity exercise is\nrecommended.\nI\nA\nRecommendations for exercise in individuals with spinal cord injury\nIn adults with spinal cord injury participation in 20 min of moderate- to vigorous-intensity aerobic exercise at least 3 times a week,\nalong with moderate-intensity resistance training 2\u00023 times per week, is recommended for cardiorespiratory ﬁtness, cardiometabolic\nhealth, and muscle strength beneﬁts.\nI\nA\nArtiﬁcial methods of inducing autonomic dysreﬂexia by causing intentional pain to the lower half of the body (‘boosting’) through\nobstruction of an indwelling urinary catheter, overly tight leg straps and electrical shocks or other methods of pain to the genitalia or\nlower limbs can be life-threatening and are not recommended.\nIII\nC\nRecommendations for exercise in individuals with ventricular assist devices\nRegular exercise, through cardiac rehabilitation, combining moderate-intensity aerobic and resistance exercise, is recommended in\nindividuals with a ventricular assist device (VAD).\nI\nA\nSports that may potentially affect any of the VAD components (e.g. with body contact) are not recommended.\nIII\nC\nPhysical activity and sports recommendations in patients and athletes with peripheral arterial disease\nIt is recommended that patients with atherosclerotic PAD perform regular exercise (at least 150 min/week of moderate aerobic\nexercise or 75 min/week of vigorous aerobic exercise or a combination thereof) as part of the secondary prevention strategy.\nI\nA\nIn patients with symptomatic LEAD, supervised exercise training programmes including walking to the maximal or submaximal dis-\ntance for at least 3 h/week are indicated.\nI\nA\nContinuation of competitive sports is recommended in athletes with traumatic or non-traumatic PAD following recovery after suc-\ncessful open surgery or percutaneous revascularization.\nI\nC\nACM = arrhythmogenic cardiomyopathy; AF = atrial ﬁbrillation; AOCA = anomalous origin of coronary arteries; BP = blood pressure; BMI = body mass index; BrS = Brugada\nsyndrome; CAD = coronary artery disease; CCS = chronic coronary syndrome; CHD = congenital heart disease; CKD = chronic kidney disease; CMR, cardiovascular magnetic\nresonance; CT = computed tomography; CV = cardiovascular; CVD= cardiovascular disease; EEG = electrocardiogram; EP = electrophysiological; ESC = European Society of\nCardiology; EP = electrophysiological; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; ICD = implantable cardioverter deﬁbrillator; LEAD = lower\nextremity artery disease; LQTS = long QT syndrome; LVEF = left ventricular ejection fraction; LVOT = left ventricular outﬂow tract; MVA = mitral valve area; NYHA = New\nYork Heart Association; PAD = peripheral arterial disease; PVC = premature ventricular contractions; SCD = sudden cardiac death; SBP = systolic blood pressure; VA = ven-\ntricular arrhythmia; VAD = ventricular assist device; VT = ventricular tachycardia.\naClass of recommendation.\nbLevel of evidence.\n78\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\nMaria B€ack, Unit of Physiotherapy, Department of Health,\nMedicine and Caring Sciences, Linko¨ping University, Linko¨ping,\nSweden, and Department of Molecular and Clinical Medicine,\nInstitute\nof\nMedicine,\nSahlgrenska\nAcademy,\nUniversity\nof\nGothenburg, and Sahlgrenska University Hospital, Gothenburg,\nSweden; Mats Bo¨rjesson, Department of Molecular and Clinical\nMedicine, Institute of Medicine, Sahlgrenska Academy, University of\nGothenburg, and Sahlgrenska University Hospital, Gothenburg,\nSweden, and Center for Health and Performance, Department of\nFood, Nutrition and Sports Science, Gothenburg University,\nGothenburg, Sweden; Stefano Caselli, Cardiovascular Center\nZurich, Hirslanden Klinik im Park, Zurich, Switzerland; Jean-\nPhilippe Collet, Sorbonne Universite´, Institut de Cardiologie,\nHoˆpital\nPitie´-Salp^etrie`re\n(APHP),\nParis,\nFrance;\nDomenico\nCorrado, Cardiac, Thoracic and Vascular Sciences, University of\nPadova, Padova, Italy; Jonathan A. Drezner, University of\nWashington, Seattle, United States of America; Martin Halle,\nPrevention and Sports Medicine, Klinikum rechts der Isar, Technical\nUniversity of Munich, Munich, Germany; Dominique Hansen,\nHasselt University, BIOMED/REVAL/Heart Centre Hasselt, Jessa\nHospital,\nHasselt,\nBelgium;\nHein\nHeidbuchel,\nCardiology,\nUniversity Hospital Antwerp and Antwerp University, Antwerp,\nBelgium; Jonathan Myers, Cardiology Division, VA Palo Alto\nHealth Care System, Palo Alto, California, United States of America\nand Cardiology Division, Stanford University, Palo Alto, California,\nUnited States of America; Josef Niebauer, University Institute of\nSports Medicine, Prevention and Rehabilitation, Paracelsus Medical\nUniversity, Salzburg, Austria and Ludwig Boltzmann Institute for\nDigital\nHealth\nand\nPrevention,\nSalzburg,\nAustria;\nMichael\nPapadakis, Cardiology Clinical Academic Group, St George’s,\nUniversity\nof\nLondon,\nLondon,\nUnited\nKingdom;\nMassimo\nFrancesco Piepoli, Heart Failure Unit, Cardiology, Guglielmo da\nSaliceto Hospital and University of Parma, Piacenza, Italy; Eva\nPrescott,\nDepartment\nof\nCardiology,\nBispebjerg\nUniversity\nHospital, Copenhagen, Denmark; Jolien W. Roos-Hesselink,\nDepartment of Cardiology, Erasmus MC, Rotterdam, Netherlands;\nA. Graham Stuart, Congenital Heart Unit, Bristol Heart Institute,\nBristol, United Kingdom; Rod S. Taylor, University of Glasgow,\nGlasgow, Scotland, United Kingdom; Paul D. Thompson, Division\nof Cardiology, Hartford Hospital, Hartford, Connecticut, United\nStates of America; Monica Tiberi, Department of Health-Sport\nMedicine, Azienda Unica Regionale Marche, Area Vasta 1, Pesaro,\nItaly; Luc Vanhees, Rehabilitation Sciences, Kuleuven, Leuven,\nBelgium; and Matthias Wilhelm, Department of Cardiology,\nInselspital, University Hospital Bern, University of Bern, Bern,\nSwitzerland.\nESC Committee for Practice Guidelines (CPG): Stephan\nWindecker (Chairperson) (Switzerland), Victor Aboyans (France),\nColin Baigent (United Kingdom), Jean-Philippe Collet (France),\nVeronica Dean (France), Victoria Delgado (Netherlands), Donna\nFitzsimons (United Kingdom), Chris P. Gale (United Kingdom),\nDiederick E. Grobbee (Netherlands), Sigrun Halvorsen (Norway),\nGerhard Hindricks (Germany), Bernard Iung (France), Peter Ju¨ni\n(Canada), Hugo A. Katus (Germany), Ulf Landmesser (Germany),\nChristophe Leclercq (France), Maddalena Lettino (Italy), Basil S.\nLewis\n(Israel),\nBe´la\nMerkely\n(Hungary),\nChristian\nMueller\n(Switzerland), Steffen E. Petersen (United Kingdom), Anna Sonia\nPetronio\n(Italy),\nDimitrios\nJ.\nRichter\n(Greece),\nMarco\nRoffi\n(Switzerland), Evgeny Shlyakhto (Russian Federation), Iain A.\nSimpson (United Kingdom), Miguel Sousa-Uva (Portugal), and Rhian\nM. Touyz (United Kingdom).\nESC National Cardiac Societies actively involved in the review\nprocess of the 2020 ESC Guidelines on Sports Cardiology and\nExercise in Patients with Cardiovascular Disease: Algeria: Algerian\nSociety of Cardiology, Mohamed Tahmi; Armenia: Armenian\nCardiologists Association, Parounak H. Zelveian; Austria: Austrian\nSociety of Cardiology, Thomas Berger; Azerbaijan: Azerbaijan\nSociety of Cardiology, Rahima Gabulova; Belarus: Belorussian\nScientific Society of Cardiologists, Svetlana Sudzhaeva; Belgium:\nBelgian Society of Cardiology, Patrizio Lancellotti; Bosnia and\nHerzegovina:\nAssociation\nof\nCardiologists\nof\nBosnia\nand\nHerzegovina, \u0002Sekib Sokolovi\u0003c; Bulgaria: Bulgarian Society of\nCardiology, Ivan Gruev; Croatia: Croatian Cardiac Society, Vedran\nVelagic; Cyprus: Cyprus Society of Cardiology, Evagoras Nicolaides;\nCzech Republic: Czech Society of Cardiology, Vladimir Tuka;\nDenmark: Danish Society of Cardiology, Hanne Rasmusen; Egypt:\nEgyptian Society of Cardiology, Hazem Khamis; Estonia: Estonian\nSociety of Cardiology, Margus Viigimaa; Finland: Finnish Cardiac\nSociety, Jari A. Laukkanen; France: French Society of Cardiology,\nGilles\nBosser;\nGermany:\nGerman\nCardiac\nSociety,\nRainer\nHambrecht; Greece: Hellenic Society of Cardiology, Alexandros\nKasiakogias; Hungary: Hungarian Society of Cardiology, Be´la\nMerkely; Iceland: Icelandic Society of Cardiology, Gunnar Thor\nGunnarsson; Ireland: Irish Cardiac Society, Brendan McAdam;\nIsrael: Israel Heart Society, Andre Keren; Italy: Italian Federation of\nCardiology, Pasquale Perrone-Filardi; Kosovo (Republic of):\nKosovo Society of Cardiology, Gani Bajraktari; Kyrgyzstan: Kyrgyz\nSociety of Cardiology, Erkin Mirrakhimov; Latvia: Latvian Society of\nCardiology, Sandra Rozen\u0002stoka; Lithuania: Lithuanian Society of\nCardiology,\nGermanas\nMarinskis;\nLuxembourg:\nLuxembourg\nSociety of Cardiology, Cristiana Banu; Malta: Maltese Cardiac\nSociety, Mark Abela; Moldova (Republic of): Moldavian Society of\nCardiology, Eleonora Vataman; Montenegro: Montenegro Society\nof Cardiology, Natasa Belada; Morocco: Moroccan Society of\nCardiology, Hasnaa Belghiti; Netherlands: Netherlands Society of\nCardiology, Harald Thune Jorstad; North Macedonia: North\nMacedonian Society of Cardiology, Elizabeta Srbinovska Kostovska;\nNorway: Norwegian Society of Cardiology, Kristina Haugaa;\nPoland: Polish Cardiac Society, Renata Gł\u0003owczy\u0003nska; Portugal:\nPortuguese Society of Cardiology, Helder Dores; Romania:\nRomanian Society of Cardiology, Florin Mitu; Russian Federation:\nRussian Society of Cardiology, Andrey Smolensky; San Marino: San\nMarino Society of Cardiology, Marina Foscoli; Serbia: Cardiology\nSociety of Serbia, Ivana Nedeljkovic; Slovakia: Slovak Society of\nCardiology,\nStefan\nFarsky;\nSlovenia:\nSlovenian\nSociety\nof\nCardiology, Zlatko Fras; Spain: Spanish Society of Cardiology,\nAraceli Boraita; Sweden: Swedish Society of Cardiology, Peder\nSo¨renssen; Switzerland: Swiss Society of Cardiology, Christian\nSchmied;\nSyrian\nArab\nRepublic:\nSyrian\nCardiovascular\nAssociation, Walid Bsata; Tunisia: Tunisian Society of Cardiology\nand Cardio-Vascular Surgery, Lilia Zakhama; Turkey: Turkish\nSociety\nof\nCardiology,\nMehmet\nUzun;\nUkraine:\nUkrainian\nESC Guidelines\n79\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n...........................................................................................................................................................................\nAssociation of Cardiology, Elena Nesukay; United Kingdom of\nGreat Britain and Northern Ireland: British Cardiovascular\nSociety, Dhrubo Rakhit.\n12. References\n1. Pelliccia A, Fagard R, Bjornstad HH, Anastassakis A, Arbustini E, Assanelli D, Biffi\nA, Borjesson M, Carre F, Corrado D, Delise P, Dorwarth U, Hirth A, Heidbuchel\nH, Hoffmann E, Mellwig KP, Panhuyzen-Goedkoop N, Pisani A, Solberg EE, van-\nBuuren F, Vanhees L, Blomstrom-Lundqvist C, Deligiannis A, Dugmore D, Glikson\nM, Hoff PI, Hoffmann A, Hoffmann E, Horstkotte D, Nordrehaug JE, Oudhof J,\nMcKenna WJ, Penco M, Priori S, Reybrouck T, Senden J, Spataro A, Thiene G.\nRecommendations for competitive sports participation in athletes with cardiovas-\ncular disease: a consensus document from the Study Group of Sports Cardiology\nof the Working Group of Cardiac Rehabilitation and Exercise Physiology and the\nWorking Group of Myocardial and Pericardial Diseases of the European Society\nof Cardiology. Eur Heart J 2005;26:1422\u00021445.\n2. Borjesson M, Dellborg M. Exercise testing post-MI: still worthwhile in the inter-\nventional era. Eur Heart J 2005;26:105\u0002106.\n3. Pelliccia A, Solberg EE, Papadakis M, Adami PE, Biffi A, Caselli S, La Gerche A,\nNiebauer J, Pressler A, Schmied CM, Serratosa L, Halle M, Van Buuren F,\nBorjesson M, Carre F, Panhuyzen-Goedkoop NM, Heidbuchel H, Olivotto I,\nCorrado D, Sinagra G, Sharma S. Recommendations for participation in competi-\ntive and leisure time sport in athletes with cardiomyopathies, myocarditis, and\npericarditis: position statement of the Sport Cardiology Section of the European\nAssociation of Preventive Cardiology (EAPC). Eur Heart J 2019;40:19\u000233.\n4. Marijon E, Uy-Evanado A, Reinier K, Teodorescu C, Narayanan K, Jouven X,\nGunson K, Jui J, Chugh SS. Sudden cardiac arrest during sports activity in middle\nage. Circulation 2015;131:1384\u00021391.\n5. Chugh SS, Weiss JB. Sudden cardiac death in the older athlete. J Am Coll Cardiol\n2015;65:493\u0002502.\n6. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney M-\nT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Lochen M-L,\nLollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N,\nSmulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S.\n2016 European Guidelines on cardiovascular disease prevention in clinical prac-\ntice: the Sixth Joint Task Force of the European Society of Cardiology and Other\nSocieties on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J\n2016;37:2315\u00022381.\n7. Mandsager K, Harb S, Cremer P, Phelan D, Nissen SE, Jaber W. Association of\ncardiorespiratory fitness with long-term mortality among adults undergoing exer-\ncise treadmill testing. JAMA Netw Open 2018;1:e183605.\n8. Shiroma EJ, Lee I-M. Physical activity and cardiovascular health: lessons learned\nfrom epidemiological studies across age, gender, and race/ethnicity. Circulation\n2010;122:743\u0002752.\n9. Radford NB, DeFina LF, Leonard D, Barlow CE, Willis BL, Gibbons LW, Gilchrist\nSC, Khera A, Levine BD. Cardiorespiratory fitness, coronary artery calcium, and\ncardiovascular disease events in a cohort of generally healthy middle-age men:\nresults\nfrom\nthe\nCooper\nCenter\nLongitudinal\nStudy.\nCirculation\n2018;137:1888\u00021895.\n10. Shah RV, Murthy VL, Colangelo LA, Reis J, Venkatesh BA, Sharma R, Abbasi SA,\nGoff DCJ, Carr JJ, Rana JS, Terry JG, Bouchard C, Sarzynski MA, Eisman A,\nNeilan T, Das S, Jerosch-Herold M, Lewis CE, Carnethon M, Lewis GD, Lima\nJAC. Association of fitness in young adulthood with survival and cardiovascular\nrisk: the Coronary Artery Risk Development in Young Adults (CARDIA) study.\nJAMA Intern Med 2016;176:87\u000295.\n11. Hussain N, Gersh BJ, Gonzalez Carta K, Sydo N, Lopez-Jimenez F, Kopecky SL,\nThomas RJ, Asirvatham SJ, Allison TG. Impact of cardiorespiratory fitness on fre-\nquency of atrial fibrillation, stroke, and all-cause mortality. Am J Cardiol\n2018;121:41\u000249.\n12. Juraschek SP, Blaha MJ, Whelton SP, Blumenthal R, Jones SR, Keteyian SJ,\nSchairer J, Brawner CA, Al-Mallah MH. Physical fitness and hypertension in a\npopulation at risk for cardiovascular disease: the Henry Ford ExercIse Testing\n(FIT) Project. J Am Heart Assoc 2014;3:e001268.\n13. Juraschek SP, Blaha MJ, Blumenthal RS, Brawner C, Qureshi W, Keteyian SJ,\nSchairer J, Ehrman JK, Al-Mallah MH. Cardiorespiratory fitness and incident dia-\nbetes:\nthe\nFIT\n(Henry\nFord\nExercIse\nTesting)\nProject.\nDiabetes\nCare\n2015;38:1075\u00021081.\n14. Vainshelboim B, Muller J, Lima RM, Nead KT, Chester C, Chan K, Kokkinos P,\nMyers J. Cardiorespiratory fitness and cancer incidence in men. Ann Epidemiol\n2017;27:442\u0002447.\n15. Powell KE, King AC, Buchner DM, Campbell WW, DiPietro L, Erickson KI,\nHillman CH, Jakicic JM, Janz KF, Katzmarzyk PT, Kraus WE, Macko RF, Marquez\nDX, McTiernan A, Pate RR, Pescatello LS, Whitt-Glover MC. The Scientific\nFoundation for the Physical Activity Guidelines for Americans, 2nd Edition. J Phys\nAct Health 2018;1\u000211.\n16. Kyu HH, Bachman VF, Alexander LT, Mumford JE, Afshin A, Estep K, Veerman\nJL, Delwiche K, Iannarone ML, Moyer ML, Cercy K, Vos T, Murray CJL,\nForouzanfar MH. Physical activity and risk of breast cancer, colon cancer, diabe-\ntes, ischemic heart disease, and ischemic stroke events: systematic review and\ndose-response meta-analysis for the Global Burden of Disease Study 2013. BMJ\n2016;354:i3857.\n17. Harmon KG, Asif IM, Maleszewski JJ, Owens DS, Prutkin JM, Salerno JC, Zigman\nML, Ellenbogen R, Rao AL, Ackerman MJ, Drezner JA. Incidence, cause, and com-\nparative frequency of sudden cardiac death in national collegiate athletic associa-\ntion athletes: a decade in review. Circulation 2015;132:10\u000219.\n18. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young\ncompetitive athletes: analysis of 1866 deaths in the United States, 1980\u00022006.\nCirculation 2009;119:1085\u00021092.\n19. Corrado D, Basso C, Rizzoli G, Schiavon M, Thiene G. Does sports activity\nenhance the risk of sudden death in adolescents and young adults? J Am Coll\nCardiol 2003;42:1959\u00021963.\n20. Maron BJ, Friedman RA, Kligfield P, Levine BD, Viskin S, Chaitman BR, Okin PM,\nSaul JP, Salberg L, Van Hare GF, Soliman EZ, Chen J, Matherne GP, Bolling SF,\nMitten MJ, Caplan A, Balady GJ, Thompson PD. Assessment of the 12-lead elec-\ntrocardiogram as a screening test for detection of cardiovascular disease in\nhealthy general populations of young people (12\u000225 years of age): a scientific\nstatement from the American Heart Association and the American College of\nCardiology. J Am Coll Cardiol 2014;64:1479\u00021514.\n21. Corrado D, Pelliccia A, Bjornstad HH, Vanhees L, Biffi A, Borjesson M,\nPanhuyzen-Goedkoop N, Deligiannis A, Solberg E, Dugmore D, Mellwig KP,\nAssanelli D, Delise P, van-Buuren F, Anastasakis A, Heidbuchel H, Hoffmann E,\nFagard R, Priori SG, Basso C, Arbustini E, Blomstrom-Lundqvist C, McKenna WJ,\nThiene G. Cardiovascular pre-participation screening of young competitive ath-\nletes for prevention of sudden death: proposal for a common European proto-\ncol. Consensus statement of the Study Group of Sport Cardiology of the\nWorking Group of Cardiac Rehabilitation and Exercise Physiology and the\nWorking Group of Myocardial and Pericardial Diseases of the European Society\nof Cardiology. Eur Heart J 2005;26:516\u0002524.\n22. Drezner JA, O’Connor FG, Harmon KG, Fields KB, Asplund CA, Asif IM, Price\nDE, Dimeff RJ, Bernhardt DT, Roberts WO. AMSSM position statement on car-\ndiovascular preparticipation screening in athletes: current evidence, knowledge\ngaps, recommendations and future directions. Br J Sports Med 2017;51:153\u0002167.\n23. Ljungqvist A, Jenoure P, Engebretsen L, Alonso JM, Bahr R, Clough A, De Bondt\nG, Dvorak J, Maloley R, Matheson G, Meeuwisse W, Meijboom E, Mountjoy M,\nPelliccia A, Schwellnus M, Sprumont D, Schamasch P, Gauthier J-B, Dubi C,\nStupp H, Thill C. The International Olympic Committee (IOC) Consensus\nStatement on periodic health evaluation of elite athletes, March 2009. Br J Sports\nMed 2009;43:631\u0002643.\n24. Hainline B, Drezner JA, Baggish A, Harmon KG, Emery MS, Myerburg RJ,\nSanchez E, Molossi S, Parsons JT, Thompson PD. Interassociation consensus\nstatement on cardiovascular care of college student-athletes. J Am Coll Cardiol\n2016;67:2981\u00022995.\n25. Preparticipation Physical Evaluation, 4th Edition [online]. American Academy of\nFamily Physicians et alet al; 2010. Available from: https://ebooks.aappublications.\norg/content/9781581104882/9781581104882.\n26. Maron BJ, Levine BD, Washington RL, Baggish AL, Kovacs RJ, Maron MS.\nEligibility and disqualification recommendations for competitive athletes with car-\ndiovascular abnormalities: Task Force 2: Preparticipation screening for cardiovas-\ncular disease in competitive athletes: a scientific statement from the American\nHeart Association. Circulation 2015;132:e267\u000272.\n27. Peterson DF, Siebert DM, Kucera KL, Thomas LC, Maleszewski JJ, Lopez-\nAnderson M, Suchsland MZ, Harmon KG, Drezner JA. Etiology of sudden cardiac\narrest and death in US competitive athletes: a 2-year prospective surveillance\nstudy. Clin J Sport Med; doi:10.1097/JSM.0000000000000598. Published online\nahead of print, 2018 Apr 9.\n28. Finocchiaro G, Papadakis M, Robertus J-L, Dhutia H, Steriotis AK, Tome M,\nMellor G, Merghani A, Malhotra A, Behr E, Sharma S, Sheppard MN. Etiology of\nsudden death in sports: insights from a United Kingdom regional registry. J Am\nColl Cardiol 2016;67:2108\u00022115.\n29. Eckart RE, Shry EA, Burke AP, McNear JA, Appel DA, Castillo-Rojas LM,\nAvedissian L, Pearse LA, Potter RN, Tremaine L, Gentlesk PJ, Huffer L, Reich SS,\nStevenson WG. Sudden death in young adults: an autopsy-based series of a pop-\nulation undergoing active surveillance. J Am Coll Cardiol 2011;58:1254\u00021261.\n30. Solberg EE, Borjesson M, Sharma S, Papadakis M, Wilhelm M, Drezner JA,\nHarmon KG, Alonso JM, Heidbuchel H, Dugmore D, Panhuyzen-Goedkoop NM,\nMellwig K-P, Carre F, Rasmusen H, Niebauer J, Behr ER, Thiene G, Sheppard\nMN, Basso C, Corrado D. Sudden cardiac arrest in sports \u0002 need for uniform\nregistration: a position paper from the Sport Cardiology Section of the European\n80\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\nAssociation for Cardiovascular Prevention and Rehabilitation. Eur J Prev Cardiol\n2016;23:657\u0002667.\n31. Maron BJ, Thompson PD, Ackerman MJ, Balady G, Berger S, Cohen D, Dimeff R,\nDouglas PS, Glover DW, Hutter AMJ, Krauss MD, Maron MS, Mitten MJ,\nRoberts WO, Puffer JC. Recommendations and considerations related to prepar-\nticipation screening for cardiovascular abnormalities in competitive athletes:\n2007 update: a scientific statement from the American Heart Association Council on\nNutrition, Physical Activity, and Metabolism. Circulation 2007;115:1455\u00021643.\n32. Drezner JA, Peterson DF, Siebert DM, Thomas LC, Lopez-Anderson M,\nSuchsland MZ, Harmon KG, Kucera KL. Survival after exercise-related sudden\ncardiac arrest in young athletes: can we do better? Sports Health 2019;11:91\u000298.\n33. McKinney J, Velghe J, Fee J, Isserow S, Drezner JA. Defining athletes and exer-\ncisers. Am J Cardiol 2019;123:532\u0002535.\n34. Giri S, Thompson PD, Kiernan FJ, Clive J, Fram DB, Mitchel JF, Hirst JA, McKay\nRG, Waters DD. Clinical and angiographic characteristics of exertion-related\nacute myocardial infarction. JAMA 1999;282:1731\u00021736.\n35. Thompson PD. Exercise prescription and proscription for patients with coronary\nartery disease. Circulation 2005;112:2354\u00022363.\n36. Marijon E, Uy-Evanado A, Dumas F, Karam N, Reinier K, Teodorescu C,\nNarayanan K, Gunson K, Jui J, Jouven X, Chugh SS. Warning symptoms are asso-\nciated with survival from sudden cardiac arrest. Ann Intern Med 2016;164:23\u000229.\n37. Nehme Z, Bernard S, Andrew E, Cameron P, Bray JE, Smith K. Warning symp-\ntoms preceding out-of-hospital cardiac arrest: do patient delays matter?\nResuscitation 2018;123:65\u000270.\n38. Kim JH, Malhotra R, Chiampas G, d’Hemecourt P, Troyanos C, Cianca J, Smith\nRN, Wang TJ, Roberts WO, Thompson PD, Baggish AL. Cardiac arrest during\nlong-distance running races. N Engl J Med 2012;366:130\u0002140.\n39. Drezner JA, Rao AL, Heistand J, Bloomingdale MK, Harmon KG. Effectiveness of\nemergency response planning for sudden cardiac arrest in United States high\nschools with automated external defibrillators. Circulation 2009;120:518\u0002525.\n40. Roberts WO, Stovitz SD. Incidence of sudden cardiac death in Minnesota high\nschool athletes 1993\u00022012 screened with a standardized pre-participation eval-\nuation. J Am Coll Cardiol 2013;62:1298\u00021301.\n41. Harmon KG, Asif IM, Klossner D, Drezner JA. Incidence of sudden cardiac death\nin\nNational\nCollegiate\nAthletic\nAssociation\nathletes.\nCirculation\n2011;123:1594\u00021600.\n42. Holst AG, Winkel BG, Theilade J, Kristensen IB, Thomsen JL, Ottesen GL,\nSvendsen JH, Haunso S, Prescott E, Tfelt-Hansen J. Incidence and etiology of\nsports-related sudden cardiac death in Denmark \u0002 implications for preparticipa-\ntion screening. Heart Rhythm 2010;7:1365\u00021371.\n43. Risgaard B, Winkel BG, Jabbari R, Glinge C, Ingemann-Hansen O, Thomsen JL,\nOttesen GL, Haunso S, Holst AG, Tfelt-Hansen J. Sports-related sudden cardiac\ndeath in a competitive and a noncompetitive athlete population aged 12 to 49\nyears: data from an unselected nationwide study in Denmark. Heart Rhythm\n2014;11:1673\u00021681.\n44. Risgaard B, Tfelt-Hansen J, Winkel BG. Sports-related sudden cardiac death: how\nto\nprove\nan\neffect\nof\npreparticipation\nscreening?\nHeart\nRhythm\n2016;13:1560\u00021562.\n45. Drezner JA, Harmon KG, Marek JC. Incidence of sudden cardiac arrest in\nMinnesota high school student athletes: the limitations of catastrophic insurance\nclaims. J Am Coll Cardiol 2014;63:1455\u00021456.\n46. Maron BJ, Haas TS, Murphy CJ, Ahluwalia A, Rutten-Ramos S. Incidence and\ncauses\nof\nsudden\ndeath\nin\nU.S.\ncollege\nathletes.\nJ\nAm\nColl\nCardiol\n2014;63:1636\u00021643.\n47. Maron BJ, Gohman TE, Aeppli D. Prevalence of sudden cardiac death during\ncompetitive sports activities in Minnesota high school athletes. J Am Coll Cardiol\n1998;32:1881\u00021884.\n48. Van Camp SP, Bloor CM, Mueller FO, Cantu RC, Olson HG. Nontraumatic\nsports death in high school and college athletes. Med Sci Sports Exerc\n1995;27:641\u0002647.\n49. Maron BJ, Haas TS, Ahluwalia A, Rutten-Ramos SC. Incidence of cardiovascular\nsudden\ndeaths\nin\nMinnesota\nhigh\nschool\nathletes.\nHeart\nRhythm\n2013;10:374\u0002377.\n50. Harmon K, Asif I, Ellenbogen R, Drezner J. The incidence of sudden cardiac\narrest and death in United States high school athletes. Br J Sports Med [Internet]\n2014;48:605.\n51. Toresdahl BG, Rao AL, Harmon KG, Drezner JA. Incidence of sudden cardiac\narrest in high school student athletes on school campus. Heart Rhythm\n2014;11:1190\u00021194.\n52. Maron BJ. Sudden death in young athletes. N Engl J Med 2003;349:1064\u00021075.\n53. de Noronha SV, Sharma S, Papadakis M, Desai S, Whyte G, Sheppard MN.\nAetiology of sudden cardiac death in athletes in the United Kingdom: a patholog-\nical study. Heart 2009;95:1409\u00021414.\n54. Suarez-Mier MP, Aguilera B, Mosquera RM, Sanchez-de-Leon MS. Pathology of\nsudden\ndeath\nduring\nrecreational\nsports\nin\nSpain.\nForensic\nSci\nInt\n2013;226:188\u0002196.\n55. Ullal AJ, Abdelfattah RS, Ashley EA, Froelicher VF. Hypertrophic cardiomyopathy\nas a cause of sudden cardiac death in the young: a meta-analysis. Am J Med\n2016;129:486\u0002496.e2.\n56. Thiene G, Rizzo S, Schiavon M, Maron MS, Zorzi A, Corrado D, Maron BJ, Basso\nC. Structurally normal hearts are uncommonly associated with sudden deaths in\nathletes and young people. J Am Coll Cardiol 2019;73:3031\u00023032.\n57. Corrado D, Basso C, Pavei A, Michieli P, Schiavon M, Thiene G. Trends in sud-\nden cardiovascular death in young competitive athletes after implementation of a\npreparticipation screening program. JAMA 2006;296:1593\u00021601.\n58. Malhotra A, Dhutia H, Finocchiaro G, Gati S, Beasley I, Clift P, Cowie C, Kenny\nA, Mayet J, Oxborough D, Patel K, Pieles G, Rakhit D, Ramsdale D, Shapiro L,\nSomauroo J, Stuart G, Varnava A, Walsh J, Yousef Z, Tome M, Papadakis M,\nSharma S. Outcomes of cardiac screening in adolescent soccer players. N Engl J\nMed 2018;379:524\u0002534.\n59. Fuller CM, McNulty CM, Spring DA, Arger KM, Bruce SS, Chryssos BE,\nDrummer EM, Kelley FP, Newmark MJ, Whipple GH. Prospective screening of\n5,615 high school athletes for risk of sudden cardiac death. Med Sci Sports Exerc\n1997;29:1131\u00021138.\n60. Wilson MG, Basavarajaiah S, Whyte GP, Cox S, Loosemore M, Sharma S.\nEfficacy of personal symptom and family history questionnaires when screening\nfor inherited cardiac pathologies: the role of electrocardiography. Br J Sports Med\n2008;42:207\u0002211.\n61. Bessem B, Groot FP, Nieuwland W. The Lausanne recommendations: a Dutch\nexperience. Br J Sports Med 2009;43:708\u0002715.\n62. Hevia AC, Fernandez MM, Palacio JMA, Martin EH, Castro MG, Reguero JJR.\nECG as a part of the preparticipation screening programme: an old and still\npresent international dilemma. Br J Sports Med 2011;45:776\u0002779.\n63. Baggish AL, Hutter AMJ, Wang F, Yared K, Weiner RB, Kupperman E, Picard\nMH, Wood MJ. Cardiovascular screening in college athletes with and without\nelectrocardiography: a cross-sectional study. Ann Intern Med 2010;152:269\u0002275.\n64. Fudge J, Harmon KG, Owens DS, Prutkin JM, Salerno JC, Asif IM, Haruta A, Pelto\nH, Rao AL, Toresdahl BG, Drezner JA. Cardiovascular screening in adolescents\nand young adults: a prospective study comparing the Pre-participation Physical\nEvaluation\nMonograph\n4th\nEdition\nand\nECG.\nBr\nJ\nSports\nMed\n2014;48:1172\u00021178.\n65. Drezner JA, Prutkin JM, Harmon KG, O’Kane JW, Pelto HF, Rao AL, Hassebrock\nJD, Petek BJ, Teteak C, Timonen M, Zigman M, Owens DS. Cardiovascular\nscreening in college athletes. J Am Coll Cardiol 2015;65:2353\u00022355.\n66. Mittleman MA, Maclure M, Tofler GH, Sherwood JB, Goldberg RJ, Muller JE.\nTriggering of acute myocardial infarction by heavy physical exertion. Protection\nagainst triggering by regular exertion. Determinants of Myocardial Infarction\nOnset Study Investigators. N Engl J Med 1993;329:1677\u00021683.\n67. Siscovick DS, Weiss NS, Fletcher RH, Lasky T. The incidence of primary cardiac\narrest during vigorous exercise. N Engl J Med 1984;311:874\u0002877.\n68. Waller BF, Roberts WC. Sudden death while running in conditioned runners\naged 40 years or over. Am J Cardiol 1980;45:1292\u00021300.\n69. Noakes TD, Opie LH, Rose AG, Kleynhans PH, Schepers NJ, Dowdeswell R.\nAutopsy-proved coronary atherosclerosis in marathon runners. N Engl J Med\n1979;301:86\u000289.\n70. Marijon E, Tafflet M, Celermajer DS, Dumas F, Perier M-C, Mustafic H, Toussaint\nJ-F, Desnos M, Rieu M, Benameur N, Le Heuzey J-Y, Empana J-P, Jouven X.\nSports-related\nsudden\ndeath\nin\nthe\ngeneral\npopulation.\nCirculation\n2011;124:672\u0002681.\n71. Maron BJ, Zipes DP, Kovacs RJ. Eligibility and disqualification recommendations\nfor competitive athletes with cardiovascular abnormalities: preamble, principles,\nand general considerations: a scientific statement from the American Heart\nAssociation\nand\nAmerican\nCollege\nof\nCardiology.\nJ\nAm\nColl\nCardiol\n2015;66:2343\u00022349.\n72. Zeltser I, Cannon B, Silvana L, Fenrich A, George J, Schleifer J, Garcia M, Barnes\nA, Rivenes S, Patt H, Rodgers G, Scott W. Lessons learned from preparticipation\ncardiovascular\nscreening\nin\na\nstate\nfunded\nprogram.\nAm\nJ\nCardiol\n2012;110:902\u0002908.\n73. Dunn TP, Pickham D, Aggarwal S, Saini D, Kumar N, Wheeler MT, Perez M,\nAshley E, Froelicher VF. Limitations of current AHA guidelines and proposal of\nnew guidelines for the preparticipation examination of athletes. Clin J Sport Med\n2015;25:472\u0002477.\n74. Drezner JA, Owens DS, Prutkin JM, Salerno JC, Harmon KG, Prosise S, Clark A,\nAsif IM. Electrocardiographic screening in national collegiate athletic association\nathletes. Am J Cardiol 2016;118:754\u0002759.\n75. Williams EA, Pelto HF, Toresdahl BG, Prutkin JM, Owens DS, Salerno JC, Harmon\nKG, Drezner JA. Performance of the American Heart Association (AHA) 14-point\nevaluation versus electrocardiography for the cardiovascular screening of high\nschool athletes: a prospective study. J Am Heart Assoc 2019;8:e012235.\n76. Price DE, McWilliams A, Asif IM, Martin A, Elliott SD, Dulin M, Drezner JA.\nElectrocardiography-inclusive screening strategies for detection of cardiovascular\nabnormalities in high school athletes. Heart Rhythm 2014;11:442\u0002449.\nESC Guidelines\n81\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\n77. Rizzo M, Spataro A, Cecchetelli C, Quaranta F, Livrieri S, Sperandii F, Cifra B,\nBorrione P, Pigozzi F. Structural cardiac disease diagnosed by echocardiography\nin asymptomatic young male soccer players: implications for pre-participation\nscreening. Br J Sports Med 2012;46:371\u0002373.\n78. Fletcher GF, Ades PA, Kligfield P, Arena R, Balady GJ, Bittner VA, Coke LA, Fleg\nJL, Forman DE, Gerber TC, Gulati M, Madan K, Rhodes J, Thompson PD,\nWilliams MA. Exercise standards for testing and training: a scientific statement\nfrom the American Heart Association. Circulation 2013;128:873\u0002934.\n79. Gianrossi R, Detrano R, Mulvihill D, Lehmann K, Dubach P, Colombo A,\nMcArthur D, Froelicher V. Exercise-induced ST depression in the diagnosis of\ncoronary artery disease. A meta-analysis. Circulation 1989;80:87\u000298.\n80. Corrado D, Schmied C, Basso C, Borjesson M, Schiavon M, Pelliccia A, Vanhees\nL, Thiene G. Risk of sports: do we need a pre-participation screening for com-\npetitive and leisure athletes? Eur Heart J 2011;32:934\u0002944.\n81. Mont L, Pelliccia A, Sharma S, Biffi A, Borjesson M, Brugada Terradellas J, Carre\nF, Guasch E, Heidbuchel H, La Gerche A, Lampert R, McKenna W, Papadakis M,\nPriori SG, Scanavacca M, Thompson P, Sticherling C, Viskin S, Wilson M,\nCorrado D, Lip GY, Gorenek B, Blomstrom Lundqvist C, Merkely B, Hindricks\nG, Hernandez-Madrid A, Lane D, Boriani G, Narasimhan C, Marquez MF, Haines\nD, Mackall J, Manuel Marques-Vidal P, Corra U, Halle M, Tiberi M, Niebauer J,\nPiepoli M. Pre-participation cardiovascular evaluation for athletic participants to\nprevent sudden death: position paper from the EHRA and the EACPR, branches\nof the ESC. Eur J Prev Cardiol 2017;24:41\u000269.\n82. Guazzi M, Adams V, Conraads V, Halle M, Mezzani A, Vanhees L, Arena R,\nFletcher GF, Forman DE, Kitzman DW, Lavie CJ, Myers J. EACPR/AHA scientific\nstatement. Clinical recommendations for cardiopulmonary exercise testing data\nassessment in specific patient populations. Circulation 2012;126:2261\u00022274.\n83. Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physi-\ncal fitness: definitions and distinctions for health-related research. Public Health\nRep 1985;100:126\u0002131.\n84. Vanhees L, De Sutter J, GeladaS N, Doyle F, Prescott E, Cornelissen V, Kouidi E,\nDugmore D, Vanuzzo D, Borjesson M, Doherty P. Importance of characteristics\nand modalities of physical activity and exercise in defining the benefits to cardio-\nvascular health within the general population: recommendations from the\nEACPR. Part I. Eur J Prev Cardiol 2012;19:670\u0002686.\n85. Vanhees L, Geladas N, Hansen D, Kouidi E, Niebauer J, Reiner Z, Cornelissen V,\nAdamopoulos S, Prescott E, Borjesson M, Bjarnason-Wehrens B, Bjornstad HH,\nCohen-Solal A, Conraads V, Corrado D, De Sutter J, Doherty P, Doyle F,\nDugmore D, Ellingsen O, Fagard R, Giada F, Gielen S, Hager A, Halle M,\nHeidbuchel H, Jegier A, Mazic S, McGee H, Mellwig KP, Mendes M, Mezzani A,\nPattyn N, Pelliccia A, Piepoli M, Rauch B, Schmidt-Trucksass A, Takken T, van\nBuuren F, Vanuzzo D. Importance of characteristics and modalities of physical\nactivity and exercise in the management of cardiovascular health in individuals\nwith cardiovascular risk factors: recommendations from the EACPR. Part II. Eur J\nPrev Cardiol 2012;19:1005\u00021033.\n86. Tjonna AE, Stolen TO, Bye A, Volden M, Slordahl SA, Odegard R, Skogvoll E,\nWisloff U. Aerobic interval training reduces cardiovascular risk factors more\nthan a multitreatment approach in overweight adolescents. Clin Sci (Lond)\n2009;116:317\u0002326.\n87. Schjerve IE, Tyldum GA, Tjonna AE, Stolen T, Loennechen JP, Hansen HEM,\nHaram PM, Heinrich G, Bye A, Najjar SM, Smith GL, Slordahl SA, Kemi OJ,\nWisloff U. Both aerobic endurance and strength training programmes improve\ncardiovascular health in obese adults. Clin Sci (Lond) 2008;115:283\u0002293.\n88. Shephard\nRJ,\nBalady,\nGJ.\nExercise\nas\ncardiovascular\ntherapy.\nCirculation\n1999;99:963\u0002972.\n89. Lavie CJ, Thomas RJ, Squires RW, Allison TG, Milani RV. Exercise training and\ncardiac rehabilitation in primary and secondary prevention of coronary heart dis-\nease. Mayo Clin Proc 2009;84:373\u0002383.\n90. Franckowiak SC, Dobrosielski DA, Reilley SM, Walston JD, Andersen RE.\nMaximal heart rate prediction in adults that are overweight or obese. J Strength\nCond Res 2011;25:1407\u00021412.\n91. Vanhees L, Stevens A. Exercise intensity: a matter of measuring or of talking? J\nCardiopulm Rehabil 2006;26:78\u000279.\n92. Myers J, Hadley D, Oswald U, Bruner K, Kottman W, Hsu L, Dubach P. Effects\nof exercise training on heart rate recovery in patients with chronic heart failure.\nAm Heart J 2007;153:1056\u00021063.\n93. Tabet J-Y, Meurin P, Ben Driss A, Thabut G, Weber H, Renaud N, Odjinkem N,\nSolal AC. Determination of exercise training heart rate in patients on beta-blockers\nafter myocardial infarction. Eur J Cardiovasc Prev Rehabil 2006;13:538\u0002543.\n94. O’Donovan G, Blazevich AJ, Boreham C, Cooper AR, Crank H, Ekelund U, Fox\nKR, Gately P, Giles-Corti B, Gill JMR, Hamer M, McDermott I, Murphy M, Mutrie\nN, Reilly JJ, Saxton JM, Stamatakis E. The ABC of physical activity for health: a\nconsensus statement from the British Association of Sport and Exercise\nSciences. J Sports Sci 2010;28:573\u0002591.\n95. Warburton DER, Nicol CW, Bredin SSD. Health benefits of physical activity: the\nevidence. CMAJ 2006;174:801\u0002809.\n96. Thomaes T, Thomis M, Onkelinx S, Goetschalckx K, Fagard R, Lambrechts D,\nVanhees L. Genetic predisposition scores associate with muscular strength, size,\nand trainability. Med Sci Sports Exerc 2013;45:1451\u00021459.\n97. Gibson OR, Taylor L, Watt PW, Maxwell NS. Cross-adaptation: heat and cold\nadaptation to improve physiological and cellular responses to hypoxia. Sports\nMed 2017;47:1751\u00021768.\n98. Tjonna AE, Lee SJ, Rognmo O, Stolen TO, Bye A, Haram PM, Loennechen JP, Al-\nShare QY, Skogvoll E, Slordahl SA, Kemi OJ, Najjar SM, Wisloff U. Aerobic inter-\nval training versus continuous moderate exercise as a treatment for the meta-\nbolic syndrome: a pilot study. Circulation 2008;118:346\u0002354.\n99. Arena R, Myers J, Forman DE, Lavie CJ, Guazzi M. Should high-intensity-aerobic\ninterval training become the clinical standard in heart failure? Heart Fail Rev\n2013;18:95\u0002105.\n100. MacDonald MJ, Currie KD. Interval exercise is a path to good health, but how\nmuch, how often and for whom? Clin Sci (Lond) 2009;116:315\u0002316.\n101. Helgerud J, Hoydal K, Wang E, Karlsen T, Berg P, Bjerkaas M, Simonsen T,\nHelgesen C, Hjorth N, Bach R, Hoff J. Aerobic high-intensity intervals improve\nVO2max more than moderate training. Med Sci Sports Exerc 2007;39:665\u0002671.\n102. Ratamess NA, Falvo MJ, Mangine GT, Hoffman JR, Faigenbaum AD, Kang J. The\neffect of rest interval length on metabolic responses to the bench press exer-\ncise. Eur J Appl Physiol 2007;100:1\u000217.\n103. Gordon NF, Kohl HW 3rd, Pollock ML, Vaandrager H, Gibbons LW, Blair SN.\nCardiovascular safety of maximal strength testing in healthy adults. Am J Cardiol\n1995;76:851\u0002853.\n104. Reynolds JM, Gordon TJ, Robergs RA. Prediction of one repetition maximum\nstrength from multiple repetition maximum testing and anthropometry. J\nStrength Cond Res 2006;20:584\u0002592.\n105. Rhea MR, Alvar BA, Burkett LN. Single versus multiple sets for strength: a\nmeta-analysis to address the controversy. Res Q Exerc Sport 2002;73:485\u0002488.\n106. Peterson MD, Rhea MR, Alvar BA. Applications of the dose-response for mus-\ncular strength development: a review of meta-analytic efficacy and reliability for\ndesigning training prescription. J Strength Cond Res 2005;19:950\u0002958.\n107. Wahid A, Manek N, Nichols M, Kelly P, Foster C, Roberts N, Scarborough P.\nQuantifying the association between physical activity and cardiovascular disease\nand diabetes: a systematic review and meta-analysis. J Am Heart Assoc\n2016;5:e002495.\n108. Lear SA, Hu W, Rangarajan S, Gasevic D, Leong D, Iqbal R, Casanova A,\nSwaminathan S, Anjana RM, Kumar R, Rosengren A, Wei L, Yang W, Chuangshi\nW, Huaxing L, Nair S, Diaz R, Swidon H, Gupta R, Mohammadifard N, Lopez-\nJaramillo P, Oguz A, Zatonska K, Seron P, Avezum A, Poirier P, Teo K, Yusuf S.\nThe effect of physical activity on mortality and cardiovascular disease in 130\n000 people from 17 high-income, middle-income, and low-income countries:\nthe PURE study. Lancet 2017;390:2643\u00022654.\n109. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman\nMJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A,\nLandmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS,\nTaskinen M-R, Tokgozoglu L, Wiklund O. 2019 ESC/EAS Guidelines for the\nmanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk: The\nTask Force for the management of dyslipidaemias of the European Society of\nCardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J\n2020;41:111\u0002188. doi: 10.1093/eurheartj/ehz455.\n110. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C,\nPrescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen\nT, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip\nJ, Muneretto C, Valgimigli M, Achenbach S, Bax JJ. 2019 ESC Guidelines for the\ndiagnosis and management of chronic coronary syndromes: The Task Force for\nthe diagnosis and management of chronic coronary syndromes of the European\nSociety of Cardiology (ESC). Eur Heart J 2020;41:407\u0002477.\n111. Braber TL, Halle NHJPM, Velthuis SSBK. Cardiac imaging to detect coronary\nartery disease in athletes aged 35 years and older. A scoping review. Scand J\nMed Sci Sports 2018;1036\u00021047.\n112. DeFina LF, Radford NB, Barlow CE, Willis BL, Leonard D, Haskell WL, Farrell\nSW, Pavlovic A, Abel K, Berry JD, Khera A, Levine BD. Association of all-cause\nand cardiovascular mortality with high levels of physical activity and concurrent\ncoronary artery calcification. JAMA Cardiol 2019;4:174.\n113. Arem H, Moore SC, Patel A, Hartge P, Berrington de Gonzalez A, Visvanathan\nK, Campbell PT, Freedman M, Weiderpass E, Adami HO, Linet MS, Lee I-M,\nMatthews\nCE.\nLeisure\ntime\nphysical\nactivity\nand\nmortality:\na\ndetailed\npooled\nanalysis\nof\nthe\ndose-response\nrelationship.\nJAMA\nIntern\nMed\n2015;175:959\u0002967.\n114. Lee D-C, Pate RR, Lavie CJ, Sui X, Church TS, Blair SN. Leisure-time running\nreduces\nall-cause\nand\ncardiovascular\nmortality\nrisk.\nJ\nAm\nColl\nCardiol\n2014;64:472\u0002481.\n115. Lollgen H, Bockenhoff A, Knapp G. Physical activity and all-cause mortality: an\nupdated meta-analysis with different intensity categories. Int J Sports Med\n2009;30:213\u0002224.\n82\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\n116. Sattelmair J, Pertman J, Ding EL, Kohl HW 3rd, Haskell W, Lee I-M. Dose\nresponse between physical activity and risk of coronary heart disease: a meta-\nanalysis. Circulation 2011;124:789\u0002795.\n117. Moore SC, Patel AV, Matthews CE, Berrington de Gonzalez A, Park Y, Katki\nHA, Linet MS, Weiderpass E, Visvanathan K, Helzlsouer KJ, Thun M, Gapstur\nSM, Hartge P, Lee I-M. Leisure time physical activity of moderate to vigorous\nintensity\nand\nmortality:\na\nlarge\npooled\ncohort\nanalysis.\nPLoS\nMed\n2012;9:e1001335.\n118. Samitz G, Egger M, Zwahlen M. Domains of physical activity and all-cause mor-\ntality: systematic review and dose-response meta-analysis of cohort studies. Int J\nEpidemiol 2011;40:1382\u00021400.\n119. Elley CR, Kerse N, Arroll B, Robinson E. Effectiveness of counselling patients\non physical activity in general practice: cluster randomised controlled trial. BMJ\n2003;326:793.\n120. Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C,\nEscaned J, Hammes H-P, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J,\nPatrono C, Seferovic P, Uva MS, Taskinen M-R, Tendera M, Tuomilehto J,\nValensi P, Zamorano JL, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ,\nBueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW,\nKirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P,\nPiepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns\nW, Windecker S, De Backer G, Sirnes PA, Ezquerra EA, Avogaro A, Badimon\nL, Baranova E, Baumgartner H, Betteridge J, Ceriello A, Fagard R, Funck-\nBrentano C, Gulba DC, Hasdai D, Hoes AW, Kjekshus JK, Knuuti J, Kolh P, Lev\nE, Mueller C, Neyses L, Nilsson PM, Perk J, Ponikowski P, Reiner Z, Sattar N,\nSchachinger V, Scheen A, Schirmer H, Stromberg A, Sudzhaeva S, Tamargo JL,\nViigimaa M, Vlachopoulos C, Xuereb RG. ESC Guidelines on diabetes, pre-\ndiabetes, and cardiovascular diseases developed in collaboration with the\nEASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of\nthe European Society of Cardiology (ESC) and developed in collaboratio. Eur\nHeart J 2013;34:3035\u00023087.\n121. Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, Toplak H.\nEuropean\nGuidelines\nfor\nobesity\nmanagement\nin\nadults.\nObes\nFacts\n2015;8:402\u0002424.\n122. You T, Arsenis NC, Disanzo BL, Lamonte MJ. Effects of exercise training on\nchronic inflammation in obesity: current evidence and potential mechanisms.\nSports Med 2013;43:243\u0002256.\n123. Keating SE, Johnson NA, Mielke GI, Coombes JS. A systematic review and\nmeta-analysis of interval training versus moderate-intensity continuous training\non body adiposity. Obes Rev 2017;18:943\u0002964.\n124. Swift DL, Johannsen NM, Lavie CJ, Earnest CP, Church TS. The role of exercise\nand physical activity in weight loss and maintenance. Prog Cardiovasc Dis\n2014;56:441\u0002447.\n125. Almeida SA, Williams KM, Shaffer RA, Brodine SK. Epidemiological patterns of\nmusculoskeletal\ninjuries\nand\nphysical\ntraining.\nMed\nSci\nSports\nExerc\n1999;31:1176\u00021182.\n126. Gilchrist J, Jones BH, Sleet DA, Kimsey CD. Exercise-related injuries among\nwomen: strategies for prevention from civilian and military studies. MMWR\nRecomm Rep 2000;49:15\u000233.\n127. Hootman JM, Macera CA, Ainsworth BE, Martin M, Addy CL, Blair SN.\nAssociation among physical activity level, cardiorespiratory fitness, and risk of\nmusculoskeletal injury. Am J Epidemiol 2001;154:251\u0002258.\n128. Lisman PJ, de la Motte SJ, Gribbin TC, Jaffin DP, Murphy K, Deuster PA. A sys-\ntematic review of the association between physical fitness and musculoskeletal\ninjury\nrisk:\nPart\n1-Cardiorespiratory\nendurance.\nJ\nStrength\nCond\nRes\n2017;31:1744\u00021757.\n129. Vincent HK, George SZ, Seay AN, Vincent KR, Hurley RW. Resistance exercise,\ndisability, and pain catastrophizing in obese adults with back pain. Med Sci Sports\nExerc 2014;46:1693\u00021701.\n130. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens\nT, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma\nT, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM,\nSchmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J,\nDominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E,\nCaufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P,\nZamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton\nC, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh\nP, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes\nPA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL,\nCoca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD,\nBauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA,\nErdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller\nH, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH,\nOstergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Ryden L et alet al\n2013 ESH/ESC Guidelines for the management of arterial hypertension: the\nTask Force for the management of arterial hypertension of the European\nSociety of Hypertension (ESH) and of the European Society of Cardiology\n(ESC). Eur Heart J 2013;34:2159\u00022219.\n131. Niebauer J, Borjesson M, Carre F, Caselli S, Palatini P, Quattrini F, Serratosa L,\nAdami PE, Biffi A, Pressler A, Schmied C, van Buuren F, Panhuyzen-Goedkoop\nN, Solberg E, Halle M, La Gerche A, Papadakis M, Sharma S, Pelliccia A.\nRecommendations for participation in competitive sports of athletes with arte-\nrial hypertension: a position statement from the sports cardiology section of\nthe European Association of Preventive Cardiology (EAPC). Eur Heart J\n2018;39:3664\u00023671.\n132. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement\nDL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J,\nRuilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH,\nMcManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C,\nAboyans V, Desormais I. 2018 ESC/ESH Guidelines for the management of\narterial hypertension. Eur Heart J 2018;39:3021\u00023104.\n133. Wen H, Wang L. Reducing effect of aerobic exercise on blood pressure of\nessential\nhypertensive\npatients:\na\nmeta-analysis.\nMedicine\n(Baltimore)\n2017;96:e6150.\n134. MacDonald HV, Johnson BT, Huedo-Medina TB, Livingston J, Forsyth KC,\nKraemer WJ, Farinatti PTV, Pescatello LS. Dynamic resistance training as stand-\nalone antihypertensive lifestyle therapy: a meta-analysis. J Am Heart Assoc\n2016;5.\n135. The World Anti-Doping Code International Standard, 2019. https://www.wada-\nama.org/sites/default/files/wada_2019_english_prohibited_list.pdf\n136. Ruschitzka F, Borer JS, Krum H, Flammer AJ, Yeomans ND, Libby P, Luscher\nTF, Solomon DH, Husni ME, Graham DY, Davey DA, Wisniewski LM, Menon\nV, Fayyad R, Beckerman B, Iorga D, Lincoff AM, Nissen SE. Differential blood\npressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis:\nthe PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib\nIntegrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure\nMeasurement). Eur Heart J 2017;38:3282\u00023292.\n137. de Sousa NMF, Magosso RF, Dipp T, Plentz RDM, Marson RA, Montagnolli AN,\nMartins RAS, Perez SEA, Baldissera V. Continuous blood pressure response at\ndifferent intensities in leg press exercise. Eur J Prev Cardiol 2014;21:1324\u00021331.\n138. de Souza Nery S, Gomides RS, da Silva GV, de Moraes Forjaz CL, Mion DJ,\nTinucci T. Intra-arterial blood pressure response in hypertensive subjects during\nlow- and high-intensity resistance exercise. Clinics (Sao Paulo) 2010;65:271\u0002277.\n139. Lamotte M, Niset G, van de Borne P. The effect of different intensity modalities\nof resistance training on beat-to-beat blood pressure in cardiac patients. Eur J\nCardiovasc Prev Rehabil 2005;12:12\u000217.\n140. Sardeli AV, do Carmo Santos L, Ferreira MLV, Gaspari AF, Rodrigues B,\nCavaglieri CR, Chacon-Mikahil MPT. Cardiovascular responses to different\nresistance exercise protocols in elderly. Int J Sports Med 2017;38:928\u0002936.\n141. Gjovaag T, Hjelmeland AK, Oygard JB, Vikne H, Mirtaheri P. Acute hemody-\nnamic and cardiovascular responses following resistance exercise to voluntary\nexhaustion. Effects of different loadings and exercise durations. J Sports Med\nPhys Fitness 2016;56:616\u0002623.\n142. Hansen D, Abreu A, Doherty P, Voller H. Dynamic strength training intensity in\ncardiovascular rehabilitation: is it time to reconsider clinical practice? A system-\natic\nreview.\nEur\nJ\nPrev\nCardiol\n2019;26:1483\u00021492.\ndoi:\n10.1177/\n2047487319847003. Epub 2 May 2019.\n143. Caselli S, Serdoz A, Mango F, Lemme E, Vaquer Segui A, Milan A, Attenhofer\nJost C, Schmied C, Spataro A, Pelliccia A. High blood pressure response to\nexercise predicts future development of hypertension in young athletes. Eur\nHeart J 2019;40:62\u000268.\n144. Kjeldsen SE, Mundal R, Sandvik L, Erikssen G, Thaulow E, Erikssen J. Supine and\nexercise systolic blood pressure predict cardiovascular death in middle-aged\nmen. J Hypertens 2001;19:1343\u00021348.\n145. Fletcher B, Berra K, Ades P, Braun LT, Burke LE, Durstine JL, Fair JM, Fletcher\nGF, Goff D, Hayman LL, Hiatt WR, Miller NH, Krauss R, Kris-Etherton P, Stone\nN, Wilterdink J, Winston M. Managing abnormal blood lipids: a collaborative\napproach. Circulation 2005;112:3184\u00023209.\n146. Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS,\nBales CW, Henes S, Samsa GP, Otvos JD, Kulkarni KR, Slentz CA. Effects of the\namount and intensity of exercise on plasma lipoproteins. N Engl J Med\n2002;347:1483\u00021492.\n147. Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DDJ, DePalma\nSM, Minissian MB, Orringer CE, Smith SCJ. 2017 Focused update of the\n2016 ACC Expert Consensus Decision Pathway on the role of non-statin\ntherapies for ldl-cholesterol lowering in the management of atherosclerotic car-\ndiovascular disease risk: a report of the American College of Cardiology\nTask Force on Expert Consensus Decision Pathways. J Am Coll Cardiol\n2017;70:1785\u00021822.\n148. Kokkinos PF, Faselis C, Myers J, Panagiotakos D, Doumas M. Interactive effects\nof fitness and statin treatment on mortality risk in veterans with dyslipidaemia:\na cohort study. Lancet 2013;381:394\u0002399.\nESC Guidelines\n83\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\n149. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M,\nStein E, Tokgozoglu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM,\nLaufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, Marz W,\nNewman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg\nHN. Statin-associated muscle symptoms: impact on statin therapy—European\nAtherosclerosis Society Consensus Panel Statement on Assessment, Aetiology\nand Management. Eur Heart J 2015;36:1012\u00021022.\n150. Lee I-M, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT. Effect of physi-\ncal inactivity on major non-communicable diseases worldwide: an analysis of\nburden of disease and life expectancy. Lancet 2012;380:219\u0002229.\n151. Cloostermans L, Wendel-Vos W, Doornbos G, Howard B, Craig CL, Kivimaki\nM, Tabak AG, Jefferis BJ, Ronkainen K, Brown WJ, Picavet SHSJ, Ben-Shlomo Y,\nLaukkanen JA, Kauhanen J, Bemelmans WJE. Independent and combined effects\nof physical activity and body mass index on the development of Type 2 diabetes\n\u0002 a meta-analysis of 9 prospective cohort studies. Int J Behav Nutr Phys Act\n2015;12:147.\n152. Ekelund U, Palla L, Brage S, Franks PW, Peters T, Balkau B, Diaz MJT, Huerta\nJM, Agnoli C, Arriola L, Ardanaz E, Boeing H, Clavel-Chapelon F, Crowe F,\nFagherazzi G, Groop L, Fons Johnsen N, Kaaks R, Khaw KT, Key TJ, de Lauzon-\nGuillain B, May A, Monninkhof E, Navarro C, Nilsson P, Nautrup Ostergaard J,\nNorat T, Overvad K, Palli D, Panico S, Redondo ML, Ricceri F, Rolandsson O,\nRomaguera D, Romieu I, Sanchez Perez MJ, Slimani N, Spijkerman A, Teucher\nB, Tjonneland A, Travier N, Tumino R, Vos W, Vigl M, Sharp S, Langeberg C,\nForouhi N, Riboli E, Feskens E, Wareham NJ. Physical activity reduces the risk\nof incident type 2 diabetes in general and in abdominally lean and obese men\nand women: the EPIC-InterAct Study. Diabetologia 2012;55:1944\u00021952.\n153. Hjerkind KV, Stenehjem JS, Nilsen TIL. Adiposity, physical activity and risk of\ndiabetes mellitus: prospective data from the population-based HUNT study,\nNorway. BMJ Open 2017;7:e013142.\n154. Rana JS, Li TY, Manson JE, Hu FB. Adiposity compared with physical inactivity\nand risk of type 2 diabetes in women. Diabetes Care 2007;30:53\u000258.\n155. Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus.\nCochrane Database Syst Rev 2006;CD002968.\n156. Zhang X, Devlin HM, Smith B, Imperatore G, Thomas W, Lobelo F, Ali MK,\nNorris K, Gruss S, Bardenheier B, Cho P, Garcia de Quevedo I, Mudaliar U,\nJones CD, Durthaler JM, Saaddine J, Geiss LS, Gregg EW. Effect of lifestyle\ninterventions on cardiovascular risk factors among adults without impaired glu-\ncose tolerance or diabetes: a systematic review and meta-analysis. PLoS One\n2017;12:e0176436.\n157. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M,\nFilippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Juni P, Lettino\nM, Marx N, Mellbin LG, Ostgren CJ, Rocca B, Roffi M, Sattar N, Seferovic PM,\nSousa-Uva M, Valensi P, Wheeler DC. 2019 ESC Guidelines on diabetes, pre-\ndiabetes, and cardiovascular diseases developed in collaboration with the\nEASD. Eur Heart J 2020;41:255\u0002323.\n158. Sluik D, Buijsse B, Muckelbauer R, Kaaks R, Teucher B, Johnsen NF, Tjonneland\nA, Overvad K, Ostergaard JN, Amiano P, Ardanaz E, Bendinelli B, Pala V,\nTumino R, Ricceri F, Mattiello A, Spijkerman AMW, Monninkhof EM, May AM,\nFranks PW, Nilsson PM, Wennberg P, Rolandsson O, Fagherazzi G, Boutron-\nRuault M-C, Clavel-Chapelon F, Castano JMH, Gallo V, Boeing H, Nothlings U.\nPhysical activity and mortality in individuals with diabetes mellitus: a prospective\nstudy and meta-analysis. Arch Intern Med 2012;172:1285\u00021295.\n159. Diabetes Prevention Program Research Group. Reduction in the incidence of\ntype 2 diabetes with lifestyle intervention or metformin. N Engl J Med\n2002;346:393\u0002403.\n160. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman\nAT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of\ndiabetes incidence and weight loss in the Diabetes Prevention Program\nOutcomes Study. Lancet 2009;374:1677\u00021686.\n161. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K,\nHamalainen H, Harkonen P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A,\nMannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J. Sustained\nreduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up\nof the Finnish Diabetes Prevention Study. Lancet 2006;368:1673\u00021679.\n162. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka\nP, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V,\nUusitupa M. Prevention of type 2 diabetes mellitus by changes in lifestyle\namong subjects with impaired glucose tolerance. N Engl J Med 2001;344:\n1343\u00021350.\n163. Hidalgo-Santamaria M, Fernandez-Montero A, Martinez-Gonzalez MA, Moreno-\nGalarraga L, Sanchez-Villegas A, Barrio-Lopez MT, Bes-Rastrollo M. Exercise\nintensity and incidence of metabolic syndrome: the SUN Project. Am J Prev Med\n2017;52:e95\u0002e101.\n164. Dube JJ, Allison KF, Rousson V, Goodpaster BH, Amati F. Exercise dose and\ninsulin sensitivity: relevance for diabetes prevention. Med Sci Sports Exerc\n2012;44:793\u0002799.\n165. da Silva DE, Grande AJ, Roever L, Tse G, Liu T, Biondi-Zoccai G, de Farias JM.\nHigh-intensity interval training in patients with type 2 diabetes mellitus: a sys-\ntematic review. Curr Atheroscler Rep 2019;21:8.\n166. Magalhaes JP, Judice PB, Ribeiro R, Andrade R, Raposo J, Dores H, Bicho M,\nSardinha LB. Effectiveness of high-intensity interval training combined with\nresistance training versus continuous moderate-intensity training combined\nwith resistance training in patients with type 2 diabetes: a one-year randomized\ncontrolled trial. Diabetes Obes Metab 2019;21:550\u0002559.\n167. Mygind ND, Michelsen MM, Pena A, Frestad D, Dose N, Aziz A, Faber R, Host\nN, Gustafsson I, Hansen PR, Hansen HS, Merz Bairey, Kastrup, CN, Prescott, J\nE. Coronary microvascular function and cardiovascular risk factors in women\nwith angina pectoris and no obstructive coronary artery disease: the iPOWER\nStudy. J Am Heart Assoc 2016;5:e003064.\n168. Murthy VL, Naya M, Foster CR, Gaber M, Hainer J, Klein J, Dorbala S,\nBlankstein R, Di Carli MF. Association between coronary vascular dysfunction\nand cardiac mortality in patients with and without diabetes mellitus. Circulation\n2012;126:1858\u00021868.\n169. Olsen RH, Pedersen LR, Jurs A, Snoer M, Haugaard SB, Prescott E. A rando-\nmised trial comparing the effect of exercise training and weight loss on micro-\nvascular function in coronary artery disease. Int J Cardiol 2015;185:229\u0002235.\n170. Yoshinaga K, Beanlands RSB, Dekemp RA, Lortie M, Morin J, Aung M, McKelvie\nR, Davies RF. Effect of exercise training on myocardial blood flow in patients\nwith stable coronary artery disease. Am Heart J 2006;151:1324.e11\u00028.\n171. Hambrecht R, Wolf A, Gielen S, Linke A, Hofer J, Erbs S, Schoene N, Schuler\nG. Effect of exercise on coronary endothelial function in patients with coronary\nartery disease. N Engl J Med 2000;342:454\u0002460.\n172. Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis\nJM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW,\nHarrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW,\nJohnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ,\nMontez MG, Murillo A, Nathan DM, Patricio J, Peters A, Pi-Sunyer X, Pownall\nH, Reboussin D, Regensteiner JG, Rickman AD, Ryan DH, Safford M, Wadden\nTA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ. Cardiovascular\neffects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med\n2013;369:145\u0002154.\n173. Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC,\nHorton ES, Castorino K, Tate DF. Physical activity/exercise and diabetes: a posi-\ntion\nstatement\nof\nthe\nAmerican\nDiabetes\nAssociation.\nDiabetes\nCare\n2016;39:2065\u00022079.\n174. Pan B, Ge L, Xun Y-Q, Chen Y-J, Gao C-Y, Han X, Zuo L-Q, Shan H-Q, Yang\nK-H, Ding G-W, Tian J-H. Exercise training modalities in patients with type 2\ndiabetes mellitus: a systematic review and network meta-analysis. Int J Behav\nNutr Phys Act 2018;15:72.\n175. Sigal RJ, Kenny GP, Boule NG, Wells GA, Prud’homme D, Fortier M, Reid RD,\nTulloch H, Coyle D, Phillips P, Jennings A, Jaffey J. Effects of aerobic training,\nresistance training, or both on glycemic control in type 2 diabetes: a random-\nized trial. Ann Intern Med 2007;147:357\u0002369.\n176. Church TS, Blair SN, Cocreham S, Johannsen N, Johnson W, Kramer K, Mikus\nCR, Myers V, Nauta M, Rodarte RQ, Sparks L, Thompson A, Earnest CP.\nEffects of aerobic and resistance training on hemoglobin A1c levels in patients\nwith\ntype\n2\ndiabetes:\na\nrandomized\ncontrolled\ntrial.\nJAMA\n2010;304:2253\u00022262.\n177. Kemps H, Krankel N, Dorr M, Moholdt T, Wilhelm M, Paneni F, Serratosa L,\nEkker Solberg E, Hansen D, Halle M, Guazzi M. Exercise training for patients\nwith type 2 diabetes and cardiovascular disease: what to pursue and how to do\nit. A position paper of the European Association of Preventive Cardiology\n(EAPC). Eur J Prev Cardiol 2019;26:709\u0002727.\n178. Umpierre D, Ribeiro PAB, Kramer CK, Leitao CB, Zucatti ATN, Azevedo MJ,\nGross JL, Ribeiro JP, Schaan BD. Physical activity advice only or structured exer-\ncise training and association with HbA1c levels in type 2 diabetes: a systematic\nreview and meta-analysis. JAMA 2011;305:1790\u00021799.\n179. Feldman DI, Al-Mallah MH, Keteyian SJ, Brawner CA, Feldman T, Blumenthal\nRS, Blaha MJ. No evidence of an upper threshold for mortality benefit at high\nlevels of cardiorespiratory fitness. J Am Coll Cardiol 2015;65:629\u0002630.\n180. Hamer M, Lavoie KL, Bacon SL. Taking up physical activity in later life and\nhealthy ageing: the English longitudinal study of ageing. Br J Sports Med\n2014;48:239\u0002243.\n181. Manini TM, Everhart JE, Patel KV, Schoeller DA, Colbert LH, Visser M, Tylavsky\nF, Bauer DC, Goodpaster BH, Harris TB. Daily activity energy expenditure and\nmortality among older adults. JAMA 2006;296:171\u0002179.\n182. Stessman J, Hammerman-Rozenberg R, Cohen A, Ein-Mor E, Jacobs JM. Physical\nactivity, function,\nand longevity\namong the very old. Arch Intern Med\n2009;169:1476\u00021483.\n183. Sabia S, Singh-Manoux A, Hagger-Johnson G, Cambois E, Brunner EJ, Kivimaki\nM. Influence of individual and combined healthy behaviours on successful aging.\nCMAJ 2012;184:1985\u00021992.\n84\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\n184. Sun Q, Townsend MK, Okereke OI, Franco OH, Hu FB, Grodstein F. Physical\nactivity at midlife in relation to successful survival in women at age 70 years or\nolder. Arch Intern Med 2010;170:194\u0002201.\n185. Dugan SA, Gabriel KP, Lange-Maia BS, Karvonen-Gutierrez C. Physical activity\nand physical function: moving and aging. Obstet Gynecol Clin North Am\n2018;45:723\u0002736.\n186. Berk DR, Hubert HB, Fries JF. Associations of changes in exercise level with\nsubsequent disability among seniors: a 16-year longitudinal study. J Gerontol A\nBiol Sci Med Sci 2006;61:97\u0002102.\n187. Thiel C, Vogt L, Tesky VA, Meroth L, Sahlender, Jakob M, Pantel, S Banzer, J W.\nCognitive intervention response is related to habitual physical activity in older\nadults. Aging Clin Exp Res 2012;24:47\u000255.\n188. Lautenschlager NT, Cox KL, Flicker L, Foster JK, van Bockxmeer FM, Xiao J,\nGreenop KR, Almeida OP. Effect of physical activity on cognitive function in\nolder\nadults\nat\nrisk\nfor\nAlzheimer\ndisease:\na\nrandomized\ntrial.\nJAMA\n2008;300:1027\u00021037.\n189. Sink KM, Espeland MA, Castro CM, Church T, Cohen R, Dodson JA, Guralnik J,\nHendrie HC, Jennings J, Katula J, Lopez OL, McDermott MM, Pahor M, Reid KF,\nRushing J, Verghese J, Rapp S, Williamson JD. Effect of a 24-month physical\nactivity intervention vs health education on cognitive outcomes in sedentary\nolder adults: the LIFE randomized trial. JAMA 2015;314:781\u0002790.\n190. Loprinzi PD, Frith E, Edwards MK, Sng E, Ashpole N. The effects of exercise on\nmemory function among young to middle-aged adults: systematic review and\nrecommendations for future research. Am J Health Promot 2018;32:691\u0002704.\n191. Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resist-\nance: underlying causes and modification by exercise training. Compr Physiol\n2013;3:1\u000258.\n192. Vigorito C, Giallauria F. Effects of exercise on cardiovascular performance in\nthe elderly. Front Physiol 2014;5:51.\n193. Power GA, Dalton BH, Behm DG, Vandervoort AA, Doherty TJ, Rice CL.\nMotor unit number estimates in masters runners: use it or lose it? Med Sci\nSports Exerc 2010;42:1644\u00021650.\n194. Power GA, Dalton BH, Behm DG, Doherty TJ, Vandervoort AA, Rice CL.\nMotor unit survival in lifelong runners is muscle dependent. Med Sci Sports Exerc\n2012;44:1235\u00021242.\n195. Rubenstein LZ, Josephson KR, Trueblood PR, Loy S, Harker JO, Pietruszka FM,\nRobbins AS. Effects of a group exercise program on strength, mobility, and falls\namong fall-prone elderly men. J Gerontol A Biol Sci Med Sci 2000;55:M317\u000221.\n196. Franco MR, Pereira LS, Ferreira PH. Exercise interventions for preventing falls\nin older people living in the community. Br J Sports Med 2014;48:867\u0002868.\n197. Chodzko-Zajko WJ, Proctor DN, Fiatarone Singh MA, Minson CT, Nigg CR,\nSalem GJ, Skinner JS. American College of Sports Medicine position stand.\nExercise\nand\nphysical\nactivity\nfor\nolder\nadults.\nMed\nSci\nSports\nExerc\n2009;41:1510\u00021530.\n198. Crocker T, Forster A, Young J, Brown L, Ozer S, Smith J, Green J, Hardy J,\nBurns E, Glidewell E, Greenwood DC. Physical rehabilitation for older people\nin long-term care. Cochrane Database Syst Rev 2013;CD004294.\n199. Bray NW, Smart RR, Jakobi JM, Jones GR. Exercise prescription to reverse\nfrailty. Appl Physiol Nutr Metab 2016;41:1112\u00021116.\n200. Forbes D, Thiessen EJ, Blake CM, Forbes SC, Forbes S. Exercise programs for\npeople with dementia. Cochrane Database Syst Rev 2013;CD006489.\n201. Liu C-J, Latham NK. Progressive resistance strength training for improving phys-\nical function in older adults. Cochrane Database Syst Rev 2009;CD002759.\n202. Fragala MS, Cadore EL, Dorgo S, Izquierdo M, Kraemer WJ, Peterson MD, Ryan\nED. Resistance training for older adults: position statement from the National\nStrength\nand\nConditioning\nAssociation.\nJ\nStrength\nCond\nRes\n2019;33:2019\u00022052.\n203. Pahor M, Guralnik JM, Ambrosius WT, Blair S, Bonds DE, Church TS, Espeland\nMA, Fielding RA, Gill TM, Groessl EJ, King AC, Kritchevsky SB, Manini TM,\nMcDermott MM, Miller ME, Newman AB, Rejeski WJ, Sink KM, Williamson JD.\nEffect of structured physical activity on prevention of major mobility disability\nin\nolder\nadults:\nthe\nLIFE\nstudy\nrandomized\nclinical\ntrial.\nJAMA\n2014;311:2387\u00022396.\n204. Gill TM, Pahor M, Guralnik JM, McDermott MM, King AC, Buford TW,\nStrotmeyer ES, Nelson ME, Sink KM, Demons JL, Kashaf SS, Walkup MP, Miller\nME. Effect of structured physical activity on prevention of serious fall injuries in\nadults aged 70\u000289: randomized clinical trial (LIFE study). BMJ 2016;352:i245.\n205. Church TS, Earnest CP, Skinner JS, Blair SN. Effects of different doses of physi-\ncal activity on cardiorespiratory fitness among sedentary, overweight or obese\npostmenopausal women with elevated blood pressure: a randomized con-\ntrolled trial. JAMA 2007;297:2081\u00022091.\n206. Powell KE, Paluch AE, Blair SN. Physical activity for health: What kind? How\nmuch? How intense? On top of what? Annu Rev Public Health 2011;32:349\u0002365.\n207. Borjesson M, Urhausen A, Kouidi E, Dugmore D, Sharma S, Halle M,\nHeidbu¨chel H, Bjo¨rnstad HH, Gielen S, Mezzani A, Corrado D, Pelliccia A,\nVanhees L. Cardiovascular evaluation of middle-aged/senior individuals engaged\nin leisure-time sport activities: position stand from the Sections of Exercise\nPhysiology\nand\nSports\nCardiology\nof\nthe\nEuropean\nAssociation\nof\nCardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil\n2011;18:446\u0002458.\n208. Orkaby AR, Forman DE. Physical activity and CVD in older adults: an expert’s\nperspective. Expert Rev Cardiovasc Ther 2018;16:1\u000210.\n209. Gillespie LD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, Clemson\nLM, Lamb SE. Interventions for preventing falls in older people living in the\ncommunity. Cochrane Database Syst Rev 2012;CD007146.\n210. Hamed A, Bohm S, Mersmann F, Arampatzis A. Follow-up efficacy of physical\nexercise interventions on fall incidence and fall risk in healthy older adults: a\nsystematic review and meta-analysis. Sport Med - Open 2018;4:56.\n211. Ganse B, Degens H, Drey M, Korhonen MT, McPhee J, Muller K, Johannes BW,\nRittweger J. Impact of age, performance and athletic event on injury rates in\nmaster athletics\n\u0002\nfirst results from an ongoing prospective study. J\nMusculoskelet Neuronal Interact 2014;14:148\u0002154.\n212. Rogers NT, Marshall A, Roberts CH, Demakakos P, Steptoe A, Scholes S.\nPhysical activity and trajectories of frailty among older adults: evidence from\nthe English Longitudinal Study of Ageing. PLoS One 2017;12:e0170878.\n213. Nelson ME, Rejeski WJ, Blair SN, Duncan PW, Judge JO, King AC, Macera CA,\nCastaneda-Sceppa C. Physical activity and public health in older adults: recom-\nmendation from the American College of Sports Medicine and the American\nHeart Association. Med Sci Sports Exerc 2007;39:1435\u00021445.\n214. Chou W-T, Tomata Y, Watanabe T, Sugawara Y, Kakizaki M, Tsuji I.\nRelationships between changes in time spent walking since middle age and inci-\ndent functional disability. Prev Med (Baltim) 2014;59:68\u000272.\n215. Tomata Y, Zhang S, Sugiyama K, Kaiho Y, Sugawara Y, Tsuji I. Changes in time\nspent walking and the risk of incident dementia in older Japanese people: the\nOhsaki Cohort 2006 Study. Age Ageing 2017;46:857\u0002860.\n216. Albert CM, Mittleman MA, Chae CU, Lee IM, Hennekens CH, Manson JE.\nTriggering of sudden death from cardiac causes by vigorous exertion. N Engl J\nMed 2000;343:1355\u00021361.\n217. Guazzi M, Arena R, Halle M, Piepoli MF, Myers J, Lavie CJ. 2016 focused update:\nclinical recommendations for cardiopulmonary exercise testing data assessment\nin specific patient populations. Eur Heart J 2016;39:1144\u00021161.\n218. Thompson PD, Franklin BA, Balady GJ, Blair SN, Corrado D, Estes NAM 3rd,\nFulton JE, Gordon NF, Haskell WL, Link MS, Maron BJ, Mittleman MA, Pelliccia\nA, Wenger NK, Willich SN, Costa F. Exercise and acute cardiovascular events\nplacing the risks into perspective: a scientific statement from the American\nHeart Association Council on Nutrition, Physical Activity, and Metabolism and the\nCouncil on Clinical Cardiology. Circulation 2007;115:2358\u00022368.\n219. Penalver JM, Mosca RS, Weitz D, Phoon CKL. Anomalous aortic origin of coro-\nnary arteries from the opposite sinus: a critical appraisal of risk. BMC Cardiovasc\nDisord 2012;12:83.\n220. Gowd BMP, Thompson PD. Isolated myocardial bridging and exercise-related\ncardiac events. Int J Sports Med 2014;35:1145\u00021150.\n221. Kalaga RV, Malik A, Thompson PD. Exercise-related spontaneous coronary\nartery dissection: case report and literature review. Med Sci Sports Exerc\n2007;39:1218\u00021220.\n222. Aengevaeren VL, Mosterd A, Braber TL, Prakken NHJ, Doevendans PA,\nGrobbee DE, Thompson PD, Eijsvogels TMH, Velthuis BK. Relationship\nbetween lifelong exercise volume and coronary atherosclerosis in athletes.\nCirculation 2017;136:138\u0002148.\n223. Shave R, Baggish A, George K, Wood M, Scharhag J, Whyte G, Gaze D,\nThompson PD. Exercise-induced cardiac troponin elevation: evidence, mecha-\nnisms, and implications. J Am Coll Cardiol 2010;56:169\u0002176.\n224. Aagaard P, Sahlen A, Braunschweig F. Performance trends and cardiac bio-\nmarkers in a 30-km cross-country race, 1993\u00022007. Med Sci Sports Exerc\n2012;44:894\u0002899.\n225. Collet J-P, Zeitouni M, Procopi N, Hulot J-S, Silvain J, Kerneis M, Thomas D,\nLattuca B, Barthelemy O, Lavie-Badie Y, Esteve J-B, Payot L, Brugier D, Lopes I,\nDiallo A, Vicaut E, Montalescot G. Long-term evolution of premature coronary\nartery disease. J Am Coll Cardiol 2019;74:1868\u00021878.\n226. Maron BJ, Araujo CG, Thompson PD, Fletcher GF, de Luna AB, Fleg JL, Pelliccia\nA, Balady GJ, Furlanello F, Van Camp SP, Elosua R, Chaitman BR, Bazzarre TL.\nRecommendations for preparticipation screening and the assessment of cardio-\nvascular disease in masters athletes: an advisory for healthcare professionals\nfrom the working groups of the World Heart Federation, the International\nFederation\nof\nSports\nMedicine,\nand\nthe\nAmerican\nHeart\nAssociation\nCommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation\n2001;103:327\u0002334.\n227. Erbel R, Mohlenkamp S, Moebus S, Schmermund A, Lehmann N, Stang A,\nDragano N, Gronemeyer D, Seibel R, Kalsch H, Brocker-Preuss M, Mann K,\nSiegrist J, Jockel K-H. Coronary risk stratification, discrimination, and reclassifi-\ncation improvement based on quantification of subclinical coronary atheroscle-\nrosis: the Heinz Nixdorf Recall Study. J Am Coll Cardiol 2010;56:1397\u00021406.\nESC Guidelines\n85\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\n228. Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O’Leary D, Carr JJ,\nGoff DC, Greenland P, Herrington DM. Comparison of novel risk markers for\nimprovement in cardiovascular risk assessment in intermediate-risk individuals.\nJAMA 2012;308:788\u0002795.\n229. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery\ncalcium score combined with Framingham score for risk prediction in asympto-\nmatic individuals. JAMA 2004;291:210\u0002215.\n230. Saad M, Pothineni NV, Thomas J, Parikh R, Kovelamudi S, Elsayed D, Nairooz R,\nFeit F. Coronary artery calcium scoring in young adults: evidence and chal-\nlenges. Curr Cardiol Rep 2018;20:10.\n231. Borjesson M, Assanelli D, Carre F, Dugmore D, Panhuyzen-Goedkoop NM,\nSeiler C, Senden J, Solberg EE. ESC Study Group of Sports Cardiology: recom-\nmendations for participation in leisure-time physical activity and competitive\nsports for patients with ischaemic heart disease. Eur J Cardiovasc Prev Rehabil\n2006;13:137\u0002149.\n232. Sirico F, Fernando F, Di Paolo F, Adami PE, Signorello MG, Sannino G, Bianco\nA, Cerrone A, Baioccato V, Filippi N, Ferrari U, Tuzi M, Nurzynska D, Di\nMeglio F, Castaldo C, D’Ascenzi F, Montagnani S, Biffi A. Exercise stress test in\napparently healthy individuals \u0002 where to place the finish line? The Ferrari cor-\nporate wellness programme experience. Eur J Prev Cardiol 2019;26:731\u0002738.\n233. Borjesson M, Dellborg M, Niebauer J, LaGerche A, Schmied C, Solberg EE,\nHalle M, Adami E, Biffi A, Carre F, Caselli S, Papadakis M, Pressler A, Rasmusen\nH, Serratosa L, Sharma S, van Buuren F, Pelliccia A. Recommendations for par-\nticipation in leisure time or competitive sports in athletes-patients with coro-\nnary artery disease: a position statement from the Sports Cardiology Section of\nthe European Association of Preventive Cardiology (EAPC). Eur Heart J\n2019;40:13\u000218.\n234. Anderson L, Thompson DR, Oldridge N, Zwisler A-D, Rees K, Martin N,\nTaylor RS. Exercise-based cardiac rehabilitation for coronary heart disease.\nCochrane Database Syst Rev 2016;CD001800.\n235. Piepoli MF, Corra U, Adamopoulos S, Benzer W, Bjarnason-Wehrens B,\nCupples M, Dendale P, Doherty P, Gaita D, Hofer S, McGee H, Mendes M,\nNiebauer J, Pogosova N, Garcia-Porrero E, Rauch B, Schmid JP, Giannuzzi P.\nSecondary prevention in the clinical management of patients with cardiovascu-\nlar diseases. Core components, standards and outcome measures for referral\nand delivery: a policy statement from the cardiac rehabilitation section of the\nEuropean Association for Cardiovascular Prevention and Rehabilitation. Eur J\nPrev Cardiol 2014;21:664\u0002681.\n236. Hachamovitch R, Rozanski A, Shaw LJ, Stone GW, Thomson LEJ, Friedman JD,\nHayes SW, Cohen I, Germano G, Berman DS. Impact of ischaemia and scar on\nthe therapeutic benefit derived from myocardial revascularization vs. medical\ntherapy among patients undergoing stress-rest myocardial perfusion scintigra-\nphy. Eur Heart J 2011;32:1012\u00021024.\n237. Hoffmann U, Ferencik M, Udelson JE, Picard MH, Truong QA, Patel MR, Huang\nM, Pencina M, Mark DB, Heitner JF, Fordyce CB, Pellikka PA, Tardif J-C, Budoff\nM, Nahhas G, Chow B, Kosinski AS, Lee KL, Douglas PS. Prognostic value of\nnoninvasive cardiovascular testing in patients with stable chest pain: insights\nfrom the PROMISE trial (Prospective Multicenter Imaging Study for Evaluation\nof Chest Pain). Circulation 2017;135:2320\u00022332.\n238. Newby DE, Adamsson PD, Berry C, Boon NA, Dweck MR, TFlather M, Forbes\nJ, Hunter A, Lewis S, MacLean S, Mills NL, Norrie J, Roditi G, Shah ASV, Timmis\nAD, vanBeek EJR WM. Coronary CT angiography and 5-year risk of myocardial\ninfarction. N Engl J Med 2018;379:924\u0002933.\n239. Sousa-Uva M, Neumann F-J, Ahlsson A, Alfonso F, Banning AP, Benedetto U,\nByrne RA, Collet J-P, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen\nSD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker\nS, Yadav R, Zembala MO. 2018 ESC/EACTS Guidelines on myocardial revascu-\nlarization. Eur J Cardiothorac Surg 2019;55:4\u000290.\n240. Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, Juni P,\nKastrati A, Kolh P, Mauri L, Montalescot G, Neumann F-J, Petricevic M, Roffi M,\nSteg PG, Windecker S, Zamorano JL. Special article 2017 ESC focused update\non dual antiplatelet therapy in coronary artery disease developed in collabora-\ntion with EACTS. Rev Esp Cardiol (Engl Ed) 2018;71:42.\n241. Albaladejo P, Samama C-M, Sie P, Kauffmann S, Memier V, Suchon P, Viallon A,\nDavid JS, Gruel Y, Bellamy L, de Maistre E, Romegoux P, Thoret S, Pernod G,\nBosson J-L. Management of severe bleeding in patients treated with direct oral\nanticoagulants:\nan\nobservational\nregistry\nanalysis.\nAnesthesiology\n2017;127:111\u0002120.\n242. Balady GJ, Williams MA, Ades PA, Bittner V, Comoss P, Foody JM, Franklin B,\nSanderson B, Southard D. Core components of cardiac rehabilitation/secondary\nprevention programs: 2007 update: a scientific statement from the American\nHeart Association Exercise, Cardiac Rehabilitation, and Prevention Committee,\nthe Council on Clinical Cardiology; the Councils on Cardiovascular Nursing,\nEpidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism;\nand the American Association of Cardiovascular and Pulmonary Rehabilitation.\nCirculation 2007;115:2675\u00022682.\n243. Verschueren S, Eskes AM, Maaskant JM, Roest AM, Latour CHM, Op Reimer\nWS. The effect of exercise therapy on depressive and anxious symptoms in\npatients with ischemic heart disease: a systematic review. J Psychosom Res\n2018;105:80\u000291.\n244. Piepoli MF, Corra U, Benzer W, Bjarnason-Wehrens B, Dendale P, Gaita D,\nMcGee H, Mendes M, Niebauer J, Zwisler A-DO, Schmid J-P. Secondary pre-\nvention through cardiac rehabilitation: from knowledge to implementation. A\nposition paper from the Cardiac Rehabilitation Section of the European\nAssociation of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc\nPrev Rehabil 2010;17:1\u000217.\n245. Haykowsky M, Scott J, Esch B, Schopflocher D, Myers J, Paterson I, Warburton\nD, Jones L, Clark AM. A meta-analysis of the effects of exercise training on left\nventricular remodeling following myocardial infarction: start early and go longer\nfor greatest exercise benefits on remodeling. Trials 2011;12:92.\n246. Angelini P, Cheong BY, Lenge De Rosen VV, Lopez JA, Uribe C, Masso AH, Ali\nSW, Davis BR, Muthupillai R, Willerson JT. Magnetic resonance imaging-based\nscreening study in a general population of adolescents. J Am Coll Cardiol\n2018;71:579\u0002580.\n247. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J,\nElliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck K-\nH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van\nVeldhuisen DJ. 2015 ESC Guidelines for the management of patients with ven-\ntricular arrhythmias and the prevention of sudden cardiac death: The Task\nForce for the Management of Patients with Ventricular Arrhythmias and the\nPrevention of Sudden Cardiac Death of the European Society of Cardiology\n(ESC). EP Europace 2015;17:1601\u00021687.\n248. Lin S, Tremmel JA, Yamada R, Rogers IS, Yong CM, Turcott R, McConnell MV,\nDash R, Schnittger I. A novel stress echocardiography pattern for myocardial\nbridge with invasive structural and hemodynamic correlation. J Am Heart Assoc\n2013;2:e000097.\n249. Grani C, Benz DC, Steffen DA, Giannopoulos AA, Messerli M, Pazhenkottil AP,\nGaemperli O, Gebhard C, Schmied C, Kaufmann PA, Buechel RR. Sports behav-\nior in middle-aged individuals with anomalous coronary artery from the oppo-\nsite sinus of Valsalva. Cardiology 2018;139:222\u0002230.\n250. Grani C, Benz DC, Steffen DA, Clerc OF, Schmied C, Possner M, Vontobel J,\nMikulicic F, Gebhard C, Pazhenkottil AP, Gaemperli O, Hurwitz S, Kaufmann\nPA, Buechel RR. Outcome in middle-aged individuals with anomalous origin of\nthe coronary artery from the opposite sinus: a matched cohort study. Eur Heart\nJ 2017;38:2009\u00022016.\n251. Van Hare GF, Ackerman MJ, Evangelista J-AK, Kovacs RJ, Myerburg RJ, Shafer\nKM, Warnes CA, Washington RL. Eligibility and disqualification recommenda-\ntions for competitive athletes with cardiovascular abnormalities: Task Force 4:\nCongenital heart disease: a scientific statement from the American Heart\nAssociation\nand\nAmerican\nCollege\nof\nCardiology.\nCirculation\n2015;132:e281\u000291.\n252. Basso C, Maron BJ, Corrado D, Thiene G. Clinical profile of congenital coro-\nnary artery anomalies with origin from the wrong aortic sinus leading to sudden\ndeath in young competitive athletes. J Am Coll Cardiol 2000;35:1493\u00021501.\n253. Finocchiaro G, Behr ER, Tanzarella G, Papadakis M, Malhotra A, Dhutia H,\nMiles C, Diemberger I, Sharma S, Sheppard MN. Anomalous coronary artery\norigin and sudden cardiac death: clinical and pathological insights from a\nnational pathology registry. JACC Clin Electrophysiol 2019;5:516\u0002522.\n254. Yamada R, Tremmel JA, Tanaka S, Lin S, Kobayashi Y, Hollak MB, Yock PG,\nFitzgerald PJ, Schnittger I, Honda Y. Functional versus anatomic assessment of\nmyocardial bridging by intravascular ultrasound: impact of arterial compression\non proximal atherosclerotic plaque. J Am Heart Assoc 2016;5:e001735.\n255. Cerrato E, Barbero U, D’Ascenzo F, Taha S, Biondi-Zoccai G, Omede P, Bianco\nM, Echavarria-Pinto M, Escaned J, Gaita F, Varbella F. What is the optimal treat-\nment for symptomatic patients with isolated coronary myocardial bridge? A sys-\ntematic\nreview\nand\npooled\nanalysis.\nJ\nCardiovasc\nMed\n(Hagerstown)\n2017;18:758\u0002770.\n256. Dimitriu-Leen AC, van Rosendael AR, Smit JM, van Elst T, van Geloven N,\nMaaniitty T, Jukema JW, Delgado V, Scholte AJHA, Saraste A, Knuuti J, Bax JJ.\nLong-term prognosis of patients with intramural course of coronary arteries\nassessed with CT angiography. JACC Cardiovasc Imaging 2017;10:1451\u00021458.\n257. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V,\nGonzalez-Juanatey\nJR, Harjola V-P, Jankowska EA, Jessup M, Linde C,\nNihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM,\nRuschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis\nand treatment of acute and chronic heart failure: The Task Force for the diag-\nnosis and treatment of acute and chronic heart failure of the European Society\nof Cardiology (ESC). Eur Heart J 2016;37:2129\u00022200.\n258. Piepoli MF, Davos C, Francis DP, Coats AJS. Exercise training meta-analysis of\ntrials in patients with chronic heart failure (ExTraMATCH). BMJ 2004;328:189.\n259. Taylor RS, Walker S, Smart NA, Piepoli MF, Warren FC, Ciani O, O’Connor C,\nWhellan D, Keteyian SJ, Coats A, Davos CH, Dalal HM, Dracup K, Evangelista\n86\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 61",
          "page": 61,
          "content": "Recommendations for exercise in individuals with arrhythmias and implantable cardiac devices |  |  | \nExercise recommendations in individuals with atrial fibrillation |  |  | \nRegular physical activity is recommended to prevent AF. | I | A | \nEvaluation and management of structural heart disease, thyroid dysfunction, alcohol or drug abuse, or other primary causes of AF is\nrecommended before engaging in sports. | I | A | \nAF ablation is recommended in exercising individuals with recurrent, symptomatic AF and/or in those who do not want drug therapy,\ngiven its impact on athletic performance. | I | B | \nSports with direct bodily contact or prone to trauma are not recommended in exercising individuals with AF who are anticoagulated. | III | C | \nRecommendations for exercise and sports participation in individuals with paroxysmal supraventricular tachycardia and pre-excitation |  |  | \nIn individuals with palpitations, a comprehensive assessment to exclude (latent) pre-excitation, structural heart disease, and VAs is\nrecommended. | I | B | \nAblation of the accessory pathway is recommended in competitive and recreational athletes with pre-excitation and documented\narrhythmias. | I | C | \nIn competitive/professional athletes with asymptomatic pre-excitation, an EP study is recommended to evaluate the risk for sudden\ndeath. | I | B | \nExercise recommendations in individuals with premature ventricular contractions or non-sustained ventricular tachycardia |  |  | \nIn exercising individuals with >2 PVCs on a baseline ECG (or >1 PVC in case of high-endurance athletes) a thorough evaluation\n_ _\n(including a detailed family history) to exclude underlying structural or arrhythmogenic conditions is recommended. | I | C | \nAmong individuals with frequent PVCs and non-sustained VT a thorough investigation with Holter monitoring, 12-lead ECG, exercise\ntest, and suitable imaging is recommended. | I | C | \nExercise recommendations in long QT syndrome |  |  | \nIt is recommended that all exercising individuals with LQTS with prior symptoms or prolonged QTc be on therapy with beta-block-\ners at target dose. | I | B | \nIt is recommended that exercising individuals with LQTS should avoid QT-prolonging drugs (www.crediblemeds.org) and electrolyte\nimbalance such as hypokalaemia and hypomagnesaemia. | I | B | \nParticipation in high-intensity recreational and competitive sports, even when on beta-blockers, is not recommended in individuals\nwith a QTc>500 ms or a genetically confirmed LQTS with a QTc>470 ms in males or >480 ms in females.\n_ _ | III | B | \nParticipation in competitive sports (with or without ICD) is not recommended in individuals with LQTS and prior cardiac arrest or\narrhythmic syncope. | III | C | \nExercise recommendations in Brugada syndrome |  |  | \nICD implantation is recommended in patients with BrS with episodes of arrhythmic syncope and/or aborted SCD. | I | C | \nPrescription of drugs that may aggravate BrS, electrolyte abnormalities, and sports practices that increase core temperature >39\u0004C\nare not recommended in individuals with overt BrS or phenotypically negative mutation carriers. | III | C | \nExercise recommendations in individuals with implantable cardiac electronic devices |  |  | \nIt is recommended that individuals with implanted devices with/without resynchronization and underlying disease follow the recom-\nmendations pertaining to the underlying disease. | I | B | \nAn ICD is not recommended as a substitute for disease-related recommendations when these mandate sports restrictions. | III | C | \nRecommendations for patients with congenital heart disease |  |  | \nParticipation in regular moderate exercise is recommended in all individuals with CHD. | I | B | \nA discussion on exercise participation and provision of an individualized exercise prescription is recommended at every CHD patient\nencounter. | I | B | \nCompetitive sport is not recommended for individuals with CHD who are in NYHA class III\u0002IV or with potentially serious\narrhythmias. | III | C | \nRecommendations for exercise in pregnancy |  |  | \nAmong pregnant women without medical or obstetric contraindications, participation in at least 150 min/week of moderate-intensity\naerobic exercise before, during, and after pregnancy is recommended. | I | B | \nRe-evaluation before continuing exercise or training is recommended in pregnant woman if they experience excessive shortness of\nbreath, severe chest pain, dizziness or syncope, regular painful contractions, vaginal bleeding, or amniotic fluid leakage. | I | A | \nAmong women with CVD who were habitually engaged in strength training or power sport disciplines before pregnancy, discussing\nthe option with the medical team before continuing and avoiding the Valsalva manoeuvre is recommended. | I | A | \nExercise or sport involving forceful physical contact, risk of falling or abdominal trauma, heavy lifting, scuba diving, or exercising at\nhigh altitude when unacclimatized are not recommended. | III | C | ",
          "rows": 33,
          "cols": 4
        },
        {
          "title": "Table on page 62",
          "page": 62,
          "content": "Vigorous exercise associated with a maximal predicted heart rate >90% of the predicted heart rate is not recommended during\npregnancy. | III | B | \nExercising while lying supine on a hard surface is not recommended after the first trimester due to the risk of decreased venous\nreturn and uterine blood flow. | III | B | \nRecommendations for exercise in chronic kidney disease |  |  | \nLow- to moderate-intensity aerobic exercise training (up to 150 min/week), and low- to moderate-intensity resistance exercise train-\ning (2 day per week, 8\u000212 exercises, 12\u000215 repetitions), and flexibility exercises are recommended in all individuals with CKD. | I | A | \nAmong patients with established osteodystrophy/osteoporosis, or coagulopathies, participation in contact sports is not\nrecommended. | III | C | \nParticipation in sport is not recommended in the following circumstances: electrolyte abnormalities, recent changes to the ECG,\nexcess inter-dialysis weight gain, changing or titration of medication regimen, pulmonary congestion, and increasing peripheral\noedema. | III | C | \nRecommendations for exercise in individuals with cancer |  |  | \nRegular exercise during and after cancer therapy is recommended to reduce cancer-related fatigue, and improve quality of life, physi-\ncal fitness, and prognosis. | I | A | \nAmong individuals treated with cardiotoxic medications, echocardiography before participation in high-intensity exercise is\nrecommended. | I | A | \nRecommendations for exercise in individuals with spinal cord injury |  |  | \nIn adults with spinal cord injury participation in 20 min of moderate- to vigorous-intensity aerobic exercise at least 3 times a week,\nalong with moderate-intensity resistance training 2\u00023 times per week, is recommended for cardiorespiratory fitness, cardiometabolic\nhealth, and muscle strength benefits. | I | A | \nArtificial methods of inducing autonomic dysreflexia by causing intentional pain to the lower half of the body (‘boosting’) through\nobstruction of an indwelling urinary catheter, overly tight leg straps and electrical shocks or other methods of pain to the genitalia or\nlower limbs can be life-threatening and are not recommended. | III | C | \nRecommendations for exercise in individuals with ventricular assist devices |  |  | \nRegular exercise, through cardiac rehabilitation, combining moderate-intensity aerobic and resistance exercise, is recommended in\nindividuals with a ventricular assist device (VAD). | I | A | \nSports that may potentially affect any of the VAD components (e.g. with body contact) are not recommended. | III | C | \nPhysical activity and sports recommendations in patients and athletes with peripheral arterial disease |  |  | \nIt is recommended that patients with atherosclerotic PAD perform regular exercise (at least 150 min/week of moderate aerobic\nexercise or 75 min/week of vigorous aerobic exercise or a combination thereof) as part of the secondary prevention strategy. | I | A | \nIn patients with symptomatic LEAD, supervised exercise training programmes including walking to the maximal or submaximal dis-\ntance for at least 3 h/week are indicated. | I | A | \nContinuation of competitive sports is recommended in athletes with traumatic or non-traumatic PAD following recovery after suc-\ncessful open surgery or percutaneous revascularization. | I | C | ",
          "rows": 19,
          "cols": 4
        }
      ],
      "keywords": [
        "arrhythmias",
        "ct",
        "cardiac",
        "asymptomatic",
        "individuals",
        "implantable",
        "exercise",
        "monitoring",
        "recommendations",
        "devices",
        "risk",
        "symptomatic",
        "ablation",
        "imaging",
        "icd",
        "recommendation"
      ]
    },
    {
      "number": "8",
      "title": "L, Jolly K, Myers J, McKelvie RS, Nilsson BB, Passino C, Witham MD, Yeh GY,",
      "start_page": 71,
      "end_page": 80,
      "content": ".............................................................................................................................................................................\nL, Jolly K, Myers J, McKelvie RS, Nilsson BB, Passino C, Witham MD, Yeh GY,\nZwisler A-DO. Impact of exercise-based cardiac rehabilitation in patients with\nheart failure (ExTraMATCH II) on mortality and hospitalisation: an individual\npatient\ndata\nmeta-analysis\nof\nrandomised\ntrials.\nEur\nJ\nHeart\nFail\n2018;20:1735\u00021743.\n260. Long L, Mordi IR, Bridges C, Sagar VA, Davies EJ, Coats AJ, Dalal H, Rees K,\nSingh SJ, Taylor RS. Exercise-based cardiac rehabilitation for adults with heart\nfailure. Cochrane Database Syst Rev 2019;1:CD003331.\n261. Rees K, Taylor RS, Singh S, Coats AJS, Ebrahim S. Exercise based rehabilitation\nfor heart failure. Cochrane Database Syst Rev 2004;CD003331.\n262. Taylor RS, Walker S, Smart NA, Piepoli MF, Warren FC, Ciani O, Whellan D,\nO’Connor C, Keteyian SJ, Coats A, Davos CH, Dalal HM, Dracup K, Evangelista\nLS, Jolly K, Myers J, Nilsson BB, Passino C, Witham MD, Yeh GY. Impact of\nexercise rehabilitation on exercise capacity and quality-of-life in heart failure:\nindividual participant meta-analysis. J Am Coll Cardiol 2019;73:1430\u00021443.\n263. Pandey A, Parashar A, Kumbhani D, Agarwal S, Garg J, Kitzman D, Levine B,\nDrazner M, Berry J. Exercise training in patients with heart failure and preserved\nejection fraction: meta-analysis of randomized control trials. Circ Heart Fail\n2015;8:33\u000240.\n264. Sagar VA, Davies EJ, Briscoe S, Coats AJS, Dalal HM, Lough F, Rees K, Singh S,\nTaylor RS. Exercise-based rehabilitation for heart failure: systematic review and\nmeta-analysis. Open Heart 2015;2:e000163.\n265. Corra U, Agostoni PG, Anker SD, Coats AJS, Crespo Leiro MG, de Boer RA,\nHarjola V-P, Hill L, Lainscak M, Lund LH, Metra M, Ponikowski P, Riley J,\nSeferovic PM, Piepoli MF. Role of cardiopulmonary exercise testing in clinical\nstratification in heart failure. A position paper from the Committee on Exercise\nPhysiology and Training of the Heart Failure Association of the European\nSociety of Cardiology. Eur J Heart Fail 2018;20:3\u000215.\n266. Scherr J, Wolfarth B, Christle JW, Pressler A, Wagenpfeil S, Halle M.\nAssociations between Borg’s rating of perceived exertion and physiological\nmeasures of exercise intensity. Eur J Appl Physiol 2013;113:147\u0002155.\n267. O’Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES,\nKraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL,\nSchulman\nKA,\nMcKelvie\nRS, Zannad F,\nPi~na IL, for the\nHF-ACTION\nInvestigators. Efficacy and safety of exercise training in patients with chronic\nheart\nfailure:\nHF-ACTION\nrandomized\ncontrolled\ntrial.\nJAMA\n2009;301:1439\u00021450.\n268. Rognmo O, Moholdt T, Bakken H, Hole T, Molstad P, Myhr NE, Grimsmo J,\nWisloff U. Cardiovascular risk of high- versus moderate-intensity aerobic exer-\ncise in coronary heart disease patients. Circulation 2012;126:1436\u00021440.\n269. Ellingsen O, Halle M, Conraads V, Stoylen A, Dalen H, Delagardelle C, Larsen\nA-I, Hole T, Mezzani A, Van Craenenbroeck EM, Videm V, Beckers P, Christle\nJW, Winzer E, Mangner N, Woitek F, Hollriegel R, Pressler A, Monk-Hansen T,\nSnoer M, Feiereisen P, Valborgland T, Kjekshus J, Hambrecht R, Gielen S,\nKarlsen T, Prescott E, Linke A. High-intensity interval training in patients with\nheart failure with reduced ejection fraction. Circulation 2017;135:839\u0002849.\n270. Piepoli MF, Conraads V, Corra U, Dickstein K, Francis DP, Jaarsma T,\nMcMurray J, Pieske B, Piotrowicz E, Schmid J-P, Anker SD, Solal AC, Filippatos\nGS, Hoes AW, Gielen S, Giannuzzi P, Ponikowski PP. Exercise training in heart\nfailure: from theory to practice. A consensus document of the Heart Failure\nAssociation and the European Association for Cardiovascular Prevention and\nRehabilitation. Eur J Heart Fail 2011;13:347\u0002357.\n271. Corra U, Piepoli MF, Carre F, Heuschmann P, Hoffmann U, Verschuren M,\nHalcox J, Giannuzzi P, Saner H, Wood D, Piepoli MF, Corra U, Benzer W,\nBjarnason-Wehrens B, Dendale P, Gaita D, McGee H, Mendes M, Niebauer J,\nZwisler A-DO, Schmid J-P. Secondary prevention through cardiac rehabilitation:\nphysical activity counselling and exercise training: key components of the posi-\ntion paper from the Cardiac Rehabilitation Section of the European Association\nof\nCardiovascular\nPrevention\nand\nRehabilitation.\nEur\nHeart\nJ\n2010;31:1967\u00021974.\n272. Gayda M, Ribeiro PAB, Juneau M, Nigam A. Comparison of different forms of\nexercise training in patients with cardiac disease: where does high-intensity\ninterval training fit? Can J Cardiol 2016;32:485\u0002494.\n273. Gomes Neto M, Duraes AR, Conceicao LSR, Saquetto MB, Ellingsen O,\nCarvalho VO. High intensity interval training versus moderate intensity continu-\nous training on exercise capacity and quality of life in patients with heart failure\nwith reduced ejection fraction: a systematic review and meta-analysis. Int J\nCardiol 2018;261:134\u0002141.\n274. Cornelis J, Beckers P, Taeymans J, Vrints C, Vissers D. Comparing exercise\ntraining modalities in heart failure: a systematic review and meta-analysis. Int J\nCardiol 2016;221:867\u0002876.\n275. Conraads VM, Beckers PJ. Exercise training in heart failure: practical guidance.\nHeart 2010;96:2025\u00022031.\n276. Williams MA, Haskell WL, Ades PA, Amsterdam EA, Bittner V, Franklin\nBA, Gulanick M, Laing ST, Stewart KJ. Resistance exercise in individuals\nwith\nand\nwithout\ncardiovascular\ndisease:\n2007\nupdate:\na\nscientific\nstatement from the American Heart Association Council on Clinical\nCardiology and Council on Nutrition, Physical Activity, and Metabolism.\nCirculation 2007;116:572\u0002584.\n277. Giuliano C, Karahalios A, Neil C, Allen J, Levinger I. The effects of resistance\ntraining on muscle strength, quality of life and aerobic capacity in patients with\nchronic heart failure \u0002 a meta-analysis. Int J Cardiol 2017;227:413\u0002423.\n278. Alvarez P, Hannawi B, Guha A. Exercise and heart failure: advancing knowledge\nand improving care. Methodist Debakey Cardiovasc J 2016;12:110\u0002115.\n279. Sadek Z, Salami A, Joumaa WH, Awada C, Ahmaidi S, Ramadan W. Best mode\nof inspiratory muscle training in heart failure patients: a systematic review and\nmeta-analysis. Eur J Prev Cardiol 2018;25:1691\u00021701.\n280. Smart NA, Giallauria F, Dieberg G. Efficacy of inspiratory muscle training in\nchronic heart failure patients: a systematic review and meta-analysis. Int J Cardiol\n2013;167:1502\u00021507.\n281. Neto MG, Martinez BP, Conceicao CS, Silva PE, Carvalho VO. Combined exer-\ncise and inspiratory muscle training in patients with heart failure: a systematic\nreview and meta-analysis. J Cardiopulm Rehabil Prev 2016;36:395\u0002401.\n282. Wu J, Kuang L, Fu L. Effects of inspiratory muscle training in chronic heart fail-\nure patients: a systematic review and meta-analysis. Congenit Heart Dis\n2018;13:194\u0002202.\n283. Tei C, Horikiri Y, Park JC, Jeong JW, Chang KS, Toyama Y, Tanaka N. Acute\nhemodynamic improvement by thermal vasodilation in congestive heart failure.\nCirculation 1995;91:2582\u00022590.\n284. Adsett JA, Mudge AM, Morris N, Kuys S, Paratz JD. Aquatic exercise training\nand stable heart failure: a systematic review and meta-analysis. Int J Cardiol\n2015;186:22\u000228.\n285. Omar W, Pandey A, Haykowsky MJ, Berry JD, Lavie CJ. The evolving role of\ncardiorespiratory fitness and exercise in prevention and management of heart\nfailure. Curr Heart Fail Rep 2018;15:75\u000280.\n286. Edelmann F, Gelbrich G, Dungen H-D, Frohling S, Wachter R, Stahrenberg R,\nBinder L, Topper A, Lashki DJ, Schwarz S, Herrmann-Lingen C, Loffler M,\nHasenfuss G, Halle M, Pieske B. Exercise training improves exercise capacity\nand diastolic function in patients with heart failure with preserved ejection frac-\ntion: results of the Ex-DHF (exercise training in diastolic heart failure) pilot\nstudy. J Am Coll Cardiol 2011;58:1780\u00021791.\n287. Kitzman DW, Brubaker P, Morgan T, Haykowsky M, Hundley G, Kraus WE,\nEggebeen J, Nicklas BJ. Effect of caloric restriction or aerobic exercise training\non peak oxygen consumption and quality of life in obese older patients with\nheart failure with preserved ejection fraction: a randomized clinical trial. JAMA\n2016;315:36\u000246.\n288. Kitzman DW, Brubaker PH, Morgan TM, Stewart KP, Little WC. Exercise train-\ning in older patients with heart failure and preserved ejection fraction: a\nrandomized, controlled, single-blind trial. Circ Heart Fail 2010;3:659\u0002667.\n289. Alves AJ, Ribeiro F, Goldhammer E, Rivlin Y, Rosenschein U, Viana JL, Duarte\nJA, Sagiv M, Oliveira J. Exercise training improves diastolic function in heart fail-\nure patients. Med Sci Sports Exerc 2012;44:776\u0002785.\n290. Gary RA, Sueta CA, Dougherty M, Rosenberg B, Cheek D, Preisser J, Neelon\nV, McMurray R. Home-based exercise improves functional performance and\nquality\nof\nlife\nin\nwomen\nwith\ndiastolic\nheart\nfailure.\nHeart\nLung\n2004;33:210\u0002218.\n291. Smart NA, Haluska B, Jeffriess L, Leung D. Exercise training in heart failure with\npreserved systolic function: a randomized controlled trial of the effects on car-\ndiac function and functional capacity. Congest Heart Fail 2012;18:295\u0002301.\n292. Pandey A, Garg S, Khunger M, Darden D, Ayers C, Kumbhani DJ, Mayo HG, de\nLemos JA, Berry JD. Dose-response relationship between physical activity and\nrisk of heart failure: a meta-analysis. Circulation 2015;132:1786\u00021794.\n293. Adams V, Reich B, Uhlemann M, Niebauer J. Molecular effects of exercise train-\ning in patients with cardiovascular disease: focus on skeletal muscle, endothe-\nlium, and myocardium. Am J Physiol Heart Circ Physiol 2017;313:H72\u0002H88.\n294. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX,\nTwomey D, Elliott AD, Kalman JM, Abhayaratna WP, Lau DH, Sanders P. Long-\nterm effect of goal-directed weight management in an atrial fibrillation cohort: a\nlong-term follow-up study (LEGACY). J Am Coll Cardiol 2015;65:2159\u00022169.\n295. Hollekim-Strand SM, Bjorgaas MR, Albrektsen G, Tjonna AE, Wisloff U, Ingul\nCB. High-intensity interval exercise effectively improves cardiac function in\npatients with type 2 diabetes mellitus and diastolic dysfunction: a randomized\ncontrolled trial. J Am Coll Cardiol 2014;64:1758\u00021760.\n296. Angadi SS, Mookadam F, Lee CD, Tucker WJ, Haykowsky MJ, Gaesser GA.\nHigh-intensity interval training vs. moderate-intensity continuous exercise train-\ning in heart failure with preserved ejection fraction: a pilot study. J Appl Physiol\n2015;119:753\u0002758.\n297. Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R,\nHendriks JML, Twomey D, Kalman JM, Abhayaratna WP, Lau DH, Sanders P.\nImpact of CARDIOrespiratory FITness on arrhythmia recurrence in obese indi-\nviduals with atrial fibrillation: the CARDIO-FIT Study. J Am Coll Cardiol\n2015;66:985\u0002996.\nESC Guidelines\n87\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\n298. Howden EJ, Sarma S, Lawley JS, Opondo M, Cornwell W, Stoller D, Urey MA,\nAdams-Huet B, Levine BD. Reversing the cardiac effects of sedentary aging in\nmiddle age \u0002 a randomized controlled trial: implications for heart failure pre-\nvention. Circulation 2018;137:1549\u00021560.\n299. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke\nW, Duvinage A, Stahrenberg R, Durstewitz K, Loffler M, Dungen H-D, Tschope\nC, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B. Effect of\nspironolactone on diastolic function and exercise capacity in patients with heart\nfailure with preserved ejection fraction: the Aldo-DHF randomized controlled\ntrial. JAMA 2013;309:781\u0002791.\n300. Givertz MM, Hartley LH, Colucci WS. Long-term sequential changes in exercise\ncapacity\nand\nchronotropic\nresponsiveness\nafter\ncardiac\ntransplantation.\nCirculation 1997;96:232\u0002237.\n301. Habedank D, Ewert R, Hummel M, Wensel R, Hetzer R, Anker SD. Changes in\nexercise capacity, ventilation, and body weight following heart transplantation.\nEur J Heart Fail 2007;9:310\u0002316.\n302. Mandak JS, Aaronson KD, Mancini DM. Serial assessment of exercise capacity\nafter heart transplantation. J Heart Lung Transplant 1995;14:468\u0002478.\n303. Grupper A, Gewirtz H, Kushwaha S. Reinnervation post-heart transplantation.\nEur Heart J 2018;39:1799\u00021806.\n304. Tucker WJ, Beaudry RI, Samuel TJ, Nelson MD, Halle M, Baggish AL,\nHaykowsky MJ. Performance limitations in heart transplant recipients. Exerc\nSport Sci Rev 2018;46:144\u0002151.\n305. Anderson L, Nguyen TT, Dall CH, Burgess L, Bridges C, Taylor RS. Exercise-\nbased cardiac rehabilitation in heart transplant recipients. Cochrane Database\nSyst Rev 2017;4:CD012264.\n306. Esefeld K, Fricke H, Haykowsky M, Halle M. Ultra-endurance exercise in a heart\ntransplant athlete: influence on myocardial function and biomarkers. Eur J Prev\nCardiol 2020;27:885\u0002887. doi: 10.1177/2047487318808636. Epub 2018 Nov 5.\n307. Rosenbaum AN, Kremers WK, Schirger JA, Thomas RJ, Squires RW, Allison\nTG, Daly RC, Kushwaha SS, Edwards BS. Association between early cardiac\nrehabilitation and long-term survival in cardiac transplant recipients. Mayo Clin\nProc 2016;91:149\u0002156.\n308. Bachmann JM, Shah AS, Duncan MS, Greevy RAJ, Graves AJ, Ni S, Ooi HH,\nWang TJ, Thomas RJ, Whooley MA, Freiberg MS. Cardiac rehabilitation and\nreadmissions\nafter\nheart\ntransplantation.\nJ\nHeart\nLung\nTransplant\n2018;37:467\u0002476.\n309. Haykowsky MJF, Riess KJ, Baggish AL. Heart transplant recipient finishes the\n118th Boston Marathon 27 years post-surgery. J Heart Lung Transplant\n2014;33:1197.\n310. Haykowsky MJ, Halle M, Baggish A. Upper limits of aerobic power and perform-\nance in heart transplant recipients: legacy effect of prior endurance training.\nCirculation 2018;137:650\u0002652.\n311. Nytrøen K, Gullestad L. Exercise after heart transplantation: an overview.\nWorld J Transplant 2013;3:78\u000290.\n312. Rustad LA, Nytrøen K, Amundsen BH, Gullestad L, Aakhus S. One year of high-\nintensity interval training improves exercise capacity, but not left ventricular\nfunction in stable heart transplant recipients: a randomised controlled trial. Eur J\nPrev Cardiol 2012;21:181\u0002191.\n313. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B,\nLancellotti P, Lansac E, Rodriguez Mu~noz D, Rosenhek R, Sjo¨gren J, Tornos Mas\nP, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL. 2017 ESC/\nEACTS Guidelines for the management of valvular heart disease. Eur Heart J\n2017;38:2739\u00022791.\n314. Rosenhek R, Rader F, Klaar U, Gabriel H, Krejc M, Kalbeck D, Schemper M,\nMaurer G, Baumgartner H. Outcome of watchful waiting in asymptomatic\nsevere mitral regurgitation. Circulation 2006;113:2238\u00022244.\n315. Baumgartner HC, Hung JC-C, Bermejo J, Chambers JB, Edvardsen T, Goldstein\nS, Lancellotti P, LeFevre M, Miller FJ, Otto CM. Recommendations on the echo-\ncardiographic assessment of aortic valve stenosis: a focused update from the\nEuropean Association of Cardiovascular Imaging and the American Society of\nEchocardiography. Eur Heart J Cardiovasc Imaging 2017;18:254\u0002275.\n316. Clavel M-A, Burwash IG, Pibarot P. Cardiac imaging for assessing low-gradient\nsevere aortic stenosis. JACC Cardiovasc Imaging 2017;10:185\u0002202.\n317. Morise AP. Exercise testing in nonatherosclerotic heart disease: hypertrophic\ncardiomyopathy,\nvalvular\nheart\ndisease,\nand\narrhythmias.\nCirculation\n2011;123:216\u0002225.\n318. Lee JKT, Franzone A, Lanz J, Siontis GCM, Stortecky S, Grani C, Roost E,\nWindecker S, Pilgrim T. Early detection of subclinical myocardial damage in\nchronic aortic regurgitation and strategies for timely treatment of asymptomatic\npatients. Circulation 2018;137:184\u0002196.\n319. Pelliccia A, Caselli S, Sharma S, Basso C, Bax JJ, Corrado D, D’Andrea A,\nD’Ascenzi F, Di Paolo FM, Edvardsen T, Gati S, Galderisi M, Heidbuchel H,\nNchimi A, Nieman K, Papadakis M, Pisicchio C, Schmied C, Popescu BA, Habib\nG, Grobbee D, Lancellotti P. European Association of Preventive Cardiology\n(EAPC) and European Association of Cardiovascular Imaging (EACVI) joint\nposition statement: recommendations for the indication and interpretation of\ncardiovascular imaging in the evaluation of the athlete’s heart. Eur Heart J\n2018;39:1949\u00021969.\n320. Verma S, Siu SC. Aortic dilatation in patients with bicuspid aortic valve. N Engl J\nMed 2014;370:1920\u00021929.\n321. Michelena HI, Khanna AD, Mahoney D, Margaryan E, Topilsky Y, Suri RM,\nEidem B, Edwards WD, Sundt TM 3rd, Enriquez-Sarano M. Incidence of aortic\ncomplications\nin\npatients\nwith\nbicuspid\naortic\nvalves.\nJAMA\n2011;306:1104\u00021112.\n322. Harris KM, Tung M, Haas TS, Maron BJ. Under-recognition of aortic and aortic\nvalve disease and the risk for sudden death in competitive athletes. J Am Coll\nCardiol 2015;65:860\u0002862.\n323. Spataro A, Pelliccia A, Rizzo M, Biffi A, Masazza G, Pigozzi F. The natural course\nof bicuspid aortic valve in athletes. Int J Sports Med 2008;29:81\u000285.\n324. Tzemos N, Therrien J, Yip J, Thanassoulis G, Tremblay S, Jamorski MT, Webb\nGD,\nSiu\nSC.\nOutcomes\nin\nadults\nwith\nbicuspid\naortic\nvalves.\nJAMA\n2008;300:1317\u00021325.\n325. Boraita A, Morales-Acuna F, Marina-Breysse M, Heras M-E, Canda A, Fuentes\nM-E, Chacon A, Diaz-Gonzalez L, Rabadan M, Parra Laca B, Perez de Isla L,\nTunon J. Bicuspid aortic valve behaviour in elite athletes. Eur Heart J Cardiovasc\nImaging 2019;20:772\u0002780.\n326. Bonow RO, Nishimura RA, Thompson PD, Udelson JE. Eligibility and disqualifi-\ncation recommendations for competitive athletes with cardiovascular abnor-\nmalities: Task Force 5: Valvular heart disease: a scientific statement from the\nAmerican Heart Association and American College of Cardiology. Circulation\n2015;132:e292\u0002e297.\n327. Pelliccia A, Maron BJ, Culasso F, Spataro A, Caselli G. Athlete’s heart in women.\nEchocardiographic characterization of highly trained elite female athletes. JAMA\n1996;276:211\u0002215.\n328. Delling FN, Rong J, Larson MG, Lehman B, Osypiuk E, Stantchev P,\nSlaugenhaupt SA, Benjamin EJ, Levine RA, Vasan RS. Familial clustering of mitral\nvalve prolapse in the community. Circulation 2015;131:263\u0002268.\n329. Freed LA, Levy D, Levine RA, Larson MG, Evans JC, Fuller DL, Lehman B,\nBenjamin EJ. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J\nMed 1999;341:1\u00027.\n330. Jeresaty RM. Mitral valve prolapse: definition and implications in athletes. J Am\nColl Cardiol 1986;7:231\u0002236.\n331. Avierinos J-F, Gersh BJ, Melton LJ 3rd, Bailey KR, Shub C, Nishimura RA, Tajik\nAJ, Enriquez-Sarano M. Natural history of asymptomatic mitral valve prolapse in\nthe community. Circulation 2002;106:1355\u00021361.\n332. Basso C, Perazzolo Marra M, Rizzo S, De Lazzari M, Giorgi B, Cipriani A, Frigo\nAC, Rigato I, Migliore F, Pilichou K, Bertaglia E, Cacciavillani L, Bauce B,\nCorrado D, Thiene G, Iliceto S. Arrhythmic mitral valve prolapse and sudden\ncardiac death. Circulation 2015;132:556\u0002566.\n333. Dejgaard LA, Skjolsvik ET, Lie OH, Ribe M, Stokke MK, Hegbom F, Scheirlynck\nES, Gjertsen E, Andresen K, Helle-Valle TM, Hopp E, Edvardsen T, Haugaa KH.\nThe mitral annulus disjunction arrhythmic syndrome. J Am Coll Cardiol\n2018;72:1600\u00021609.\n334. Perazzolo Marra M, Basso C, De Lazzari M, Rizzo S, Cipriani A, Giorgi B,\nLacognata C, Rigato I, Migliore F, Pilichou K, Cacciavillani L, Bertaglia E, Frigo\nAC, Bauce B, Corrado D, Thiene G, Iliceto S. Morphofunctional abnormalities\nof mitral annulus and arrhythmic mitral valve prolapse. Circ Cardiovasc Imaging\n2016;9:e005030.\n335. Cristina B, Sabino I, Gaetano T, Martina PM. Mitral valve prolapse, ventricular\narrhythmias, and sudden death. Circulation 2019;140:952\u0002964.\n336. Gati S, Malhotra A, Sharma S. Exercise recommendations in patients with valvu-\nlar heart disease. Heart 2019;105:106\u0002110.\n337. Caselli S, Mango F, Clark J, Pandian NG, Corrado D, Autore C, Pelliccia A.\nPrevalence and clinical outcome of athletes with mitral valve prolapse.\nCirculation 2018;137:2080\u00022082.\n338. Ermakov S, Gulhar R, Lim L, Bibby D, Fang Q, Nah G, Abraham TP, Schiller\nNB, Delling FN. Left ventricular mechanical dispersion predicts arrhythmic risk\nin mitral valve prolapse. Heart 2019;105:1063\u00021069.\n339. Groves PH, Lewis NP, Ikram S, Maire R, Hall RJ. Reduced exercise capacity in\npatients with tricuspid regurgitation after successful mitral valve replacement\nfor rheumatic mitral valve disease. Br Heart J 1991;66:295\u0002301.\n340. Andersen MJ, Nishimura RA, Borlaug BA. The hemodynamic basis of exercise\nintolerance in tricuspid regurgitation. Circ Heart Fail 2014;7:911\u0002917.\n341. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo R Di, Eggebrecht H,\nEvangelista A, Falk V, Frank H, Gaemperli O, Grabenwoger M, Haverich A, Iung\nB, Manolis AJ, Meijboom F, Nienaber CA, Roffi M, Rousseau H, Sechtem U,\nSirnes PA, Allmen RS von, Vrints CJM. 2014 ESC Guidelines on the diagnosis\nand treatment of aortic diseases: document covering acute and chronic aortic\ndiseases of the thoracic and abdominal aorta of the adult. The Task Force for\nthe Diagnosis and Treatment of Aortic Diseases of the European Society of\nCardiology (ESC). Eur Heart J 2014;35:2873\u00022926.\n88\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\n342. Braverman AC, Harris KM, Kovacs RJ, Maron BJ. Eligibility and Disqualification\nRecommendations\nfor\nCompetitive\nAthletes\nWith\nCardiovascular\nAbnormalities: Task Force 7: Aortic diseases, including Marfan syndrome: a sci-\nentific statement from the American Heart Association and American College\nof Cardiology. J Am Coll Cardiol 2015;66:2398\u00022405.\n343. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DEJ, Eagle KA,\nHermann LK, Isselbacher EM, Kazerooni EA, Kouchoukos NT, Lytle BW,\nMilewicz DM, Reich DL, Sen S, Shinn JA, Svensson LG, Williams DM. 2010\nACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diag-\nnosis and management of patients with thoracic aortic disease: a report of the\nAmerican College of Cardiology Foundation/American Heart Association Task\nForce on Practice Guidelines. Circulation 2010;121:e266\u0002369.\n344. Boraita A, Heras M-E, Morales F, Marina-Breysse M, Canda A, Rabadan M,\nBarriopedro M-I, Varela A, de la Rosa A, Tunon J. Reference values of aortic\nroot in male and female white elite athletes according to sport. Circ Cardiovasc\nImaging 2016;9:e005292.\n345. Iskandar A, Thompson PD. A meta-analysis of aortic root size in elite athletes.\nCirculation 2013;127:791\u0002798.\n346. Pelliccia A, Di Paolo FM, De Blasiis E, Quattrini FM, Pisicchio C, Guerra E,\nCulasso F, Maron BJ. Prevalence and clinical significance of aortic root dilation\nin highly trained competitive athletes. Circulation 2010;122:698\u0002706.\n347. Gati S, Malhotra A, Sedgwick C, Papamichael N, Dhutia H, Sharma R, Child AH,\nPapadakis M, Sharma S. Prevalence and progression of aortic root dilatation in\nhighly trained young athletes. Heart 2019;105:920\u0002925.\n348. Benninghoven D, Hamann D, von Kodolitsch Y, Rybczynski M, Lechinger J,\nSchroeder F, Vogler M, Hoberg E. Inpatient rehabilitation for adult patients\nwith Marfan syndrome: an observational pilot study. Orphanet J Rare Dis\n2017;12:127.\n349. Thijssen CGE, Bons LR, Go¨kalp AL, Van Kimmenade RRJ, Mokhles MM, Pelliccia\nA, Takkenberg JJM, Roos-Hesselink JW. Exercise and sports participation in\npatients with thoracic aortic disease: a review. Expert Rev Cardiovasc Ther\n2019;17:251\u0002266.\n350. Itagaki R, Kimura N, Itoh S, Yamaguchi A, Adachi H. Acute type a aortic dissec-\ntion associated with a sporting activity. Surg Today 2017;47:1163\u00021171.\n351. Stefani L, Galanti G, Toncelli L, Manetti P, Vono MC, Rizzo M, Maffulli N.\nBicuspid aortic valve in competitive athletes. Br J Sports Med 2008;42:31\u00025; dis-\ncussion 35.\n352. Gibson C, Nielsen C, Alex R, Cooper K, Farney M, Gaufin D, Cui JZ, van\nBreemen C, Broderick TL, Vallejo-Elias J, Esfandiarei M. Mild aerobic exercise\nblocks elastin fiber fragmentation and aortic dilatation in a mouse model of\nMarfan syndrome associated aortic aneurysm. J Appl Physiol 2017;123:147\u0002160.\n353. Mas-Stachurska A, Siegert A-M, Batlle M, Blanco Gorbenko Del, Meirelles, D,\nRubies, T, Bonorino, C, Serra-Peinado, F, Bijnens, C, Baudin, B, Sitges, J, Mont,\nM, Guasch, L Egea, E G. Cardiovascular benefits of moderate exercise training\nin Marfan syndrome: insights from an animal model. J Am Heart Assoc\n2017;6:pii:e006438.\n354. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young\ncompetitive athletes analysis of 1866 deaths in the United States, 1980\u00022006.\nCirculation 2009;119:1085\u00021092.\n355. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P,\nHagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J,\nNihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH,\nTillmanns C, Watkins H. 2014 ESC Guidelines on diagnosis and management of\nhypertrophic cardiomyopathy: the Task Force for the diagnosis and manage-\nment of hypertrophic cardiomyopathy of the European Society of Cardiology\n(ESC). Eur Heart J 2014;35:2733\u00022779.\n356. Maron BJ, Chaitman BR, Ackerman MJ, Baye´s de Luna A, Corrado D, Crosson\nJE, Deal BJ, Driscoll DJ, Estes NAM, Ara\u0003ujo CGS, Liang DH, Mitten MJ,\nMyerburg RJ, Pelliccia A, Thompson PD, Towbin JA VCS. Working Groups of\nthe American Heart Association Committee on Exercise Cardiac Rehabilitation\nand Prevention, Councils on Clinical Cardiology and Cardiovascular Disease in\nthe Young. Recommendations for physical activity and recreational sports par-\nticipation. Circulation 2004;109:2807\u00022816.\n357. Maron BJ, Ackerman MJ, Nishimura RA, Pyeritz RE, Towbin JA, Udelson JE.\nTask Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocar-\nditis, and Marfan syndrome. J Am Coll Cardiol 2005;45:1340\u00021345.\n358. Dejgaard LA, Haland TF, Lie OH, Ribe M, Bjune T, Leren IS, Berge KE,\nEdvardsen T, Haugaa KH. Vigorous exercise in patients with hypertrophic cardi-\nomyopathy. Int J Cardiol 2018;250:157\u0002163.\n359. Lampert R, Olshansky B, Heidbuchel H, Lawless C, Saarel E, Ackerman M,\nCalkins H, Estes NAM, Link MS, Maron BJ, Marcus F, Scheinman M, Wilkoff BL,\nZipes DP, Berul CI, Cheng A, Jordaens L, Law I, Loomis M, Willems R, Barth C,\nBroos K, Brandt C, Dziura J, Li F, Simone L, Vandenberghe K, Cannom D.\nSafety of sports for athletes with implantable cardioverter-defibrillators: long-\nterm\nresults\nof\na\nprospective\nmultinational\nregistry.\nCirculation\n2017;135:2310\u00022312.\n360. Pelliccia A, Lemme E, Maestrini V, Di Paolo FM, Pisicchio C, Di Gioia G, Caselli\nS. Does sport participation worsen the clinical course of hypertrophic cardio-\nmyopathy? Clinical outcome of hypertrophic cardiomyopathy in athletes.\nCirculation 2018;137:531\u0002533.\n361. Finocchiaro G, Papadakis M, Tanzarella G, Dhutia H, Miles C, Tome M, Behr\nER, Sharma S, Sheppard MN. Sudden death can be the first manifestation of\nhypertrophic cardiomyopathy: data from a United Kingdom Pathology Registry.\nJACC Clin Electrophysiol 2019;5:252\u0002254.\n362. Klempfner R, Kamerman T, Schwammenthal E, Nahshon A, Hay I, Goldenberg\nI, Dov F, Arad M. Efficacy of exercise training in symptomatic patients with\nhypertrophic cardiomyopathy: results of a structured exercise training program\nin a cardiac rehabilitation center. Eur J Prev Cardiol 2015;22:13\u000219.\n363. Saberi S, Wheeler M, Bragg-Gresham J, Hornsby W, Agarwal PP, Attili A,\nConcannon M, Dries AM, Shmargad Y, Salisbury H, Kumar S, Herrera JJ, Myers\nJ, Helms AS, Ashley EA, Day SM. Effect of moderate-intensity exercise training\non peak oxygen consumption in patients with hypertrophic cardiomyopathy: a\nrandomized clinical trial. JAMA 2017;317:1349\u00021357.\n364. Sheikh N, Papadakis M, Panoulas VF, Prakash K, Millar L, Adami P, Zaidi A, Gati\nS, Wilson M, Carr-White G, Tome´ MTE, Behr ER, Sharma S. Comparison of\nhypertrophic cardiomyopathy in Afro-Caribbean versus white patients in the\nUK. Heart 2016;102:1797\u00021804.\n365. Sorajja P, Ommen SR, Nishimura RA, Gersh BJ, Berger PB, Tajik AJ. Adverse\nprognosis of patients with hypertrophic cardiomyopathy who have epicardial\ncoronary artery disease. Circulation 2003;108:2342\u00022348.\n366. Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ. Spectrum and\nprognostic significance of arrhythmias on ambulatory Holter electrocardiogram\nin hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;45:697\u0002704.\n367. Mentias A, Raeisi-Giglou P, Smedira NG, Feng K, Sato K, Wazni O, Kanj M,\nFlamm SD, Thamilarasan M, Popovic ZB, Lever HM, Desai MY. Late gadolinium\nenhancement in patients with hypertrophic cardiomyopathy and preserved sys-\ntolic function. J Am Coll Cardiol 2018;72:857\u0002870.\n368. Weng Z, Yao J, Chan RH, He J, Yang X, Zhou Y, He Y. Prognostic value of\nLGE-CMR in HCM: a meta-analysis. JACC Cardiovasc Imaging 2016;9:1392\u00021402.\n369. Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, Lesser JR,\nGruner C, Crean AM, Rakowski H, Udelson JE, Rowin E, Lombardi M, Cecchi F,\nTomberli B, Spirito P, Formisano F, Biagini E, Rapezzi C, De Cecco CN, Autore\nC, Cook EF, Hong SN, Gibson CM, Manning WJ, Appelbaum E, Maron MS.\nPrognostic value of quantitative contrast-enhanced cardiovascular magnetic res-\nonance for the evaluation of sudden death risk in patients with hypertrophic\ncardiomyopathy. Circulation 2014;130:484\u0002495.\n370. Ismail TF, Jabbour A, Gulati A, Mallorie A, Raza S, Cowling TE, Das B, Khwaja J,\nAlpendurada FD, Wage R, Roughton M, McKenna WJ, Moon JC, Varnava A,\nShakespeare C, Cowie MR, Cook SA, Elliott P, O’Hanlon R, Pennell DJ, Prasad\nSK. Role of late gadolinium enhancement cardiovascular magnetic resonance in\nthe\nrisk\nstratification\nof\nhypertrophic\ncardiomyopathy.\nHeart\n2014;100:1851\u00021858.\n371. Olivotto I, Maron BJ, Montereggi A, Mazzuoli F, Dolara A, Cecchi F. Prognostic\nvalue of systemic blood pressure response during exercise in a community-\nbased patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol\n1999;33:2044\u00022051.\n372. Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP, McKenna WJ.\nProspective prognostic assessment of blood pressure response during exercise\nin patients with hypertrophic cardiomyopathy. Circulation 1997;96:2987\u00022991.\n373. O’Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, Biagini E,\nGimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM. A novel clinical\nrisk prediction model for sudden cardiac death in hypertrophic cardiomyopathy\n(HCM risk-SCD). Eur Heart J 2014;35:2010\u00022020.\n374. Spirito P, Autore C, Formisano F, Assenza GE, Biagini E, Haas TS, Bongioanni S,\nSemsarian C, Devoto E, Musumeci B, Lai F, Yeates L, Conte MR, Rapezzi C,\nBoni L, Maron BJ. Risk of sudden death and outcome in patients with hypertro-\nphic cardiomyopathy with benign presentation and without risk factors. Am J\nCardiol 2014;113:1550\u00021555.\n375. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, Calkins H,\nCorrado D, Cox MGPJ, Daubert JP, Fontaine G, Gear K, Hauer R, Nava A,\nPicard MH, Protonotarios N, Saffitz JE, Sanborn DMY, Steinberg JS, Tandri H,\nThiene G, Towbin JA, Tsatsopoulou A, Wichter T, Zareba W. Diagnosis of\narrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modifica-\ntion of the task force criteria. Circulation 2010;121:1533\u00021541.\n376. Miles C, Finocchiaro G, Papadakis M, Gray B, Westaby J, Ensam B, Basu J, Parry-\nWilliams G, Papatheodorou E, Paterson C, Malhotra A, Robertus JL, Ware JS,\nCook SA, Asimaki A, Witney A, Chis Ster I, Tome M, Sharma S, Behr ER,\nSheppard MN. Sudden death and left ventricular involvement in arrhythmogenic\ncardiomyopathy. Circulation 2019;139:1786\u00021797.\n377. Sen-Chowdhry S, Syrris P, Prasad SK, Hughes SE, Merrifield R, Ward D, Pennell\nDJ, McKenna WJ. Left-dominant arrhythmogenic cardiomyopathy: an under-\nrecognized clinical entity. J Am Coll Cardiol 2008;52:2175\u00022187.\nESC Guidelines\n89\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\n378. Corrado D, van Tintelen PJ, McKenna WJ, Hauer RNW, Anastastakis A,\nAsimaki A, Basso C, Bauce B, Brunckhorst C, Bucciarelli-Ducci C, Duru F,\nElliott P, Hamilton RM, Haugaa KH, James CA, Judge D, Link MS, Marchlinski FE,\nMazzanti A, Mestroni L, Pantazis A, Pelliccia A, Marra MP, Pilichou K, Platonov\nPGA, Protonotarios A, Rampazzo A, Saffitz JE, Saguner AM, Schmied C, Sharma\nS, Tandri H, Te Riele ASJM, Thiene G, Tsatsopoulou A, Zareba W, Zorzi A,\nWichter T, Marcus FI, Calkins H. Arrhythmogenic right ventricular cardiomyop-\nathy: evaluation of the current diagnostic criteria and differential diagnosis. Eur\nHeart J 2020;41:1414\u00021429.\n379. Calkins H, Corrado D, Marcus F. Risk stratification in arrhythmogenic right ven-\ntricular cardiomyopathy. Circulation 2017;136:2068\u00022082.\n380. Cadrin-Tourigny J, Bosman LP, Nozza A, Wang W, Tadros R, Bhonsale A,\nBourfiss M, Fortier A, Lie ØH, Saguner AM, Svensson A, Andorin A, Tichnell C,\nMurray B, Zeppenfeld K, van den Berg MP, Asselbergs FW, Wilde AAM, Krahn\nAD, Talajic M, Rivard L, Chelko S, Zimmerman SL, Kamel IR, Crosson JE, Judge\nDP, Yap S-C, van der Heijden JF, Tandri H, Jongbloed JDH, Guertin M-C, van\nTintelen JP, Platonov PG, Duru F, Haugaa KH, Khairy P, Hauer RNW, Calkins\nH, te Riele ASJM, James CA. A new prediction model for ventricular arrhyth-\nmias\nin\narrhythmogenic\nright\nventricular\ncardiomyopathy.\nEur\nHeart\nJ\n2019;40:1850\u00021858.\n381. Maupain C, Badenco N, Pousset F, Waintraub X, Duthoit G, Chastre T,\nHimbert C, Hebert J-L, Frank R, Hidden-Lucet F, Gandjbakhch E. Risk stratifica-\ntion in arrhythmogenic right ventricular cardiomyopathy/dysplasia without an\nimplantable cardioverter-defibrillator. JACC Clin Electrophysiol 2018;4:757\u0002768.\n382. Kirchhof P, Fabritz L, Zwiener M, Witt H, Schafers M, Zellerhoff S, Paul M,\nAthai T, Hiller K-H, Baba HA, Breithardt G, Ruiz P, Wichter T, Levkau B. Age-\nand training-dependent development of arrhythmogenic right ventricular cardi-\nomyopathy\nin\nheterozygous\nplakoglobin-deficient\nmice.\nCirculation\n2006;114:1799\u00021806.\n383. Benito B, Gay-Jordi G, Serrano-Mollar A, Guasch E, Shi Y, Tardif J-C, Brugada J,\nNattel S, Mont L. Cardiac arrhythmogenic remodeling in a rat model of long-\nterm intensive exercise training. Circulation 2011;123:13\u000222.\n384. James CA, Bhonsale A, Tichnell C, Murray B, Russell SD, Tandri H, Tedford RJ,\nJudge DP, Calkins H. Exercise increases age-related penetrance and arrhythmic\nrisk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated\ndesmosomal mutation carriers. J Am Coll Cardiol 2013;62:1290\u00021297.\n385. Ruwald A-C, Marcus F, Estes NAM 3rd, Link M, McNitt S, Polonsky B, Calkins\nH, Towbin JA, Moss AJ, Zareba W. Association of competitive and recreational\nsport participation with cardiac events in patients with arrhythmogenic right\nventricular cardiomyopathy: results from the North American multidisciplinary\nstudy\nof\narrhythmogenic\nright\nventricular\ncardiomyopath.\nEur\nHeart\nJ\n2015;36:1735\u00021743.\n386. Saberniak J, Hasselberg NE, Borgquist R, Platonov PG, Sarvari SI, Smith H-J,\nRibe M, Holst AG, Edvardsen T, Haugaa KH. Vigorous physical activity impairs\nmyocardial function in patients with arrhythmogenic right ventricular cardiomy-\nopathy\nand\nin\nmutation\npositive\nfamily\nmembers.\nEur\nJ\nHeart\nFail\n2014;16:1337\u00021344.\n387. Sawant AC, Bhonsale A, te Riele ASJM, Tichnell C, Murray B, Russell SD,\nTandri H, Tedford RJ, Judge DP, Calkins H, James CA. Exercise has a dispropor-\ntionate role in the pathogenesis of arrhythmogenic right ventricular dysplasia/\ncardiomyopathy in patients without desmosomal mutations. J Am Heart Assoc\n2014;3:e001471.\n388. Lie OH, Dejgaard LA, Saberniak J, Rootwelt C, Stokke MK, Edvardsen T,\nHaugaa KH. Harmful effects of exercise intensity and exercise duration in\npatients\nwith\narrhythmogenic\ncardiomyopathy.\nJACC\nClin\nElectrophysiol\n2018;4:744\u0002753.\n389. Lampert R, Olshansky B, Heidbuchel H, Lawless C, Saarel E, Ackerman M,\nCalkins H, Estes NAM, Link MS, Maron BJ, Marcus F, Scheinman M, Wilkoff BL,\nZipes DP, Berul CI, Cheng A, Law I, Loomis M, Barth C, Brandt C, Dziura J, Li\nF, Cannom D. Safety of sports for athletes with implantable cardioverter-\ndefibrillators:\nresults\nof\na\nprospective,\nmultinational\nregistry.\nCirculation\n2013;127:2021\u00022030.\n390. Dalal D, Nasir K, Bomma C, Prakasa K, Tandri H, Piccini J, Roguin A, Tichnell C,\nJames C, Russell SD, Judge DP, Abraham T, Spevak PJ, Bluemke DA, Calkins H.\nArrhythmogenic right\nventricular dysplasia: a\nUnited\nStates\nexperience.\nCirculation 2005;112:3823\u00023832.\n391. Gupta R, Tichnell C, Murray B, Rizzo S, Te Riele A, Tandri H, Judge DP, Thiene\nG, Basso C, Calkins H, James CA. Comparison of features of fatal versus nonfa-\ntal cardiac arrest in patients with arrhythmogenic right ventricular dysplasia/car-\ndiomyopathy. Am J Cardiol 2017;120:111\u0002117.\n392. Corrado D, Calkins H, Link MS, Leoni L, Favale S, Bevilacqua M, Basso C, Ward\nD, Boriani G, Ricci R, Piccini JP, Dalal D, Santini M, Buja G, Iliceto S, Estes NAM\n3rd, Wichter T, McKenna WJ, Thiene G, Marcus FI. Prophylactic implantable\ndefibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/\ndysplasia and no prior ventricular fibrillation or sustained ventricular tachycar-\ndia. Circulation 2010;122:1144\u00021152.\n393. Orgeron GM, James CA, Te Riele A, Tichnell C, Murray B, Bhonsale A, Kamel\nIR, Zimmerman SL, Judge DP, Crosson J, Tandri H, Calkins H. Implantable\ncardioverter-defibrillator therapy in arrhythmogenic right ventricular dysplasia/\ncardiomyopathy: predictors of appropriate therapy, outcomes, and complica-\ntions. J Am Heart Assoc 2017;6.\n394. Sadjadieh G, Jabbari R, Risgaard B, Olesen MS, Haunso S, Tfelt-Hansen J,\nWinkel BG. Nationwide (Denmark) study of symptoms preceding sudden death\ndue\nto\narrhythmogenic\nright\nventricular\ncardiomyopathy.\nAm\nJ\nCardiol\n2014;113:1250\u00021254.\n395. Bhonsale A, James CA, Tichnell C, Murray B, Gagarin D, Philips B, Dalal D,\nTedford R, Russell SD, Abraham T, Tandri H, Judge DP, Calkins H. Incidence\nand predictors of implantable cardioverter-defibrillator therapy in patients with\narrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implant-\nable cardioverter-defibrillator implantation for primary prevention. J Am Coll\nCardiol 2011;58:1485\u00021496.\n396. Link MS, Laidlaw D, Polonsky B, Zareba W, McNitt S, Gear K, Marcus F, Estes\nNAM 3rd. Ventricular arrhythmias in the North American multidisciplinary\nstudy of ARVC: predictors, characteristics, and treatment. J Am Coll Cardiol\n2014;64:119\u0002125.\n397. Piccini JP, Dalal D, Roguin A, Bomma C, Cheng A, Prakasa K, Dong J, Tichnell\nC, James C, Russell S, Crosson J, Berger RD, Marine JE, Tomaselli G, Calkins H.\nPredictors of appropriate implantable defibrillator therapies in patients with\narrhythmogenic right ventricular dysplasia. Heart Rhythm 2005;2:1188\u00021194.\n398. Saguner AM, Vecchiati A, Baldinger SH, Rueger S, Medeiros-Domingo A,\nMueller-Burri AS, Haegeli LM, Biaggi P, Manka R, Luscher TF, Fontaine G,\nDelacretaz E, Jenni R, Held L, Brunckhorst C, Duru F, Tanner FC. Different\nprognostic value of functional right ventricular parameters in arrhythmogenic\nright\nventricular\ncardiomyopathy/dysplasia.\nCirc\nCardiovasc\nImaging\n2014;7:230\u0002239.\n399. Wichter T, Paul M, Wollmann C, Acil T, Gerdes P, Ashraf O, Tjan TDT,\nSoeparwata R, Block M, Borggrefe M, Scheld HH, Breithardt G, Bocker D.\nImplantable cardioverter/defibrillator therapy in arrhythmogenic right ventricu-\nlar cardiomyopathy: single-center experience of long-term follow-up and com-\nplications in 60 patients. Circulation 2004;109:1503\u00021508.\n400. Rigato I, Bauce B, Rampazzo A, Zorzi A, Pilichou K, Mazzotti E, Migliore F,\nMarra MP, Lorenzon A, De Bortoli M, Calore M, Nava A, Daliento L, Gregori\nD, Iliceto S, Thiene G, Basso C, Corrado D. Compound and digenic hetero-\nzygosity predicts lifetime arrhythmic outcome and sudden cardiac death in des-\nmosomal gene-related arrhythmogenic right ventricular cardiomyopathy. Circ\nCardiovasc Genet 2013;6:533\u0002542.\n401. Gandjbakhch E, Redheuil A, Pousset F, Charron P, Frank R. Clinical diagnosis,\nimaging, and genetics of arrhythmogenic right ventricular cardiomyopathy/dys-\nplasia: JACC state-of-the-art review. J Am Coll Cardiol 2018;72:784\u0002804.\n402. Merner ND, Hodgkinson KA, Haywood AFM, Connors S, French VM,\nDrenckhahn J-D, Kupprion C, Ramadanova K, Thierfelder L, McKenna W,\nGallagher\nB,\nMorris-Larkin\nL,\nBassett\nAS,\nParfrey\nPS,\nYoung\nT-L.\nArrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant,\nlethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene.\nAm J Hum Genet 2008;82:809\u0002821.\n403. Dhutia H, Malhotra A, Yeo TJ, Ster IC, Gabus V, Steriotis A, Dores H, Mellor\nG, Garc\u0003ıa-Corrales C, Ensam B, Jayalapan V, Ezzat VA, Finocchiaro G, Gati S,\nPapadakis M, Tome-Esteban M, Sharma S. Inter-rater reliability and downstream\nfinancial implications of electrocardiography screening in young athletes. Circ\nCardiovasc Qual Outcomes 2017;10:e003881.\n404. Gati S, Rajani R, Carr-White GS, Chambers JB. Adult left ventricular noncom-\npaction: reappraisal of current diagnostic imaging modalities. JACC Cardiovasc\nImaging 2014;7:1266\u00021275.\n405. Gati S, Chandra N, Bennett RL, Reed M, Kervio G, Panoulas VF, Ghani S, Sheikh\nN, Zaidi A, Wilson M, Papadakis M, Carre´ F, Sharma S. Increased left ventricular\ntrabeculation in highly trained athletes: do we need more stringent criteria for the\ndiagnosis of left ventricular non-compaction in athletes? Heart 2013;99:401\u0002408.\n406. Gati S, Papadakis M, Papamichael ND, Zaidi A, Sheikh N, Reed M, Sharma R,\nThilaganathan B, Sharma S. Reversible de novo left ventricular trabeculations in\npregnant women: implications for the diagnosis of left ventricular noncompac-\ntion in low-risk populations. Circulation 2014;130:475\u0002483.\n407. Zemrak F, Ahlman MA, Captur G, Mohiddin SA, Kawel-Boehm N, Prince MR,\nMoon JC, Hundley WG, Lima JAC, Bluemke DA, Petersen SE. The relationship\nof left ventricular trabeculation to ventricular function and structure over a 9.5-\nyear follow-up: the MESA study. J Am Coll Cardiol 2014;64:1971\u00021980.\n408. Caselli S, Ferreira D, Kanawati E, Di Paolo F, Pisicchio C, Attenhofer Jost C,\nSpataro A, Jenni R, Pelliccia A. Prominent left ventricular trabeculations in com-\npetitive athletes: a proposal for risk stratification and management. Int J Cardiol\n2016;223:590\u0002595.\n409. Caselli S, Attenhofer Jost CH, Jenni R, Pelliccia A. Left ventricular noncompac-\ntion diagnosis and management relevant to pre-participation screening of ath-\nletes. Am J Cardiol 2015;116:801\u0002808.\n90\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\n410. Gati S, Merghani A, Sharma S. Increased left ventricular trabeculation does not\nnecessarily equate to left ventricular noncompaction in athletes. JAMA Intern\nMed 2015;175:1247.\n411. Gati S, Sharma S. The dilemmas in diagnosing left ventricular non-compaction in\nathletes. Eur Heart J 2015;36:891\u0002893.\n412. Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Bohm M, Duboc D,\nGimeno J, de Groote P, Imazio M, Heymans S, Klingel K, Komajda M, Limongelli\nG, Linhart A, Mogensen J, Moon J, Pieper PG, Seferovic PM, Schueler S,\nZamorano JL, Caforio ALP, Charron P. Proposal for a revised definition of\ndilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its impli-\ncations for clinical practice: a position statement of the ESC working group on\nmyocardial and pericardial diseases. Eur Heart J 2016;37:1850\u00021858.\n413. Hasselberg NE, Haland TF, Saberniak J, Brekke PH, Berge KE, Leren TP,\nEdvardsen T, Haugaa KH. Lamin A/C cardiomyopathy: young onset, high pene-\ntrance,\nand\nfrequent\nneed\nfor\nheart\ntransplantation.\nEur\nHeart\nJ\n2018;39:853\u0002860.\n414. Ortiz-Genga MF, Cuenca S, Dal Ferro M, Zorio E, Salgado-Aranda R, Climent\nV, Padron-Barthe L, Duro-Aguado I, Jimenez-Jaimez J, Hidalgo-Olivares VM,\nGarcia-Campo E, Lanzillo C, Suarez-Mier MP, Yonath H, Marcos-Alonso S,\nOchoa JP, Santome JL, Garcia-Giustiniani D, Rodriguez-Garrido JL, Dominguez\nF, Merlo M, Palomino J, Pena ML, Trujillo JP, Martin-Vila A, Stolfo D, Molina P,\nLara-Pezzi E, Calvo-Iglesias FE, Nof E, Calo L, Barriales-Villa R, Gimeno-Blanes\nJR, Arad M, Garcia-Pavia P, Monserrat L. Truncating FLNC mutations are asso-\nciated with high-risk dilated and arrhythmogenic cardiomyopathies. J Am Coll\nCardiol 2016;68:2440\u00022451.\n415. Halliday BP, Cleland JGF, Goldberger JJ, Prasad SK. Personalizing risk stratifica-\ntion for sudden death in dilated cardiomyopathy: the past, present, and future.\nCirculation 2017;136:215\u0002231.\n416. Holloway CJ, Dass S, Suttie JJ, Rider OJ, Cox P, Cochlin LE, Jackson H, Fast AM,\nJohnson AW, Karamitsos TD, Neubauer S, Clarke K. Exercise training in dilated\ncardiomyopathy improves rest and stress cardiac function without changes in\ncardiac high energy phosphate metabolism. Heart 2012;98:1083\u00021090.\n417. Stolen KQ, Kemppainen J, Ukkonen H, Kalliokoski KK, Luotolahti M, Lehikoinen\nP, Hamalainen H, Salo T, Airaksinen KEJ, Nuutila P, Knuuti J. Exercise training\nimproves biventricular oxidative metabolism and left ventricular efficiency in\npatients with dilated cardiomyopathy. J Am Coll Cardiol 2003;41:460\u0002467.\n418. Harmon KG, Drezner JA, Maleszewski JJ, Lopez-Anderson M, Owens D,\nPrutkin JM, Asif IM, Klossner D, Ackerman MJ. Pathogeneses of sudden cardiac\ndeath\nin\nnational\ncollegiate\nathletic\nassociation\nathletes.\nCirc\nArrhythm\nElectrophysiol 2014;7:198\u0002204.\n419. Claessen G, Schnell F, Bogaert J, Claeys M, Pattyn N, De Buck F, Dymarkowski\nS, Claus P, Carre F, Van Cleemput J, La Gerche A, Heidbuchel H. Exercise car-\ndiac magnetic resonance to differentiate athlete’s heart from structural heart\ndisease. Eur Heart J Cardiovasc Imaging 2018;19:1062\u00021070.\n420. Millar LM, Fanton Z, Finocchiaro G, Sanchez-Fernandez G, Dhutia H, Malhotra\nA, Merghani A, Papadakis M, Behr ER, Bunce N, Oxborough D, Reed M,\nO’Driscoll J, Tome Esteban MT, D’Silva A, Carr-White G, Webb J, Sharma R,\nSharma S. Differentiation between athlete’s heart and dilated cardiomyopathy\nin athletic individuals. Heart 2020;106:1059\u00021065.\n421. Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, Morarji K, Brown\nTDH, Ismail NA, Dweck MR, Di Pietro E, Roughton M, Wage R, Daryani Y,\nO’Hanlon R, Sheppard MN, Alpendurada F, Lyon AR, Cook SA, Cowie MR,\nAssomull RG, Pennell DJ, Prasad SK. Association of fibrosis with mortality and\nsudden cardiac death in patients with nonischemic dilated cardiomyopathy.\nJAMA 2013;309:896\u0002908.\n422. Neilan TG, Coelho-Filho OR, Danik SB, Shah RV, Dodson JA, Verdini DJ,\nTokuda M, Daly CA, Tedrow UB, Stevenson WG, Jerosch-Herold M,\nGhoshhajra BB, Kwong RY. CMR quantification of myocardial scar provides\nadditive prognostic information in nonischemic cardiomyopathy. JACC Cardiovasc\nImaging 2013;6:944\u0002954.\n423. Masci PG, Doulaptsis C, Bertella E, Del Torto A, Symons R, Pontone G,\nBarison A, Droogne W, Andreini D, Lorenzoni V, Gripari P, Mushtaq S, Emdin\nM, Bogaert J, Lombardi M. Incremental prognostic value of myocardial fibrosis\nin patients with non-ischemic cardiomyopathy without congestive heart failure.\nCirc Heart Fail 2014;7:448\u0002456.\n424. Perazzolo Marra M, De Lazzari M, Zorzi A, Migliore F, Zilio F, Calore C, Vettor\nG, Tona F, Tarantini G, Cacciavillani L, Corbetti F, Giorgi B, Miotto D, Thiene\nG, Basso C, Iliceto S, Corrado D. Impact of the presence and amount of myo-\ncardial fibrosis by cardiac magnetic resonance on arrhythmic outcome and sud-\nden cardiac death in nonischemic dilated cardiomyopathy. Heart Rhythm\n2014;11:856\u0002863.\n425. Cattin M-E, Ferry A, Vignaud A, Mougenot N, Jacquet A, Wahbi K, Bertrand\nAT, Bonne G. Mutation in lamin A/C sensitizes the myocardium to exercise-\ninduced mechanical stress but has no effect on skeletal muscles in mouse.\nNeuromuscul Disord 2016;26:490\u0002499.\n426. Pasotti M, Klersy C, Pilotto A, Marziliano N, Rapezzi C, Serio A, Mannarino S,\nGambarin F, Favalli V, Grasso M, Agozzino M, Campana C, Gavazzi A, Febo O,\nMarini M, Landolina M, Mortara A, Piccolo G, Vigano M, Tavazzi L, Arbustini E.\nLong-term outcome and risk stratification in dilated cardiolaminopathies. J Am\nColl Cardiol 2008;52:1250\u00021260.\n427. Skjølsvik ET, Hasselberg NE, Dejgaard LA, Lie ØH, Andersen K, Holm T,\nEdvardsen T, Haugaa KH. Exercise is associated with impaired left ventricular\nsystolic function in patients with lamin A/C genotype. J Am Heart Assoc\n2020;9:e012937.\n428. Kumar S, Baldinger SH, Gandjbakhch E, Maury P, Sellal J-M, Androulakis AFA,\nWaintraub X, Charron P, Rollin A, Richard P, Stevenson WG, Macintyre CJ, Ho\nCY, Thompson T, Vohra JK, Kalman JM, Zeppenfeld K, Sacher F, Tedrow UB,\nLakdawala NK. Long-term arrhythmic and nonarrhythmic outcomes of lamin A/\nC mutation carriers. J Am Coll Cardiol 2016;68:2299\u00022307.\n429. van Rijsingen IAW, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, van\nder Kooi AJ, van Tintelen JP, van den Berg MP, Pilotto A, Pasotti M, Jenkins S,\nRowland C, Aslam U, Wilde AAM, Perrot A, Pankuweit S, Zwinderman AH,\nCharron P, Pinto YM. Risk factors for malignant ventricular arrhythmias in lamin\nA/C\nmutation\ncarriers:\na\nEuropean\ncohort\nstudy.\nJ\nAm\nColl\nCardiol\n2012;59:493\u0002500.\n430. Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu\nM, Helio T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W,\nMogensen J, Pinto YM, Ristic A, Schultheiss H-P, Seggewiss H, Tavazzi L, Thiene\nG, Yilmaz A, Charron P, Elliott PM. Current state of knowledge on aetiology,\ndiagnosis, management, and therapy of myocarditis: a position statement of the\nEuropean Society of Cardiology Working Group on myocardial and pericardial\ndiseases. Eur Heart J 2013;34:2636\u00022648.\n431. Sinagra G, Anzini M, Pereira NL, Bussani R, Finocchiaro G, Bartunek J, Merlo M.\nMyocarditis in clinical practice. Mayo Clin Proc 2016;91:1256\u00021266.\n432. Breinholt JP, Moulik M, Dreyer WJ, Denfield SW, Kim JJ, Jefferies JL, Rossano\nJW, Gates CM, Clunie SK, Bowles KR, Kearney DL, Bowles NE, Towbin JA.\nViral epidemiologic shift in inflammatory heart disease: the increasing involve-\nment of parvovirus B19 in the myocardium of pediatric cardiac transplant\npatients. J Heart Lung Transplant 2010;29:739\u0002746.\n433. Yilmaz A, Klingel K, Kandolf R, Sechtem U. A geographical mystery: do cardio-\ntropic viruses respect national borders? J Am Coll Cardiol 2008;52:82; author\nreply 82\u000283.\n434. Magnani JW, Danik HJS, Dec GWJ, DiSalvo TG. Survival in biopsy-proven myo-\ncarditis: a long-term retrospective analysis of the histopathologic, clinical, and\nhemodynamic predictors. Am Heart J 2006;151:463\u0002470.\n435. Smith SC, Ladenson JH, Mason JW, Jaffe AS. Elevations of cardiac troponin I\nassociated with myocarditis. Experimental and clinical correlates. Circulation\n1997;95:163\u0002168.\n436. Morgera T, Di Lenarda A, Dreas L, Pinamonti B, Humar F, Bussani R, Silvestri F,\nChersevani D, Camerini F. Electrocardiography of myocarditis revisited: clinical\nand prognostic significance of electrocardiographic changes. Am Heart J\n1992;124:455\u0002467.\n437. Pinamonti B, Alberti E, Cigalotto A, Dreas L, Salvi A, Silvestri F, Camerini F.\nEchocardiographic findings in myocarditis. Am J Cardiol 1988;62:285\u0002291.\n438. Caforio ALP, Calabrese F, Angelini A, Tona F, Vinci A, Bottaro S, Ramondo A,\nCarturan E, Iliceto S, Thiene G, Daliento L. A prospective study of biopsy-\nproven myocarditis: prognostic relevance of clinical and aetiopathogenetic fea-\ntures at diagnosis. Eur Heart J 2007;28:1326\u00021333.\n439. Schnell F, Claessen G, La Gerche A, Bogaert J, Lentz P-A, Claus P, Mabo P,\nCarre F, Heidbuchel H. Subepicardial delayed gadolinium enhancement in\nasymptomatic athletes: let sleeping dogs lie? Br J Sports Med 2016;50:111\u0002117.\n440. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT,\nWhite JA, Abdel-Aty H, Gutberlet M, Prasad S, Aletras A, Laissy J-P, Paterson I,\nFilipchuk NG, Kumar A, Pauschinger M, Liu P. Cardiovascular magnetic reso-\nnance\nin\nmyocarditis:\na\nJACC\nwhite\npaper.\nJ\nAm\nColl\nCardiol\n2009;53:1475\u00021487.\n441. Radenkovic D, Weingartner S, Ricketts L, Moon JC, Captur G. T1 mapping in\ncardiac MRI. Heart Fail Rev 2017;22:415\u0002430.\n442. Nadjiri J, Nieberler H, Hendrich E, Greiser A, Will A, Martinoff S, Hadamitzky\nM. Performance of native and contrast-enhanced T1 mapping to detect myocar-\ndial damage in patients with suspected myocarditis: a head-to-head comparison\nof different cardiovascular magnetic resonance techniques. Int J Cardiovasc\nImaging 2017;33:539\u0002547.\n443. Aquaro GD, Perfetti M, Camastra G, Monti L, Dellegrottaglie S, Moro C, Pepe\nA, Todiere G, Lanzillo C, Scatteia A, Di Roma M, Pontone G, Perazzolo Marra\nM, Barison A, Di Bella G. Cardiac MR with late gadolinium enhancement in\nacute myocarditis with preserved systolic function: ITAMY Study. J Am Coll\nCardiol 2017;70:1977\u00021987.\n444. Mewton N, Dernis A, Bresson D, Zouaghi O, Croisille P, Flocard E, Douek P,\nBonnefoy-Cudraz E. Myocardial biomarkers and delayed enhanced cardiac\nESC Guidelines\n91\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\nmagnetic resonance relationship in clinically suspected myocarditis and insight\non clinical outcome. J Cardiovasc Med (Hagerstown) 2015;16:696\u0002703.\n445. Grun S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, Kispert E-M,\nHill S, Ong P, Klingel K, Kandolf R, Sechtem U, Mahrholdt H. Long-term follow-\nup of biopsy-proven viral myocarditis: predictors of mortality and incomplete\nrecovery. J Am Coll Cardiol 2012;59:1604\u00021615.\n446. Schumm J, Greulich S, Wagner A, Grun S, Ong P, Bentz K, Klingel K, Kandolf R,\nBruder O, Schneider S, Sechtem U, Mahrholdt H. Cardiovascular magnetic res-\nonance risk stratification in patients with clinically suspected myocarditis. J\nCardiovasc Magn Reson 2014;16:14.\n447. van de Schoor FR, Aengevaeren VL, Hopman MTE, Oxborough DL, George\nKP, Thompson PD, Eijsvogels TMH. Myocardial fibrosis in athletes. Mayo Clin\nProc 2016;91:1617\u00021631.\n448. Ammirati E, Moroni F, Sormani P, Peritore A, Milazzo A, Quattrocchi G,\nCipriani M, Oliva F, Giannattasio C, Frigerio M, Roghi A, Camici PG, Pedrotti P.\nQuantitative changes in late gadolinium enhancement at cardiac magnetic reso-\nnance in the early phase of acute myocarditis. Int J Cardiol 2017;231:216\u0002221.\n449. Gr€ani C, Eichhorn C, Bie`re L, Kaneko K, Murthy VL, Agarwal V, Aghayev A,\nSteigner M, Blankstein R, Jerosch-Herold M, Kwong RY. Comparison of myo-\ncardial fibrosis quantification methods by cardiovascular magnetic resonance\nimaging for risk stratification of patients with suspected myocarditis. J Cardiovasc\nMagn Reson 2019;21:14.\n450. Matthias H, Alexander N, Uwe K, Michel N, Wolfgang P, Wolfgang H, Andreas\nM, Bernhard W, Carsten T, Heinz-Peter S, Matthias P. Complication rate of\nright ventricular endomyocardial biopsy via the femoral approach. Circulation\n2008;118:1722\u00021728.\n451. Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A,\nHill S, Mahrholdt H, Voehringer M, Schieber M, Klingel K, Kandolf R, Bohm M,\nSechtem U. Comparative evaluation of left and right ventricular endomyocardial\nbiopsy: differences in complication rate and diagnostic performance. Circulation\n2010;122:900\u0002909.\n452. Cooper LTJ, Hare JM, Tazelaar HD, Edwards WD, Starling RC, Deng MC,\nMenon S, Mullen GM, Jaski B, Bailey KR,, Cunningham MW, Dec GW.\nUsefulness of immunosuppression for giant cell myocarditis. Am J Cardiol\n2008;102:1535\u00021539.\n453. Bohm P, Scharhag J, Meyer T. Data from a nationwide registry on sports-\nrelated sudden cardiac deaths in Germany. Eur J Prev Cardiol 2016;23:649\u0002656.\n454. Phillips M, Robinowitz M, Higgins JR, Boran KJ, Reed T, Virmani R. Sudden car-\ndiac death in Air Force recruits. A 20-year review. JAMA 1986;256:2696\u00022699.\n455. Kiel RJ, Smith FE, Chason J, Khatib R, Reyes MP. Coxsackievirus B3 myocarditis\nin C3H/HeJ mice: description of an inbred model and the effect of exercise on\nvirulence. Eur J Epidemiol 1989;5:348\u0002350.\n456. Gatmaitan BG, Chason JL, Lerner AM. Augmentation of the virulence of murine\nCoxsackie-virus\nB-3\nmyocardiopathy\nby\nexercise.\nJ\nExp\nMed\n1970;131:1121\u00021136.\n457. Ilback NG, Fohlman J, Friman G. Exercise in Coxsackie B3 myocarditis: effects\non heart lymphocyte subpopulations and the inflammatory reaction. Am Heart J\n1989;117:1298\u00021302.\n458. Cabinian AE, Kiel RJ, Smith F, Ho KL, Khatib R, Reyes MP. Modification of\nexercise-aggravated Coxsackie virus B3 murine myocarditis by T lymphocyte\nsuppression in an inbred model. J Lab Clin Med 1990;115:454\u0002462.\n459. Pelliccia A, Corrado D, Bjornstad HH, Panhuyzen-Goedkoop N, Urhausen A,\nCarre F, Anastasakis A, Vanhees L, Arbustini E, Priori S. Recommendations for\nparticipation in competitive sport and leisure-time physical activity in individuals\nwith cardiomyopathies, myocarditis and pericarditis. Eur J Cardiovasc Prev Rehabil\n2006;13:876\u0002885.\n460. Maron BJ, Udelson JE, Bonow RO, Nishimura RA, Ackerman MJ, Estes NAM\n3rd, Cooper LTJ, Link MS, Maron MS. Eligibility and disqualification recommen-\ndations for competitive athletes with cardiovascular abnormalities: Task Force\n3: Hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyop-\nathy and other cardiomyopathies, and myocarditis. A scientific statement from\nthe American Heart Association and American College of Cardiology.\nCirculation 2015;132:e273\u0002280.\n461. Gati S, Sharma S, Pennell D. The role of cardiovascular magnetic resonance\nimaging in the assessment of highly trained athletes. JACC Cardiovasc Imaging\n2018;11:1327\u00021339.\n462. Enrico A, Manlio C, Claudio M, Claudia R, Daniela P, Paola S, Riccardo M,\nMarisa V, Patrizia P, Cristina C, Antonio M, Aurelia G, Daniele B, Silvia G, PG\nB., Stefania C, CS I., Cristina G, Alberto M, Valentina C, Marco M, Carlo L,\nJeness C, Piergiuseppe A, Giovanni P, Laura S, Annalisa T, Giuseppe DT, Carlo\nC, Armando B, Fabrizio M, Andrea M, Antonio C, Michele S, Antonello G,\nMaria F, Fabrizio O, CP G., null null. Clinical presentation and outcome in a\ncontemporary\ncohort\nof\npatients\nwith\nacute\nmyocarditis.\nCirculation\n2018;138:1088\u00021099.\n463. Alessandro Z, Martina PM, Ilaria R, Manuel DL, Angela S, Alice N, Kalliopi P,\nFederico M, Stefania R, Benedetta G, Giorgio DC, Patrizio S, Luis S, Giampiero\nP, Elia DM, Antonio P, Cristina B, Maurizio S, Barbara B, Sabino I, Gaetano T,\nDomenico C. Nonischemic left ventricular scar as a substrate of life-threatening\nventricular arrhythmias and sudden cardiac death in competitive athletes. Circ\nArrhythmia Electrophysiol 2016;9:e004229.\n464. Anzini M, Merlo M, Sabbadini G, Barbati G, Finocchiaro G, Pinamonti B, Salvi A,\nPerkan A, Di Lenarda A, Bussani R, Bartunek J, Sinagra G. Long-term evolution\nand prognostic stratification of biopsy-proven active myocarditis. Circulation\n2013;128:2384\u00022394.\n465. Imazio M, Gaita F, LeWinter M. Evaluation and treatment of pericarditis: a sys-\ntematic review. JAMA 2015;314:1498\u00021506.\n466. Imazio M, Spodick DH, Brucato A, Trinchero R, Adler Y. Controversial issues\nin the management of pericardial diseases. Circulation 2010;121:916\u0002928.\n467. Pelliccia A, Solberg EE, Papadakis M, Adami PE, Biffi A, Caselli S, La Gerche A,\nNiebauer J, Pressler A, Schmied CM, Serratosa L, Halle M, Van Buuren F,\nBorjesson M, Carre` F, Panhuyzen-Goedkoop NM, Heidbuchel H, Olivotto I,\nCorrado D, Sinagra G, Sharma S. Recommendations for participation in com-\npetitive and leisure time sport in athletes with cardiomyopathies, myocarditis,\nand pericarditis: position statement of the Sport Cardiology Section of the\nEuropean\nAssociation\nof\nPreventive\nCardiology\n(EAPC).\nEur\nHeart\nJ\n2018;40:19\u000233.\n468. La Gerche A, Robberecht C, Kuiperi C, Nuyens D, Willems R, de Ravel T,\nMatthijs G, Heidbuchel H. Lower than expected desmosomal gene mutation\nprevalence in endurance athletes with complex ventricular arrhythmias of right\nventricular origin. Heart 2010;96:1268\u00021274.\n469. Heidbuchel H. The athlete’s heart is a proarrhythmic heart, and what that\nmeans for clinical decision making. EP Europace 2018;20:1401\u00021411.\n470. Du X, Dong J, Ma C. Is atrial fibrillation a preventable disease? J Am Coll Cardiol\n2017;69:1968\u00021982.\n471. Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and inci-\ndence of atrial fibrillation in older adults: the cardiovascular health study.\nCirculation 2008;118:800\u0002807.\n472. Rienstra M, Hobbelt AH, Alings M, Tijssen JGP, Smit MD, Brugemann J,\nGeelhoed B, Tieleman RG, Hillege HL, Tukkie R, Van Veldhuisen DJ, Crijns H,\nVan Gelder IC IR. Targeted therapy of underlying conditions improves sinus\nrhythm maintenance in patients with persistent atrial fibrillation: results of the\nRACE 3 trial. Eur Hear J 2018;39:2987\u00022996.\n473. Elliott AD, Maatman B, Emery MS, Sanders P. The role of exercise in atrial fibril-\nlation prevention and promotion: finding optimal ranges for health. Heart\nRhythm 2017;14:1713\u00021720.\n474. Andersen K, Farahmand B, Ahlbom A, Held C, Ljunghall S, Michaelsson K,\nSundstrom J. Risk of arrhythmias in 52 755 long-distance cross-country skiers: a\ncohort study. Eur Heart J 2013;34:3624\u00023631.\n475. Aizer A, Gaziano JM, Cook NR, Manson JE, Buring JE, Albert CM. Relation of\nvigorous exercise to risk of atrial fibrillation. Am J Cardiol 2009;103:1572\u00021577.\n476. Kwok CS, Anderson SG, Myint PK, Mamas MA, Loke YK. Physical activity and\nincidence of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol\n2014;177:467\u0002476.\n477. La Gerche A, Schmied CM. Atrial fibrillation in athletes and the interplay\nbetween exercise and health. Eur Heart J 2013;34:3599\u00023602.\n478. Elosua R, Arquer A, Mont L, Sambola A, Molina L, Garcia-Moran E, Brugada J,\nMarrugat J. Sport practice and the risk of lone atrial fibrillation: a case-control\nstudy. Int J Cardiol 2006;108:332\u0002337.\n479. Mont L, Sambola A, Brugada J, Vacca M, Marrugat J, Elosua R, Pare C, Azqueta\nM, Sanz G. Long-lasting sport practice and lone atrial fibrillation. Eur Heart J\n2002;23:477\u0002482.\n480. Heidbuchel H, Anne W, Willems R, Adriaenssens B, Van de Werf F, Ector H.\nEndurance sports is a risk factor for atrial fibrillation after ablation for atrial flut-\nter. Int J Cardiol 2006;107:67\u000272.\n481. Morseth B, Graff-Iversen S, Jacobsen BK, Jorgensen L, Nyrnes A, Thelle DS,\nVestergaard P, Lochen M-L. Physical activity, resting heart rate, and atrial fibrilla-\ntion: the Tromso Study. Eur Heart J 2016;37:2307\u00022313.\n482. Kawabata M, Hirao K, Horikawa T, Suzuki K, Motokawa K, Suzuki F, Azegami K,\nHiejima K. Syncope in patients with atrial flutter during treatment with class Ic\nantiarrhythmic drugs. J Electrocardiol 2001;34:65\u000272.\n483. Brembilla-Perrot B, Houriez P, Beurrier D, Claudon O, Terrier de la Chaise A,\nLouis P. Predictors of atrial flutter with 1: 1 conduction in patients treated with\nclass\nI\nantiarrhythmic\ndrugs\nfor\natrial\ntachyarrhythmias.\nInt\nJ\nCardiol\n2001;80:7\u000215.\n484. Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L, Marchi P, Calzolari\nM, Solano A, Baroffio R, Gaggioli G. Outpatient treatment of recent-onset atrial\nfibrillation\nwith\nthe\n“pill-in-the-pocket”\napproach.\nN\nEngl\nJ\nMed\n2004;351:2384\u00022391.\n485. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M,\nDiener H-C, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J,\nPopescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron\nEsquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R,\n92\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\nDeftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B,\nGuenoun M, Hohnloser SH, Kolh P, Lip GYH, Manolis A, McMurray J,\nPonikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P,\nTamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL,\nZeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation\ndeveloped\nin\ncollaboration\nwith\nEACTS.\nEur\nJ\nCardiothorac\nSurg\n2016;50:e1\u0002e88.\n486. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler\nKG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R,\nCamm AJ, Heidbuchel H. The 2018 European Heart Rhythm Association\nPractical Guide on the use of non-vitamin K antagonist oral anticoagulants in\npatients with atrial fibrillation. Eur Heart J 2018;39:1330\u00021393.\n487. Calkins H, Hindricks G, Cappato R, Kim Y-H, Saad EB, Aguinaga L, Akar JG,\nBadhwar V, Brugada J, Camm J, Chen P-S, Chen S-A, Chung MK, Nielsen JC,\nCurtis AB, Davies DW, Day JD, d’Avila A, de Groot NMSN, Di Biase L,\nDuytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G,\nGerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM,\nJalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R,\nLewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF,\nNakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E,\nReynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao H-M, Verma\nA, Wilber DJ, Yamane T. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert\nconsensus statement on catheter and surgical ablation of atrial fibrillation. Heart\nRhythm 2017;14:e275\u0002e444.\n488. Calvo N, Mont L, Tamborero D, Berruezo A, Viola G, Guasch E, Nadal M,\nAndreu D, Vidal B, Sitges M, Brugada J. Efficacy of circumferential pulmonary\nvein\nablation\nof\natrial\nfibrillation\nin\nendurance\nathletes.\nEuropace\n2010;12:30\u000236.\n489. Koopman P, Nuyens D, Garweg C, La Gerche A, De Buck S, Van Casteren L,\nAlzand B, Willems R, Heidbuchel H. Efficacy of radiofrequency catheter ablation\nin athletes with atrial fibrillation. Europace 2011;13:1386\u00021393.\n490. Abdulla J, Nielsen JR. Is the risk of atrial fibrillation higher in athletes than in the\ngeneral population? A systematic review and meta-analysis. EP Europace\n2009;11:1156\u00021159.\n491. Sorbo MD, Buja GF, Miorelli M, Nistri S, Perrone C, Manca S, Grasso F,\nGiordano GM, Nava A. [The prevalence of the Wolff-Parkinson-White syn-\ndrome\nin\na\npopulation\nof\n116,542\nyoung\nmales].\nG\nItal\nCardiol\n1995;25:681\u0002687.\n492. Sano S, Komori S, Amano T, Kohno I, Ishihara T, Sawanobori T, Ijiri H, Tamura\nK. Prevalence of ventricular preexcitation in Japanese schoolchildren. Heart\n1998;79:374\u0002378.\n493. Timmermans C, Smeets JL, Rodriguez LM, Vrouchos G, van den Dool A,\nWellens HJ. Aborted sudden death in the Wolff-Parkinson-White syndrome.\nAm J Cardiol 1995;76:492\u0002494.\n494. Waxman MB, Wald RW, Sharma AD, Huerta F, Cameron DA. Vagal techniques\nfor termination of paroxysmal supraventricular tachycardia. Am J Cardiol\n1980;46:655\u0002664.\n495. Miljoen H, Ector J, Garweg C, Saenen J, Huybrechts W, Sarkozy A, Willems R\nHH. Differential presentation of AV nodal reentrant tachycardia in athletes and\nnon-athletes. EP Europace 2019;21:944\u0002949.\n496. Obeyesekere MN, Leong-Sit P, Massel D, Manlucu J, Modi S, Krahn AD, Skanes\nAC, Yee R, Gula LJ, Klein GJ. Risk of arrhythmia and sudden death in patients\nwith\nasymptomatic\npreexcitation:\na\nmeta-analysis.\nCirculation\n2012;125:2308\u00022315.\n497. Wellens HJ, Rodriguez LM, Timmermans C, Smeets JP. The asymptomatic\npatient\nwith\nthe\nWolff-Parkinson-White\nelectrocardiogram.\nPacing\nClin\nElectrophysiol 1997;20:2082\u00022086.\n498. Gaita F, Giustetto C, Riccardi R, Mangiardi L, Brusca A. Stress and pharmaco-\nlogic tests as methods to identify patients with Wolff-Parkinson-White syn-\ndrome at risk of sudden death. Am J Cardiol 1989;64:487\u0002490.\n499. Pappone C, Manguso F, Santinelli R, Vicedomini G, Sala S, Paglino G, Mazzone\nP, Lang CC, Gulletta S, Augello G, Santinelli O, Santinelli V. Radiofrequency\nablation in children with asymptomatic Wolff-Parkinson-White syndrome. N\nEngl J Med 2004;351:1197\u00021205.\n500. Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomstrom-Lundqvist C,\nCalkins H, Corrado D, Deftereos SG, Diller G-P, Gomez-Doblas JJ, Gorenek B,\nGrace A, Ho SY, Kaski J-C, Kuck K-H, Lambiase PD, Sacher F, Sarquella-\nBrugada G, Suwalski P, Zaza A. 2019 ESC Guidelines for the management of\npatients with supraventricular tachycardia. The Task Force for the management\nof patients with supraventricular tachycardia of the European Society of\nCardiology (ESC). Eur Heart J 2019;41:655\u0002720.\n501. Bjornstad H, Storstein L, Meen HD, Hals O. Ambulatory electrocardiographic\nfindings in top athletes, athletic students and control subjects. Cardiology\n1994;84:42\u000250.\n502. Zorzi A, Mastella G, Cipriani A, Berton G, Del Monte A, Gusella B, Nese A,\nPortolan L, Sciacca F, Tikvina S, Tollot S, Trovato D, Iliceto S, Schiavon M,\nCorrado D. Burden of ventricular arrhythmias at 12-lead 24-hour ambulatory\nECG monitoring in middle-aged endurance athletes versus sedentary controls.\nEur J Prev Cardiol 2018;25:2003\u00022011.\n503. Biffi A, Pelliccia A, Verdile L, Fernando F, Spataro A, Caselli S, Santini M, Maron\nBJ. Long-term clinical significance of frequent and complex ventricular tachyar-\nrhythmias in trained athletes. J Am Coll Cardiol 2002;40:446\u0002452.\n504. Palatini P, Maraglino G, Sperti G, Calzavara A, Libardoni M, Pessina AC, Dal\nPalu C. Prevalence and possible mechanisms of ventricular arrhythmias in ath-\nletes. Am Heart J 1985;110:560\u0002567.\n505. Lee V, Perera D, Lambiase P. Prognostic significance of exercise-induced pre-\nmature ventricular complexes: a systematic review and meta-analysis of obser-\nvational studies. Heart Asia 2017;9:14\u000224.\n506. Lin C-Y, Chang S-L, Chung F-P, Chen Y-Y, Lin Y-J, Lo L-W, Hu Y-F, Tuan T-C,\nChao T-F, Liao J-N, Chang Y-T, Lin C-H, Allamsetty S, Walia R, Te ALD,\nYamada S, Chiang S-J, Tsao H-M, Chen S-A. Long-term outcome of non-\nsustained ventricular tachycardia in structurally normal hearts. PLoS One\n2016;11:e0160181.\n507. Hutchinson MD, Garcia FC. An organized approach to the localization, map-\nping, and ablation of outflow tract ventricular arrhythmias. J Cardiovasc\nElectrophysiol 2013;24:1189\u00021197.\n508. Luebbert J, Auberson D, Marchlinski F. Premature ventricular complexes in\napparently normal hearts. Card Electrophysiol Clin 2016;8:503\u0002514.\n509. Haissaguerre M, Nademanee K, Hocini M, Cheniti G, Duchateau J, Frontera A,\nSacher F, Derval N, Denis A, Pambrun T, Dubois R, Jais P, Benoist D, Walton\nRD, Nogami A, Coronel R, Potse M, Bernus O. Depolarization versus repolari-\nzation abnormality underlying inferolateral J-wave syndromes: new concepts in\nsudden\ncardiac\ndeath\nwith\napparently\nnormal\nhearts.\nHeart\nRhythm\n2019;16:781\u0002790.\n510. Leenhardt A, Glaser E, Burguera M, Nurnberg M, Maison-Blanche P, Coumel P.\nShort-coupled variant of torsade de pointes. A new electrocardiographic entity\nin\nthe\nspectrum\nof\nidiopathic\nventricular\ntachyarrhythmias.\nCirculation\n1994;89:206\u0002215.\n511. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB,\nDeal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill\nSC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017\nAHA/ACC/HRS guideline for management of patients with ventricular arrhyth-\nmias and the prevention of sudden cardiac death: executive summary. A report\nof the American College of Cardiology/American Heart Association Task Force\non Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm\n2018;15:e190\u0002e252.\n512. Latchamsetty R, Bogun F. Premature ventricular complexes and premature\nventricular\ncomplex\ninduced\ncardiomyopathy.\nCurr\nProbl\nCardiol\n2015;40:379\u0002422.\n513. Morshedi-Meibodi A, Evans JC, Levy D, Larson MG, Vasan RS. Clinical corre-\nlates and prognostic significance of exercise-induced ventricular premature\nbeats\nin\nthe\ncommunity:\nthe\nFramingham\nHeart\nStudy.\nCirculation\n2004;109:2417\u00022422.\n514. Selzman KA, Gettes LS. Exercise-induced premature ventricular beats: should\nwe do anything differently? Circulation 2004;109:2374\u00022375.\n515. Zorzi A, Perazzolo Marra M, Rigato I, De Lazzari M, Susana A, Niero A,\nPilichou K, Migliore F, Rizzo S, Giorgi B, De Conti G, Sarto P, Serratosa L,\nPatrizi G, De Maria E, Pelliccia A, Basso C, Schiavon M, Bauce B, Iliceto S,\nThiene G, Corrado D. Nonischemic left ventricular scar as a substrate of life-\nthreatening ventricular arrhythmias and sudden cardiac death in competitive\nathletes.\nCirc\nArrhythm\nElectrophysiol\n2016;9:e004229.\ndoi:\n10.1161/\nCIRCEP.116.004229. Originally published July 7, 2016.\n516. Cipriani A, Zorzi A, Sarto P, Donini M, Rigato I, Bariani R, De Lazzari M,\nPilichou K, Thiene G, Iliceto S, Basso C, Corrado D, Perazzolo Marra M, Bauce\nB. Predictive value of exercise testing in athletes with ventricular ectopy eval-\nuated by cardiac magnetic resonance. Heart Rhythm 2019;16:239\u0002248.\n517. Gimeno JR, Tome-Esteban M, Lofiego C, Hurtado J, Pantazis A, Mist B,\nLambiase P, McKenna WJ, Elliott PM. Exercise-induced ventricular arrhythmias\nand risk of sudden cardiac death in patients with hypertrophic cardiomyopathy.\nEur Heart J 2009;30:2599\u00022605.\n518. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M,\nDeSimone L, Coltorti F, Bloise R, Keegan R, Cruz Filho FES, Vignati G, Benatar\nA, DeLogu A. Clinical and molecular characterization of patients with catecho-\nlaminergic polymorphic ventricular tachycardia. Circulation 2002;106:69\u000274.\n519. Heidbuchel H, Hoogsteen J, Fagard R, Vanhees L, Ector H, Willems R, Van\nLierde J. High prevalence of right ventricular involvement in endurance athletes\nwith ventricular arrhythmias. Role of an electrophysiologic study in risk stratifi-\ncation. Eur Heart J 2003;24:1473\u00021480.\n520. Sofi F, Capalbo A, Pucci N, Giuliattini J, Condino F, Alessandri F, Abbate R,\nGensini GF, Califano S. Cardiovascular evaluation, including resting and exercise\nelectrocardiography, before participation in competitive sports: cross sectional\nstudy. BMJ 2008;337:a346.\nESC Guidelines\n93\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\n521. Haugaa KH, Leren IS, Berge KE, Bathen J, Loennechen JP, Anfinsen O-G, Fruh\nA, Edvardsen T, Kongsgard E, Leren TP, Amlie JP. High prevalence of exercise-\ninduced arrhythmias in catecholaminergic polymorphic ventricular tachycardia\nmutation-positive family members diagnosed by cascade genetic screening.\nEuropace 2010;12:417\u0002423.\n522. Sharma S, Drezner JA, Baggish A, Papadakis M, Wilson MG, Prutkin JM, La\nGerche A, Ackerman MJ, Borjesson M, Salerno JC, Asif IM, Owens DS, Chung\nEH, Emery MS, Froelicher VF, Heidbuchel H, Adamuz C, Asplund CA, Cohen\nG, Harmon KG, Marek JC, Molossi S, Niebauer J, Pelto HF, Perez MV, Riding\nNR, Saarel T, Schmied CM, Shipon DM, Stein R, Vetter VL, Pelliccia A, Corrado\nD. International recommendations for electrocardiographic interpretation in\nathletes. Eur Heart J 2018;39:1466\u00021480.\n523. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, Vicentini\nA, Spazzolini C, Nastoli J, Bottelli G, Folli R, Cappelletti D. Risk stratification in\nthe long-QT syndrome. N Engl J Med 2003;348:1866\u00021874.\n524. Sy RW, van der Werf C, Chattha IS, Chockalingam P, Adler A, Healey JS, Perrin\nM, Gollob MH, Skanes AC, Yee R, Gula LJ, Leong-Sit P, Viskin S, Klein GJ,\nWilde AA, Krahn AD. Derivation and validation of a simple exercise-based\nalgorithm for prediction of genetic testing in relatives of LQTS probands.\nCirculation 2011;124:2187\u00022194.\n525. Chandra N, Bastiaenen R, Papadakis M, Panoulas VF, Ghani S, Duschl J, Foldes\nD, Raju H, Osborne R, Sharma S. Prevalence of electrocardiographic anomalies\nin young individuals: relevance to a nationwide cardiac screening program. J Am\nColl Cardiol 2014;63:2028\u00022034.\n526. Basavarajaiah S, Wilson M, Whyte G, Shah A, Behr E, Sharma S. Prevalence and\nsignificance of an isolated long QT interval in elite athletes. Eur Heart J\n2007;28:2944\u00022949.\n527. Johnson JN, Ackerman MJ. Return to play? Athletes with congenital long QT\nsyndrome. Br J Sports Med 2013;47:28\u000233.\n528. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C,\nDenjoy I, Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink\nP, Wilde AA, Toivonen L, Zareba W, Robinson JL, Timothy KW, Corfield V,\nWattanasirichaigoon D, Corbett C, Haverkamp W, Schulze-Bahr E, Lehmann\nMH, Schwartz K, Coumel P, Bloise R. Genotype-phenotype correlation in the\nlong-QT syndrome: gene-specific triggers for life-threatening arrhythmias.\nCirculation 2001;103:89\u000295.\n529. Schwartz PJ, Ackerman MJ. The long QT syndrome: a transatlantic clinical\napproach to diagnosis and therapy. Eur Heart J 2013;34:3109\u00023116.\n530. Vincent GM, Schwartz PJ, Denjoy I, Swan H, Bithell C, Spazzolini C, Crotti L,\nPiippo K, Lupoglazoff J-M, Villain E, Priori SG, Napolitano C, Zhang L. High effi-\ncacy of beta-blockers in long-QT syndrome type 1: contribution of noncompli-\nance and QT-prolonging drugs to the occurrence of beta-blocker treatment\n“failures”. Circulation 2009;119:215\u0002221.\n531. Ackerman MJ, Zipes DP, Kovacs RJ, Maron BJ. Eligibility and disqualification rec-\nommendations for competitive athletes with cardiovascular abnormalities: Task\nForce 10: The cardiac channelopathies: a scientific statement from the\nAmerican Heart Association and American College of Cardiology. Circulation\n2015;132:e326\u00029.\n532. Drezner JA, Rogers KJ. Sudden cardiac arrest in intercollegiate athletes: detailed\nanalysis\nand\noutcomes\nof\nresuscitation\nin\nnine\ncases.\nHeart\nRhythm\n2006;3:755\u0002759.\n533. Brugada P, Brugada J. Right bundle branch block, persistent ST segment eleva-\ntion and sudden cardiac death: a distinct clinical and electrocardiographic syn-\ndrome. A multicenter report. J Am Coll Cardiol 1992;20:1391\u00021396.\n534. Brugada J, Campuzano O, Arbelo E, Sarquella-Brugada G, Brugada R. Present\nstatus of Brugada syndrome: JACC state-of-the-art review. J Am Coll Cardiol\n2018;72:1046\u00021059.\n535. Frustaci A, Priori SG, Pieroni M, Chimenti C, Napolitano C, Rivolta I, Sanna T,\nBellocci F, Russo MA. Cardiac histological substrate in patients with clinical phe-\nnotype of Brugada syndrome. Circulation 2005;112:3680\u00023687.\n536. Frustaci A, Russo MA, Chimenti C. Structural myocardial abnormalities in\nasymptomatic family members with Brugada syndrome and SCN5A gene muta-\ntion. Eur Heart J 2009;30:1763.\n537. Catalano O, Antonaci S, Moro G, Mussida M, Frascaroli M, Baldi M, Cobelli F,\nBaiardi P, Nastoli J, Bloise R, Monteforte N, Napolitano C, Priori SG. Magnetic\nresonance investigations in Brugada syndrome reveal unexpectedly high rate of\nstructural abnormalities. Eur Heart J 2009;30:2241\u00022248.\n538. van Hoorn F, Campian ME, Spijkerboer A, Blom MT, Planken RN, van Rossum\nAC, de Bakker JMT, Wilde AAM, Groenink M,, Tan HL. SCN5A mutations in\nBrugada syndrome are associated with increased cardiac dimensions and\nreduced contractility. PLoS One 2012;7:e42037.\n539. Baranchuk A, Nguyen T, Ryu MH, Femenia F, Zareba W, Wilde AAM, Shimizu\nW, Brugada P, Perez-Riera AR. Brugada phenocopy: new terminology and pro-\nposed classification. Ann Noninvasive Electrocardiol 2012;17:299\u0002314.\n540. Bayes de Luna A, Brugada J, Baranchuk A, Borggrefe M, Breithardt G,\nGoldwasser D, Lambiase P, Riera AP, Garcia-Niebla J, Pastore C, Oreto G,\nMcKenna W, Zareba W, Brugada R, Brugada P. Current electrocardiographic\ncriteria for diagnosis of Brugada pattern: a consensus report. J Electrocardiol\n2012;45:433\u0002442.\n541. Chockalingam P, Rammeloo LA, Postema PG, Hruda J, Clur S-AB, Blom NA,\nWilde AA. Fever-induced life-threatening arrhythmias in children harboring an\nSCN5A mutation. Pediatrics 2011;127:e239\u0002e244. doi: 10.1542/peds.2010-1688.\n542. Miyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y, Ogawa S. Autonomic\nand antiarrhythmic drug modulation of ST segment elevation in patients with\nBrugada syndrome. J Am Coll Cardiol 1996;27:1061\u00021070.\n543. Mizumaki K, Fujiki A, Tsuneda T, Sakabe M, Nishida K, Sugao M, Inoue H. Vagal\nactivity modulates spontaneous augmentation of ST elevation in the daily life of\npatients with Brugada syndrome. J Cardiovasc Electrophysiol 2004;15:667\u0002673.\n544. Matsuo K, Kurita T, Inagaki M, Kakishita M, Aihara N, Shimizu W, Taguchi A,\nSuyama K, Kamakura S, Shimomura K. The circadian pattern of the develop-\nment of ventricular fibrillation in patients with Brugada syndrome. Eur Heart J\n1999;20:465\u0002470.\n545. Probst V, Denjoy I, Meregalli PG, Amirault J-C, Sacher F, Mansourati J, Babuty\nD, Villain E, Victor J, Schott J-J, Lupoglazoff J-M, Mabo P, Veltmann C, Jesel L,\nChevalier P, Clur S-AB, Haissaguerre M, Wolpert C, Le Marec H, Wilde AAM.\nClinical aspects and prognosis of Brugada syndrome in children. Circulation\n2007;115:2042\u00022048.\n546. Takigawa M, Noda T, Shimizu W, Miyamoto K, Okamura H, Satomi K, Suyama\nK, Aihara N, Kamakura S, Kurita T. Seasonal and circadian distributions of ven-\ntricular\nfibrillation\nin\npatients\nwith\nBrugada\nsyndrome.\nHeart\nRhythm\n2008;5:1523\u00021527.\n547. Michowitz Y, Milman A, Sarquella-Brugada G, Andorin A, Champagne J,\nPostema PG, Casado-Arroyo R, Leshem E, Juang JJM, Giustetto C, Tfelt-Hansen\nJ, Wijeyeratne YD, Veltmann C, Corrado D, Kim S-H, Delise P, Maeda S,\nGourraud J-B, Sacher F, Mabo P, Takahashi Y, Kamakura T, Aiba T, Conte G,\nHochstadt A, Mizusawa Y, Rahkovich M, Arbelo E, Huang Z, Denjoy I,\nNapolitano C, Brugada R, Calo L, Priori SG, Takagi M, Behr ER, Gaita F, Yan G-\nX, Brugada J, Leenhardt A, Wilde AAM, Brugada P, Kusano KF, Hirao K, Nam\nG-B, Probst V, Belhassen B. Fever-related arrhythmic events in the multicenter\nsurvey\non\narrhythmic\nevents\nin\nBrugada\nsyndrome.\nHeart\nRhythm\n2018;15:1394\u00021401.\n548. Rossenbacker T, Carroll SJ, Liu H, Kuiperi C, de Ravel TJL, Devriendt K,\nCarmeliet P, Kass RS, Heidbuchel H. Novel pore mutation in SCN5A manifests\nas a spectrum of phenotypes ranging from atrial flutter, conduction disease, and\nBrugada syndrome to sudden cardiac death. Heart Rhythm 2004;1:610\u0002615.\n549. Kasanuki H, Ohnishi S, Ohtuka M, Matsuda N, Nirei T, Isogai R, Shoda M,\nToyoshima Y, Hosoda S. Idiopathic ventricular fibrillation induced with vagal\nactivity\nin\npatients\nwithout\nobvious\nheart\ndisease.\nCirculation\n1997;95:2277\u00022285.\n550. Arai Y, Saul JP, Albrecht P, Hartley LH, Lilly LS, Cohen RJ, Colucci WS.\nModulation of cardiac autonomic activity during and immediately after exercise.\nAm J Physiol 1989;256:H132\u000241.\n551. Smith ML, Hudson DL, Graitzer HM, Raven PB. Exercise training bradycardia:\nthe role of autonomic balance. Med Sci Sports Exerc 1989;21:40\u000244.\n552. Deharo JC, Bongiorni MG, Rozkovec A, Bracke F, Defaye P, Fernandez-Lozano\nI, Golzio PG, Hansky B, Kennergren C, Manolis AS, Mitkowski P, Platou ES.\nPathways for training and accreditation for transvenous lead extraction: a\nEuropean\nHeart\nRhythm\nAssociation\nposition\npaper.\nEuropace\n2012;14:124\u0002134.\n553. Lamas GA, Keefe JM. The effects of equitation (horseback riding) on a\nmotion responsive DDDR pacemaker. Pacing Clin Electrophysiol 1990;13:\n1371\u00021373.\n554. Deering JA, Pederson DN. Pacemaker lead fracture associated with weightlift-\ning: a report of two cases. Mil Med 1993;158:833\u0002834.\n555. Gould L, Betzu R, Taddeo M, Judge JD, Lee J. Pulse generator failure due to\nblunt trauma. Clin Cardiol 1988;11:581\u0002582.\n556. Grieco JG, Scanlon PJ, Pifarre R. Pacing lead fracture after a deceleration injury.\nAnn Thorac Surg 1989;47:453\u0002454.\n557. Schuger CD, Mittleman R, Habbal B, Wagshal A, Huang SK. Ventricular lead\ntransection and atrial lead damage in a young softball player shortly after the\ninsertion\nof\na\npermanent\npacemaker.\nPacing\nClin\nElectrophysiol\n1992;15:1236\u00021239.\n558. Altun A, Erdogan O. Pacemaker lead failure suggestive of crush injury. Cardiol\nRev 2003;11:256.\n559. Noble SL, Burri H, Sunthorn H. Complete section of pacemaker lead due to\nsubclavian crush. Med J Aust 2005;182:643.\n560. Exner DV, Rothschild JM, Heal S, Gillis AM. Unipolar sensing in contemporary\npacemakers: using myopotential testing to define optimal sensitivity settings. J\nInterv Card Electrophysiol 1998;2:33\u000240.\n561. Jain P, Kaul U, Wasir HS. Myopotential inhibition of unipolar demand pace-\nmakers: utility of provocative manoeuvres in assessment and management. Int J\nCardiol 1992;34:33\u000239.\n94\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n.............................................................................................................................................................................\n562. Heidbuchel H, Willems R, Jordaens L, Olshansky B, Carre F, Fernandez Lozano\nI, Wilhelm M, Mussigbrodt A, Huybrechts W, Morgan J, Anfinsen OG, Prior D,\nMont L, Mairesse GH, Boveda S, Duru F, Kautzner J, Viskin S, Geelen P,\nCygankiewicz I, Hoffman E, Vanden LR. Intensive recreational athletes in the\nprospective multinational ICD Sports Safety Registry: results from the\nEuropean cohort. Eur J Prev Cardiol 2019;26:764\u0002775.\n563. Barry MJ, Edgman-Levitan S. Shared decision making \u0002 pinnacle of patient-\ncentered care. N Engl J Med 2012;366:780\u0002781.\n564. Rahman B, Macciocca I, Sahhar M, Kamberi S, Connell V, Duncan RE.\nAdolescents with implantable cardioverter defibrillators: a patient and parent\nperspective. Pacing Clin Electrophysiol 2012;35:62\u000272.\n565. Olshansky B, Atteya G, Cannom D, Heidbuchel H, Saarel EV, Anfinsen O-G,\nCheng A, Gold MR, Mussigbrodt A, Patton KK, Saxon LA, Wilkoff BL, Willems\nR, Dziura J, Li F, Brandt C, Simone L, Wilhelm M, Lampert R. Competitive ath-\nletes with implantable cardioverter-defibrillators \u0002 how to program? Data\nfrom the Implantable Cardioverter-Defibrillator Sports Registry. Heart Rhythm\n2019;16:581\u0002587.\n566. Auricchio A, Schloss EJ, Kurita T, Meijer A, Gerritse B, Zweibel S, AlSmadi FM,\nLeng CT, Sterns LD. Low inappropriate shock rates in patients with single- and\ndual/triple-chamber implantable cardioverter-defibrillators using a novel suite of\ndetection\nalgorithms:\nPainFree\nSST\ntrial\nprimary\nresults.\nHeart\nRhythm\n2015;12:926\u0002936.\n567. Theuns DAMJ, Brouwer TF, Jones PW, Allavatam V, Donnelley S, Auricchio A,\nKnops RE, Burke MC. Prospective blinded evaluation of a novel sensing meth-\nodology designed to reduce inappropriate shocks by the subcutaneous implant-\nable cardioverter-defibrillator. Heart Rhythm 2018;15:1515\u00021522.\n568. Camm CF, James CA, Tichnell C, Murray B, Bhonsale A, te Riele ASJM, Judge\nDP, Tandri H, Calkins H. Prevalence of atrial arrhythmias in arrhythmogenic\nright ventricular dysplasia/cardiomyopathy. Heart Rhythm 2013;10:1661\u00021668.\n569. Zeitler EP, Sanders GD, Singh K, Greenfield RA, Gillis AM, Wilkoff BL, Piccini\nJP, Al-Khatib SM. Single vs. dual chamber implantable cardioverter-defibrillators\nor programming of implantable cardioverter-defibrillators in patients without a\nbradycardia pacing indication: systematic review and meta-analysis. Europace\n2018;20:1621\u00021629.\n570. Wilkoff BL, Fauchier L, Stiles MK, Morillo CA, Al-Khatib SM, Almendral J,\nAguinaga L, Berger RD, Cuesta A, Daubert JP, Dubner S, Ellenbogen KA, Estes\nNAM 3rd, Fenelon G, Garcia FC, Gasparini M, Haines DE, Healey JS, Hurtwitz\nJL, Keegan R, Kolb C, Kuck K-H, Marinskis G, Martinelli M, Mcguire M, Molina\nLG, Okumura K, Proclemer A, Russo AM, Singh JP, Swerdlow CD, Teo WS,\nUribe W, Viskin S, Wang C-C, Zhang S. 2015 HRS/EHRA/APHRS/SOLAECE\nexpert consensus statement on optimal implantable cardioverter-defibrillator\nprogramming and testing. EP Europace 2016;18:159\u0002183.\n571. Sinha A-M, Stellbrink C, Schuchert A, Mox B, Jordaens L, Lamaison D, Gill J,\nKaplan A, Merkely B. Clinical experience with a new detection algorithm for dif-\nferentiation of supraventricular from ventricular tachycardia in a dual-chamber\ndefibrillator. J Cardiovasc Electrophysiol 2004;15:646\u0002652.\n572. Deisenhofer I, Kolb C, Ndrepepa G, Schreieck J, Karch M, Schmieder S,\nZrenner B, Schmitt C. Do current dual chamber cardioverter defibrillators have\nadvantages over conventional single chamber cardioverter defibrillators in\nreducing inappropriate therapies? A randomized, prospective study. J Cardiovasc\nElectrophysiol 2001;12:134\u0002142.\n573. van der Linde D, Konings EEM, Slager MA, Witsenburg M, Helbing WA,\nTakkenberg JJM, Roos-Hesselink JW. Birth prevalence of congenital heart dis-\nease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol\n2011;58:2241\u00022247.\n574. Longmuir PE, Brothers JA, de Ferranti SD, Hayman LL, Van Hare GF, Matherne\nGP, Davis CK, Joy EA, McCrindle BW. Promotion of physical activity for chil-\ndren and adults with congenital heart disease: a scientific statement from the\nAmerican Heart Association. Circulation 2013;127:2147\u00022159.\n575. Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M.\nLifetime prevalence of congenital heart disease in the general population from\n2000 to 2010. Circulation 2014;130:749\u0002756.\n576. Inuzuka R, Diller G-P, Borgia F, Benson L, Tay ELW, Alonso-Gonzalez R, Silva\nM, Charalambides M, Swan L, Dimopoulos K, Gatzoulis MA. Comprehensive\nuse of cardiopulmonary exercise testing identifies adults with congenital heart\ndisease\nat\nincreased\nmortality\nrisk\nin\nthe\nmedium\nterm.\nCirculation\n2012;125:250\u0002259.\n577. Pelliccia A, Adami PE, Quattrini F, Squeo MR, Caselli S, Verdile L, Maestrini V,\nDi Paolo F, Pisicchio C, Ciardo R, Spataro A. Are Olympic athletes free from\ncardiovascular diseases? Systematic investigation in 2352 participants from\nAthens 2004 to Sochi 2014. Br J Sports Med 2017;51:238\u0002243.\n578. Pierpont ME, Basson CT, Benson DWJ, Gelb BD, Giglia TM, Goldmuntz E,\nMcGee G, Sable CA, Srivastava D, Webb CL. Genetic basis for congenital heart\ndefects: current knowledge: a scientific statement from the American Heart\nAssociation Congenital Cardiac Defects Committee, Council on Cardiovascular\nDisease in the Young. Circulation 2007;115:3015\u00023038.\n579. Correia\nJD,\nda\nRosa\nEB,\nSilveira\nDB,\nGrapiglia\nCG,\nCanabarro\nST,\nWaterkemper R, Zen PRG, Rosa RFM. Major extracardic malformations among\npatients with congenital heart defects. Int J Cardiol 2016;214:154\u0002156.\n580. Lui GK, Saidi A, Bhatt AB, Burchill LJ, Deen JF, Earing MG, Gewitz M, Ginns J,\nKay JD, Kim YY, Kovacs AH, Krieger EV, Wu FM, Yoo S-J. Diagnosis and man-\nagement of noncardiac complications in adults with congenital heart disease: a\nscientific\nstatement\nfrom\nthe\nAmerican\nHeart\nAssociation.\nCirculation\n2017;136:e348\u0002e392.\n581. Hacker A-L, Oberhoffer R, Hager A, Ewert P, Muller J. Age-related cardiovascu-\nlar\nrisk\nin\nadult\npatients\nwith\ncongenital\nheart\ndisease.\nInt\nJ\nCardiol\n2019;277:90\u000296.\n582. Giannakoulas G, Ntiloudi D. Acquired cardiovascular disease in adult patients\nwith congenital heart disease. Heart 2018;104:546\u0002547.\n583. Koyak Z, Harris L, de Groot JR, Silversides CK, Oechslin EN, Bouma BJ, Budts\nW, Zwinderman AH, Van Gelder IC, Mulder BJM. Sudden cardiac death in adult\ncongenital heart disease. Circulation 2012;126:1944\u00021954.\n584. Zomer AC, Vaartjes I, Uiterwaal CSPM, van der Velde ET, van den Merkhof\nLFM, Baur LHB, Ansink TJM, Cozijnsen L, Pieper PG, Meijboom FJ, Grobbee\nDE, Mulder BJM. Circumstances of death in adult congenital heart disease. Int J\nCardiol 2012;154:168\u0002172.\n585. Scanlan S. Shaun White’s biggest fans are the ones that share his heart condi-\ntion. USA Today, 2018. https://eu.usatoday.com/story/sports/olympics/2018/02/\n13/shaun-whites-biggest-fans-ones-share-his-heart-condition/333985002/.\n586. Lynge TH, Jeppesen AG, Winkel BG, Glinge C, Schmidt MR, Sondergaard L,\nRisgaard B, Tfelt-Hansen J. Nationwide study of sudden cardiac death in people\nwith congenital heart defects aged 0 to 35 years. Circ Arrhythm Electrophysiol\n2018;11:e005757.\n587. Tutarel O, Gabriel H, Diller G-P. Exercise: friend or foe in adult congenital\nheart disease? Curr Cardiol Rep 2013;15:416.\n588. van Dissel AC, Blok IM, Hooglugt J-LQ, de Haan FH, Jorstad HT, Mulder BJM,\nBouma BJ, Winter MM. Safety and effectiveness of home-based, self-selected\nexercise training in symptomatic adults with congenital heart disease: a pro-\nspective, randomised, controlled trial. Int J Cardiol 2019;278:59\u000264.\n589. Eijsvogels TMH, Thompson PD, Franklin BA. The “extreme exercise hypoth-\nesis”: recent findings and cardiovascular health implications. Curr Treat Options\nCardiovasc Med 2018;20:84.\n590. Kim JH, Baggish AL. Strenuous exercise and cardiovascular disease outcomes.\nCurr Atheroscler Rep 2017;19:1.\n591. Dua JS, Cooper AR, Fox KR, Graham Stuart A. Exercise training in adults\nwith congenital heart disease: feasibility and benefits. Int J Cardiol 2010;138:\n196\u0002205.\n592. Duppen N, Takken T, Hopman MTE, ten Harkel ADJ, Dulfer K, Utens EMWJ,\nHelbing WA. Systematic review of the effects of physical exercise training pro-\ngrammes in children and young adults with congenital heart disease. Int J Cardiol\n2013;168:1779\u00021787.\n593. Cordina RL, O’Meagher S, Karmali A, Rae CL, Liess C, Kemp GJ, Puranik R,\nSingh N, Celermajer DS. Resistance training improves cardiac output, exercise\ncapacity and tolerance to positive airway pressure in Fontan physiology. Int J\nCardiol 2013;168:780\u0002788.\n594. Duppen N, Etnel JR, Spaans L, Takken T, van den Berg-Emons RJ, Boersma E,\nSchokking M, Dulfer K, Utens EM, Helbing W, Hopman MT. Does exercise\ntraining improve cardiopulmonary fitness and daily physical activity in children\nand young adults with corrected tetralogy of Fallot or Fontan circulation? A\nrandomized controlled trial. Am Heart J 2015;170:606\u0002614.\n595. Chaix M-A, Marcotte F, Dore A, Mongeon F-P, Mondesert B, Mercier L-A,\nKhairy P. Risks and benefits of exercise training in adults with congenital heart\ndisease. Can J Cardiol 2016;32:459\u0002466.\n596. Muller J, Amberger T, Berg A, Goeder D, Remmele J, Oberhoffer R, Ewert P,\nHager A. Physical activity in adults with congenital heart disease and associa-\ntions with functional outcomes. Heart 2017;103:1117\u00021121.\n597. Budts W, Borjesson M, Chessa M, van Buuren F, Trigo Trindade P, Corrado D,\nHeidbuchel H, Webb G, Holm J, Papadakis M. Physical activity in adolescents\nand adults with congenital heart defects: individualized exercise prescription.\nEur Heart J 2013;34:3669\u00023674.\n598. Takken T, Giardini A, Reybrouck T, Gewillig M, Hovels-Gurich HH, Longmuir\nPE, McCrindle BW, Paridon SM, Hager A. Recommendations for physical activ-\nity, recreation sport, and exercise training in paediatric patients with congenital\nheart disease: a report from the Exercise, Basic & Translational Research\nSection of the European Association of Cardiovascular Prevention. Eur J Prev\nCardiol 2012;19:1034\u00021065.\n599. Muscogiuri G, Secinaro A, Ciliberti P, Fuqua M, Nutting A. Utility of cardiac\nmagnetic resonance imaging in the management of adult congenital heart dis-\nease. J Thorac Imaging 2017;32:233\u0002244.\n600. Sparrow P, Merchant N, Provost Y, Doyle D, Nguyen E, Paul N. Cardiac MRI\nand CT features of inheritable and congenital conditions associated with sudden\ncardiac death. Eur Radiol 2009;19:259\u0002270.\nESC Guidelines\n95\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026\n\n\n..........................................................................................................\n601. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka\nM, Williams PG, Souza R. Haemodynamic definitions and updated clinical classi-\nfication of pulmonary hypertension. Eur Respir J 2019;53:1801913.\n602. Moller T, Brun H, Fredriksen PM, Holmstrom H, Pettersen E, Thaulow E. Moderate\naltitude increases right ventricular pressure and oxygen desaturation in adolescents\nwith surgically closed septal defect. Congenit Heart Dis 2010;5:556\u0002564.\n603. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure\nduring rest and exercise in healthy subjects: a systematic review. Eur Respir J\n2009;34:888\u0002894.\n604. Augustine DX, Coates-Bradshaw LD, Willis J, Harkness A, Ring L, Grapsa J,\nCoghlan G, Kaye N, Oxborough D, Robinson S, Sandoval J, Rana BS, Siva A,\nNihoyannopoulos P, Howard LS, Fox K, Bhattacharyya S, Sharma V, Steeds RP,\nMathew T. Echocardiographic assessment of pulmonary hypertension: a guide-\nline protocol from the British Society of Echocardiography. Echo Res Pract\n2018;5:G11\u0002G24.\n605. Galie N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, Simonneau G,\nPeacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA,\nHansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA,\nTrindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the diag-\nnosis and treatment of pulmonary hypertension: the Joint Task Force for the\ndiagnosis and treatment of pulmonary hypertension of the European Society of\nCardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J\n2016;37:67\u0002119.\n606. Muller J, Heck PB, Ewert P, Hager A. Noninvasive screening for pulmonary\nhypertension by exercise testing in congenital heart disease. Ann Thorac Surg\n2017;103:1544\u00021549.\n607. Dimopoulos K, Wort SJ, Gatzoulis MA. Pulmonary hypertension related to con-\ngenital heart disease: a call for action. Eur Heart J 2014;35:691\u0002700.\n608. Grunig E, Eichstaedt C, Barbera J-A, Benjamin N, Blanco I, Bossone E, Cittadini\nA, Coghlan G, Corris P, D’Alto M, D’Andrea A, Delcroix M, de Man F, Gaine S,\nGhio S, Gibbs S, Gumbiene L, Howard LS, Johnson M, Jureviciene E, Kiely DG,\nKovacs G, MacKenzie A, Marra AM, McCaffrey N, McCaughey P, Naeije R,\nOlschewski H, Pepke-Zaba J, Reis A, Santos M, Saxer S, Tulloh RM, Ulrich S,\nVonk Noordegraaf A, Peacock AJ. ERS statement on exercise training and reha-\nbilitation in patients with severe chronic pulmonary hypertension. Eur Respir J\n2019;53:1800332.\n609. Kuijpers JM, Koolbergen DR, Groenink M, Boekholdt SM, Meijboom FJ,\nJongbloed MRM, Hoendermis ES, Duijnhouwer AL, Mulder BJM, Bouma BJ.\nAortic dissection and prophylactic surgery in congenital heart disease. Int J\nCardiol 2019;274:113\u0002116.\n610. Zhao Q, Shi K, Yang Z-G, Diao K-Y, Xu H-Y, Liu X, Guo Y-K. Predictors of\naortic dilation in patients with coarctation of the aorta: evaluation with dual-\nsource computed tomography. BMC Cardiovasc Disord 2018;18:124.\n611. Loomba RS, Buelow MW, Aggarwal S, Arora RR, Kovach J, Ginde S.\nArrhythmias in adults with congenital heart disease: what are risk factors for\nspecific arrhythmias? Pacing Clin Electrophysiol 2017;40:353\u0002361.\n612. Khairy P, Van Hare GF, Balaji S, Berul CI, Cecchin F, Cohen MI, Daniels CJ,\nDeal BJ, Dearani JA, Groot N de, Dubin AM, Harris L, Janousek J, Kanter RJ,\nKarpawich PP, Perry JC, Seslar SP, Shah MJ, Silka MJ, Triedman JK, Walsh EP,\nWarnes CA. PACES/HRS expert consensus statement on the recognition and\nmanagement of arrhythmias in adult congenital heart disease: developed in\npartnership\nbetween\nthe\nPediatric\nand\nCongenital\nElectrophysiology\nSociety (PACES) and the Heart Rhythm Society (HRS). Can J Cardiol\n2014;30:e1\u0002e63.\n613. Diller G-P, Dimopoulos K, Okonko D, Li W, Babu-Narayan SV, Broberg CS,\nJohansson B, Bouzas B, Mullen MJ, Poole-Wilson PA, Francis DP, Gatzoulis\nMA. Exercise intolerance in adult congenital heart disease: comparative\nseverity,\ncorrelates,\nand\nprognostic\nimplication.\nCirculation\n2005;112:\n828\u0002835.\n614. Mantegazza V, Apostolo A, Hager A. Cardiopulmonary exercise testing in adult\ncongenital heart disease. Ann Am Thorac Soc 2017;14:S93\u0002S101.\n615. Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehabil\nMed 1970;2:92\u000298.\n616. Kempny A, Dimopoulos K, Uebing A, Moceri P, Swan L, Gatzoulis MA, Diller\nG-P. Reference values for exercise limitations among adults with congenital\nheart disease. Relation to activities of daily life \u0002 single centre experience and\nreview of published data. Eur Heart J 2012;33:1386\u00021396.\n617. d’Udekem Y. Cardiorespiratory fitness, not the severity of the condition, dic-\ntates\nlate\noutcomes\nafter\nFontan\nprocedures.\nJ\nAm\nColl\nCardiol\n2017;69:2745\u00022747.\n618. Evangelista A, Flachskampf FA, Erbel R, Antonini-Canterin F, Vlachopoulos C,\nRocchi G, Sicari R, Nihoyannopoulos P, Zamorano J, Pepi M, Breithardt O-A,\nPlonska-Gosciniak E. Echocardiography in aortic diseases: EAE recommenda-\ntions for clinical practice. Eur J Echocardiogr 2010;11:645\u0002658.\n619. Ait Ali L, Pingitore A, Piaggi P, Brucini F, Passera M, Marotta M, Cadoni A,\nPassino C, Catapano G, Festa P. Respiratory training late after Fontan interven-\ntion:\nimpact\non\ncardiorespiratory\nperformance.\nPediatr\nCardiol\n2018;39:695\u0002704.\n620. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden\ndeath in young competitive athletes. Clinical, demographic, and pathological\nprofiles. JAMA 1996;276:199\u0002204.\n621. Maron BJ, Haas TS, Ahluwalia A, Murphy CJ, Garberich RF. Demographics and\nepidemiology of sudden deaths in young competitive athletes: from the United\nStates National Registry. Am J Med 2016;129:1170\u00021177.\n622. Locati EH, Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Lehmann MH,\nTowbin JA, Priori SG, Napolitano C, Robinson JL, Andrews M, Timothy K, Hall\nWJ. Age- and sex-related differences in clinical manifestations in patients with\ncongenital long-QT syndrome: findings from the International LQTS Registry.\nCirculation 1998;97:2237\u00022244.\n623. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gen-\nder as a risk factor for torsades de pointes associated with cardiovascular drugs.\nJAMA 1993;270:2590\u00022597.\n96\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/1/17/5898937 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "moderate",
        "ct",
        "myers",
        "jolly",
        "passino",
        "heart failure",
        "witham",
        "risk",
        "nilsson",
        "mckelvie"
      ]
    },
    {
      "number": "9",
      "title": "Delivering to 20+ European Countries.",
      "start_page": 81,
      "end_page": 81,
      "content": "LITTMANN\nRATING\n9/10\nLITTMANN\nRATING\n10+\nDelivering to 20+ European Countries.\nFREE CASE ANY LITTMANN® CORE\nFREECASE\nadd code at the checkout to apply\nSHOP NOW\nFREE CASE ANY LITTMANN® CARD IV\nFREECASE\nadd code at the checkout to apply\nSHOP NOW\nTo deliver the best \npatient care, you\nneed the tools \nto match.\nLittmann® Cardiology IV™\n& Littmann® CORE Digital\nStethoscopes\nKeep your tools safe\nwith laser engraving.\n♥☺♫★♠",
      "tables": [],
      "keywords": [
        "european",
        "countries",
        "delivering"
      ]
    }
  ]
}